

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
16 February 2006 (16.02.2006)

PCT

(10) International Publication Number
WO 2006/017443 A2

(51) International Patent Classification:

A61K 31/519 (2006.01) C07D 487/02 (2006.01)

(21) International Application Number:

PCT/US2005/027274

(22) International Filing Date: 1 August 2005 (01.08.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/598,173 2 August 2004 (02.08.2004) US
60/698,516 12 July 2005 (12.07.2005) US(71) Applicant (for all designated States except US): **OSI PHARMACEUTICALS, INC.** [US/US]; 58 South Service Road, Suite 110, Melville, NY 11747 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **AHMED, Saleh** [GB/GB]; Watlington Road, Oxford OX4 6LT (GB). **BARBA, Oscar** [IT/GB]; Watlington Road, Oxford OX4 6LT (GB). **BLOXHAM, Jason** [GB/GB]; Watlington Road, Oxford OX4 6LT (GB). **DAWSON, Graham** [GB/GB]; Watlington Road, Oxford OX4 6LT (GB). **GATTRELL, William** [GB/GB]; Watlington Road, Oxford OX4 6LT (GB). **KITCHIN, John** [GB/GB]; Watlington Road, Oxford, OX4 6LT (GB). **PEGG, Neil, Anthony** [GB/GB]; Watlington Road, Oxford, OX4 6LT (GB). **SABA, Imaad** [GB/GB]; Watlington Road, Oxford, OX4 6LT (GB). **SHADIQ, Shazia** [GB/GB]; Watlington Road, Oxford, OX4 6LT (GB). **SMITH, Colin, Peter, Sambrook** [GB/GB]; Watlington Road, Oxford, OX4 6LT (GB). **SMYTH, Don** [GB/GB]; Watlington Road, Oxford, OX4 6LT (GB). **STEINIG, Arno, G.** [DE/US]; 1 Bioscience Park Drive, Farmingdale, NY 11735 (US). **WILKES, Robin** [GB/GB]; Watlington Road, Oxford, OX4 6LT (GB). **FOREMAN, Kenneth** [US/US]; 1 Bioscience Park Drive, Farmingdale, NY 11735 (US). **WENG, Qinghua, Felix** [CN/US]; 1 Bioscience Park Drive, Farmingdale, NY 11735 (US). **STOLZ, Kathryn** [US/US]; 1 Bioscience Park Drive, Farmingdale, NY 11735 (US). **TAVARES, Paula** [BR/US]; 1 Bioscience Park Drive, Farmingdale, NY 11735 (US). **PANICKER, Bijoy** [IN/US]; 1 Bioscience Park Drive, Farmingdale, NY 11735 (US). **LI, An-Hu** [CN/US]; 1 Bioscience ParkDrive, Farmingdale, NY 11735 (US). **DONG, Hanqing** [CN/US]; 1 Bioscience Park Drive, Farmingdale, NY 11735 (US). **MA, Lifu** [CN/US]; 1 Bioscience Park Drive, Farmingdale, NY 11735 (US). **COX, Matthew** [GB/US]; 1 Bioscience Park Drive, Farmingdale, NY 11735 (US).(74) Agent: **LEE, Shu, M.**; OSI Pharmaceuticals, Inc., 58 South Service Road, Suite 110, Melville, NY 11747 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

[Continued on next page]

(54) Title: ARYL-AMINO SUBSTITUTED PYRROLOPYRIMIDINE MULTI-KINASE INHIBITING COMPOUNDS



(57) Abstract: Compounds represented by Formula (I): or stereoisomers or pharmaceutically acceptable salts thereof, are inhibitors of least two of the Abl, Aurora-A, Blk, c-Raf, cSRC, Src, PRK2, FGFR3, Flt3, Lck, Mek1, PDK-1, GSK3 β , EGFR, p70S6K, BMX, SGK, CaMKII, Tie-2, IGF-IR, Ron, Ret, and KDR kinases in animals, including humans, for the treatment and/or prevention of various diseases and conditions such as cancer.



- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR,

GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

- of inventorship (Rule 4.17(iv)) for US only

Published:

- without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

TITLE OF THE INVENTION

**ARYL-AMINO SUBSTITUTED PYRROLOPYRIMIDINE MULTI-KINASE
INHIBITING COMPOUNDS**

BACKGROUND OF THE INVENTION

[1] The present invention is directed to novel pyrrolopyrimidine compounds, their salts, and compositions comprising them. In particular, the present invention is directed to novel aryl-amino substituted pyrrolopyrimidine compounds that inhibit the activity of at least two of the Abl, Aurora-A, Blk, c-Raf, cSRC, Src, PRK2, FGFR3, Flt3, Lck, Mek1, PDK-1, GSK3 β , EGFR, p70S6K, BMX, SGK, CaMKII, Tie-2, Ret, IGF-1R, Ron, and KDR kinases in animals, including humans, for the treatment and/or prevention of various diseases and conditions such as cancer.

[2] Cells may migrate and divide inappropriately if the signals for division or motility cannot be stopped. This might occur if the complex system of control proteins and messengers, which signal changes in the actin system, goes awry. One such control factor is the proto-oncogene protein Abl, a tyrosine kinase. It is implicated in cancer, including leukemia. Accordingly, it is desirable to identify inhibitors of Abl.

[3] The Aurora kinase family is one regulator of chromosome segregation – regulating the structure and function of centrosomes and mitotic spindle. One member, the Aurora-A kinase, has been shown to play a role in tumorigenesis – being located at a chromosomal hot-spot, 20q13, frequently amplified in a variety of human cancers such as those of colon, ovary, breast and pancreas. It appears that overexpression of Aurora-A kinase alone is sufficient to cause aneuploidy in normal diploid epithelial cells. Over-expression of Aurora-A kinase in NIH3T3 cells results in centrosome aneuploidy. Thus, it is desirable to identify inhibitors of Aurora-A.

[4] Shortly after birth, mice expressing an activated, mutant form of Blk form massive, monoclonal lymphomas and die. (S.V. Desiderio at H. Hughes Medical Institute). Thus, it is likely that Blk regulates cell proliferation. Further, experiments with Blk antisense appear to implicate Blk kinase with growth inhibition and apoptosis. (X. Yao and D.W. Scott, Proc. Nat. Acad. Sci., 90:7946-7950(1993)). Thus, it is desirable to identify inhibitors of Blk.

[5] C-Raf is an extracellular signal-regulated kinase and a downstream effector of Ras. It functions to suppress apoptosis and regulates cell differentiation. Thus, over-expression can lead to unwarranted suppression of apoptosis and unchecked cell differentiation. Thus, it is desirable to identify inhibitors of c-Raf.

[6] The cytoplasmic tyrosine kinase cSRC, or c-Src, is involved in the signal transduction pathway and is elevated in breast cancer cell lines. Similarly, Src is involved in

the regulation of cell growth and transformation. Thus over-expression of Src or cSRC can lead to excess proliferation. Thus, it is desirable to identify inhibitors of Src or c-SRC.

[7] The Protein Kinase c-Related Kinase 2, or PRK2, mediates cytoskeletal organization. It has been implicated in promoting the PDK1-dependent activation of Akt, thereby regulating cell-cycle progression, cell growth, cell survival, cell motility and adhesion, translation of mRNA into protein, and angiogenesis. Thus, it is desirable to identify inhibitors of PRK2.

[8] FGFR3 and Tie-2 are receptor tyrosine kinases that are believed to be important mediators of tumor angiogenesis. For example, FGFR3 mutations are often seen in bladder cancer cells. Tie-2 is a protein receptor found on cells lining blood vessels. When activated by growth factors secreted by tumor cells, Tie2 triggers vessel cell walls to part and grow new capillaries. Thus, it is desirable to identify inhibitors of FGFR3 or Tie-2. Flt3, also known as "vascular endothelial cell growth factor receptor 3" or VEGFR-3, is believed to assist in vascular development important to angiogenesis. Thus, it is desirable to identify inhibitors of Flt3.

[9] Lck, along with fyn, is an Src kinase implicated in cancer, including breast and colon cancer. Accordingly, it is desirable to identify inhibitors of Lck.

[10] Mek1 is a kinase in the Ras pathway strongly implicated in many cancers, including breast, colon, and ovarian cancer. Thus, it is desirable to identify inhibitors of Mek1.

[11] PDK-1 is a kinase that activates the PI3K/PKB signalling pathway, which is often uncoupled and separate from the EGFR pathway. In particular, a PDK-1 phosphorylating step is essential to activation of PKB (D.R. Alessi et al., Curr. Biol., 7:261-269(1997)). Additionally, PDK-1 activates other oncogene kinases such as PKA, ribosomal p90 S6 kinase (RSK), p70 S6 kinase (S6K), serum and glucocorticoid activated kinase (SGK), PKC-related kinase-2 (PRK-2) and MSK-1 (R.M. Biondi et al., Biochem. J., 372:1-13(2003)). Thus, inhibition of PDK-1 can be multiply effective in treatment of cancer and tumors, including glioblastoma, melanoma, prostate, endometrial carcinoma, breast, ovarian, and non-small cell lung cancer (NSCLC), because PDK-1 regulates several oncogenic pathways. Accordingly, it is desirable to identify compounds that inhibit PDK-1.

[12] GSK3 β kinase is believed to play a strong part in cancers such as breast, ovarian, pancreatic, and prostate cancer. Thus, it is desirable to identify compounds that inhibit GSK3 β .

[13] Cell division involves signalling pathways from the cell exterior and interior. Signals travel the pathways and regulate the various activities of cell cycle control genes. Cancer cells have mis-regulation of such signal pathways and control genes – thereby leading to inappropriate or uncontrolled cell division. Over-expression of oncogenes (proteins that

signal cells to proliferate) is one such mis-regulation. The Epidermal Growth Factor Receptor (EGFR) is one such oncogene, which is over-expressed in cancers such as brain, breast, gastrointestinal, lung, ovary and prostate cancers. There are selective EGFR inhibitors being investigated for use against cancer. For example, the 4-anilinoquinazoline compound Tarceva® inhibits only EGFR kinase with high potency, although it can inhibit the signal transduction of other receptor kinases that probably heterodimerize with the EGFR. Nevertheless, other compounds that inhibit EGFR remain needed.

[14] The serine-threonine kinase p70S6K is at the end of one pathway that controls cell growth and is frequently activated in many tumors, including uterine, adenocarcinoma, myeloma, and prostate cancers. Thus, it is desirable to identify compounds that inhibit p70S6K.

[15] BMX is a tyrosine kinase involved in interleukin-6 induced differentiation of prostate cancer cells. It plays a role in EGF-induced apoptosis of breast cancer cells, and is expressed in granulocytes and myeloid leukemias, as well as other cancers. Thus, it is desirable to identify compounds that inhibit BMX.

[16] The serum and glucocorticoid-induced protein kinase ("SGK") is a downstream target in the PI3K/Akt pathway, believed to play a part in cancers such as breast and prostate cancer. Thus, it is desirable to identify compounds that inhibit SGK.

[17] Ca²⁺/calmodulin-dependent protein kinase II ("CaMKII") indirectly modulates Fas-mediated signalling in glioma. Therefore inhibition of CaMK II may be effective in the treatment of glioma. See, Bao Feng Yang et al., J.Biological Chemistry, 278:7043-7050(2003). Thus, it is desirable to identify compounds that inhibit CaMKII.

[18] Ret is a proto-oncogene implicated in many cancers such as thyroid cancer. Thus, it is desirable to identify compounds that inhibit Ret.

[19] Endothelial-cell specific receptor protein tyrosine kinases such as KDR and Tie-2 mediate the angiogenic process, and are thus involved in supporting the progression of cancers and other diseases involving inappropriate vascularization (e.g., diabetic retinopathy, choroidal neovascularization due to age-related macular degeneration, psoriasis, arthritis, retinopathy of prematurity, infantile hemangiomas). Thus, it is desirable to identify compounds that inhibit KDR.

[20] Ron (recepteur d'origine natais) is a receptor tyrosine kinase that is part of the MET proto-oncogene family. Inhibition of Ron has been shown to lead to a decrease in proliferation and induction of apoptosis. Thus, it is desirable to identify inhibitors of Ron.

[21] IGF-1R (type 1 insulin-like growth factor receptor) performs important roles in cell division, development, and metabolism, and in its activated state, plays a role in oncogenesis and suppression of apoptosis. IGF-1R is known to be overexpressed in a number of cancer cell lines (IGF-1R overexpression is linked to acromegaly and to cancer of the

prostate). By contrast, down-regulation of IGF-1R expression has been shown to result in the inhibition of tumorigenesis and an increased apoptosis of tumor cells. Thus, it is desirable to identify compounds that inhibit IGF-1R.

[22] Some cancers develop resistance to certain kinase inhibitors over time and treatment. Resistance to a particular kinase inhibitor can be mediated by a loss of suppression of an enzyme at a branchpoint in the kinase pathway. The loss of suppression may lead to inappropriate activation of a parallel pathway from the original pathway. Thus, it is desirable to identify compounds that inhibit at least two kinases in order to provide compounds that are more efficacious than a very specific narrowly targeted compound that inhibits only one kinase. In particular, it is desirable to identify compounds that inhibit at least two of the Abl, Aurora-A, Blk, c-Raf, cSRC, Src, PRK2, FGFR3, Flt3, Lck, Mek1, PDK-1, GSK3 β , EGFR, p70S6K, BMX, SGK, CaMKII, Tie-2, Ret, IGF-1R, Ron, and KDR kinases in animals, including humans, for the treatment and/or prevention of various diseases and conditions such as cancer.

[23] U.S. Patent No. 6,232,320, International Patent Publication Nos. WO 00/75145 and 99/62908 describes cell adhesion inhibiting antiinflammatory compounds. International Patent Publication No.03/080064 describes kinase inhibitors. U.S. Patent No. 6,713,474 describes pyrrolopyrimidines as therapeutic agents.

[24] U.S. Patent No. 6,541,481 describes substituted bicyclic derivatives useful as anticancer agents.

[25] T. Peng et al., J. Chem. Inf. Comput. Sci.:43:298-303(2003) describes 3D-QSAR and receptor modeling of tyrosine kinase inhibitors with flexible atom receptor model (FLARM). International Patent Publication No. WO 98/43973 describes intermediate products and method for the production of pyrimidine derivatives. U.S. Patent No. 6,610,847, International Patent Publication Nos. WO 99/65908 and WO 99/65909 describe pyrrolo[2,3-d]pyrimidine compounds. U.S. Patent No. 6,635,762 describes monocyclic-7H-pyrrolo[2,3-d]pyrimidine compounds. International Patent Publication No. WO 02/30944 describes fluorescent nucleobase conjugates having anionic linkers. International Patent Publication No. WO 04/009600 describes 1-heterocyclyalkyl-3-sulfonylazaindole or azaindazole derivatives as 5-hydroxytryptamine-6 ligands. International Patent Publication No. WO04/007479 describes 3-guanidinocarbonyl-1-heteroaryl-indole derivatives. International Patent Publication No. WO 03/101990 describes 1-(aminoalkyl)-3-sulfonylazaindoles as 5-hydroxytryptamine-6 ligands.

[26] International Patent Publication No. WO 02/096909 describes optical resolution of (1-benzyl-4-methylpiperidin-3-yl)-methylamine and the use thereof for the preparation of pyrrolo 2,3-pyrimidine derivatives as protein kinase inhibitors. International Patent Publication No. WO02/50306 describes processes for determining the biological

activity of epidermal growth factor receptor tyrosine kinase inhibitors. International Patent Publication No. WO02/41882 describes combination comprising an agent decreasing VEGF activity and an agent decreasing EGF activity.

[27] International Patent Publication No. WO 03/000187 describes novel pyrazolo- and pyrrolo-pyrimidines. International Patent Publication No. WO 02/057267, U.S. Patent Nos. 6,686,366, 6,680,324, and 6,673,802 describe compounds specific to adenosine A1, A2A, and A3 receptors. International Patent Publication No. WO 01/47507 describes combinations of a receptor tyrosine kinase inhibitor with an organic compound capable of binding to α 1-acidic glycoprotein. International Patent Publication No. WO 04/013141 describes condensed pyridines and pyrimidines with TIE2 (TEK) activity. International Patent Publication No. WO 04/014850 describes substituted aminopyrimidines as neurokinin antagonists.


[28] International Patent Publication No. WO 03/000695 describes pyrrolopyrimidines as protein kinase inhibitors. U.S. Patent No. 6,187,778 describes 4-aminopyrrole (3,4-d) pyrimidines as neuropeptide Y receptor antagonists. U.S. Patent No. 6,140,317, 6,140,332, and 6,180,636 describe pyrrolopyrimidines. U.S. Patent Nos. 6,696,455, 6,537,999 and 5,877,178 describe pyrimidine derivatives. U.S. Patent No. 5,958,930 describes pyrrolo pyrimidine and furo pyrimidine derivatives.

[29] International Patent Publication No. 03/000688 describes the preparation of azaindoles as protein kinase inhibitors. International Patent Publication Nos. WO 03/018021 and WO 03/018022 describe pyrimidines for treating IGF-1R related disorders, International Patent Publication No. WO 02/092599 describes pyrrolopyrimidines for the treatment of a disease that responds to an inhibition of the IGF-1R tyrosine kinase, International Patent Publication No. WO 01/72751 describes pyrrolopyrimidines as tyrosine kinase inhibitors. International Patent Publication No. WO 00/71129 describes pyrrolotriazine inhibitors of kinases. International Patent Publication No. WO 97/28161 describes pyrrolo[2,3-d]pyrimidines and their use as tyrosine kinase inhibitors.

[30] Although the anticancer compounds described above have made a significant contribution to the art, there is a continuing need to improve anticancer pharmaceuticals with better selectivity or potency, reduced toxicity, or fewer side effects.

SUMMARY OF THE INVENTION

[31] Compounds represented by Formula (I):




(I)

or stereoisomers or pharmaceutically acceptable salts thereof, are inhibitors of least two of the Abl, Aurora-A, Blk, c-Raf, cSRC, Src, PRK2, FGFR3, Flt3, Lck, Mek1, PDK-1, GSK3 β , EGFR, p70S6K, BMX, SGK, CaMKII, Tie-2, Ret, Ron, IGF-1R, and KDR kinases in animals, including humans, for the treatment and/or prevention of various diseases and conditions such as cancer

DETAILED DESCRIPTION OF THE INVENTION



[32] The present invention relates to compounds of Formula I:




(I)


[33] or a pharmaceutically acceptable salt thereof, wherein

[34] X is N or C-CN;



[36] Z is hetaryl, -C₁₋₆alkyl-O-C₁₋₆alkyl-, -C₀₋₆alkyl-(heterocyclyl), -C₀₋₆alkyl-(hetaryl), -C(O)-C₀₋₆alkyl, -C(O)-C₀₋₆alkyl-O-C₀₋₆alkyl, -C(O)-C₀₋₆alkyl-O-C₁₋₆alkyl-O-C₀₋₆alkyl, -C(O)-C₀₋₆alkyl-N(C₀₋₆alkyl)(C₀₋₆alkyl), -C(O)-C₀₋₆alkyl-(heterocyclyl), -C(O)-C₀₋₆alkyl-(heterocyclyl)-C(O)-C₀₋₆alkyl, -C(O)-C₀₋₆alkyl- (hetaryl), -S(O)₂-C₀₋₆alkyl, -S(O)₂-N(C₀₋₆alkyl)(C₀₋₆alkyl), or -S(O)₂-(hetaryl), wherein any of the alkyl, heterocyclyl, or hetaryl optionally is substituted with 1-6 independent halo, OH, -C₀₋₆alkyl-O-C₀₋₆alkyl, -C₀₋₆alkyl-N(C₀₋₆alkyl)(C₀₋₆alkyl), -C(O)-C₀₋₆alkyl-N(C₀₋₆alkyl)(C₀₋₆alkyl), -C(O)-C₀₋₆alkyl-(heterocyclyl), or -C₀₋₆alkyl;






in which the wavy bond is the point of attachment, and wherein the piperazine or morpholine moieties are optionally substituted with 1-6 independent C_{0-6} alkyl groups;

[38] Y is $-C(C_{0-6}alkyl)(C_{0-6}alkyl)-$, $-N(C_{0-6}alkyl)-$, $-N(C_{0-6}alkyl)-C_{1-6}alkyl-$, O, S, $>N-C_{2-6}alkyl-N-(C_{0-6}alkyl)(C_{0-6}alkyl)$, $>N-C_{2-6}alkyl-O-C_{0-6}alkyl$, $>N-C_{1-6}alkyl-C(O)-NH-C_{0-6}alkyl$, or $>N-C_{2-6}alkyl-N-C(O)-C_{1-6}alkyl$; and

















[39] R1 is aryl, hetaryl, or heterocyclyl, optionally substituted with 1-6 independent halo, $-CN$, $-OH$, $-C_{0-6}alkyl$, $-C_{3-10}cycloalkyl$, $-haloC_{1-6}alkyl$, $-C_{2-6}alkynyl$, $-N(C_{0-6}alkyl)(C_{0-6}alkyl)$, $-C(O)-C_{0-6}alkyl-N(C_{0-6}alkyl)(C_{0-6}alkyl)$, $-C(O)-C_{0-6}alkyl-(heterocyclyl)$, $-C_{1-6}alkyl-C(O)-C_{0-6}alkyl-N(C_{0-6}alkyl)(C_{0-6}alkyl)$, $-O-C_{0-6}alkyl-(heterocyclyl)$, $-C_{0-6}alkyl-O-C_{0-6}alkyl$, $-C_{0-6}alkyl-N(C_{0-6}alkyl)(C_{0-6}alkyl)$, $-O-C_{0-6}alkyl-(hetaryl)$, $-S(O)_2-N(C_{0-6}alkyl)(C_{0-6}alkyl)$, aryl, hetaryl, or heterocyclyl substituents, or substituted with an oxo ($=O$) using a bond from the aryl, hetaryl, or heterocyclyl ring, wherein any of the substituents optionally is substituted with 1-6 independent halo, CN, OH, $-C_{0-6}alkyl-O-C_{0-6}alkyl$, $-C_{0-6}alkyl-N(C_{0-6}alkyl)(C_{0-6}alkyl)$, $-C(O)-C_{0-6}alkyl-N(C_{0-6}alkyl)(C_{0-6}alkyl)$, $-C(O)-C_{0-6}alkyl-(heterocyclyl)$, or $C_{0-6}alkyl$.


[40] It is preferred that X is N.


[41] It is preferred that Cy is .

[42] It is preferred that Y is $-N(C_{0-6}alkyl)-$.


[43] Examples of R1 include, but are not limited to, the following groups, wherein the wavy bond is connected to Y:


			
			
			
			







[44] Examples of Z include, but are not limited to, the following groups, wherein the dotted line is connected to Cy:








[47] In an embodiment of the first aspect, the present invention is directed to a compound represented by Formula (I), or a stereoisomer, or a pharmaceutically acceptable

salt thereof, wherein X is N, Cy is , and the other variables are as described above.


[48] In another embodiment of the first aspect, the present invention is directed to a compound represented by Formula (I), or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein X is N, Y is $-N(C_{0-6}\text{alkyl})-$, and the other variables are as described above.


[49] In a second aspect, the present invention is directed to a compound represented by:










or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein R2 is $-C_{0-6}\text{alkyl}$, $-C_{2-6}\text{alkyl}-N-(C_{0-6}\text{alkyl})(C_{0-6}\text{alkyl})$, $-C_{2-6}\text{alkyl}-O-C_{0-6}\text{alkyl}$, $-C_{1-6}\text{alkyl}-C(O)-NH-C_{0-6}\text{alkyl}$, or $-C_{2-6}\text{alkyl}-N-C(O)-C_{1-6}\text{alkyl}$; and the other variables are as described above for Formula (I).


[50] In an embodiment of the second aspect, the present invention is directed to a compound represented by:




or a stereoisomer, or a pharmaceutically acceptable salt thereof wherein  is selected from the following table:










or a stereoisomer, or a pharmaceutically acceptable salt thereof.

[51] In a third aspect, the present invention is directed to a compound represented by:




or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein R2 is $-C_{0-6}$ alkyl, $-C_{2-6}$ alkyl-N-(C_{0-6} alkyl)(C_{0-6} alkyl), $-C_{2-6}$ alkyl-O- C_{0-6} alkyl, $-C_{1-6}$ alkyl-C(O)-NH- C_{0-6} alkyl, or $-C_{2-6}$ alkyl-N-C(O)- C_{1-6} alkyl; and the other variables are as described above for Formula (I).


[52] In an embodiment of the third aspect, the present invention is directed to a compound represented by:




wherein

is selected from the following table:











or a stereoisomer, or a pharmaceutically acceptable salt thereof.

[53] In a fourth aspect, the present invention is directed to a compound represented by Formula (I), or a stereoisomer, or a pharmaceutically acceptable salt thereof,

wherein Y-R1 is , , or  and the other variables are as described above.



















[54] In a fifth aspect, the present invention is directed to a compound represented by Formula (I), or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein X is C-CN and the other variables are as described above.


[55] In an embodiment of the fifth aspect, the present invention is directed to a compound represented by Formula (I), or a stereoisomer, or a pharmaceutically acceptable


salt thereof, wherein X is C-CN, Cy is , and the other variables are as described above.


[56] In another embodiment of the fifth aspect, the present invention is directed to a compound represented by Formula (I), or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein X is C-CN, Y is -N(C₀₋₆alkyl)-, and the other variables are as described above.


[57] The compounds of the present invention include


		
		
		
		
		
		
































[58] While the preferred groups for each variable have generally been listed above separately for each variable, preferred compounds of this invention include those in which several or each variable in Formula (I) is selected from the preferred, more preferred, most

preferred, especially or particularly listed groups for each variable. Therefore, this invention is intended to include all combinations of preferred, more preferred, most preferred, especially and particularly listed groups.

- [59] The compounds of the present invention include:
- [60] 4-[4-(4-Fluoro-3-thiazol-5-ylphenylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl ester;
- [61] 4-[4-(4-Fluoro-3-thiazol-5-ylphenylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butylamide;
- [62] 4-{4-[4-Fluoro-3-(1H-imidazol-2-yl)-phenylamino]-7H-pyrrolo[2,3-d]-pyrimidin-6-yl}-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl ester;
- [63] 4-{4-[4-Fluoro-3-(1H-imidazol-2-yl)-phenylamino]-7H-pyrrolo[2,3-d]-pyrimidin-6-yl}-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butylamide;
- [64] 4-[4-(4-Fluoro-3-imidazol-1-ylphenylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl ester;
- [65] 4-[4-(4-Fluoro-3-imidazol-1-ylphenylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butylamide;
- [66] 4-{4-[4-Fluoro-3-(4-methylpiperazin-1-yl)-phenylamino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl}-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl ester;
- [67] 4-{4-[4-Fluoro-3-(4-methylpiperazin-1-yl)-phenylamino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl}-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butylamide;
- [68] 4-{4-[4-Fluoro-3-(1-methylazetidin-3-ylmethyl)-phenylamino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl}-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl ester;
- [69] 4-{4-[4-Fluoro-3-(1-methylazetidin-3-ylmethyl)-phenylamino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl}-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butylamide;
- [70] 4-{4-[4-Fluoro-3-(1-methylazetidin-3-yloxy)-phenylamino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl}-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl ester;
- [71] 4-{4-[4-Fluoro-3-(1-methylazetidin-3-yloxy)-phenylamino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl}-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl ester;
- [72] 4-{4-[4-Fluoro-3-(4-methylpiperazin-1-ylmethyl)-phenylamino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl}-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl ester;
- [73] 4-{4-[4-Fluoro-3-(4-methylpiperazin-1-ylmethyl)-phenylamino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl}-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butylamide;
- [74] 4-{4-[4-Fluoro-3-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-phenylamino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl}-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl ester;
- [75] 4-{4-[4-Fluoro-3-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-phenylamino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl}-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl amide;

- [76] 4-{4-[4-Fluoro-3-(1-methyl-2,5-dihydro-1*H*-pyrrol-3-yl)-phenylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester;
- [77] 4-{4-[4-Fluoro-3-(1-methyl-2,5-dihydro-1*H*-pyrrol-3-yl)-phenylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl amide;
- [78] (*S*)-4-{4-[4-Fluoro-3-(1-methylpyrrolidin-3-yl)-phenylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester;
- [79] (*S*)-4-{4-[4-Fluoro-3-(1-methylpyrrolidin-3-yl)-phenylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl amide;
- [80] (*R*)-4-{4-[4-Fluoro-3-(1-methylpyrrolidin-3-yl)-phenylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester;
- [81] (*R*)-4-{4-[4-Fluoro-3-(1-methylpyrrolidin-3-yl)-phenylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl amide;
- [82] {4-[4-(Benzothiazol-6-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridin-1-yl}-(2,2,4-trimethylpiperazin-1-yl)-methanone;
- [83] {4-[4-(Benzothiazol-6-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridin-1-yl}-(2,4,5-trimethylpiperazin-1-yl)-methanone;
- [84] {4-[4-(Benzothiazol-6-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridin-1-yl}-(3,4,5-trimethylpiperazin-1-yl)-methanone;
- [85] {4-[4-(Benzothiazol-6-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridin-1-yl}-[4-(2,2,2-trifluoroethyl)-piperazin-1-yl]-methanone;
- [86] {4-[4-(Benzothiazol-6-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridin-1-yl}-(4-*tert*-butylpiperazin-1-yl)-methanone;
- [87] Benzothiazol-6-yl-[6-(3,6-dihydro-2*H*-[1,2']bipyridinyl-4-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl]-amine;
- [88] Benzothiazol-6-yl-[6-(1-thiazol-2-yl-1,2,3,6-tetrahydropyridin-4-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl]-amine;
- [89] Benzothiazol-6-yl-[6-(1-oxazol-2-yl-1,2,3,6-tetrahydropyridin-4-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl]-amine;
- [90] 4-[4-(3-Phenyl-3*H*-benzimidazol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester;
- [91] 4-[4-(3-Phenyl-3*H*-benzimidazol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butylamide;
- [92] 4-{4-[3-(2-Carbamoylphenyl)-3*H*-benzimidazol-5-ylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butylamide;
- [93] 4-{4-[3-(2-Carbamoylphenyl)-3*H*-benzimidazol-5-ylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester;

- [94] 4-{4-[3-(2-Aminoethyl)-3*H*-benzimidazol-5-ylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butylamide;
- [95] 4-{4-[3-(2-Aminoethyl)-3*H*-benzimidazol-5-ylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester;
- [96] 4-{4-[3-(2-Dimethylaminoethyl)-3*H*-benzimidazol-5-ylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butylamide;
- [97] 4-{4-[3-(2-Dimethylaminoethyl)-3*H*-benzimidazol-5-ylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester;
- [98] 4-{4-[3-(2-Acetylaminoethyl)-3*H*-benzimidazol-5-ylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butylamide;
- [99] 4-{4-[3-(2-Acetylaminoethyl)-3*H*-benzimidazol-5-ylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester;
- [100] 4-[4-(Imidazo[1,2-*a*]pyridin-6-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butylamide;
- [101] 4-[4-(Imidazo[1,2-*a*]pyridin-6-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester;
- [102] 4-[4-(3-Methylimidazo[1,2-*a*]pyridin-6-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butylamide;
- [103] 4-[4-(3-Methylimidazo[1,2-*a*]pyridin-6-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester;
- [104] 4-[4-(3-Phenylimidazo[1,2-*a*]pyridin-6-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butylamide;
- [105] 4-[4-(3-Phenylimidazo[1,2-*a*]pyridin-6-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester;
- [106] 4-{4-[3-(2-Carbamoylphenyl)-imidazo[1,2-*a*]pyridin-6-ylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butylamide;
- [107] 4-{4-[3-(2-Carbamoylphenyl)-imidazo[1,2-*a*]pyridin-6-ylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester;
- [108] 4-{4-[3-(2-Dimethylaminoethyl)-imidazo[1,2-*a*]pyridin-6-ylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butylamide;
- [109] 4-{4-[3-(2-Dimethylaminoethyl)-imidazo[1,2-*a*]pyridin-6-ylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester;
- [110] 4-{4-[3-(2-Acetylaminoethyl)-imidazo[1,2-*a*]pyridin-6-ylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butylamide;
- [111] 4-{4-[3-(2-Acetylaminoethyl)-imidazo[1,2-*a*]pyridin-6-ylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester;

- [112] 4-[4-(3-Dimethylaminomethylimidazo[1,2-*a*]pyridin-6-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butylamide;
- [113] 4-[4-(3-Dimethylaminomethylimidazo[1,2-*a*]pyridin-6-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester;
- [114] 4-[4-(7-Aminomethyl-1*H*-indazol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butylamide;
- [115] 4-[4-(7-Aminomethyl-1*H*-indazol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester;
- [116] 4-[4-(7-Aminomethyl-1-methyl-1*H*-indazol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butylamide;
- [117] 4-[4-(7-Aminomethyl-1-methyl-1*H*-indazol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester;
- [118] 4-[4-(7-Dimethylaminomethyl-1-methyl-1*H*-indazol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butylamide;
- [119] 4-[4-(7-Dimethylaminomethyl-1-methyl-1*H*-indazol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester;
- [120] 4-[4-(7-Dimethylaminomethyl-1*H*-indazol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butylamide;
- [121] 4-[4-(7-Dimethylaminomethyl-1*H*-indazol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester;
- [122] 4-{4-[7-(2-Dimethylaminoethyl)-1*H*-indazol-5-ylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butylamide;
- [123] 4-{4-[7-(2-Dimethylaminoethyl)-1*H*-indazol-5-ylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester;
- [124] 4-{4-[7-(2-Dimethylaminoethyl)-1-methyl-1*H*-indazol-5-ylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butylamide;
- [125] 4-{4-[7-(2-Dimethylaminoethyl)-1-methyl-1*H*-indazol-5-ylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester;
- [126] 4-[4-(Imidazo[1,5-*a*]pyridin-6-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butylamide;
- [127] 4-[4-(Imidazo[1,5-*a*]pyridin-6-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester;
- [128] 4-[4-(3-Methylimidazo[1,5-*a*]pyridin-6-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butylamide;
- [129] 4-[4-(3-Methylimidazo[1,5-*a*]pyridin-6-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester;

- [130] 4-[4-(1-Methylimidazo[1,5-*a*]pyridin-6-ylamino)-7*H*-pyrrolo[2,3-*d*]-pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butylamide;
- [131] 4-[4-(1-Methylimidazo[1,5-*a*]pyridin-6-ylamino)-7*H*-pyrrolo[2,3-*d*]-pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester;
- [132] 4-[4-(Imidazo[1,5-*a*]pyridin-7-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butylamide;
- [133] 4-[4-(Imidazo[1,5-*a*]pyridin-7-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester;
- [134] 4-[4-(3-Methylimidazo[1,5-*a*]pyridin-7-ylamino)-7*H*-pyrrolo[2,3-*d*]-pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butylamide;
- [135] 4-[4-(3-Methylimidazo[1,5-*a*]pyridin-7-ylamino)-7*H*-pyrrolo[2,3-*d*]-pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester;
- [136] 4-[4-(1-Methylimidazo[1,5-*a*]pyridin-7-ylamino)-7*H*-pyrrolo[2,3-*d*]-pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butylamide;
- [137] 4-[4-(1-Methylimidazo[1,5-*a*]pyridin-7-ylamino)-7*H*-pyrrolo[2,3-*d*]-pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester;
- [138] 4-[4-(Benzothiazol-6-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid (2-hydroxy-1,1-dimethylethyl)-amide;
- [139] 4-[4-(1-Methyl-1*H*-indazol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid (2-hydroxy-1,1-dimethylethyl)-amide;
- [140] 4-[4-(Benzothiazol-6-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid (2-methoxy-1,1-dimethylethyl)-amide;
- [141] 4-[4-(1-Methyl-1*H*-indazol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid (2-methoxy-1,1-dimethylethyl)-amide;
- [142] 4-[4-(Benzothiazol-6-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid (2-dimethylamino-1,1-dimethylethyl)-amide;
- [143] 4-[4-(1-Methyl-1*H*-indazol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid (2-dimethylamino-1,1-dimethylethyl)-amide;
- [144] 4-[4-(Benzothiazol-6-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid (1,1-dimethyl-2-pyrrolidin-1-ylethyl)-amide;
- [145] 4-[4-(1-Methyl-1*H*-indazol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid (1,1-dimethyl-2-pyrrolidin-1-ylethyl)-amide;
- [146] 4-[4-(Benzothiazol-6-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid (1,1-dimethyl-2-morpholin-4-ylethyl)-amide;
- [147] 4-[4-(1-Methyl-1*H*-indazol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid (1,1-dimethyl-2-morpholin-4-ylethyl)-amide;

- [148] 4-[4-(1*H*-Indol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butylamide;
- [149] 4-[4-(Quinolin-6-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butylamide;
- [150] (Hexahydropyrrolo[1,2-*a*]pyrazin-2-yl)-{4-[4-(imidazo[1,2-*a*]pyridin-6-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridin-1-yl}-methanone;
- [151] (Hexahydropyrrolo[1,2-*a*]pyrazin-2-yl)-{4-[4-(3-methyl-3*H*-benzoimidazol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridin-1-yl}-methanone;
- [152] (Hexahydropyrrolo[1,2-*a*]pyrazin-2-yl)-{4-[4-(1-methyl-1*H*-indazol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridin-1-yl}-methanone;
- [153] {4-[4-(Benzothiazol-6-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridin-1-yl}-(hexahydropyrrolo[1,2-*a*]pyrazin-2-yl)-methanone.
- [154] As used herein, unless stated otherwise, “alkyl” as well as other groups having the prefix “alk” such as, for example, alkoxy, alkanyl, alkenyl, alkynyl, and the like, means carbon chains which may be linear or branched or combinations thereof. Examples of alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, sec- and tert-butyl, pentyl, hexyl, heptyl and the like. “Alkenyl”, “alkynyl” and other like terms include carbon chains having at least one unsaturated carbon-carbon bond.
- [155] As used herein, for example, “C₀₋₄alkyl” is used to mean an alkyl having 0-4 carbons – that is, 0, 1, 2, 3, or 4 carbons in a straight or branched configuration. An alkyl having no carbon is hydrogen when the alkyl is a terminal group. An alkyl having no carbon is a direct bond when the alkyl is a bridging (connecting) group.
- [156] As used herein, the “>” symbol in front of a nitrogen atom refers to two bonds not to the same atom (not a double bond to the nitrogen).
- [157] The terms “cycloalkyl” and “carbocyclic ring” mean carbocycles containing no heteroatoms, and include mono-, bi-, and tricyclic saturated carbocycles, as well as fused and bridged systems. Such fused ring systems can include one ring that is partially or fully unsaturated, such as a benzene ring, to form fused ring systems, such as benzofused carbocycles. Cycloalkyl includes such fused ring systems as spirofused ring systems. Examples of cycloalkyl and carbocyclic rings include C3-10cycloalkyl groups, particularly C3-8cycloalkyl groups, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and decahydronaphthalene, adamantane, indanyl, 1,2,3,4-tetrahydronaphthalene and the like.
- [158] The term “halogen” includes fluorine, chlorine, bromine, and iodine atoms.
- [159] The term “carbamoyl” unless specifically described otherwise means -C(O)-NH- or -NH-C(O)-.
- [160] The term “aryl” is well known to chemists. The preferred aryl groups are phenyl and naphthyl, more preferably phenyl.

[161] The term “hetaryl” is well known to chemists. The term includes 5- or 6-membered heteroaryl rings containing 1–4 heteroatoms chosen from oxygen, sulfur, and nitrogen in which oxygen and sulfur are not next to each other. Examples of such heteroaryl rings are furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, and triazinyl. The term “hetaryl” includes hetaryl rings with fused carbocyclic ring systems that are partially or fully unsaturated, such as a benzene ring, to form a benzofused hetaryl. For example, benzimidazole, benzoxazole, benzothiazole, benzofuran, quinoline, isoquinoline, quinoxaline, and the like. The term “hetaryl” also includes fused 5-6, 5-5, 6-6 ring systems, optionally possessing one nitrogen atom at a ring junction. Examples of such hetaryl rings include, but are not limited to, pyrrolopyrimidinyl, imidazo[1,2-*a*]pyridinyl, imidazo[2,1-*b*]thiazolyl, imidazo[4,5-*b*]pyridine, pyrrolo[2,1-*f*][1,2,4]triazinyl, and the like. Hetaryl groups may be attached to other groups through their carbon atoms or the heteroatom(s), if applicable. For example, pyrrole may be connected at the nitrogen atom or at any of the carbon atoms.

[162] Unless otherwise stated, the terms “heterocyclic ring”, “heterocyclyl” and “heterocycle” are equivalent, and include 4–10-membered, e.g. 5-membered, saturated or partially saturated rings containing 1–4 heteroatoms chosen from oxygen, sulfur, and nitrogen. The sulfur and oxygen heteroatoms are not directly attached to one another. Any nitrogen heteroatoms in the ring may optionally be substituted with C₁₋₄alkyl. Examples of heterocyclic rings include azetidine, oxetane, tetrahydrofuran, tetrahydropyran, oxepane, oxocane, thietane, thiazolidine, oxazolidine, oxazetidine, pyrazolidine, isoxazolidine, isothiazolidine, tetrahydrothiophene, tetrahydrothiopyran, thiepane, thiocane, azetidine, pyrrolidine, piperidine, N-methylpiperidine, azepane, 1,4-diazapane, azocane, [1,3]dioxane, oxazolidine, piperazine, homopiperazine, morpholine, thiomorpholine, 1,2,3,6-tetrahydropyridine and the like. Other examples of heterocyclic rings include the oxidized forms of the sulfur-containing rings. Thus, tetrahydrothiophene-1-oxide, tetrahydrothiophene-1,1-dioxide, thiomorpholine-1-oxide, thiomorpholine-1,1-dioxide, tetrahydrothiopyran-1-oxide, tetrahydrothiopyran-1,1-dioxide, thiazolidine-1-oxide, and thiazolidine-1,1-dioxide are also considered to be heterocyclic rings. The term “heterocyclic” also includes fused ring systems and can include a carbocyclic ring that is partially or fully unsaturated, such as a benzene ring, to form benzofused heterocycles. For example, 3,4-dihydro-1,4-benzodioxine, tetrahydroquinoline, tetrahydroisoquinoline and the like.

[163] Compounds described herein may contain one or more asymmetric centers and may thus give rise to diastereomers and optical isomers. The present invention includes all such possible diastereomers as well as their racemic mixtures, their substantially pure resolved enantiomers, all possible geometric isomers, and pharmaceutically acceptable salts

thereof. The above Formula (I) is shown without a definitive stereochemistry at certain positions. The present invention includes all stereoisomers of Formula (I) and pharmaceutically acceptable salts thereof. Further, mixtures of stereoisomers as well as isolated specific stereoisomers are also included. During the course of the synthetic procedures used to prepare such compounds, or in using racemization or epimerization procedures known to those skilled in the art, the products of such procedures can be a mixture of stereoisomers.

[164] When a tautomer of the compound of Formula (I) exists, the present invention includes any possible tautomers and pharmaceutically acceptable salts thereof, and mixtures thereof, except where specifically stated otherwise.

[165] When the compound of Formula (I) and pharmaceutically acceptable salts thereof exist in the form of solvates or polymorphic forms, the present invention includes any possible solvates and polymorphic forms. A type of a solvent that forms the solvate is not particularly limited so long as the solvent is pharmacologically acceptable. For example, water, ethanol, propanol, acetone or the like can be used.

[166] The invention also encompasses a pharmaceutical composition that is comprised of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier.

[167] Preferably the composition is comprised of a pharmaceutically acceptable carrier and a non-toxic therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[168] Moreover, within this preferred embodiment, the invention encompasses a pharmaceutical composition for the treatment of disease by inhibiting glycogen phosphorylase, resulting in the prophylactic or therapeutic treatment of diabetes, hyperglycemia, hypercholesterolemia, hyperinsulinemia, hyperlipidemia, hypertension, atherosclerosis or tissue ischemia e.g. myocardial ischemia comprising a pharmaceutically acceptable carrier and a non-toxic therapeutically effective amount of compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[169] The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids. When the compound of the present invention is acidic, its corresponding salt can be conveniently prepared from pharmaceutically acceptable non-toxic bases, including inorganic bases and organic bases. Salts derived from such inorganic bases include aluminum, ammonium, calcium, copper (ic and ous), ferric, ferrous, lithium, magnesium, potassium, sodium, zinc and the like salts. Particularly preferred are the ammonium, calcium, magnesium, potassium and sodium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, as well as cyclic amines and substituted amines such as

naturally occurring and synthesized substituted amines. Other pharmaceutically acceptable organic non-toxic bases from which salts can be formed include arginine, betaine, caffeine, choline, N'N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine and the like.

[170] When the compound of the present invention is basic, its corresponding salt can be conveniently prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids. Such acids include, for example, acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pantoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid and the like. Particularly preferred are citric, hydrobromic, hydrochloric, maleic, phosphoric, sulfuric, and tartaric acids.

[171] Since the compounds of Formula (I) are intended for pharmaceutical use they are preferably provided in substantially pure form, for example at least 60% pure, more suitably at least 75% pure especially at least 98% pure (% are on a weight for weight basis).

[172] The pharmaceutical compositions of the present invention comprise a compound represented by Formula (I), or a pharmaceutically acceptable salt thereof, as an active ingredient, a pharmaceutically acceptable carrier and optionally other therapeutic ingredients or adjuvants. The compositions include those suitable for oral, rectal, topical, and parenteral (including subcutaneous, intramuscular, and intravenous) administration, although the most suitable route in any given case will depend on the particular host, and nature and severity of the conditions for which the active ingredient is being administered. The compositions are preferably suitable for oral administration. The pharmaceutical compositions may be conveniently presented in unit dosage form and prepared by any of the methods well known in the art of pharmacy.

[173] In practice, the compounds of Formula (I), or pharmaceutically acceptable salts thereof, can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g. oral or parenteral (including intravenous). Thus, the pharmaceutical compositions of the present invention can be presented as discrete units suitable for oral administration such as capsules, sachets or tablets each containing a predetermined amount of the active ingredient. Further, the compositions can be presented as a powder, as granules, as a solution, as a suspension in an aqueous liquid, as a non-aqueous liquid, as an oil-in-water

emulsion, or as a water-in-oil liquid emulsion. In addition to the common dosage forms set out above, the compounds of Formula (I), or pharmaceutically acceptable salts thereof, may also be administered by controlled release means and/or delivery devices. The compositions may be prepared by any of the methods of pharmacy. In general, such methods include a step of bringing into association the active ingredient with the carrier that constitutes one or more necessary ingredients. In general, the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both. The product can then be conveniently shaped into the desired presentation.

[174] Thus, the pharmaceutical compositions of this invention may include a pharmaceutically acceptable carrier and a compound of Formula (I) or a pharmaceutically acceptable salt thereof. The compounds of Formula (I), or pharmaceutically acceptable salts thereof, can also be included in pharmaceutical compositions in combination with one or more other therapeutically active compounds.

[175] The pharmaceutical carrier employed can be, for example, a solid, liquid, or gas. Examples of solid carriers include lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, and stearic acid. Examples of liquid carriers are sugar syrup, peanut oil, olive oil, and water. Examples of gaseous carriers include carbon dioxide and nitrogen.

[176] In preparing the compositions for oral dosage form, any convenient pharmaceutical media may be employed. For example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, and the like may be used to form oral liquid preparations such as suspensions, elixirs and solutions; while carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like may be used to form oral solid preparations such as powders, capsules and tablets. Because of their ease of administration, tablets and capsules are the preferred oral dosage units whereby solid pharmaceutical carriers are employed. Optionally, tablets may be coated by standard aqueous or nonaqueous techniques.

[177] A tablet containing the composition of this invention may be prepared by compression or molding, optionally with one or more accessory ingredients or adjuvants. Compressed tablets may be prepared by compressing, in a suitable machine, the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent. Each tablet preferably contains from about 0.05mg to about 5g of the active ingredient and each sachet or capsule preferably contains from about 0.05mg to about 5g of the active ingredient.

[178] For example, a formulation intended for oral administration to humans may contain from about 0.5mg to about 5g of active agent, compounded with an appropriate and convenient amount of carrier material, which may vary from about 5 to about 95% of the total composition. Unit dosage forms will generally contain from about 1mg to about 2g of the active ingredient, typically 25mg, 50mg, 100mg, 200mg, 300mg, 400mg, 500mg, 600mg, 800mg, or 1000mg.

[179] Pharmaceutical compositions of the present invention suitable for parenteral administration may be prepared as solutions or suspensions of the active compounds in water. A suitable surfactant can be included such as, for example, hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils. Further, a preservative can be included to prevent the detrimental growth of microorganisms.

[180] Pharmaceutical compositions of the present invention suitable for injectable use include sterile aqueous solutions or dispersions. Furthermore, the compositions can be in the form of sterile powders for the extemporaneous preparation of such sterile injectable solutions or dispersions. In all cases, the final injectable form must be sterile and must be effectively fluid for easy syringability. The pharmaceutical compositions must be stable under the conditions of manufacture and storage; thus, preferably should be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g. glycerol, propylene glycol and liquid polyethylene glycol), vegetable oils, and suitable mixtures thereof.

[181] Pharmaceutical compositions of the present invention can be in a form suitable for topical use such as, for example, an aerosol, cream, ointment, lotion, dusting powder, or the like. Further, the compositions can be in a form suitable for use in transdermal devices. These formulations may be prepared, utilizing a compound of Formula (I), or a pharmaceutically acceptable salt thereof, via conventional processing methods. As an example, a cream or ointment is prepared by admixing hydrophilic material and water, together with about 5wt% to about 10wt% of the compound, to produce a cream or ointment having a desired consistency.

[182] Pharmaceutical compositions of this invention can be in a form suitable for rectal administration wherein the carrier is a solid. It is preferable that the mixture forms unit dose suppositories. Suitable carriers include cocoa butter and other materials commonly used in the art. The suppositories may be conveniently formed by first admixing the composition with the softened or melted carrier(s) followed by chilling and shaping in molds.

[183] In addition to the aforementioned carrier ingredients, the pharmaceutical formulations described above may include, as appropriate, one or more additional carrier

ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including anti-oxidants) and the like. Furthermore, other adjuvants can be included to render the formulation isotonic with the blood of the intended recipient. Compositions containing a compound of Formula (I), or a pharmaceutically acceptable salt thereof, may also be prepared in powder or liquid concentrate form.

[184] Generally, dosage levels on the order of 0.01mg/kg to about 150mg/kg of body weight per day are useful in the treatment of the above-indicated conditions, or alternatively about 0.5mg to about 7g per patient per day. For example, lung cancer may be effectively treated by the administration of from about 0.01 to 50mg of the compound per kilogram of body weight per day, or alternatively about 0.5mg to about 3.5g per patient per day. Similarly, breast cancer may be effectively treated by the administration of from about 0.01 to 50mg of the compound per kilogram of body weight per day, or alternatively about 0.5mg to about 3.5g per patient per day.

[185] It is understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing therapy.

[186] The compounds of Formula (I) and pharmaceutically acceptable salts thereof, may be used in the treatment of diseases or conditions in which the Abl, Aurora-A, Blk, c-Raf, cSRC, Src, PRK2, FGFR3, Flt3, Lck, Mek1, PDK-1, GSK3 β , EGFR, p70S6K, BMX, SGK, CaMKII, Tie-2, Ret, Ron, IGF-1R, or KDR kinases plays a role.

[187] Thus the invention also provides a method for the treatment of a disease or condition in which the Abl, Aurora-A, Blk, c-Raf, cSRC, Src, PRK2, FGFR3, Flt3, Lck, Mek1, PDK-1, GSK3 β , EGFR, p70S6K, BMX, SGK, CaMKII, Tie-2, Ret, Ron, IGF-1R, or KDR kinases plays a role comprising a step of administering to a subject in need thereof an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[188] Diseases or conditions in which the Abl, Aurora-A, Blk, c-Raf, cSRC, Src, PRK2, FGFR3, Flt3, Lck, Mek1, PDK-1, GSK3 β , EGFR, p70S6K, BMX, SGK, CaMKII, Tie-2, Ret, Ron, IGF-1R, or KDR kinases plays a role include lung, breast, prostate, pancreatic, head and neck cancers, as well as leukemia.

[189] The invention also provides a method for the treatment of cancers of the lung, breast, prostate, pancreas, head, neck or blood comprising a step of administering to a subject in need thereof an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[190] The invention also provides a method for the treatment of lung cancer, breast cancer, prostate cancer, pancreatic cancer, head cancer, neck cancer, or leukemia in a human

demonstrating such cancers comprising a step of administering to a subject in need thereof an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[191] The invention also provides a method for the treatment of cancers of the lung, breast, prostate, pancreas, head, neck, or blood comprising a step of administering to a patient in need thereof an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[192] The invention also provides the use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in the treatment of a condition as defined above.

[193] The invention also provides the use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a condition as defined above.

[194] In the methods of the invention the term "treatment" includes both therapeutic and prophylactic treatment.

[195] The compounds of Formula (I), or pharmaceutically acceptable salts thereof, may be administered alone or in combination with one or more other therapeutically active compounds. The other therapeutically active compounds may be for the treatment of the same disease or condition as the compounds of Formula (I) or a different disease or condition. The therapeutically active compounds may be administered simultaneously, sequentially or separately.

[196] The compounds of Formula (I) may be administered with other active compounds for the treatment of cancers of the lung, breast, prostate, pancreas, head, neck, or blood - for example AVASTIN, IRESSA, TARCEVA, ERBITUX, or cisplatin.

[197] The compounds of Formula (I) may also be administered in combination with AVASTIN, IRESSA, TARCEVA, ERBITUX, or cisplatin.

[198] The compounds of Formula (I) may exhibit advantageous properties compared to known kinase inhibitors, for example, the compounds may exhibit improved solubility thus improving absorption properties and bioavailability. Furthermore the compounds of Formula (I) may exhibit further advantageous properties such as reduced inhibition of cytochrome P450 enzymes, meaning that they are less likely to cause adverse drug-drug interactions than known kinase inhibitors.

EXPERIMENTAL

[199] Scheme 1 – Scheme 5, the **EXAMPLES**, and **INTERMEDIATES** serve to demonstrate how to synthesize compounds of this invention, but in no way limit the invention.


[200] The following abbreviations are used:

NMR Nuclear magnetic resonance



LC/MS Liquid chromatography mass spectrometry

LDA	Lithium diisopropylamide
DCM	Dichloromethane
THF	Tetrahydrofuran
MeCN	Acetonitrile
DMSO	Dimethylsulfoxide
BOC or Boc	t-butyloxycarbonyl
PyBrop	Bromotri(pyrrolidino)phosphonium hexafluorophosphate
DMF	<i>N,N</i> -dimethylformamide
PS-DIEA	Polymer supported diisopropylethylamine
EDCI or EDC	1-(3-dimethylaminopropyl)-3-ethylcarbodiimide
HOBt	1-hydroxybenzotriazole
DMAP	4-dimethylaminopyridine
HATU	<i>O</i> -(7-azabenzotriazol-1-yl)- <i>N,N,N',N'</i> -tetramethyluronium-hexafluorophosphate
Ex	Example
TLC	Thin layer chromatography
Min or mins	minute(s)
Hr, hrs, or h	hour(s)
RT, rt, or r.t	room temperature
Rt, or t_R	Retention time


DESCRIPTION OF THE CHEMISTRY




[201] Compound of Formula I-A is equal to compound of Formula I wherein X =



[202] Compound of Formula I-B is equal to compound of Formula I wherein X =



[203] **Scheme 1** below describes how compounds of Formula I-A may be synthesized.




[204] Compound of Formula II is commercially available or can be prepared by methods described in the literature (e.g., *J. Chem. Soc.* **1960**, 131–138; *J. Heterocyclic Chem.* **1969**, 6(2), 207–213). A benzenesulfonyl group is introduced under typical reaction conditions with typical bases and sulfonylating reagents in typical solvents to give compound of Formula III. Typical reagents and solvents include, but are not limited to, sodium hydride in DMF or THF, alkoxides such as potassium *tert*-butoxide in THF, a biphasic system consisting of aqueous NaOH and methylene chloride. Typical sulfonylating reagents are, e.g., benzenesulfonyl chloride or the corresponding anhydride. Typical conditions include, but are not limited to, -20°C to RT, at atmospheric pressure, with equimolar amounts of base and sulfonylating reagent, although larger amounts can be used if desirable. Compounds of Formula III can be iodinated under typical metallation / iodination conditions to yield compounds of Formula IV. Typical conditions include, but are not limited to, adding a lithium amide base, such as LDA or LiTMP, to a cooled (about -78°C to about 0°C) solution of compound of Formula III in an ether-type solvent, such as THF, 2-methyl-THF, DME, and the like (optionally containing other solvents such as aliphatic or aromatic hydrocarbons), and reacting the resulting species with an iodine source such as I_2 , ICl, or *N*-iodosuccinimide. Compounds of Formula V can be prepared from compounds of Formula IV by reacting with

bases such as NaOH in alcoholic solvents such as MeOH at typical reaction temperatures from about -10°C to about 40°C . Compounds of Formula VIII can be prepared by palladium-mediated coupling with a boronate of Formula VI under typical Suzuki conditions well known to someone skilled in the art. It will be appreciated that instead of the pinacol boronate shown, other boronate esters or the free boronic acids may also be used. Furthermore, reaction of the corresponding trialkyl tin derivatives of VI (i.e., compounds with, e.g., $\text{Bu}_3\text{Sn}-$ in place of the pinacolboronate) under typical Stille coupling conditions may also be used to prepare compounds of Formula VIII from compounds of Formula V. In an alternative route, compound of Formula III can be reacted with a strong base such as LDA, lithium tetramethylpiperidide, or the like, in an ether-type solvent such as THF, DME, and the like, and then reacted with a protected 4-piperidone VII, to give compounds of Formula VIII directly. Displacement of the chloride of compounds of Formula VIII with HYR1 under typical chloride displacement conditions gives compounds of Formula I-A. Alternatively, the order of steps may be reversed: Compound of Formula V is first reacted with HYR1 under typical chloride displacement conditions to yield compounds of Formula IX, followed by palladium-mediated coupling with a boronate of Formula VI under typical Suzuki conditions as described above to give compounds of Formula I-A.

[205] If deemed advantageous, the removal of the benzenesulfonyl group may also be performed after chloride displacement and Suzuki coupling under substantially similar reaction conditions. Someone skilled in the art will realize that other groups may be used in place of the benzenesulfonyl group for the metalation / iodination reaction. Examples include, but are not limited to, toluenesulfonyl, *tert*-butoxycarbonyl, and *tert*-butylcarbamoyl. Furthermore, instead of introducing an iodine in the reaction from compound of Formula III to compound of Formula IV one may introduce a bromine using, e.g., bromine, CBr_4 , or NBS under otherwise identical conditions and react the resulting compound in the same way as described above.


[206] Further manipulation of the substituents Z may be desirable, and Scheme 2 below describes how compounds wherein $\text{Z} = \text{tert-butoxycarbonyl}$ (Boc) may be used for that purpose.



[207] Compound of Formula I-A-Boc can be reacted with HCl in a typical solvent to give the hydrochloride salt of Formula I-A-H. Typical solvents include, but are not limited to, dioxane, MeOH, and water. Compounds of Formula I-A-H can be reacted with acids, anhydrides, acid halides, chloroformates, carbamoyl halides, sulfonyl halides, sulfamoyl halides, sulfonic anhydrides, and the like, under conditions described in the examples to give compounds of Formula I-A. Alternatively, a compound of Formula VIII-Boc can be reacted with HCl as described above to give the hydrochloride salt of Formula X. Introduction of the Z substituents as described above to yield a compound of Formula VIII, followed by chloride displacement with HYR1 gives compounds of Formula I-A.

[208] Someone skilled in the art will realize that acids other than HCl can be used for removal of the Boc group in compounds of Formula VIII-Boc and I-A-Boc.


[209] When HYR1 is equal to HNR1R2, someone skilled in the art will recognize that a variety of typical reaction conditions, typical solvents, and typical additives are available for the conversion of VIII to I-B and of VIII-Boc to I-B-Boc, shown in **Scheme 3**.




[210] Generally, VIII or VIII-Boc are reacted with HNR1R2 in a suitable solvent. Typical solvents include, but are not limited to, alcohols such as ethanol, isopropyl alcohol, butanol, or trifluoroethanol (TFE); or polar solvents such as DMF, NMP, or DMSO. If deemed necessary, typical additives such as HCl and TFA may be added. The reaction is typically carried out at about 40°C to about 150°C. If a relatively low boiling alcohol is used as solvent, it may be advisable to conduct the reaction in a pressure reactor. Alternatively, typical transition-metal mediated chloride displacement conditions well known to someone skilled in the art can be used. These conditions typically involve reacting VIII or VIII-Boc with HNR1R2, a transition metal compound, a suitable ligand, and a base in a suitable solvent. Someone skilled in the art will recognize that especially when acidic additives are used, the Boc group may be partially or completely removed simultaneously, so that compounds of Formula I-B-H are solely obtained or in a mixture with compounds of Formula I-B-Boc. If one wishes to obtain compounds of Formula I-B-Boc, the reaction mixture containing compounds of Formula I-B-H (either exclusively or as mixture with compounds of Formula I-B-Boc) can directly be treated with a base such as triethylamine or

diisopropylethylamine and di-*tert*-butyldicarbonate without the need for isolation. If one wishes to obtain compounds of Formula I-B-H, a mixture with compounds of Formula I-B-Boc can directly be treated with suitable acids to remove the Boc group completely.


[211] In some cases, compounds of Formula HNR₁R₂ are commercially available or synthesized according to literature procedures. In cases where neither is available, compounds of Formula HNR₁R₂ were synthesized via procedures described in the experimental section herein.



[212] Compound of Formula I-C is equal to compound of Formula I wherein X =



[213] **Scheme 4** below describes how compounds of Formula I-C may be synthesized.




[214] The compound of Formula XII is known in the literature and may be prepared according to a published procedure (*Tetrahedron Lett.* **2004**, *45*, 2317–2319). Typical conditions for the removal of the triisopropylsilyl group to obtain compound of Formula XIII include, but are not limited to, treatment with tetrabutylammonium fluoride, or

acids such as HCl or H₂SO₄ in alcoholic solvents. A compound of Formula XIV may be obtained from a compound of Formula XIII as described above for the conversion of a compound of Formula II to a compound of Formula III. A compound of Formula XV may be obtained from a compound of Formula XIV as described above for the conversion of a compound of Formula III to a compound of Formula IV. Compounds of Formula XVI can be obtained by reacting compound of Formula XV with HNR₁R₂ in a typical solvent under typical reaction conditions. Typical solvents include, but are not limited to, alcohols such as trifluoroethanol (TFE) with additives such as HCl and TFA. The reaction is typically carried out at about 40°C to about 120°C. If the reaction temperature is higher than the boiling point of the reaction mixture, a pressure reactor should be used. The benzenesulfonyl group of compounds of Formula XVI can be removed to give compounds of Formula XVII under conditions described above for the conversion of a compound of Formula IV to a compound of Formula V. Compounds of Formula XIX can be prepared from compounds of Formula XVII by palladium-mediated coupling with a boronate of Formula VI under typical Suzuki conditions well known to someone skilled in the art. It will be appreciated that instead of the pinacol boronate shown, other boronate esters or the free boronic acids may also be used. Furthermore, reaction of the corresponding trialkyl tin derivatives of VI (i.e., compounds with, e.g., Bu₃Sn- in place of the pinacolboronate) under typical Stille coupling conditions may also be used to prepare compounds of Formula XVII from compounds of Formula XVI. Alternatively, the benzenesulfonyl group in compound of Formula XV may be removed first to yield compound of Formula XVIII, followed by coupling with a boronate of Formula VI to give compounds of Formula XX, and chloride displacement with HNR₁R₂ to give compounds of Formula XIX, under conditions described above. Finally, compounds of Formula I-C may be obtained from compounds of Formula XIX by transition metal-mediated conversion of the bromo to the cyano substituents. Typical conditions include, but are not limited to, reaction with Pd₂dba₃, dppf, and Zn(CN)₂ in DMF/water.

[215] Someone skilled in the art will realize that other groups may be used in place of the benzenesulfonyl group for the metalation / iodination reaction. Examples include, but are not limited to, toluenesulfonyl, *tert*-butoxycarbonyl, and *tert*-butylcarbonyl. Furthermore, if Z = Boc, the chloride displacement in compounds of Formula XX under the conditions described above may lead to removal of the Boc group to give a compound of Formula XIX wherein Z = H. Such a compound can be treated with a base such as triethylamine or diisopropylethylamine and di-*tert*-butyldicarbonate to obtain a compound of Formula XIX wherein Z = Boc, or with other appropriate reagents to introduce the desired Z substituent.

[216] Further manipulation of the substituents Z may be desirable, and **Scheme 5** below describes how compounds wherein Z = *tert*-butoxycarbonyl (Boc) may be used for that purpose.



[217] Compounds of Formula XX-Boc, XIX-Boc, or I-C-Boc can be reacted with HCl in a typical solvent to give the hydrochloride salt of Formula XX-H, XIX-H, or I-C-H, respectively. Typical solvents include, but are not limited to, dioxane, MeOH, and water. Compounds of Formula XX-H, XIX-H, or I-C-H can be reacted with acids, anhydrides, acid halids, chloroformates, carbamoyl halides, sulfonyl halides, sulfamoyl halids, sulfonic anhydrides, and the like, under conditions described in the examples to give compounds of Formula XX, XIX, or I-C, respectively. Someone skilled in the art will realize that acids other than HCl can be used for removal of the Boc group in compounds of Formula XX-Boc, XIX-Boc, and I-C-Boc.

[218] It would be appreciated by those skilled in the art that in some situations, a substituent that is identical or has the same reactivity to a functional group which has been modified in one of the following processes, will have to undergo protection followed by deprotection to afford the desired product and avoid undesired side reactions. Alternatively, another of the processes described within this invention may be employed in order to avoid competing functional groups. Examples of suitable protecting groups and methods for their addition and removal may be found in the following reference: "Protective Groups in Organic Syntheses", T. W. Greene and P. G. M. Wuts, John Wiley and Sons, 1989.

[219] All melting points were determined with a Mel-Temp II apparatus and are uncorrected. Commercially available anhydrous solvents and HPLC-grade solvents were used without further purification. ^1H NMR and ^{13}C NMR spectra were recorded with Varian or Bruker instruments (400 MHz for ^1H , 100.6 MHz for ^{13}C) at rt with TMS or the residual solvent peak as internal standards. The line positions or multiplets are given in ppm (δ) and the coupling constants (J) are given as absolute values in Hertz, while the multiplicities in ^1H

NMR spectra are abbreviated as follows: s (singlet), d (doublet), t (triplet), q (quartet), quint (quintet), m (multiplet), m_c (centered multiplet), br (broadened), AA'BB'. The signal multiplicities in ¹³C NMR spectra were determined using the DEPT135 pulse sequence and are abbreviated as follows: + (CH or CH₃), - (CH₂), C_{quart} (C). LC/MS analysis was performed using a Gilson 215 autosampler and Gilson 819 autoinjector attached to a Hewlett Packard HP1100 and a Micromass ZQ2000 mass spectrometer. XTERRA MS C18 5μ 4.6×50mm columns with detection at 254 nm and electrospray ionization in positive mode were used. For mass-directed purification (MDP), a Waters / MicromassZQ system was used.

[220] The tables below list the mobile phase gradients (solvent A: acetonitrile; solvent B: 0.01% formic acid in HPLC water) and flow rates for the analytical HPLC programs.

Polar_5min

Time	A%	B%	Flow Rate (mL/min) MicromassZQ
0.00	5	95	1.3
3.00	90	10	1.3
3.50	90	10	1.3
4.00	5	95	1.3
5.00	5	95	1.3

Polar_15min

Time	A%	B%	Flow Rate (mL/min) MicromassZQ
0.00	5	95	1.3
1.00	30	70	1.3
7.50	90	10	1.3
10.00	100	0	1.3
13.00	5	95	
15.00	5	95	1.3

Nonpolar_5min

Time	A%	B%	Flow Rate (mL/min) MicromassZQ
0.00	25	75	1.3
3.00	99	1	1.3

Time	A%	B%	Flow Rate (mL/min) MicromassZQ
3.50	99	1	1.3
4.00	25	75	1.3
5.00	25	75	1.3

Nonpolar_7min


Time	A%	B%	Flow Rate (mL/min) MicromassZQ
0.00	25	75	1.3
4.00	100	0	1.3
5.50	100	0	1.3
6.00	25	75	1.3
7.00	25	75	1.3

Nonpolar_15min

Time	A%	B%	Flow Rate (mL/min) MicromassZQ
0.00	15	85	1.3
7.50	99	1	1.3
11.00	99	1	1.3
12.50	15	85	1.3
15.00	15	85	1.3

Syntheses of EXAMPLES and INTERMEDIATES


[221] 4-Chloro-7-(phenylsulfonyl)-7H-pyrrolo[2,3-*d*]pyrimidine (compound of Formula II).



[222] To a solution of 4-chloro-7H-pyrrolo[2,3-*d*]pyrimidine (10g, 0.065mol) in THF (300mL) was added potassium tert-butoxide (9.15g, 0.082mol) at r.t. over 5min. A slight exotherm was noticed and suspension was cooled with the aid of a water bath. Benzenesulfonyl chloride (10.5mL, 0.082mol) was then added drop-wise over a period of


10min and the resulting suspension stirred for a further 3h. Then water (20mL) was added drop-wise and the solution was then stirred for 15min. The solvent was evaporated under reduced pressure and the reaction mixture was eluted with ethyl acetate (1.2 l), washed with brine (2 x 100mL), dried and concentrated. The resulting solid was triturated with ethyl acetate (50mL) to afford 4-chloro-7-(phenylsulfonyl)-7*H*-pyrrolo[2,3-*d*]pyrimidine as an off-white solid. ¹H NMR (CDCl₃, 400 MHz) δ 6.75 (1H, d), 7.55-7.625 (2H, t), 7.70 (1H, t), 7.82 (1H, d), 8.25 (1H, d) and 8.80 (1H, s).

[223] 4-Chloro-6-iodo-7-(phenylsulfonyl)-7*H*-pyrrolo[2,3-*d*]pyrimidine
(compound of Formula III).




[224] To a stirred solution of 4-chloro-7-(phenylsulfonyl)-7*H*-pyrrolo[2,3-*d*]pyrimidine (5.0g, 0.017mol) in THF (200mL) under inert atmosphere, at -78°C, was added 2.0M LDA solution (9.8mL, 0.0195mol) over a period of 15min. After 1h a solution of iodine (4.97g, 0.0196mol) in THF (50mL) was added dropwise over a period of 15min. The resulting solution was stirred for a further 3h. Water (10mL) was then added and the mixture allowed to reach r.t. The mixture was diluted with DCM (1l), washed with brine (2 x 100mL), dried and concentrated under reduced pressure. The resulting solid was triturated with MeCN to afford the 4-chloro-6-iodo-7-(phenylsulfonyl)-7*H*-pyrrolo[2,3-*d*]pyrimidine. ¹H NMR (CDCl₃, 400 MHz) 7.05 (1H, s), 7.50 (2H, t), 7.60 (1H, t), 8.20 (2H, d) and 8.65 (1H, br s).

[225] 4-Chloro-6-iodo-7*H*-pyrrolo[2,3-*d*]pyrimidine (compound of Formula IV).



[226] To a stirred solution of 4-chloro-6-iodo-7-(phenylsulfonyl)-7*H*-pyrrolo[2,3-*d*]pyrimidine (538mg, 1.283mmol) in THF (6.0mL) was added 5M sodium hydroxide methanolic solution (1.8mL, 0.009mmol). After 10min the solvent was removed under reduced pressure, sat. ammonium chloride solution (5.0mL) was added and the mixture evaporated to dryness. The resulting solid was triturated with water to afford 4-chloro-6-iodo-7*H*-pyrrolo[2,3-*d*]pyrimidine. ¹H NMR (d₆-DMSO, 400 MHz) 6.90(1H, s) and 8.55 (1H, s).

[227] *tert*-Butyl 4-(4-chloro-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl)-3,6-dihydropyridine-1(2*H*)-carboxylate (compound of Formula VIII-Boc).



[228] To a suspension of 4-chloro-6-iodo-7*H*-pyrrolo[2,3-*d*]pyrimidine (5.0g, 0.018mol) in 1,4-dioxane (120mL) and water (30mL) were added 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester (5.97g, 0.0193mol), potassium carbonate (4.9g, 0.036mol) and PdCl₂(dppf)·CH₂Cl₂ (0.73g, 0.89mmol). The flask was evacuated and refilled with N₂ (3×). The mixture was heated at 100°C overnight. LC-MS showed the reaction was complete. The mixture was diluted with ethyl acetate (200mL), then washed with brine (2×50mL), and dried over anhydrous sodium sulfate. The filtrate was concentrated under reduced pressure to ≈100mL, the resulting white precipitate was collected by filtration to give the first batch of the title compound. The filtrate was concentrated and the residue was purified by chromatography on silica gel, eluting with Hex:EtOAc = 70:30 → 50:50 to give a white solid (containing pinacol), which was further crystallized with EtOAc/hexanes to give the second batch of the title compound as a white solid. LC-MS (ES, Pos.): 335/337 (3/1) [MH⁺]. ¹H NMR (CDCl₃, 400 MHz): δ = 1.51 (s, 9H), 2.61 (m, 2H), 3.70 (m, 2H), 4.20 (m, 2H), 6.27 (s, 1H), 6.55 (s, 1H), 8.61 (s, 1H), 10.3 (brs, 1H).

[229] *Alternative synthesis:* To a -78°C solution of 4-chloro-7-phenylbenzenesulfonyl-7*H*-pyrrolo[2,3-*d*]pyrimidine (1.00g, 3.41mmol) in anhydrous THF (15mL) was added LDA solution (1.5M in cyclohexanes; 3.41mL, 5.12mmol) dropwise over 5min. The mixture was left to stir for 1h after which time 1-Boc-4-piperidone (0.82g, 4.09mmol) was added as a solution in THF (5mL) and the mixture left to warm to rt over a weekend. The solution was diluted with EtOAc (150mL) and partitioned over water. The organic layer was washed with brine, dried (MgSO₄), filtered and concentrated *in vacuo*. Purification by column chromatography on silica gel loading in DCM and eluting with 5:1 Hexanes:EtOAc stepwise to EtOAc yielded the title compound as an off-white powder.


[230] *General method for the reaction of amines with tert-butyl 4-(4-chloro-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl)-3,6-dihydropyridine-1(2H)-carboxylate to generate compounds of Formula I-B-Boc:*

[231] Amine HNR₁R₂ (0.215mmol) was added to a solution of *tert*-butyl 4-(4-chloro-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl)-3,6-dihydropyridine-1(2*H*)-carboxylate (0.18mmol) in butanol (4mL). The reaction was heated to 95°C for 2h. If the reaction was incomplete the reaction temperature was increased to 105°C, and if required to 115°C, until all the starting

material was consumed. The solvent was removed and the residue purified on silica gel by elution with dichloromethane: methanol to yield the product of Formula I-B-Boc.









Alternatively, purification may be possible by HPLC, crystallization, or trituration.








[232] The following **EXAMPLES** were prepared using the general method described above. In **Table 1**, reference is to formula **I-B-Boc**:

















[233] Table 1. .








EX.	R1-N-R2 	NMR	NMR Solvent	MH ⁺	HPLC Rt (min)
1		11.9(NH,s), 9.6(NH), 9.2(H,s), 8.9(H,s), 8.4(H,s), 8.1(H,m), 7.9(H,d), 6.8(H,s), 6.4(H,brs), 4.1(2H,brs), 3.6(2H,brs), 2.5(2H, brs), 1.4(9H,s)	DMSO	449	3.57
2		11.9(NH,s), 9.2(1H), 8.2(1H), 7.8(2H,d), 6.95(2H,d), 6.7(1H, s), 6.4(1H,s), 5.0 (1H,m), 4.0(2H, br.s), 3.9-3.7(4H,m), 3.6(2H, t), 2.5(2H,br), 2.2(1H,m), 2.0(1H,m), 1.4(9H,s)	DMSO	478	3.22
3		11.9(NH,s), 9.2(1H), 8.2(1H), 7.8(2H,d), 6.9(2H,m), 7.25(1H,m), 6.9(2H,s), 6.7(1H,s), 6.4(1H,s), 4.4(2H,t), 4.2(2H, t), 4.0 (2H,s), 3.6 (1H, t), 2.5(2H,br.s), 1.4(9H,s)	DMSO	502	2.77
4		12.0(NH, s), 9.2(1H), 8.2(1H), 7.7(2H,d), 6.9(2H,d), 6.7(1H,s), 6.4(1H,br.s), 4.0(4H,m), 3.6(6H,m), 2.5(8H,m), 1.9(2H,m) 1.4(9H,s)	DMSO	535	2.77
5		11.8(NH,s), 9.6(NH), 8.7(H,m), 8.6(H,s), 8.3(H,s), 8.2(H,m), 8.1(H,m), 7.9(H,m), 7.4(H,m) 6.7(H,s), 6.4(H,s), 4.1(2H,brs), 3.6(2H,brs), 2.5(2H, brs), 1.4(9H,s)	DMSO	442	3.47




EX.	R1-N-R2 	NMR	NMR Solvent	MH ⁺	HPLC Rt (min)
6		11.7(NH,s), 9.0(NH), 8.2(H,s), 7.4(2H,m), 6.8(H,m), 6.7(H,s), 6.4(H,s), 4.1(3H,brs), 3.6(2H,brs), 2.5(2H, brs), 2.2(3H,s), 1.4(9H,s)	DMSO	421	3.29
7		11.9(NH,s), 9.4(NH), 8.4(H,s), 8.2(H,s), 7.9(H,m), 7.4(H,m), 7.2(H,m), 6.8(H,s), 6.4(H,s), 4.1(2H,brs), 3.6(2H,brs), 2.5(3H, brs), 1.4(9H,s)	DMSO	415	3.81
8		11.8(NH), 9.7(NH), 8.3(H,s), 8.1(2H,m), 7.6(2H,m), 6.8(H,s), 6.4(H,s), 4.1(2H,brs), 3.6(2H,brs), 2.6(6H,s), 2.5(2H, brs), 1.4(9H,s)	DMSO	498	3.87
9		11.9(NH,s), 11.2(NH,s), 9.2(NH), 8.2(H,s), 8.0(H,s), 7.5(H,m), 7.2(H,m), 6.6(H,s), 6.4(H,s), 5.2(NH2), 4.1(2H,brs), 3.6(2H,brs), 2.5(2H, brs), 1.4(9H,s)	DMSO	447	3.57
10		11.9(NH,s), 11.1(NH,s), 9.4(NH), 8.6(H,s), 8.4(H,s), 8.0(H,s), 7.7(H,m), 7.4(H,m), 6.9(H,s), 6.4(H,s), 4.1(2H,brs), 3.6(2H,brs), 2.5(2H, brs), 1.4(9H,s)	DMSO	431	3.49
11		11.9(NH,s), 9.3 (NH,s), 8.2(H,s), 7.0(H,m), 6.7(2H,m), 6.5(H,m), 6.4(H,s), 5.1(NH), 4.1(2H,brs), 4.0(4H,m), 3.6(2H,brs), 3.0(4H,m), 2.5(2H, brs), 1.4(9H,s)	DMSO	510	3.42
12		11.9(NH, s), 9.6(NH), 8.6(H,s), 8.4(H,s), 8.2(H,m), 7.5(2H,m), 6.8(H,s), 6.4(H,s), 4.1(2H,brs), 3.6(2H,brs), 2.5(2H, brs), 1.4(9H,s)	DMSO	416	3.86
13		11.9(NH, s), 9.2(NH), 8.2(H,s), 7.7(2H,m), 7.0(2H,m), 6.7(H,s), 6.4(H,s), 4.1(2H,brs), 3.8(4H,m), 3.6(2H,brs), 3.1(4H,m), 2.5(2H, brs), 1.4(9H,s)	DMSO	477	3.34

EX.	R1-N-R2 	NMR	NMR Solvent	MH ⁺	HPLC Rt (min)
14		12.0(NH, s), 9.6(NH), 8.4(2H,m), 8.2(H,m), 7.6(H,m), 7.4(H,m), 6.8(H,s), 6.4(H,s), 4.1(2H,brs), 3.6(2H,brs), 2.5(2H, brs), 1.4(9H,s)	DMSO	459	4.07
15		11.9(NH, s), 9.4(NH), 8.3(H,s), 8.2(H,s), 8.1(H,m), 7.8(H,s), 7.4(2H,m), 6.9(H,s), 6.7(H,s), 6.4(H,s), 4.1(2H,brs), 3.9(3H,s), 3.6(2H,brs), 2.5(2H,brs), 1.4(9H,s)	DMSO	471	3.47
16		11.9(NH, s), 9.5(NH), 8.4(2H,m), 8.2(H,m), 7.9(H,brs), 7.3-7.5(3H,m), 6.8(H,s), 6.4(H,s), 4.1(2H,brs), 3.6(2H,brs), 2.5(2H,brs), 1.4(9H,s)	DMSO	435	3.17
17		11.9(NH, s), 9.4(NH), 8.3(H,s), 8.0(2H,m), 7.4(2H,m), 6.8(H,s), 6.4(H,s), 4.1(2H,brs), 3.6(2H,brs), 2.5(2H, brs), 1.4(9H,s)	DMSO	426	3.86
18		12.0(NH, s), 9.5(NH, s), 8.5(1H, s), 8.35(1H, s), 8.3(1H, br m), 8.0(1H, d), 7.7(1H, s), 7.45(1H, m), 7.4(1H, m), 6.8(1H, s), 6.4(1H, br), 4.1(2H, br s), 3.6(2H, m), 2.5(2H, obscured), 1.5(9H, s)	DMSO	459	3.31
19		12.0(NH, s), 9.5(NH,s), 8.35(H,s), 8.2(1H, t), 7.8(H, dd), 7.4(H, t), 7.1(H, dd), 6.8(H, s), 6.4(H, s), 4.1(2H, br, s), 3.6(2H, br, m), 2.5(2H, obscured), 1.5(9H, s)	DMSO	426	3.92
20		11.9 (NH,s), 11.0 (NH,s), 9.6(NH,s), 8.7(1H, s), 8.4(1H, s), 8.2(1H, m), 7.7(1H, m), 7.6(1H, t), 6.9(1H, s), 6.4(1H, br s), 4.1(2H, br s), 3.6(2H, m), 2.5(2H, obscured), 1.5(9H, s)	DMSO	458	3.14


EX.	R1-N-R2 	NMR	NMR Solvent	MH ⁺	HPLC Rt (min)
21		12.0(NH, s), 9.8(NH), 9.0(H,s), 8.6(3H,m), 8.3(H,m), 8.1(H,m), 7.6(H,s), 7.1(H,s), 6.8(H,s), 4.1(2H,brs), 3.6(2H,brs), 2.5(2H,brs), 1.4(9H,s)	DMSO	443	3.11
22		11.9(NH, s), 11.0(NH,s), 9.7(NH), 8.1(H,s), 7.6(H,m), 7.5(H,m), 7.4(H,m), 7.0(H,m), 6.6(H,s), 6.4(H,s), 4.1(2H,brs), 3.6(2H,brs), 2.5(2H,brs), 1.4(9H,s)	DMSO	431	3.19
23		8.6(H,d), 8.3(H,s), 8.25(H,s), 7.9(3H, m), 7.8(H,d), 7.5(H,t), 7.4(H,t), 6.7(H,s), 6.3(H, br.s), 4.2(2H, br.s), 3.7(2H, br.s), 2.6(2H, br.s), 1.5(9H,s)	CD ₃ OD	469	3.27
24		10.8(NH, br.s), 8.9(NH,s), 8.7(H,d), 8.5(H,s), 7.9(2H,m), 7.7(H,d), 7.6(H,t), 7.4(2H,d), 7.1(H,s), 6.2(H,NH,m), 4.2(2H, br.s), 3.7(2H, br.s), 2.6(2H, br.s), 1.5(9H,s)	CDCl ₃	469	3.06
25		11.9(NH, s), 9.9(NH,s), 8.25(H,s), 7.6(H, d), 7.2(H, dd), 6.9(H,d), 6.75(H, s), 6.4(H,br,s), 6.0(2H, s), 4.05(2H, br, s), 3.6(2H, br, m), 2.5(2H, br, s), 1.5(9H, s)	DMSO	436	3.94
26		12.0(NH, s), 9.6(NH, s), 8.8(H, s), 8.4(H, s), 7.9 and 7.7(2H, Abq), 6.9(H,s), 6.4(H, br, s), 4.1(2H, br, s), 3.6(2H, br, m), 2.5(2H, obscured), 1.5(9H, s)	DMSO	433	3.69
27		11.9(NH, s), 11.0 (NH, s), 9.2(H, s), 8.3(H, s), 8.2(H, s), 7.5(H, d), 7.3(H, dd), 7.25(H, t), 6.8(H, s), 6.4(2H, br, s), 4.1(2H, br, s), 3.6(2H, br, m), 2.5(2H, br, s), 1.5(9H, s)	DMSO	431	4.07

EX.	R1-N-R2 	NMR	NMR Solvent	MH ⁺	HPLC Rt (min)
28		11.9(NH, s), 9.3(NH, s), 8.3(H, s), 7.9(2H, d), 7.35(2H, t), 7.0(H, t), 6.8(H, s), 6.4(H, br, s), 4.1(2H, br, s), 3.6(2H, br, m), 2.5(2H, obscured), 1.5(9H, s)	DMSO	392	3.44
29		8.9(H, s), 8.3(H, s), 8.2(H, s), 7.8(H, d), 7.7(H, d), 6.7(H, s), 6.3(H, br, s), 4.1(2H, br, m), 3.7(2H, br, m), 2.6(2H, br, m), 1.5(9H, s)	CD ₃ OD	433	3.25
30		12.0(NH, s), 9.4(NH, s), 8.8(NH, s), 8.2(1H, s), 8.1(1H, s), 7.8(1H, m), 7.5(1H, s), 7.3(1H, m), 7.2(1H, m), 6.6(1H, s), 6.5(1H, s), 6.3(1H, s), 4.1(2H, br s), 3.6(2H, m), 2.5(2H, obscured), 1.5(9H, s)	DMSO	458	3.19
31		12.9(NH, s), 11.8(NH, s), 8.95(NH, s), 8.1(H, s), 8.0(H, s), 7.7(H, s), 7.45(H, s), 6.3(2H, br), 4.0(2H, br), 3.5(2H, m), 2.4(2H, m), 2.3(3H, s), 1.45(9H, s)	DMSO	446	2.95
32		11.9(NH, s), 10.3(NH, s), 9.2(NH, s), 8.2(H, s), 7.8(H, s), 7.5(H, dd), 6.8(H, d), 6.7(H, s), 6.4(H, br s), 4.05(2H, br s), 3.6(2H, m), 3.5(2H, s), 2.5(2H, br), 1.5(9H, s)	DMSO	447	2.92
33		11.8(NH, s), 9.9(NH, s), 9.4(NH, s), 8.3(1H, s), 8.1(1H, s), 7.6(1H, m), 7.2(2H, m), 6.9(1H, s), 6.4(1H, s), 4.1(2H, br s), 3.6(2H, m), 2.5(2H, obscured), 2.1(3H, s), 1.5(9H, s)	DMSO	449	2.99
34		11.9(NH, s), 9.9(NH, s), 9.0(1H, s), 8.9(1H, s), 8.8(1H, s), 8.5(1H, s), 8.3(1H, m), 8.1(1H, m), 6.8(1H, s), 6.4(1H, s), 4.1(2H, br s), 3.6(2H, m), 2.5(2H, obscured), 2.0(3H, s), 1.5(9H, s)	DMSO	444	3.54

EX.	R1-N-R2 	NMR	NMR Solvent	MH ⁺	HPLC Rt (min)
35		12.35 (NH,s), 11.90 (NH,s), 9.32 (NH), 8.34 (H,s), 8.26 (H,s), 8.14 (H,s), 7.55 (H,d, J=8.8 Hz), 7.50 (H,dd, J=8.8,1.6 Hz), 6.78 (H,s), 6.39 (H,s), 4.04 (2H,brs), 3.57 (2H,brs), 2.48 (2H,brs), 1.44 (9H,s)	DMSO	432	2.72
36		12.0(NH, s), 9.5(NH, s), 8.4(1H, m), 8.2-8.3(3H, m), 7.4(2H, m), 6.8(1H, s), 6.4(1H, s), 4.1(2H, br s), 3.6(2H, m), 2.8(3H, d), 2.5(2H, obscured), 1.5(9H, s)	DMSO	449	3.17
37		12.0(NH, s), 9.6(NH, s), 8.7(2H, s), 8.4(1H, s), 7.7(2H, s), 6.8(1H, s), 6.4(1H, s), 4.1(2H, br s), 3.6(2H, m), 2.5(2H, obscured), 1.5(9H, s)	DMSO	433	3.22
38		11.9(NH, s), 9.6(NH, s), 8.5(1H, s), 8.3(1H, s), 8.2(2H, d), 8.0(1H, d), 7.8(1H, d), 7.6(1H, d), 7.5(1H, m), 6.9(1H, s), 6.4(1H, s), 4.1(2H, br s), 3.6(2H, m), 2.5(2H, obscured), 1.5(9H, s)	DMSO	475	3.57
39		11.9(NH, s), 9.5(NH, s), 9.2(1H, s), 8.5(1H, s), 8.4(1H, s), 8.1(1H, s), 8.0(1H, d), 7.6(1H, d), 7.4(1H, m), 6.9(1H, s), 6.4(1H, s), 4.1(2H, br s), 3.6(2H, m), 2.5(2H, obscured), 1.5(9H, s)	DMSO	475	3.40
40		11.8(NH, s), 9.5(NH, s), 9.1(1H, s), 8.5(1H, s), 8.4(1H, s), 8.2(1H, s), 8.0(1H, d), 7.4(1H, m), 7.4(1H, m), 6.8(1H, s), 6.4(1H, s), 4.1(2H, br s), 3.6(2H, m), 2.5(2H, obscured), 1.5(9H, s)	DMSO	475	3.44
41		9.1(1H, s), 8.4(1H, d), 8.3(1H, d), 8.2(1H, s), 7.7(1H, q), 6.8(1H, s), 6.4(1H, br s), 4.15(2H, br s), 3.7(2H, m), 2.55(2H, br s), 1.5(9H, s)	CD ₃ OD	449	3.51


EX.		NMR	NMR Solvent	MH ⁺	HPLC Rt (min)
42		Not recorded		456	3.27
43		Not recorded		436	2.84

[234] Alternative synthesis of 4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl ester (EXAMPLE 1):



[235] PdCl₂(dppf)₂·CH₂Cl₂ (8.2mg, 0.010mmol) was added into the mixture of benzothiazol-6-yl-(6-iodo-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine (78.7mg, 0.200mmol), 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl ester (68.0mg, 0.220mmol), and K₂CO₃ (55.3mg, 2.00mmol) in DMF:H₂O (2.5mL:0.5mL). The combined mixture was bubbled with N₂ for 5min and was then heated at 100°C under N₂ for 16h. After that time, the mixture was concentrated *in vacuo* and purified by MS directed purification. One obtained the title compound as light brown solid. ¹H NMR (CD₃OD, 400 MHz): δ 1.40 (s, 9 H), 2.49 (brs, 2 H), 3.57 (brs, 2 H), 4.03 (brs, 2 H), 6.20 (brs, 1 H), 6.61 (s, 1 H), 7.68 (dd, 1 H, *J* = 2.0 & 8.8 Hz), 7.90 (d, 1 H, *J* = 8.8 Hz), 8.19 (s, 1 H), 8.64 (d, 1 H, *J* = 2.0 Hz), 9.02 (s, 1 H). MS (ES⁺): *m/z* 449 (100) [MH⁺].


[236] **Benzothiazol-6-yl-(6-iodo-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine** (compound of Formula IX wherein R1 = benzothiazol-6-yl and Y = NH).



[237] Following the *General method for the reaction of amines with tert-butyl 4-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-3,6-dihydropyridine-1(2H)-carboxylate* to generate compounds of Formula I-B-Boc, but using 4-chloro-6-iodo-7H-pyrrolo[2,3-d]pyrimidine and

benzothiazol-6-ylamine, one obtained the title compound. MS (ES⁺): *m/z* 393.88 (100) [MH⁺].

[238] **Example 44: 4-[4-(1*H*-Indazol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester.**




[239] A mixture of 4-(4-chloro-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl)-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester (136mg, 0.41mmol) and 5-aminoindazole (65mg, 0.49mmol) in *n*-BuOH (2mL) were heated at 120°C for 3h, then cooled and the solvent removed *in vacuo*. The mixture was dissolved in DMSO/MeOH and purified by RP-HPLC (gradient 5 to 75 % MeCN/H₂O over 15min, 0.01 % formic acid as buffer, flow rate 15mL/min). Upon concentration of desired fractions, a white powder precipitated that was filtered, washed with ether and dried *in vacuo* to reveal the title compound. ¹H NMR (400 MHz, DMSO-*d*⁶): δ = 1.42 (s, 9H), 2.44 (brs, 2H), 3.55 (brs, 2H), 4.03 (brs, 2H), 6.39 (brs, 1H), 6.76 (brs, 1H), 7.53–7.60 (m, 2H), 8.06 (s, 1H), 8.21–8.30 (m, 2H), 9.78 (brs, 1H), 12.08 (brs, 1H). MS (ES⁺): *m/z* 432.2 (20) [MH⁺].

General method for removal of the Boc protecting group:

[240] Compound of Formula I-B-Boc (1eq) was added to HCl in dioxane (4M) (20equiv) at rt. After 18h the resultant solid was filtered off to yield the hydrochloride solid I-B-H.

[241] **EXAMPLE 45: (1*H*-Indazol-5-yl)-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl]-amine.**




[242] 4-[4-(1*H*-Indazol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester (1g, 2.32mmol) was added to 4M HCl in dioxane (16mL) and stirred for 18h. The solid was then filtered off, washed with ether and dried to yield the title compounds as an off-white solid. ¹H NMR (d₄ MeOH, 400 MHz) 8.23

(1H, s), 8.2 (1H, s), 8.0 (1H, s), 7.8 (1H, d), 7.6 (1H, d), 6.85 (1H, br.s), 6.42 (1H, s), 4.0 (2H, s), 3.5 (2H, m), 2.85 (2H, br. s).


[243] Alternative solvents for removal of the Boc group include, but are not limited to, MeOH and water, as demonstrated here with **EXAMPLE 45**: A suspension of *tert*-butyl 4-[4-(1*H*-indazol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylate (670mg, 1.55mmol) in 4 N HCl (aq) (20mL) was stirred at rt for 18h. The precipitates were collected by filtration and washed with ether (3×10mL) to afford (1*H*-indazol-5-yl)-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl]amine as tri-HCl salt. ¹H-NMR (DMSO-*d*₆, 400 MHz): δ = 2.63 (m, 2 H), 3.30 (m, 2 H), 3.79 (m, 2 H), 6.52 (s, br, 1 H), 7.44 (dd, *J* = 2.0, 8.8 Hz, 1 H), 7.72 (d, *J* = 8.8 Hz, 1 H), 7.95 (s, 1 H), 8.18 (d, *J* = 1.2 Hz, 1 H), 8.26 (s, 1 H), 9.59 (s, 1 H). MS (ES⁺): *m/z* 332.12 [MH⁺]. HPLC: *t*_R = 0.44 and 1.37 min (ZQ2000, polar_5min).

[244] **EXAMPLE 46: (1*H*-Indazol-5-yl)-[6-(1-methanesulfonyl-1,2,3,6-tetrahydropyridin-4-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl]-amine.**




[245] (1*H*-Indazol-5-yl)-[6-(1,2,3,6-tetrahydro-pyridin-4-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl]-amine hydrochloride (80mg, 0.217mmol), Hunigs base (113μL, 0.653mmol) and methanesulfonyl chloride (17μL, 0.2177mmol) were combined in DMF at rt and stirred overnight. The reaction was concentrated *in vacuo* and residue purified on silica gel by elution with tetrahydrofuran:dichloromethane (3:2) to yield the title compound as white solid. ¹H NMR (*d*₆-DMSO, 400MHz) 9.4(1H, br. s), 8.4 (1H, s), 8.3(1H,s), 8.0(1H,s), 7.7(1H, d), 7.5(1H, d), 6.8(1H, s), 6.4(1H,s), 3.9(2H, s), 3.4(2H, m), 3.0(3H,s) and 2.6(2H, s); LC/MS: *m/z* 410 [M+H]⁺, *R*_t = 2.82min.

[246] **EXAMPLE 47: 2-Dimethylamino-1-{4-[4-(1*H*-indazol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridin-1-yl}-ethanone.**




[247] (1H-Indazol-5-yl)-[6-(1,2,3,6-tetrahydro-pyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-amine hydrochloride (80mg, 0.217mmol), N,N-dimethylglycine (22.4mg, 0.277mmol), PyBrop (101mg, 0.217mmol) and Hünigs base (113μL, 0.653mmol) were combined in DMF (3mL) and stirred at rt for 37h. The DMF was removed *in vacuo* and the residue was absorbed onto silica. Purification on silica gel by elution with tetrahydrofuran:methanol:conc ammonia (30:1:1) yielded a white solid. ¹H NMR (d₆-DMSO, 400MHz) Rotamers observed: 9.32 & 9.30 (1H, rotamers, 2s), 8.37 & 8.36 (1H, rotamers, 2s), 8.26 (1H, s), 8.0 (1H, s), 7.68 (2H, d), 7.53 (1H, d), 6.78 & 6.75 (1H, rotamers, 2s), 6.4 (1H, s), 4.3 (1H, s), 4.2 (1H, s), 3.76 & 3.71 (2H, rotamers, 2t), 3.18 & 3.14 (2H, rotamers, 2s), 2.5 (2H, m), 2.23 & 2.21 (6H, rotamers, 2s); LC/MS: *m/z* 416 [M+H]⁺, Rt = 2.52min.

[248] **EXAMPLE 48: 1-{4-[4-(1H-Indazol-5-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-ethanone.**




[249] (1H-Indazol-5-yl)-[6-(1,2,3,6-tetrahydro-pyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-amine hydrochloride (60mg, 0.137mmol), HATU (63mg, 0.164mmol) and Hunigs base (100μL, 0.576mmol) were combined in DMF (4mL) and stirred for 30min. Acetic acid (8μL, 0.168mmol) was added and the solution was stirred overnight. Another portion of acetic acid (8μL, 0.168mmol) was added and the stirred for a further 4h. The DMF was removed *in vacuo* and the residue was loaded onto silica. Purification on silica by elution with dichloromethane:methanol (95:5) yielded the title compound as a yellow solid. ¹H NMR (400 MHz, DMSO-d₆): δ = 2.03 & 2.07 (2s, rotamers, 3H), 2.44 & 2.53 (2s, rotamers, 2H), 3.62–3.67 (m, 2H), 4.11 & 4.18 (2s, rotamers, 2H), 6.39 (s, 1H), 6.72 & 6.76 (2s, rotamers, 1H), 7.50 (d, *J* = 8.8 Hz, 1H), 7.63 (d, *J* = 8.8 Hz, 1H), 8.03 (s, 1H), 8.24 (s, 1H), 8.33 (brs, 1H), 9.35 (brs, 1H), 11.90 (brs, 1H). MS (ES⁺): *m/z* 374.5 (100) [MH⁺].

[250] **EXAMPLE 49: 2,2,2-Trifluoro-1-{4-[4-(1H-indazol-5-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-ethanone.**



[251] (1H-Indazol-5-yl)-[6-(1,2,3,6-tetrahydro-pyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-amine hydrochloride (150mg, 0.34mmol), Hunigs base (239 μ L, 1.37mmol) and trifluoroacetic anhydride (96mL, 0.68mmol) were combined in DMF (6mL) and stirred overnight. Trifluoroacetic anhydride (96mL, 0.68mmol) was added and the mixture was stirred a further 2h. The DMF was removed *in vacuo* and the residue was partitioned between dichloromethane and 1M HCl (aq). The organic layer was separated and dried over anhydrous magnesium sulphate, filtered and evaporated *in vacuo*. Purification on silica gel by elution with ethyl acetate yielded the title compound as a yellow solid. ¹H NMR (400 MHz, DMSO-*d*⁶): δ = 2.58–2.64 (brm, 2H), 3.78–3.86 (m, 2H), 4.27 & 4.32 (2s, rotamers, 2H), 6.38 & 6.40 (2s, rotamers, 1H), 6.76 & 6.80 (2s, rotamers, 1H), 7.50 (d, *J* = 8.8 Hz, 1H), 7.63 (d, *J* = 8.8 Hz, 1H), 8.03 (s, 1H), 8.24 (s, 1H), 8.32–8.35 (m, 1H), 9.34 (s, 1H), 11.95 (s, 1H). MS (ES⁺): *m/z* 428.4 (100).

[252] **EXAMPLE 50: 4-[4-(1H-Indol-5-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl ester.**




[253] A suspension of 4-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl ester (606.0mg, 1.810mmol, 1eq) and 5-aminoindole (548.9mg, 4.153mmol, 2.3eq) in *n*-BuOH (30mL) was stirred at 120°C for 23h, after which it was concentrated *in vacuo*, to a dark brown foam. The crude material (1.2974 g) was dissolved in mixtures of DCM and MeOH (DCM alone was insufficient), to which DiPEA (0.4mL, 2mmol, 1eq) was added to ensure that material was free base and not HCl salt. The crude material was adsorbed onto Hydromatrix, dry loaded, and purified by chromatography on silica gel [Jones Flashmaster, 50g / 150mL cartridge, eluting with MeOH:DCM 1% → 5% → 10%]. Trituration of combined and concentrated product fractions in DCM / sonication gave the title compound as white solid. ¹H NMR (400 MHz, DMSO-*d*₆): δ = 1.43 (s, 9H), 2.44 (s, br, 2H), 3.55 (t, *J* = 5.6 Hz, 2H), 4.03 (s, br, 2H), 6.35 (s, br, 1H), 6.40 (t, *J* = 2.0 Hz, 1H), 6.67 (s, br, 1H), 7.29–7.41 (m, 3H), 8.03 (s, br, 1H), 8.19 (s, 1H), 9.14 (s, –NH), 10.99 (s, –NH), 11.81 (d, *J* = 1.6 Hz, –NH). MS (ES⁺): *m/z* 431.04 (100) [MH⁺]. HPLC: *t*_R = 2.42 min (ZQ2000, polar_5min).

[254] *Alternative preparation:* 4-[7-Benzenesulfonyl-4-(1H-indol-5-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl ester


(84mg, 0.147mmol) in THF (2mL) was treated with a 5M solution of NaOH in MeOH (1mL). After 10min the reaction was evaporated to dryness and conc. NH_4Cl solution and water (enough to dissolve all inorganic salts) were added, the mixture was extracted with EtOAc (3 x 4mL), the combined organic was washed with brine, dried over anhydrous magnesium sulphate, filtered, and concentrated to leave the title compound as pale pink solid.

[255] 4-[7-Benzenesulfonyl-4-(1*H*-indol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]-pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester.



[256] 4-(7-Benzenesulfonyl-4-chloro-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl)-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester (150mg, 0.31mmol) in butanol (5mL) was treated with 5-aminoindole (50mg, 0.38mmol) and heated to 80°C for 2h and then 85°C for 1h. The mixture was evaporated to dryness and pre-absorbed onto silica. Purification on silica by elution with dichloromethane:methanol (97:3) yielded a slightly pink solid. ^1H NMR (d_6 -DMSO, 400MHz) 9.4(NH), 8.3(1H, s), 8.0(2H, d), 7.9(1H, s), 7.7(1H, m), 7.6(2H, m), 7.4(2H, m), 7.2(1H, m), 6.8(1H, br. s), 6.4(1H, s), 6.0(1H, s), 4.1(2H, m), 3.6(2H, m), 2.5(2H, m), and 1.5(9H, s); LC/MS: m/z 570 $[\text{M}+\text{H}]^+$, R_t = 4.07 min.

[257] 4-(7-Benzenesulfonyl-4-chloro-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl)-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester.



[258] 7-Benzenesulfonyl-4-chloro-6-iodo-7*H*-pyrrolo[2,3-*d*]pyrimidine (4.05g, 9.65mmol), 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester (2.985g, 9.65mmol), potassium carbonate (2.935g, 21.25mmol) and dichlorobis(triphenylphosphine)-palladium(II) (678mg, 0.96mmol) were combined in dioxane/water (85mL:21mL) and heated to 90°C for 2h. After cooling the reaction mixture was extracted with ethyl acetate (3 x 50mL), the organic layers were combined and washed with aqueous sodium bicarbonate, brine and finally water. The organic layer was dried over anhydrous magnesium sulphate, filtered and pre-absorbed onto silica *in*

vacuo. Purification on silica gel by gradient elution with isohexane:ethyl acetate (6:1) finishing with isohexane:ethyl acetate (4:1) yielded a yellow solid. ¹H NMR (d₆-DMSO, 400MHz) 8.8(1H, s), 8.0 (2H, d), 7.8(1H,m), 7.6(2H,m), 6.8(1H, s), 6.0(1H, s), 4.1(2H, br. s), 3.6(2H,m), 2.5(2H, br. s), and 1.5(9H, s); LC/MS: *m/z* 474 [M+H]⁺, Rt =4.42min

[259] Functionalisation of (1H-Indazol-5-yl)-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-amine hydrochloride (compound of Formula I-B-H wherein R₂ = H and R₁ = indazol-5-yl) to yield compounds of Formula I-B wherein R₂ = H, R₁ = indazol-5-yl, and Z is as defined previously:

[260] *Preferred method with Acid Chlorides, Chloroformates, Carbamoyl Chlorides, Sulfamoyl chlorides, Sulfonyl chlorides & Isocyanates.*

[261] To a solution of 1H-indazol-5-yl-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-amine hydrochloride (40mg, 0.11mmol) in DMF (1.5mL) was added diisopropylethylamine (57μL, 3eq., 0.33mmol) at r.t., followed by the appropriate capping reagent (acid chloride, chloroformate, carbamoyl chloride, sulfamoyl chloride, sulfonyl chloride or isocyanate) (1eq., 0.11mmol). The reaction was stirred at r.t. overnight. After this time, the reaction was quenched with methanol (0.5mL) and the solvent was evaporated under reduced pressure. The resultant residue was purified by mass-directed HPLC using water / acetonitrile mixtures optionally containing formic acid, trifluoroacetic acid, or ammonium carbonate to optimize separation.

[262] (Alternative methods including the use of polymer-supported diisopropylethylamine (PS-DIEA) under the conditions outlined above, or use of the free base 1H-indazol-5-yl-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-amine (prepared by stirring of 1H-indazol-5-yl-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-amine hydrochloride with MP-Carbonate resin in methanol over 2h at r.t.) with reduced amounts of diisopropylethylamine present (1eq.) were also used to prepare some of the compounds described).


[263] *Preferred method with Carboxylic Acids.*

[264] To a mixture of the appropriate carboxylic acid (1eq., 0.1088mmol), 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide hydrochloride (EDCI·HCl) (31.3mg., 1.5eq., 0.163mmol), N-hydroxybenzotriazole monohydrate (HOBt·H₂O) (22.1mg., 1.5eq., 0.163mmol) and a catalytic amount of 4-dimethylaminopyridine (DMAP) was added DMF (2mL) followed by triethylamine (54μL, 3.5eq., 0.38mmol). The solution was stirred at r.t. for 5min before 1H-indazol-5-yl-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-amine hydrochloride (40mg, 0.11mmol) was added in a single portion. The reaction was stirred at r.t. overnight. After this time, the reaction was diluted with ethyl

acetate (5mL) and an aqueous solution of sodium bicarbonate (2mL). The organic layer was collected and the aqueous layer extracted with ethyl acetate (2 x 5mL). The combined organic layer was washed with water (2mL), dried over anhydrous magnesium sulphate, filtered and the solvent was evaporated under reduced pressure. The resultant residue was purified by mass-directed HPLC. Alternatively, crude reaction mixtures were taken directly, the solvent was evaporated under reduced pressure and the residue was purified by mass-directed HPLC.







[265] (An alternative method using the free base 1H-indazol-5-yl-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-amine (prepared by stirring of 1H-indazol-5-yl-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-amine hydrochloride with MP-Carbonate resin in methanol over 2h at r.t.) with reduced amounts of triethylamine (1.5eq.) was also used to prepare some of the compounds described).





[266] **Table 2:** Examples of compounds prepared by functionalisation of (1H-indazol-5-yl)-[6-(1,2,3,6-tetrahydro-pyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-amine hydrochloride or (1H-indazol-5-yl)-[6-(1,2,3,6-tetrahydro-pyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-amine (prepared by stirring of (1H-indazol-5-yl)-[6-(1,2,3,6-tetrahydro-pyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-amine, as described above.




[267] **Table 2**

EX.	Z	NMR	NMR Solvent	MH ⁺	HPLC Rt (Min)
51		12.0 (1H, s), 9.4 (1H, s), 8.4 (2H, s), 8.2 (1H, s), 8.0 (1H, s), 7.7 (1H, d), 7.5 (1H, d), 6.8 (1H, d), 6.4 (1H, br.s), 4.2 (4H, m), 3.6 (2H, m), 3.3 (3H, s), 2.5 (2H, m, obscured)	DMSO	404	2.81
52		12.1 (1H, s), 9.3 (1H, s), 8.5 (1H, br. s), 8.4 (1H, s), 8.2 (1H, s), 8.0 (1H, s), 7.7 (1H, d), 7.5 (1H, d), 6.8 (1H, s), 6.4 (1H, br.s), 4.0 (2H, br.s), 3.6 (4H, m), 3.4 (2H, m, partially obscured), 3.2 (4H, m), 2.5 (2H, m, obscured)	DMSO	445	2.64

EX.	Z	NMR	NMR Solvent	MH ⁺	HPLC Rt (Min)
53		12.3 (1H, s), 9.4 (1H, s), 8.6 (1H, s), 8.4 (1H, d), 8.2 (1H, s), 8.0 (1H, s), 7.7 (1H, d), 7.5 (1H, d), 6.8 (1H, d), 6.4 (1H, br.s), 4.3 (2H, m), 4.2 (1H, br.s), 3.8 (3H, m), 3.2 (1H, m), 3.0 (1H, m), 2.6 (1H, m), 2.5 (2H, m, partially obscured), 2.0 (3H, s), 1.7 (2H)	DMSO	485	2.56
54		11.9 (1H, s), 9.4 (1H, s), 8.5 (1H, s), 8.4 (1H, s), 8.2 (1H, s), 8.0 (1H, s), 7.7 (1H, d), 7.5 (1H, d), 7.4 (1H, s), 6.8 (1H, s), 6.4 (1H, br.s), 3.8 (2H, br.s), 3.7 (3H, s), 3.4 (2H, m, partially obscured), 2.5 (2H, m, obscured), 2.3 (3H, s)	DMSO	490	2.67
55		11.8 (1H, s), 9.3 (1H, s), 8.4 (1H, s), 8.2 (1H, s), 8.0 (1H, s), 7.7 (1H, d), 7.5 (1H, d), 6.8 (1H, s), 6.4 (1H, br.s), 4.2 (2H, m), 4.1 (2H, m), 3.6 (2H, m), 3.5 (2H, m), 3.3 (3H, s), 2.5 (2H, m, obscured)	DMSO	434	2.67
56		12.0 (1H, s), 9.4 (1H, s), 8.5 (1H, s), 8.4 (1H, s), 8.2 (1H, s), 8.0 (1H, s), 7.7 (1H, d), 7.5 (1H, d), 6.8 (1H, s), 6.4 (1H, br.s), 4.1 (2H, m), 3.6 (3H, s + 2H, m), 2.5 (2H, m, obscured)	DMSO	390	2.81
57		11.7 (1H, s), 9.3 (1H, s), 8.6 (1H, s), 8.4 (1H, s), 8.2 (1H, s), 8.0 (1H, s), 7.7 (1H, d), 7.5 (1H, d), 6.8 (1H, s), 6.4 (1H, br.s), 3.9 (2H, m), 3.4 (2H, m), 2.8 (6H, s), 2.6 (2H, m)	DMSO	439	2.86
58		11.8 (1H, s), 9.3 (1H, s), 8.4 (2H, br. s), 8.2 (1H, s), 8.0 (1H, s), 7.7 (1H, d), 7.5 (1H, d), 6.8 (1H, d), 6.4 (1H, br.s), 4.2 (1H, br. s), 4.1 (1H, br. s), 3.6 (2H, m), 2.6 (4H, m), 2.5 (2H, m, obscured), 2.4 (4H, m), 1.5 (4H, m), 1.4 (2H, m)	DMSO	471	2.29

EX.	Z	NMR	NMR Solvent	MH ⁺	HPLC Rt (Min)
59		12.0 (1H, s), 9.4 (1H, s), 8.4 (2H, br. s), 8.2 (1H, s), 8.0 (1H, s), 7.7 (1H, d), 7.5 (1H, d), 6.8 (1H, d), 6.4 (1H, br.s), 4.2 (1H, br. s), 4.1 (1H, br. s), 3.7 (2H, m), 2.6 (2H, m, obscured), 2.4 (2H, m), 2.2 (2H, m), 2.1 (6H, 2 x s), 1.7 (2H, m)	DMSO	445	2.37
60		11.8 (1H, s), 9.4 (1H, s), 8.7 (2H, s), 8.5 (1H, s), 8.4 (1H, s), 8.2 (1H, s), 8.0 (1H, s), 7.9 (1H, d), 7.7 (1H, d), 7.5 (2H, d), 6.8 (1H, s), 6.5 & 6.3 (1H, 2 x br.s, rotamers), 4.3 (1H, br.s), 4.2 & 3.9 (1H, 2 x m, rotamers), 3.6 (2H, m, partially obscured), 2.4 (2H, m).	DMSO	437	2.51
61		<i>Not recorded</i>		436	2.15
62		<i>Not recorded</i>		416	2.18


[268] **EXAMPLE 63:** {6-[1-(2-Chloropyrimidin-4-yl)-1,2,3,6-tetrahydropyridin-4-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}-(1H-indazol-5-yl)-amine.



[269] Following the Preferred method with Acid Chlorides, Chloroformates, Carbamoyl Chlorides, Sulfamoyl chlorides, Sulfonyl chlorides & Isocyanates, but using 2,4-dichloropyrimidine as capping reagent, one obtained the title compound. MS (ES⁺): *m/z* 444.03/446.06 (38/13) [MH⁺]. HPLC: *t_R* = 2.21 min (ZQ2000, polar_5min).




[270] Following the Preferred method with Acid Chlorides, Chloroformates, Carbamoyl Chlorides, Sulfamoyl chlorides, Sulfonyl chlorides & Isocyanates, using benzo[thiazol-6-yl]-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine

trihydrochloride and the appropriate capping reagent, one obtained the examples listed in TABLE 3.




[271] **Table 3**

EX.	Z	[MH ⁺]	HPLC <i>t_R</i> (min) (ZQ2000, polar_5min)
64		454.08	2.23
65		453.07	2.64
66		447.07	2.79
67		448.15	2.61
68		460.08	2.64
69		519.10	1.83
70		446.12	2.51
71		474.11	2.77
72		498.12	2.71


EX.	Z	[MH ⁺]	HPLC <i>t_R</i> (min) (ZQ2000, polar_5min)
73		536.03	3.09
74		493.06	2.71
75		502.03	2.96

[272] **EXAMPLE 76:** 4-[4-(1*H*-Indazol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]-pyrimidin-6-yl]-piperidine-1-carboxylic acid *tert*-butyl ester.



[273] A rapidly stirred mixture of 4-[4-(1*H*-indazol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester (0.1g) and 10% palladium on carbon (10mg) was heated in ethanol (20mL) at 100°C under a 100PSI hydrogen atmosphere for 6h. After this time the mixture was cooled, filtered through celite and concentrated. Crystallisation from methanol/ethyl acetate afforded the title compound. ¹H NMR (300MHz, DMSO) δ = 1.44 (9H, s), 1.55 (1H, m), 2.0 (2H, m), 2.89 (3H, m), 4.06 (2H, m), 6.46 (1H, s), 7.52 (1H, d), 7.66 (1H, d), 8.07 (1H, s), 8.12 (1H, s), 8.18 (1H, s) and 9.15 (1H, s). MH⁺ 434.16.

[274] **EXAMPLE 77:** 4-[4-(1*H*-Indazol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]-pyrimidin-6-yl]-1-(2-methoxyethyl)-1*H*-pyridin-2-one.



[275] A mixture of (1*H*-indazol-5-yl)-(6-iodo-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)-amine (0.076g), 1-(2-methoxy-ethyl)-2-oxo-1,2-dihydro-pyridine-4-boronic acid (36mg), PdCl₂(PPh₃)₂ (7mg) and potassium carbonate (76mg) in dioxane/water (4:1) (5mL) was heated to 100°C for 48h. Purification via chromatography afforded the title compound as a

pale yellow solid. δ_H 3.30 (3H, s), 3.62 (2H, t), 4.18 (2H, t), 5.99 (1H, dd), 6.89 (1H, d), (7.27 (1H, s), 7.57 (2H, d), 7.69 (2H, m), 8.09 (1H, s), 8.16 (1H, s), 8.18 (1H, s) and 9.67 (1H, s). MH^+ 402.13.


[276] A mixture of trifluoromethanesulfonic acid 1-(2-methoxy-ethyl)-2-oxo-1,2-dihydro-pyridin-4-yl ester (0.5g, 1.66mmol), bis-(pinacolato)di-boron (0.464g, 1.83mmol), potassium acetate (0.488g, 4.98mmol), $PdCl_2(dppf)$ (0.04g, 0.05mmol), dppf (0.028g) in dioxane was heated at 80°C for 24h. The mixture was cooled, diluted with water (15mL) and extracted with ethyl acetate (3 x 5mL). The aqueous layer was concentrated and purification via elution through a silica plug afforded 1-(2-methoxy-ethyl)-2-oxo-1,2-dihydro-pyridine-4-boronic acid. MH^+ 198.03.

[277] A round bottom flask was charged with 4-hydroxy-1-(2-methoxy-ethyl)-1H-pyridin-2-one (5.39mmol), DCM (15mL) and triethylamine (1mL, 7mmol) and cooled to -78°C. Triflic anhydride (1mL, 7mmol) was added drop-wise, and after stirring for a further 20min the cooling bath was removed and the mixture allowed to reach rt. After 1.5h, the mixture was diluted with further DCM, washed with aqueous saturated sodium hydrogen carbonate solution, brine, dried and concentrated. Purification via flash chromatography afforded trifluoromethanesulfonic acid 1-(2-methoxy-ethyl)-2-oxo-1,2-dihydro-pyridin-4-yl ester (1.1g) as a colourless oil. MH^+ 301.98.

[278] A mixture of 4-benzyloxy-1-(2-methoxy-ethyl)-1H-pyridin-2-one (1.4g) and 10% palladium on carbon (100mg) was stirred in ethyl acetate (50mL) under a hydrogen atmosphere for 17h. Then, the mixture was filtered through celite and concentrated to afford 4-hydroxy-1-(2-methoxy-ethyl)-1H-pyridin-2-one as a colourless solid. δ_H (300MHz, CH_3OD) 3.67 (2H, t), 4.10 (2H, t), 4.86 (3H, s), 5.85 (1H, d), 6.04 (1H, dd) and 7.48 (1H, d).


[279] To a mixture of 4-benzyloxy-2(1H)-pyridine (2g, 9.94mmol) and caesium carbonate (6.5g, 19.88mmol) in DMF (20mL) was added 2-bromoethyl methyl ether (1.4mL, 14.91mmol). After stirring for 17h the mixture was poured into water and extracted with ethyl acetate. The combined organics were washed with brine, dried and concentrated. Purification via flash chromatography afforded 4-benzyloxy-1-(2-methoxy-ethyl)-1H-pyridin-2-one. MH^+ 201.96.

[280] **EXAMPLE 78: 4-[4-(Quinolin-6-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl ester.**




[281] To a stirred suspension of sodium hydride (60% dispersion in mineral oil) (24mg, 0.6mmol) in anhydrous DMSO (4mL) under argon, was added 6-hydroxyquinoline (239mg, 1.65mmol). The mixture was allowed to stir at rt for 1h. To this mixture was added 1-[6-(1-*tert*-butoxycarbonyl-1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-*d*]pyrimidin-4-yl]-4-aza-1-azonia-bicyclo[2.2.2]octane chloride (100mg, 0.3mmol) in DMSO (0.3mL), and the mixture stirred for a further 16h. TLC analysis showed no starting material so the mixture was neutralised with glacial acetic acid and basified with saturated aqueous sodium bicarbonate solution. The product was extracted in to EtOAc (3 x 50mL), the organics dried with MgSO₄, filtered and concentrated under reduced pressure. The resulting residue was purified on silica gel by elution with iso-hexane: ethyl acetate to yield the title compound. ¹H NMR (DMSO, 400MHz) 1.4 (9H, s), 2.5 (2H, broad), 3.6 (2H, broad), 4.1 (2H, broad), 6.5 (1H, m), 6.7 (1H, s), 7.6 (1H, m), 7.7 (1H, d), 7.9 (1H, s), 8.1 (1H, d), 8.3 (1H, s), 8.4 (1H, d), 8.9 (1H, s), 12.4 (NH, s). MH⁺ = 444.24

[282] **1-[6-(1-*tert*-Butoxycarbonyl-1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-*d*]pyrimidin-4-yl]-4-aza-1-azoniabicyclo[2.2.2]octane chloride.**



[283] To a stirred solution of 1M *tert*-butyl 4-(4-chloro-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl)-3,6-dihydropyridine-1(2H)-carboxylate (200mg, 0.6mmol) in anhydrous DMSO (0.6mL), was added 1,4-Diaza-bicyclo[2.2.2]octane (370mg, 3.3mmol). The mixture was stirred under argon at rt until TLC analysis showed no starting material was present. The resulting solution containing the title compound was used directly in the next step.

[284] **EXAMPLE 79: Benzothiazol-6-yl-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-*d*]pyrimidin-4-yl]amine trihydrochloride.**




[285] To a suspension of benzothiazol-6-yl-(6-iodo-7H-pyrrolo[2,3-*d*]pyrimidin-4-yl)-amine (4.05g, 10.3mmol) in 1,2-dimethoxyethane (125mL) and water (25mL) were added 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl ester (3.50g, 11.3mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloro palladium(II), complex with dichloromethane (1:1) (420mg, 0.51mmol) and potassium carbonate (2.85g, 20.6mmol). The flask was evacuated and refilled with N₂ (3×). The

mixture was heated at 80°C overnight. The reaction mixture was diluted with EtOAc (200mL) and water (50mL) and filtered through a pad of celite. The organic phase was separated, and the aqueous phase was extracted with EtOAc (2 × 50mL). The combined organic phases were washed with brine (100mL), and dried over anhydrous sodium sulfate. Evaporation under reduced pressure afforded a brown solid. To a suspension of this crude material in methylene chloride (30mL) was added 4M HCl/1,4-dioxane (30mL), and the resulting mixture was stirred at rt overnight. The mixture was diluted with CH₂Cl₂ (30mL), and the light-yellow solid was collected by filtration and dried *in vacuo* to give the title compound. LC-MS (ES, Pos.): 349 [MH⁺]. ¹H NMR (DMSO-d₆, 400 MHz): δ = 2.51 (m, 2H), 3.34 (m, 2H), 3.81 (m, 2H), 6.52 (s, 1H), 7.09 (s, 1H), 7.73 (dd, *J* = 8.7 Hz, 2.0 Hz, 1H), 8.22 (d, *J* = 8.7 Hz, 1H), 8.36 (d, *J* = 2.0 Hz, 1H), 8.51 (s, 1H), 9.46 (s, 1H).


[286] *Alternative preparation:* A mixture of 4-(4-chloro-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl)-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester (5.02g, 15mmol) and 1,3-benzothiazol-6-amine (2.25g, 15mmol) in 1-butanol (50mL) was heated at 115°C overnight, LC-MS showed the desired product and some de-Boc product. After the mixture was cooled to rt, it was diluted with hexane (50mL), the gray solid was collected by filtration, a mixture of the desired product and some de-Boc product, which was directly used in the next step. To a suspension of this material in methylene chloride (30mL) was added 4M HCl/1,4-dioxane (30mL), the resulting mixture was stirred at rt for 5h. The mixture was then diluted with CH₂Cl₂ (30mL), and the light-yellow solid was collected by filtration and dried *in vacuo*.

[287] **EXAMPLE 80: 3-{4-[4-(Benzothiazol-6-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carbonyl}-benzoic acid methyl ester.**




[288] The title compound was obtained following the Preferred method with Acid Chlorides, Chloroformates, Carbamoyl Chlorides, Sulfamoyl chlorides, Sulfonyl chlorides & Isocyanates, using benzothiazol-6-yl-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl]amine trihydrochloride and isophthalic acid monomethyl ester. ¹H NMR (DMSO, 400 MHz): δ = 9.6(1H,s), 9.25(1H,s), 8.9(1H,s), 8.3(1H,s), 8.1-8.0(3H,m), 7.9(1H,d), 7.75 (1H, d), 7.65(1H, t), 6.85(1H, s), 6.5(1H, m), 6.3(1H, m), 4.3(1H, m), 4.1(1H, m), 3.9(3H, s), 3.6(1H, m), 2.6(1H, m). [MH⁺ - CH₃] = 512.45.

[289] **EXAMPLE 81: 3-{4-[4-(Benzothiazol-6-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carbonyl}-benzoic acid.**




[290] 3-{4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carbonyl}-benzoic acid methyl ester (0.624mmol) was suspended in a mixture of MeOH (6.0mL) and water (2.0mL). 2M NaOH solution (1.0mmol) was then added to the above suspension and the reaction temperature increased to 65°C. The resulting suspension was stirred for a further period of 16h. The mixture was allowed to reach r.t and diluted with EtOAc (30mL) and washed with 2M NaOH (2×20mL). The aqueous phase was then acidified by careful addition of conc. HCl solution until pH≈1. The resulting brown precipitate was then filtered and dried under vacuum affording the title compound. ¹H NMR (DMSO, 400 MHz): δ = 9.45(1H,s), 8.7(1H,s), 8.15(1H,d), 8.1(1H,d), 8.0(1H,s), 7.8(1H,d), 7.7 (1H, d), 7.6(1H, t), 6.9(1H, s), 6.6(1H, m), 6.35(1H, m), 4.35(1H, m), 4.1(1H, m), 3.9(1H, m), 2.6(1H, m). [MH⁺ – CO₂] = 498.25.

[291] **EXAMPLE 82: 1-{4-[4-(1H-Indazol-5-ylamino)-7H-pyrrolo[2,3-d]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-yl}-2-phenylethanone.**




[292] To a solution of (1H-indazol-5-yl)-[6-(1,2,3,6-tetrahydropyridine-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine tri-hydrochloride (73.6mg, 0.2mmol) and phenylacetyl chloride (31mg, 0.2mmol) in dichloromethane (1.5mL) was added *i*-Pr₂NH (0.1mL). The resulting mixture was stirred at rt for 3h. MeOH (0.3mL) was added to quench the reaction. Solvents were removed and the residue was dissolved in DMF (≈2mL), which was purified by mass-directed HPLC to obtain the title compound. ¹H-NMR (DMSO-d₆, 400 MHz): δ = 2.34 (m, 2 H), 3.72 (t, *J* = 5.6 Hz, 2 H), 3.80 (d, *J* = 17.6 Hz, 2 H), 4.21 (d, *J* = 35.6 Hz, 2 H), 6.40 (s, 1 H), 6.73 (d, *J* = 38.4 Hz, 1 H), 7.22-7.34 (m, 4 H), 7.51 (d, *J* = 8.8 Hz, 1 H), 7.63 (m, 1 H), 8.04 (s, 1 H), 8.25 (d, *J* = 4.4 Hz, 1 H), 8.37 (t, *J* = 7.2 Hz, 1 H), 9.33 (d, *J* = 13.6 Hz, 1 H), 11.92 (d, *J* = 14.8 Hz, 1 H), 12.97 (s, 1 H). MS (ES⁺): *m/z* 450.07 [MH⁺]. HPLC: *t_R* = 2.17 min (ZQ2000, polar_5min).

[293] **EXAMPLE 83: Phenyl 4-[4-(1H-indazol-5-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylate.**




[294] The title compound was obtained following the Preferred method with Acid Chlorides, Chloroformates, Carbamoyl Chlorides, Sulfamoyl chlorides, Sulfonyl chlorides & Isocyanates, using phenyl chloroformate. $^1\text{H-NMR}$ (DMSO-d_6 , 400 MHz): δ = 2.58-2.62 (m, 2 H), 3.70 (m, 1 H), 3.84 (m, 1 H), 4.16 (m, 1 H), 4.35 (m, 1 H), 6.45 (s, 1 H), 6.81 (s, 1 H), 7.17 (d, J = 8.4 Hz, 2 H), 7.23 (t, J = 6.8 Hz, 1 H), 7.40 (t, J = 7.2 Hz, 2 H), 7.52 (d, J = 8.8 Hz, 1 H), 7.66 (d, J = 7.2 Hz, 1 H), 8.05 (s, 1 H), 8.26 (s, 1 H), 8.38 (s, 1 H), 9.36 (s, 1 H), 11.97 (s, 1 H), 12.97 (s, 1 H). MS (ES $^+$): m/z 452.02 [MH^+]. HPLC: t_R = 2.38 min (ZQ2000, polar_5min).

[295] **EXAMPLE 84:** *N*-Methyl-*N*-phenyl 4-[4-(1*H*-indazol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxamide.



[296] The title compound was obtained following the Preferred method with Acid Chlorides, Chloroformates, Carbamoyl Chlorides, Sulfamoyl chlorides, Sulfonyl chlorides & Isocyanates, using *N*-methyl-*N*-phenylcarbamoylchloride. $^1\text{H-NMR}$ (DMSO-d_6 , 400 MHz): δ = 2.20 (m, 2 H), 3.13 (s, 3 H), 3.78 (m, 2 H), 6.28 (s, 1 H), 6.66 (s, 1 H), 7.14 (d, J = 7.2 Hz, 1 H), 7.18 (d, J = 8.4 Hz, 2 H), 7.38 (t, J = 7.2 Hz, 2 H), 7.50 (d, J = 8.8 Hz, 1 H), 7.64 (d, J = 9.2 Hz, 1 H), 8.04 (s, 1 H), 8.24 (d, J = 5.2 Hz, 1 H), 8.36 (d, J = 6.4 Hz, 1 H), 9.29 (s, 1 H), 11.85 (s, 1 H), 12.96 (s, 1 H). MS (ES $^+$): m/z 465.04 [MH^+]. HPLC: t_R = 2.25 min (ZQ2000, polar_5min).


[297] **EXAMPLE 85:** 4-[4-(1*H*-Indazol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]-pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxythioamide.



[298] The title compound was obtained following the Preferred method with Acid Chlorides, Chloroformates, Carbamoyl Chlorides, Sulfamoyl chlorides, Sulfonyl chlorides & Isocyanates, using phenyl isothiocyanate. $^1\text{H-NMR}$ (DMSO-d_6 , 400 MHz): δ = 2.62 (m, 2 H), 4.17 (t, J = 6.0 Hz, 2 H), 4.55 (m, 2 H), 6.44 (s, 1 H), 6.80 (s, 1 H), 7.14 (m, 1 H), 7.31-7.33


(m, 3 H), 7.52 (d, $J = 8.8$ Hz, 1 H), 7.66 (d, $J = 8.8$ Hz, 1 H), 8.05 (s, 1 H), 8.27 (d, $J = 1.2$ Hz, 1 H), 8.38 (d, $J = 6.8$ Hz, 1 H), 9.36 (s, 1 H), 11.95 (s, 1 H), 12.97 (s, 1 H). MS (ES⁺): m/z 467.00 [MH⁺]. HPLC: $t_R = 2.33$ min (ZQ2000, polar_5min).

[299] **EXAMPLE 86:** *tert*-Butyl 4-[4-(1*H*-indazol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxamide.




[300] The title compound was obtained following the Preferred method with Acid Chlorides, Chloroformates, Carbamoyl Chlorides, Sulfamoyl chlorides, Sulfonyl chlorides & Isocyanates, using *tert*-butyl isocyanate. ¹H-NMR (DMSO-*d*₆, 400 MHz): $\delta = 1.28$ (s, 9 H), 2.44 (m, 2 H), 3.52 (t, $J = 4.8$ Hz, 2 H), 3.99 (m, 2 H), 5.79 (s, 1 H), 6.40 (s, 1 H), 6.74 (s, 1 H), 7.52 (d, $J = 8.8$ Hz, 1 H), 7.66 (dd, $J = 1.6, 8.8$ Hz, 1 H), 8.05 (s, 1 H), 8.25 (s, 1 H), 8.37 (s, 1 H), 9.32 (s, 1 H), 11.90 (s, 1 H), 12.97 (s, 1 H). MS (ES⁺): m/z 431.04 [MH⁺]. HPLC: $t_R = 2.14$ min (ZQ2000, polar_5min).

[301] **EXAMPLE 87:** Ethyl 4-[4-(1*H*-indazol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxamide.




[302] The title compound was obtained following the Preferred method with Acid Chlorides, Chloroformates, Carbamoyl Chlorides, Sulfamoyl chlorides, Sulfonyl chlorides & Isocyanates, using ethyl isocyanate. ¹H-NMR (CD₃OD, 400 MHz): $\delta = 1.14$ (t, $J = 6.4$ Hz, 3 H), 2.54 (m, 2 H), 3.23 (q, $J = 6.8$ Hz, 2 H), 3.65 (t, $J = 5.2$ Hz, 2 H), 4.11 (m, 2 H), 6.40 (s, 1 H), 6.68 (s, br, 1 H), 7.47 (d, $J = 8.8$ Hz, 1 H), 7.76 (d, $J = 8.4$ Hz, 1 H), 7.98 (s, 1 H), 8.12 (s, 1 H), 8.17 (s, 1 H). MS (ES⁺): m/z 403.05 [MH⁺]. HPLC: $t_R = 1.86$ min (ZQ2000, polar_5min).

[303] **EXAMPLE 88:** 4-[4-(1*H*-Indazol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]-pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid (2-fluorophenyl)-amide.




[304] The title compound was obtained following the Preferred method with Acid Chlorides, Chloroformates, Carbamoyl Chlorides, Sulfamoyl chlorides, Sulfonyl chlorides & Isocyanates, using 2-fluorophenyl isocyanate. ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ = 2.53–2.59 (m, 2H), 3.70 (t, J = 5.2 Hz, 2H), 4.19 (s, br, 2H), 6.45 (s, br, 1H), 6.78 (s, 1H), 7.10–7.16 (m, 2H), 7.17–7.23 (m, 1H), 7.42–7.49 (m, 1H), 7.52 (d, J = 9.2 Hz, 1H), 7.66 (dd, J = 8.8, 1.6 Hz, 1H), 8.05 (s, 1H), 8.26 (s, 1H), 8.34 (s, –NH), 8.37 (s, 1H), 9.33 (s, –NH), 11.93 (s, –NH), 12.96 (s, –NH). MS (ES⁺): m/z 469.02 (100) [MH^+]. HPLC: t_R = 2.16 min (ZQ2000, polar_5min).

[305] **EXAMPLE 89: 4-[4-(1*H*-Indazol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]-pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid (3-fluorophenyl)-amide.**




[306] The title compound was obtained following the Preferred method with Acid Chlorides, Chloroformates, Carbamoyl Chlorides, Sulfamoyl chlorides, Sulfonyl chlorides & Isocyanates, using 3-fluorophenyl isocyanate. ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ = 2.44–2.56 (m, 2H), 3.70 (t, J = 5.6 Hz, 2H), 4.21 (s, br, 2H), 6.46 (s, br, 1H), 6.70–6.80 (m, 2H), 7.22–7.32 (m, 2H), 7.44–7.55 (m, 2H), 7.65 (dd, J = 8.8, 1.6 Hz, 1H), 8.05 (s, 1H), 8.26 (s, 1H), 8.36 (d, J = 2.0 Hz, 1H), 8.75 (s, –NH), 9.33 (s, –NH), 11.92 (s, –NH), 12.96 (s, –NH). MS (ES⁺): m/z 469.02 (100) [MH^+]. HPLC: t_R = 2.32 min (ZQ2000, polar_5min).

[307] **EXAMPLE 90: 4-[4-(1*H*-Indazol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]-pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid (4-fluorophenyl)-amide.**




[308] The title compound was obtained following the Preferred method with Acid Chlorides, Chloroformates, Carbamoyl Chlorides, Sulfamoyl chlorides, Sulfonyl chlorides & Isocyanates, using 4-fluorophenyl isocyanate. ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ = 2.44–2.56 (m, 2H), 3.67–3.72 (m, 2H), 4.19 (d, J = 1.2 Hz, 2H), 6.46 (s, br, 1H), 6.77 (s, 1H), 7.08 (t, J = 8.8 Hz, 2H), 7.47–7.54 (m, 3H), 7.66 (dd, J = 8.8, 2.0 Hz, 1H), 8.05 (s, 1H), 8.26 (s, 1H), 8.36 (d, J = 1.2 Hz, 1H), 8.57 (s, –NH), 9.33 (s, –NH), 12.96 (s, –NH). MS (ES⁺): m/z 469.02 (100) [MH^+]. HPLC: t_R = 2.26 min (ZQ2000, polar_5min).

[309] **EXAMPLE 91: 4-[4-(1*H*-Indazol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]-pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid (2-methoxyphenyl)-amide.**




[310] The title compound was obtained following the Preferred method with Acid Chlorides, Chloroformates, Carbamoyl Chlorides, Sulfamoyl chlorides, Sulfonyl chlorides & Isocyanates, using 2-methoxyphenyl isocyanate. ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ = 2.53–2.56 (m, 2H), 3.68 (t, J = 5.2 Hz, 2H), 3.83 (s, 3H), 4.19 (s, br, 2H), 6.44 (s, br, 1H), 6.78 (s, 1H), 6.85–6.95 (m, 1H), 6.99–7.04 (m, 2H), 7.52 (d, J = 9.2 Hz, 1H), 7.64–7.68 (m, 2H), 7.70 (s, –NH), 8.05 (s, 1H), 8.26 (s, 1H), 8.37 (s, 1H), 9.34 (s, –NH), 11.94 (s, –NH), 12.97 (s, –NH). MS (ES $^+$): m/z 481.03 (100) [MH^+]. HPLC: t_R = 2.23 min (ZQ2000, polar₅min).

[311] **EXAMPLE 92: 4-[4-(1H-Indazol-5-ylamino)-7H-pyrrolo[2,3-d]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid (3-methoxyphenyl)-amide.**



[312] The title compound was obtained following the Preferred method with Acid Chlorides, Chloroformates, Carbamoyl Chlorides, Sulfamoyl chlorides, Sulfonyl chlorides & Isocyanates, using 3-methoxyphenyl isocyanate. ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ = 2.43–2.47 (m, 2H), 3.67–3.70 (m, 2H), 3.71 (s, 3H), 4.19 (s, br, 2H), 6.46 (s, br, 1H), 6.52 (ddd, J = 7.6, 2.4, 1.6 Hz, 1H), 6.77 (s, 1H), 7.07–7.12 (m, 1H), 7.14 (dd, J = 8.0, 7.6 Hz, 1H), 7.19 (t, J = 2.0 Hz, 1H), 7.52 (d, J = 8.8 Hz, 1H), 7.66 (dd, J = 8.8, 1.6 Hz, 1H), 8.05 (s, 1H), 8.26 (s, 1H), 8.37 (s, 1H), 8.53 (s, –NH), 9.33 (s, –NH), 11.92 (s, –NH), 12.97 (s, –NH). MS (ES $^+$): m/z 481.03 (100) [MH^+]. HPLC: t_R = 2.23 min (ZQ2000, polar₅min).


[313] **EXAMPLE 93: 4-[4-(1H-Indazol-5-ylamino)-7H-pyrrolo[2,3-d]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid (4-methoxyphenyl)-amide.**



[314] The title compound was obtained following the Preferred method with Acid Chlorides, Chloroformates, Carbamoyl Chlorides, Sulfamoyl chlorides, Sulfonyl chlorides & Isocyanates, using 4-methoxyphenyl isocyanate. ^1H NMR (400 MHz, $\text{MeOH}-d_4$): δ = 2.61 (s, br, 2H), 3.75–3.80 (m, 2H), 3.77 (s, 3H), 4.26 (s, br, 2H), 6.44 (s, br, 1H), 6.63–6.78 (s, br, 1H), 6.86 (dd, J = 6.8, 2.0 Hz, 2H), 7.25 (dd, J = 6.8, 2.0 Hz, 2H), 7.48 (dd, J = 8.8, 2.4 Hz,


1H), 7.77 (d, $J = 8.8$ Hz, 1H), 7.98 (d, $J = 2.4$ Hz, 1H), 8.13 (s, 1H), 8.18 (s, 1H). MS (ES⁺): m/z 480.97 (100) [MH⁺]. HPLC: $t_R = 2.13$ min (ZQ2000, polar_5min).

[315] **EXAMPLE 94: 4-[4-(1H-Indazol-5-ylamino)-7H-pyrrolo[2,3-d]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid phenylamide.**




[316] The title compound was obtained following the Preferred method with Acid Chlorides, Chloroformates, Carbamoyl Chlorides, Sulfamoyl chlorides, Sulfonyl chlorides & Isocyanates, using phenyl isocyanate. ¹H NMR (400 MHz, DMSO- d_6): $\delta = 2.43$ – 2.57 (m, 2H), 3.69 (m, 2H), 4.21 (s, br, 2H), 6.51 (s, br, 1H), 6.75–6.84 (s, br, 1H), 6.95 (t, $J = 7.2$ Hz, 1H), 7.24 (t, $J = 8.8$ Hz, 2H), 7.49 (d, $J = 7.6$ Hz, 2H), 7.51–7.57 (s, br, 1H), 7.60–7.67 (s, br, 1H), 8.08–8.20 (m, br, 1H + –NH), 8.25 (s, 1H), 8.55 (s, 1H), 13.01–13.31 (s, br, –NH). MS (ES⁺): m/z 451.01 (100) [MH⁺]. HPLC: $t_R = 2.21$ min (ZQ2000, polar_5min).

[317] **EXAMPLE 95: 4-[4-(1H-Indazol-5-ylamino)-7H-pyrrolo[2,3-d]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid benzylamide.**




[318] The title compound was obtained following the Preferred method with Acid Chlorides, Chloroformates, Carbamoyl Chlorides, Sulfamoyl chlorides, Sulfonyl chlorides & Isocyanates, using benzyl isocyanate. ¹H NMR (400 MHz, DMSO- d_6): $\delta = 2.44$ – 2.53 (m, 2H), 3.60 (t, $J = 5.2$ Hz, 2H), 4.07 (s, br, 2H), 4.28 (d, $J = 5.6$ Hz, 2H), 6.42 (s, br, 1H), 6.75 (s, 1H), 7.14 (t, $J = 5.6$ Hz, –NH), 7.18–7.23 (m, 1H), 7.25–7.34 (m, 4H), 7.51 (d, $J = 8.8$ Hz, 1H), 7.65 (dd, $J = 9.2, 2.0$ Hz, 1H), 8.04 (s, 1H), 8.25 (s, 1H), 8.36 (d, $J = 0.8$ Hz, 1H), 9.31 (s, –NH), 11.88 (s, –NH), 12.96 (s, –NH). MS (ES⁺): m/z 465.04 (100) [MH⁺]. HPLC: $t_R = 2.20$ min (ZQ2000, polar_5min).

[319] **EXAMPLE 96: 4-[4-(1H-Indazol-5-ylamino)-7H-pyrrolo[2,3-d]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid amide.**




[320] The title compound was obtained following the Preferred method with Acid Chlorides, Chloroformates, Carbamoyl Chlorides, Sulfamoyl chlorides, Sulfonyl chlorides & Isocyanates, using trimethylsilyl isocyanate. ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ = 2.33 (s, br, 2H), 3.53 (t, J = 5.6 Hz, 2H), 4.00 (d, J = 2.4 Hz, 2H), 6.03 (s, $-\text{NH}_2$), 6.39 (s, br, 1H), 6.75 (s, 1H), 7.51 (d, J = 9.2 Hz, 1H), 7.65 (dd, J = 8.8, 2.0 Hz, 1H), 8.04 (s, 1H), 8.25 (s, 1H), 8.36 (d, J = 1.6 Hz, 1H), 9.30 (s, $-\text{NH}$), 11.88 (s, $-\text{NH}$), 12.96 (s, $-\text{NH}$). MS (ES $^+$): m/z 375.13 (100) [MH^+]. HPLC: t_R = 1.76 min (ZQ2000, polar_5min).

[321] **EXAMPLE 97: 4-[4-(1*H*-Indazol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]-pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid pyridin-3-ylamide.**



[322] The title compound was obtained following the Preferred method with Acid Chlorides, Chloroformates, Carbamoyl Chlorides, Sulfamoyl chlorides, Sulfonyl chlorides & Isocyanates, using 3-pyridyl isocyanate. ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ = 2.48–2.57 (m, 2H), 3.75 (t, J = 5.6 Hz, 2H), 4.27 (s, br, 2H), 6.54 (s, br, 1H), 6.79 (s, br, 1H), 7.50 (dd, J = 8.8, 1.6 Hz, 1H), 7.67 (d, J = 8.8 Hz, 1H), 7.76 (dd, J = 8.8, 5.6 Hz, 1H), 8.08–8.13 (m, 1H), 8.15 (d, J = 0.4 Hz, 1H), 8.26 (s, 1H), 8.30–8.37 (m, 1H), 8.41 (d, J = 4.4 Hz, 1H), 8.99 (d, J = 2.4 Hz, 1H), 9.33 (s, $-\text{NH}$), 10.87 (s, br, $-\text{NH}$), 12.68 (s, br, $-\text{NH}$), 13.06 (s, br, $-\text{NH}$). MS (ES $^+$): m/z 452.02 (10) [MH^+]. HPLC: t_R = 1.75 min (ZQ2000, polar_5min).

[323] **EXAMPLE 98: 2-Pyridinyl 4-[4-(1*H*-indazol-5-ylamino)-7*H*-pyrrolo-[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxamide.**




[324] A solution of 2-aminopyridine (22.6mg, 0.24mmol) and diimidazol-1-ylmethanone (CDI, 39mg, 0.24mmol) in DMF (0.75mL) was stirred at 50°C for 1h. After cooling to rt, *i*-Pr₂NEt (0.14mL, 0.8mmol) was added, followed by (1*H*-indazol-5-yl)-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl]amine tri-HCl (88.1mg, 0.2mmol). The mixture was stirred at rt for 2h and 50°C for 3h. The resulting mixture was filtered and submitted to mass-directed HPLC purification to yield the title compound. ^1H -NMR(CD_3OD , 400 MHz): δ = 2.66 (m, 2 H), 3.88 (t, J = 6.0 Hz, 2 H), 4.37 (m, 2 H), 6.45 (s, 1 H), 6.71 (s, br, 1 H), 7.38 (t, J = 6.0 Hz, 1 H), 7.48 (dd, J = 2.0, 9.2 Hz, 1 H), 7.66 (d, J = 8.8 Hz, 1 H), 7.76 (d, J = 8.8 Hz, 1 H), 7.98 (d, J = 1.2 Hz, 1 H), 8.16 (d, J = 12.4 Hz, 1 H),

8.22 (dt, $J = 1.6, 8.8$ Hz, 1 H). 8.29 (d, $J = 6.0$ Hz, 1 H). MS (ES⁺): m/z 451.95 [MH⁺].


HPLC: $t_R = 1.77$ min (ZQ2000, polar_5min).

[325] **EXAMPLE 99: 4-Pyridinyl 4-[4-(1*H*-indazol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxamide.**




[326] The title compound was prepared following the procedure for the corresponding 2-pyridyl compound, but using 4-aminopyridine. ¹H-NMR(DMSO-*d*₆, 400 MHz): $\delta = 3.72$ (t, $J = 6.4$ Hz, 2 H), 4.22 (m, 2 H), 6.46 (s, 1 H), 6.68 (s, br, 1 H), 6.78 (s, 1 H), 7.51-7.53 (m, 2 H), 7.55 (dd, $J = 1.6, 8.8$ Hz, 1 H), 8.05 (s, 1 H), 8.26 (d, $J = 2.0$ Hz, 1 H), 8.30-8.33 (m, 2 H), 8.36 (s, 1 H), 8.99 (s, 1 H), 9.34 (s, 1 H), 11.94 (s, 1 H), 12.97 (s, 1 H). MS (ES⁺): m/z 452.02 [MH⁺]. HPLC: $t_R = 1.62$ min (ZQ2000, polar_5min).

[327] **EXAMPLE 100: 1-{4-[4-(Benzothiazol-6-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridin-1-yl}-2-pyridin-3-ylethanone.**




[328] To a suspension of benzothiazol-6-yl-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl]amine tri-HCl (137mg, 0.300mmol), 3-pyridinylacetic acid·HCl (78.1mg, 0.450mmol), and EDC (115mg, 0.600mmol) in DMF (1mL) was added *N,N*-diisopropylethylamine (0.261mL, 1.50mmol). The mixture became a clear solution after being stirred for a few minutes and was stirred overnight. The products, which precipitated from the solution during the reaction, were collected by filtration, washed with dichloromethane (2×1mL), and dried *in vacuo* to afford the title compound as a white solid. ¹H-NMR (DMSO-*d*₆, 400 MHz): $\delta = 2.73$ (s, 2 H), 2.89 (s, 2 H), 3.78 (dt, $J = 4.0, 18.8$ Hz, 2 H), 3.86 (d, $J = 20$ Hz, 2 H), 4.19 (s, 1 H), 4.33 (s, 1 H), 6.45 (d, $J = 5.2$ Hz, 1 H), 6.84 (d, $J = 16.8$ Hz, 1 H), 7.33-7.36 (m, 1 H), 7.65 (t, $J = 8.0$ Hz, 1 H), 7.87 (dt, $J = 2.0, 8.0$ Hz, 1 H), 7.95 (s, 1 H), 8.04 (d, $J = 9.2$ Hz, 1 H), 8.34 (d, $J = 3.6$ Hz, 1 H), 8.44-8.48 (m, 1 H), 8.92 (s, 1 H), 9.24 (s, 1 H), 9.62 (d, $J = 7.6$ Hz, 1 H). MS (ES⁺): m/z 467.94 [MH⁺]. HPLC: $t_R = 1.98$ min (ZQ2000, polar_5min).

[329] **EXAMPLE 101: 4-(4-(1,3-Benzothiazol-6-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl)-*N*-(4-fluorophenyl)-3,6-dihydropyridine-1(2*H*)-carboxamide.**




[330] To a suspension of benzothiazol-6-yl-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine trihydrochloride (50.0mg, 0.11mmol) in DMF (1.5mL) was added *N,N*-diisopropylethylamine (0.04mL, 0.20mmol). The reaction mixture stirred at -20°C for 5 min prior to the addition of 4-fluorophenyl isocyanate (9.5mg, 0.07mmol) in DMF (0.5mL). The mixture was left to stir at rt for 1h. The mixture was concentrated *in vacuo* and purified via MDP, which afforded the title compound as a white solid. MS (ES⁺): *m/z*: 485.88 (100) [MH⁺]. HPLC: *t_r* = 2.73 min (ZQ2000: polar_5 min). ¹H NMR (400 MHz, CDCl₃): δ = 2.52 – 2.56 (m, 2H), 3.31 (s, 1H), 3.70 (t, 2H), 4.20 (s, 2H), 6.94 (m, 1H), 6.86 (d, *J* = 0.8 Hz, 1H), 7.06 – 7.11 (m, 2H), 7.48 – 7.51 (m, 2H), 7.87 (dd, *J* = 2.4, 8.8 Hz, 1H), 8.04 (d, *J* = 8.8 Hz, 1H), 8.35 (s, 1H), 8.59 (s, 1H), 8.92 (d, *J* = 2.0 Hz, 1H), 9.24 (s, 1H), 9.62 (s, 1H).

[331] **EXAMPLE 102: 4-(4-(1,3-Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-d]-pyrimidin-6-yl)-N-(2-fluorophenyl)-3,6-dihydropyridine-1(2H)-carboxamide.**



[332] The procedure for **EXAMPLE 101** was followed except for replacing 4-fluorophenyl isocyanate with 2-fluorophenyl isocyanate. ¹H NMR (400 MHz, DMSO-*d*₆): δ = 2.57 (s, br, 2H), 3.71 (t, *J* = 5.2 Hz, 2H), 4.21 (s, br, 2H), 6.49 (s, br, 1H), 6.87 (d, *J* = 2.0 Hz, 1H), 7.10–7.16 (m, 2H), 7.17–7.23 (m, 1H), 7.42–7.49 (m, 1H), 7.88 (dd, *J* = 8.8, 2.0 Hz, 1H), 8.04 (d, *J* = 8.8 Hz, 1H), 8.34 (s, br, –NH), 8.35 (s, 1H), 8.92 (d, *J* = 2.0 Hz, 1H), 9.24 (s, 1H), 9.61 (s, –NH), 12.03 (s, –NH). MS (ES⁺): 485.98 (100) [MH⁺]. HPLC: *t_R* = 2.69 min (ZQ2000, polar_5min).


[333] **EXAMPLE 103: 4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-d]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid phenylamide.**



[334] The procedure for **EXAMPLE 101** was followed except for replacing 4-fluorophenyl isocyanate with phenyl isocyanate. ¹H NMR (400 MHz, DMSO-*d*₆): δ = 2.57 (s, br, 2H), 3.71 (t, *J* = 5.2 Hz, 2H), 4.21 (d, *J* = 1.6 Hz, 2H), 6.49 (s, br, 1H), 6.86 (d, *J* = 2.0 Hz, 1H), 6.95 (m, 1H), 7.24 (m, 2H), 7.49 (dd, *J* = 8.8, 1.2 Hz, 2H), 7.88 (dd, *J* = 8.8, 2.4


Hz, 1H), 8.04 (d, $J = 8.8$ Hz, 1H), 8.35 (s, 1H), 8.54 (s, -NH), 8.92 (d, $J = 2.4$ Hz, 1H), 9.24 (s, 1H), 9.61 (s, -NH), 12.03 (d, $J = 2.0$ Hz, -NH). MS (ES⁺): m/z 468.01 (100) [MH⁺]. HPLC: $t_R = 2.70$ min (ZQ2000, polar_5min).

[335] **EXAMPLE 104:** 4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-d]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid amide.




[336] The procedure for **EXAMPLE 101** was followed except for replacing 4-fluorophenyl isocyanate with trimethylsilyl isocyanate. ¹H NMR (400 MHz, DMSO-*d*₆): δ = 2.42–2.52 (m, 2H), 3.55 (t, $J = 5.6$ Hz, 2H), 4.02 (d, $J = 2.0$ Hz, 2H), 6.04 (s, -NH₂), 6.43 (s, br, 1H), 6.83 (d, $J = 2.0$ Hz, 1H), 7.88 (dd, $J = 8.8, 2.4$ Hz, 1H), 8.04 (d, $J = 8.8$ Hz, 1H), 8.34 (s, 1H), 8.92 (d, $J = 2.4$ Hz, 1H), 9.23 (s, 1H), 9.59 (s, -NH), 11.99 (s, -NH). MS (ES⁺): m/z 392.06 (100) [MH⁺]. HPLC: $t_R = 2.10$ min (ZQ2000, polar_5min).

[337] **EXAMPLE 105:** 4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-d]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butylamide.




[338] The procedure for **EXAMPLE 101** was followed except for replacing 4-fluorophenyl isocyanate with *tert*-butyl isocyanate. Workup was carried out as follows: Residue was triturated in hot MeOH and was filtered. No solid was obtained but filtrate instantly precipitated. This off-white solid was filtered and again the filtrate was concentrated *in vacuo*, resuspended in MeOH, and filtered again (3×), until solid no longer precipitated from filtrate. Solid afforded the title compound, as an off-white solid. Mass directed purification (MDPS) of filtrate yielded a second batch of the title compound, as an off-white solid. ¹H NMR (400 MHz, DMSO-*d*₆): 1.28 (s, 9H), 2.43–2.56 (m, 2H), 3.53 (t, $J = 5.6$ Hz, 2H), 3.99 (d, $J = 2.0$ Hz, 2H), 5.79 (s, -NH), 6.43 (s, br, 1H), 6.82 (d, $J = 1.2$ Hz, 1H), 7.88 (dd, $J = 8.8, 2.0$ Hz, 1H), 8.04 (d, $J = 8.8$ Hz, 1H), 8.34 (s, 1H), 8.92 (d, $J = 2.0$ Hz, 1H), 9.23 (s, 1H), 9.59 (s, -NH), 11.99 (s, -NH). MS (ES⁺): m/z 448.04 (100) [MH⁺]. HPLC: $t_R = 2.63$ min (ZQ2000, polar_5min).

[339] **EXAMPLE 106:** 4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-d]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid isopropylamide.




[340] The procedure for **EXAMPLE 101** was followed except for replacing 4-fluorophenyl isocyanate with isopropyl isocyanate. For purification, no chromatography was performed; material was triturated twice in MeOH to obtain the title compound as orange solid. ^1H NMR (400 MHz, DMSO- d_6): δ = 1.01 (d, J = 6.8 Hz, 6H), 2.37–2.45 (m, 2H), 3.49 (t, J = 5.6 Hz, 2H), 3.73 (dsept, J = 6.8, 6.8 Hz, 1H), 3.94 (d, J = 1.6 Hz, 2H), 6.20 (d, J = 7.6 Hz, 1H), 6.44 (s, br, 1H), 6.83 (d, J = 1.6 Hz, 1H), 7.88 (dd, J = 8.8, 2.0 Hz, 1H), 8.04 (d, J = 8.8 Hz, 1H), 8.34 (s, 1H), 8.92 (d, J = 2.0 Hz, 1H), 9.23 (s, 1H), 9.58 (s, –NH), 11.98 (s, –NH). MS (ES+): m/z 434.04 (100) [MH^+]. HPLC: t_R = 2.43 min (ZQ2000, polar_5min).

[341] **EXAMPLE 107: 4-(4-(1,3-Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-d]-pyrimidin-6-yl)methylpiperazine-1-carboxamide.**



[342] To a suspension of benzothiazol-6-yl-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-amine tris-hydrochloride (200mg, 0.44mmol) in *N,N*-dimethylformamide (6mL) was added *N,N*-diisopropylethylamine (0.5mL, 3mmol). The reaction mixture was stirred at 0°C for 5min prior to the addition of 4-methylpiperazine-1-carbonyl chloride hydrochloride (87mg, 0.44mmol). The resulting mixture was stirred at 0°C for 1h, diluted with water (50mL), and the resulting precipitate was collected by filtration, washed with EtOAc (5mL), and dried *in vacuo* to give the title compound. LC-MS (ES, Pos.): 474 [MH^+], and ^1H NMR (DMSO- d_6 , 400 MHz): δ = 1.99 (s, 3H), 2.24 (m, 4H), 2.50 (m, 2H), 3.18 (m, 4H), 3.41 (m, 2H), 3.93 (m, 2H), 6.41 (s, 1H), 6.82 (s, 1H), 7.87 (d, J = 8.8 Hz, 1H), 8.04 (d, J = 8.8 Hz, 1H), 8.34 (s, 1H), 8.91 (s, 1H), 9.23 (s, 1H), 9.59 (s, 1H), 11.99 (s, 1H).


[343] **EXAMPLE 108: 4-(4-(1,3-Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-d]-pyrimidin-6-yl)-*N,N*-dimethyl-3,6-dihydropyridine-1(2H)-carboxamide.**



[344] The procedure for **EXAMPLE 101** was followed except for replacing 4-fluorophenyl isocyanate with *N,N*-dimethylcarbamoyl chloride. MS (ES+): m/z : 419.98 (100)


[MH⁺]. HPLC: t_r = 2.35 min (ZQ2000: polar_5 min). ¹H NMR (400 MHz, DMSO-d₆): δ = 2.77 (s, 6H), 3.31 – 3.39 (m, 4H), 3.89 (d, J = 2.4 Hz, 2H), 6.42 (s, 1H), 6.82 (d, J = 2.0 Hz, 1H), 7.86 – 7.89 (dd, J = 2.0, 9.2 Hz, 1H), 8.03 (d, J = 9.2 Hz, 1H), 8.34 (s, 1H), 8.91 (d, J = 2.0 Hz, 1H), 9.23 (s, 1H), 9.60 (s, 1H).

[345] **EXAMPLE 109: 6-[1-[4-(Dimethylamino)butanoyl]-1,2,3,6-tetrahydropyridin-4-yl]-N-1,3-benzothiazol-6-yl-7H-pyrrolo[2,3-*d*]pyrimidin-4-amine.**




[346] To a solution of benzothiazol-6-yl-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-*d*]pyrimidin-4-yl]-amine trihydrochloride (50.0mg, 0.11mmol) in DMF (3mL) was added 4-(dimethylamino)butyric acid hydrochloride (17mg, 0.13mmol), TBTU (42mg, 0.13mmol) and *N,N*-diisopropylethylamine (0.1mL). The reaction mixture was left to stir at rt over the weekend. The crude mixture was concentrated *in vacuo* and purified via MDP, which afforded the title compound as a tan solid. MS (ES⁺): m/z : 461.99 (100) [MH⁺]. HPLC: t_r = 1.82 min (ZQ2000: polar_5 min). ¹H NMR (400 MHz, DMSO-d₆): δ = 1.63 – 1.68 (m, 2H), 2.10 (s, 3H), 2.11 (s, 3H), 2.18 – 2.24 (m, 2H), 2.33 – 2.43 (m, 2H), 2.54 – 2.56 (m, 2H), 3.67 – 3.72 (m, 2H), 4.15 (bs, 1H), 4.21 (bs, 1H), 6.45 (s, 1H), 6.84 (d, J = 6.4 Hz, 1H), 7.87 (dd, J = 1.6, 8.8 Hz, 1H), 8.03 (d, J = 8.8 Hz, 1H), 8.34 (s, 1H), 8.92 (s, 1H), 9.23 (s, 1H), 9.61 (s, 1H), 12.02 (d, J = 11.2 Hz, 1H).

[347] **EXAMPLE 110: 6-[1-(3-Hydroxy-2,2-dimethylpropanoyl)-1,2,3,6-tetrahydropyridin-4-yl]-N-1,3-benzothiazol-6-yl-7H-pyrrolo[2,3-*d*]pyrimidin-4-amine.**




[348] To a mixture of benzothiazol-6-yl-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-*d*]pyrimidin-4-yl]amine trihydrochloride (50.0mg, 0.11mmol) in DMF (3mL) was added 2,2-dimethyl-3-hydroxypropionic acid (150mg, 1.3mmol), TBTU (42.0mg, 0.13mmol) and *N,N*-diisopropylethylamine (0.1mL, 0.50mmol). The reaction mixture stirred at rt for 16h. The mixture was concentrated *in vacuo* and purified via MDP, which afforded the title compound as yellow solid. MS (ES⁺): m/z : 448.96 (100) [MH⁺]. HPLC: t_r = 2.35 min (ZQ2000: polar_5 min). ¹H NMR (400 MHz, DMSO-d₆): δ = 1.20 (s, 6H), 3.19 (s, 1H), 3.46 (s, 2H), 3.79 – 3.81 (m, 2H), 4.21 (s, 2H), 4.59 (bs, 1H), 6.43 (s, 1H), 6.84 (d, J = 1.6 Hz, 1H), 7.87 (dd, J = 1.6, 8.8 Hz, 1H), 8.03 (d, J = 8.8 Hz, 1H), 8.34 (s, 1H), 8.91 (d, J = 2.0 Hz, 1H), 9.23 (s, 1H), 9.62 (s, 1H), 12.03 (s, 1H).

[349] **EXAMPLE 111: 6-[1-(2,2-Dimethyl-3-oxopropanoyl)-1,2,3,6-tetrahydropyridin-4-yl]-N-1,3-benzothiazol-6-yl-7H-pyrrolo[2,3-*d*]pyrimidin-4-amine.**




[350] To a solution of 6-[1-(3-hydroxy-2,2-dimethylpropanoyl)-1,2,3,6-tetrahydropyridin-4-yl]-N-1,3-benzothiazol-6-yl-7H-pyrrolo[2,3-*d*]pyrimidin-4-amine (Example 110) (150mg, 0.33mmol) in DMSO (4mL) was added EDC (190mg, 1mmol). The reaction mixture stirred at rt for 5h. The mixture was taken up in a large amount of EtOAc and extracted with water. The combined organic extracts were dried over sodium sulfate and concentrated *in vacuo*, which afforded the title compound as a yellow solid. MS (ES⁺): *m/z*: 446.93 (100) [MH⁺]. HPLC: *t_r* = 2.53 min (ZQ2000: polar_5 min). ¹H NMR (400 MHz, DMSO-*d*₆): δ = 1.37 (s, 6H) 3.39 – 3.69 (m, 3H), 3.70 – 4.22 (m, 3H), 6.21 (bs, 1H), 6.82 (s, 1H), 6.84 (d, *J* = 1.6 Hz, 1H), 7.87 (dd, *J* = 1.6, 8.8 Hz, 1H), 8.03 (d, *J* = 8.8 Hz, 1H), 8.34 (s, 1H), 8.91 (d, *J* = 2.0 Hz, 1H), 9.23 (s, 1H), 9.62 (s, 1H), 12.03 (s, 1H).

[351] **EXAMPLE 112: 6-[1-[4-(Dimethylamino)butanoyl]-1,2,3,6-tetrahydropyridin-4-yl]-N-1,3-benzothiazol-6-yl-7H-pyrrolo[2,3-*d*]pyrimidin-4-amine.**



[352] The procedure for **EXAMPLE 109** was followed except for replacing 2,2-dimethyl-3-hydroxypropionic acid with 2,2-dimethyl-3-piperidin-1-ylpropanoic acid. The mixture was purified via MDP, which afforded the title compound as a yellow solid. MS (ES⁺): *m/z*: 516.06 (100) [MH⁺]. HPLC: *t_r* = 1.98 min (ZQ2000: polar_5 min). ¹H NMR (400 MHz, DMSO-*d*₆): δ = 1.21 (s, 6H), 1.26 – 1.28 (m, 2H), 1.37 – 1.41 (m, 5H), 2.30 – 2.34 (m, 5H), 2.47 – 2.49 (m, 2H), 3.75 – 3.77 (m, 2H), 4.26 (s, 2H), 6.44 (s, 1H), 6.82 (d, *J* = 2.0 Hz, 1H), 7.87 (dd, *J* = 2.4, 8.8 Hz, 1H), 8.03 (d, *J* = 8.8 Hz, 1H), 8.34 (s, 1H), 8.91 (d, *J* = 2.0 Hz, 1H), 9.23 (s, 1H), 9.59 (s, 1H), 12.01 (s, 1H).


[353] **2,2-Dimethyl-3-piperidin-1-ylpropanoic acid.**



[354] To a solution of benzyl-2,2-dimethyl-3-piperidin-1-ylpropanoate (117.0mg, 0.42 mmol) in ethanol (5mL) was slowly added 10% wt Palladium in carbon (50mg, 0.05mmol). The reaction mixture was left to stir at rt for 1h under hydrogen. The mixture was


filtered through Celite and concentrated *in vacuo*, which afforded the title compound as a yellow solid. ^1H NMR (400 MHz, CDCl_3): δ = 1.22 (s, 6H), 1.28 – 1.39 (bs, 2H), 1.74 – 1.79 (m, 4H), 2.76 (s, 2H), 2.79 – 3.08 (bs, 4H).

[355] Benzyl-2,2-dimethyl-3-piperidin-1-ylpropanoate.




[356] To a solution of benzyl-2,2-dimethyl-3-oxopropanoate (200mg, 1.0mmol) in DCM (30mL) were added piperidine (0.10mL, 1.1mmol) and sodium triacetoxyborohydride (400mg, 2.0mmol). The reaction mixture was left to stir at rt for 16h. The mixture was partitioned between DCM and water and treated with saturated NaHCO_3 . The combined organic extracts were dried over Na_2SO_4 and concentrated *in vacuo*. Purification via silica gel chromatography (5% EtOAc in Hexane) afforded the title compound as a yellow oil. MS (ES+): m/z : 276.18 (100) $[\text{MH}^+]$. HPLC: t_r = 1.97 min (ZQ2000: polar_5 min). ^1H NMR (400 MHz, CDCl_3): δ = 1.17 (s, 6H), 1.28 – 1.37 (m, 2H), 1.40 – 1.46 (m, 4H), 2.34 – 2.36 (m, 4H), 2.44 (s, 2H), 5.09 (s, 2H), 7.25 – 7.34 (m, 5H).

[357] Benzyl-2,2-dimethyl-3-oxopropanoate.



[358] A mixture of DMSO (10mL, 200mmol) and DCM (0.2mL) was added to a mixture of oxalyl chloride (8.1mL, 0.096 mol) and DCM (350mL) at -72°C . The resulting mixture was left to stir for 30min at -72°C . To the mixture was added 1-benzyl-3-hydroxy-2,2-dimethylpropanoate (5g, 19.2mmol) in DCM (300mL). The reaction mixture stirred at -72°C for 30min. The reaction was quenched with triethylamine (67mL, 0.48 mol) and the reaction was allowed to slowly warm to rt. The mixture was partitioned between DCM and water, treated with saturated sodium bicarbonate and brine, dried over Na_2SO_4 and concentrated *in vacuo*, which afforded the title compound as a yellow oil. ^1H NMR (400 MHz, CDCl_3): δ = 1.35 (s, 6H), 5.11 (s, 2H), 7.31 – 7.39 (m, 5H), 9.68 (s, 1H).


[359] 1-Benzyl-3-hydroxy-2,2-dimethylpropanoate.



[360] To a solution of 2,2-dimethyl-3-hydroxypropionic acid (10g, 86.3mmol) in methanol (55mL) and water (6mL) was added cesium carbonate (10g, 30.0mmol) as a 20% solution in water. The reaction mixture was left to stir at rt for 15min. The mixture was concentrated *in vacuo* and the water was removed by making an azeotrope with toluene and


concentrating it down. This process was repeated 3× and it yielded a white solid. The resulting solid was dissolved in DMF (55mL) and benzyl bromide (8.20mL, 68.9mmol) was added. The reaction was left to stir at rt for 16h. The mixture was partitioned between water and EtOAc. The organic layer was further partitioned between ethylacetate and sodium bicarbonate solution to remove excess acid. The organic extracts were dried over sodium sulfate, filtered and concentrated *in vacuo*, which afforded the product as a yellow oil. ¹H NMR (400 MHz, CDCl₃): δ = 1.21 (s, 6H), 2.77 (bs, 1H), 3.57 (s, 2H), 5.13 (s, 2H), 7.26 – 7.43 (m, 5H).

[361] **EXAMPLE 113: 6-[1-(2,2-Dimethyl-4-methylpiperazin-1-yl)propanoyl]-1,2,3,6-tetrahydropyridin-4-yl]-N-1,3-benzothiazol-6-yl-7H-pyrrolo[2,3-d]pyrimidin-4-amine.**




[362] The procedure from **EXAMPLE 110** was followed except for replacing 2,2-dimethyl-3-hydroxypropionic acid with 2,2-dimethyl-3-(4-methylpiperazin-1-yl)propanoic acid. The mixture was precipitated with water and the gravity filtration afforded the title compound as a tan solid. MS (ES⁺): *m/z*: 531.04 (10) [MH⁺]. HPLC: *t_r* = 1.94 min (ZQ2000: polar_5 min). ¹H NMR (400 MHz, DMSO-*d*₆): δ = 1.21 (s, 6H), 2.04 (s, 3H), 2.06 – 2.20 (m, 4H), 2.23 – 2.38 (m, 4H), 2.51 – 2.52 (m, 4H), 3.75 – 3.77 (m, 2H), 4.23 (s, 2H), 6.44 (s, 1H), 6.82 (d, *J* = 2.0 Hz, 1H), 7.87 (dd, *J* = 2.4, 8.8 Hz, 1H), 8.03 (d, *J* = 8.8 Hz, 1H), 8.33 (s, 1H), 8.91 (d, *J* = 2.0 Hz, 1H), 9.22 (s, 1H), 9.58 (s, 1H), 12.01 (s, 1H).

[363] **2,2-Dimethyl-3-(4-methylpiperazin-1-yl)propanoic acid.**



[364] The procedure for 2,2-dimethyl-3-piperidin-1-ylpropanoic acid was followed except for replacing benzyl-2,2-dimethyl-3-piperidin-1-ylpropanoate with benzyl 2,2-dimethyl-3-(4-methylpiperazin-1-yl)propanoate. The compound was obtained as a yellow solid. ¹H NMR (400 MHz, CDCl₃): δ = 1.24 (s, 6H), 2.33 (s, 3H), 2.44 – 2.92 (m, 10H).

[365] **Benzyl 2,2-dimethyl-3-(4-methylpiperazin-1-yl)propanoate.**




[366] The procedure for benzyl-2,2-dimethyl-3-piperidin-1-ylpropanoate was followed except for replacing piperidine with 1-methylpiperazine. Purification via silica gel chromatography (5% EtOAc in hexane) afforded the title compound as a yellow oil. MS

(ES+): m/z : 291.20 (100) $[MH^+]$. HPLC: t_r = 2.08 min (ZQ2000: polar_5 min). ^1H NMR (400 MHz, $CDCl_3$): δ = 1.18 (s, 6H), 2.09 (s, 3H), 2.23 – 2.33 (m, 4H), 2.39 – 2.50 (m, 6H), 5.11 (s, 2H) 7.31 – 7.36 (m, 5H).

[367] General procedure for preparation of an α, α -dimethylpropane-1-one library:


[368] To a solution of benzothiazol-6-yl-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-*d*]pyrimidin-4-yl]-amine tris-hydrochloride (525.0mg) in DMF (12mL) and dichloromethane (1mL) at 4°C was added *N,N*-diisopropylethylamine (3eq.) followed by 3-chloropivaloyl chloride (0.178g, 1.0eq). The resulting mixture was allowed to warm up to rt and left overnight before it was applied for next step reaction without any further purification. The mixture was divided into 13 aliquots, and 1mg of KI, 5eq. of *N,N*-diisopropylethylamine, and 10eq. of corresponding amine were added. If an amine was used as hydrochloride, additional 2eq. of *N,N*-diisopropylethylamine were added. The solutions were degassed with N_2 and heated at 80°C for 96h. The products were purified by preparative HPLC with water / acetonitrile / formic acid mixture and are assumed to be formate salts.

[369] **EXAMPLE 114: 1-{4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-3-chloro-2,2-dimethylpropan-1-one.**




[370] LC/MS: m/z 466.89/468.92 $[MH^+]$ (100/35), t_R = 2.81 min (ZQ2000, polar_5min).

[371] **EXAMPLE 115: 1-{4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-2,2-dimethyl-3-pyrrolidin-1-ylpropan-1-one.**




[372] Following the general procedure, the title compound was isolated as yellow powder. ^1H NMR (400 MHz, $DMSO-d_6$): δ = 12.01 (s, 1H), 9.60 (s, 1H), 9.23 (s, 1H), 8.91 (d, 1H, J = 2.0 Hz), 8.32 (s, 1H), 8.21 (s, 2H), 8.05 (d, 1H, J = 8.9 Hz), 7.88 (dd, 1H, J = 2.0 Hz & 8.9 Hz), 6.83 (s, 1H), 6.43 (s, 1H), 4.24 (br s, 2H), 3.76 (t, 2H, J = 5.7 Hz), 3.41 (m, 6H), 2.67 (s, 2H), 1.60 (m, 4H), 1.23 (br s, 6H). LC/MS: m/z 502.03 $[MH^+]$ (100), t_R = 1.92 min (ZQ2000, polar_5min).

[373] **EXAMPLE 116:** 1-{4-[4-(Benzothiazol-6-ylamino)-7*H*-pyrrolo[2,3-*d*]-pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridin-1-yl}-3-diethylamino-2,2-dimethylpropan-1-one.




[374] Following the general procedure, the title compound was isolated as yellow powder. ¹H NMR (400 MHz, DMSO-*d*₆): δ = 11.94 (d, 1H, *J* = 15.8 Hz), 9.48 (s, 1H), 9.17 (s, 1H), 8.85 (d, 1H, *J* = 2.0 Hz), 8.25 (s, 1H), 8.13 (s, 2H), 7.96 (d, 1H, *J* = 8.9 Hz), 7.79 (dd, 1H, *J* = 2.0 Hz & 8.9 Hz), 6.76 (br s, 1H), 6.37 (br s, 1H), 4.21 (br s, 2H), 3.71 (t, 2H, *J* = 5.3 Hz), 2.52 (br s, 2H), 2.40 (m, 6H), 1.14 (s, 6H), 0.82 (t, 6H, *J* = 7.0 Hz). LC/MS: *m/z* 504.06 (95) [MH⁺], *t*_R = 1.92 min (ZQ2000, polar_5min).

[375] **EXAMPLE 117:** 1-{4-[4-(Benzothiazol-6-ylamino)-7*H*-pyrrolo[2,3-*d*]-pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridin-1-yl}-3-*tert*-butylamino-2,2-dimethylpropan-1-one.




[376] Following the general procedure, the title compound was isolated as yellow powder. ¹H NMR (400 MHz, DMSO-*d*₆): δ = 11.98 (s, 1H), 9.56 (s, 1H), 9.19 (s, 1H), 8.85 (d, 1H, *J* = 2.0 Hz), 8.24 (s, 1H), 8.15 (s, 2H), 7.97 (d, 1H, *J* = 8.9 Hz), 7.79 (dd, 1H, *J* = 2.0 Hz & 8.9 Hz), 6.78 (s, 1H), 6.37 (br s, 1H), 4.14 (s, 2H), 3.75 (t, 2H, *J* = 5.4 Hz), 2.71 (s, 2H), 2.52 (br s, 2H), 1.26 (s, 6H), 1.09 (s, 9H). LC/MS: *m/z* 504.06 [MH⁺] (95), *t*_R = 1.99 min (ZQ2000, polar_5min).

[377] **EXAMPLE 118:** 1-{4-[4-(Benzothiazol-6-ylamino)-7*H*-pyrrolo[2,3-*d*]-pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridin-1-yl}-3-dimethylamino-2,2-dimethylpropan-1-one.




[378] Following the general procedure, but saturating the reaction mixture with dimethylamine gas in a sealed tube and conducting the reaction at rt for 4 d, the title compound was isolated as yellow powder. LC/MS: *m/z* 476.06 [MH⁺] (45), *t*_R = 1.85 min (ZQ2000, polar_5min).

[379] **EXAMPLE 119: 1-{4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-d]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-3-(3-hydroxypyrrolidin-1-yl)-2,2-dimethylpropan-1-one.**




[380] Following the general procedure, the title compound was isolated as yellow powder. ^1H NMR (400 MHz, DMSO- d_6): δ = 11.95 (s, 1H), 9.54 (s, 1H), 9.17 (s, 1H), 8.85 (d, 1H, J = 2.0 Hz), 8.24 (s, 1H), 8.16 (s, 2H), 7.97 (d, 1H, J = 8.9 Hz), 7.78 (dd, 1H, J = 2.0 Hz & 8.9 Hz), 6.77 (d, 1H), 6.37 (br s, 1H), 4.17 (br s, 2H), 4.01 (m, 1H), 3.71 (t, 2H, J = 5.2 Hz), 3.15 (m, 1H), 2.74 (m, 1H), 2.52 (br s, 2H), 2.51 (m, 2H), 2.26 (dd, 1H, J = 4.0 Hz & 9.6 Hz), 2.08 (s, 1H), 1.77 (m, 1H), 1.38 (m, 1H), 1.15 (s, 6H). LC/MS: m/z 518.02 [MH^+] (50), t_R = 1.87 min (ZQ2000, polar_5min).

[381] **EXAMPLE 120: 3-Azepan-1-yl-1-{4-[4-(benzothiazol-6-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-2,2-dimethylpropan-1-one.**



[382] Following the general procedure, the title compound was isolated as yellow powder. ^1H NMR (400 MHz, DMSO- d_6): δ = 11.96 (s, 1H), 9.53 (s, 1H), 9.19 (s, 1H), 8.85 (d, 1H, J = 2.1 Hz), 8.27 (s, 1H), 8.09 (s, 2H), 7.97 (d, 1H, J = 8.7 Hz), 7.80 (dd, 1H, J = 2.1 Hz & 8.7 Hz), 6.77 (s, 1H), 6.37 (s, 1H), 4.20 (s, 2H), 3.73 (t, 2H, J = 5.3 Hz), 3.29 (t, 1H, J = 6.0 Hz), 3.22 (t, 1H, J = 6.0 Hz), 2.74 (s, 2H), 2.68 (t, 4H, J = 8.6 Hz), 1.48 (br s, 4H), 1.41 (br s, 4H), 1.15 (br s, 6H). LC/MS: m/z 530.03 [MH^+] (15), t_R = 2.03 min (ZQ2000, polar_5min).


[383] **EXAMPLE 121: 1-{4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-d]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-3-(4-hydroxypiperidin-1-yl)-2,2-dimethylpropan-1-one.**



[384] Following the general procedure, the title compound was isolated as yellow powder. ^1H NMR (400 MHz, DMSO- d_6): δ = 11.97 (s, 1H), 9.53 (s, 1H), 9.17 (s, 1H), 8.84 (d, 1H, J = 2.0 Hz), 8.28 (s, 1H), 8.10 (s, 2H), 7.98 (d, 1H, J = 8.9 Hz), 7.83 (dd, 1H, J = 2.0


Hz & 8.9 Hz), 6.67 (s, 1H), 6.36 (s, 1H), 4.19 (br s, 2H), 3.71 (t, 2H, $J = 5.5$ Hz), 3.50 (m, 2H), 3.29 (m, 1H), 2.62 (m, 2H), 2.52 (m, 2H), 2.08 (t, 2H, $J = 9.4$ Hz), 1.54 (m, 2H), 1.25 (m, 2H), 1.15 (s, 6H). LC/MS: m/z 532.05 [MH^+] (15), $t_R = 1.89$ min (ZQ2000, polar_5min).

[385] **EXAMPLE 122: 1-{4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-d]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-3-(4-isopropylpiperazin-1-yl)-2,2-dimethylpropan-1-one.**




[386] Following the general procedure, the title compound was isolated as yellow powder. ^1H NMR (400 MHz, DMSO- d_6): $\delta = 11.95$ (s, 1H), 9.53 (s, 1H), 9.18 (s, 1H), 8.85 (s, 1H), 8.27 (s, 1H), 8.13 (s, 2H), 7.97 (d, 1H, $J = 9.7$ Hz), 7.80 (d, 1H, $J = 9.7$ Hz), 6.76 (s, 1H), 6.37 (br s, 1H), 4.17 (br s, 2H), 3.68 (t, 2H, $J = 5.4$ Hz), 3.35 (m, 4H), 2.31 (br s, 8H), 1.15 (s, 6H), 0.75 (d, 6H, $J = 6.4$ Hz). LC/MS: m/z 559.10 [MH^+] (20), $t_R = 1.98$ min (ZQ2000, polar_5min).

[387] **EXAMPLE 123: 1-{4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-d]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-2,2-dimethyl-3-morpholin-4-ylpropan-1-one.**




[388] Following the general procedure, the title compound was isolated as yellow powder. ^1H NMR (400 MHz, DMSO- d_6): $\delta = 11.96$ (s, 1H), 9.54 (s, 1H), 9.17 (s, 1H), 8.85 (d, 1H, $J = 2.0$ Hz), 8.31 (s, 1H), 8.01 (s, 2H), 7.97 (d, 1H, $J = 8.6$ Hz), 7.81 (dd, 1H, $J = 2.0$ Hz & 8.6 Hz), 6.76 (s, 1H), 6.38 (br s, 1H), 4.18 (br s, 2H), 3.69 (m, 6H), 3.38 (t, 2H, $J = 4.4$ Hz), 2.52 (m, 2H), 2.32 (t, 2H, $J = 4.4$ Hz), 2.17 (s, 2H), 1.15 (s, 6H). LC/MS: m/z 518.02 [MH^+] (100), $t_R = 1.91$ min (ZQ2000, polar_5min).

[389] **EXAMPLE 124: 1-{4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-d]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-3-(4,4-difluoropiperidin-1-yl)-2,2-dimethylpropan-1-one.**




[390] Following the general procedure, but using 4,4-difluoropiperidine hydrochloride and an additional 2eq. of *N,N*-diisopropylethylamine, the title compound was isolated as yellow powder. ¹H NMR (400 MHz, DMSO-*d*₆): δ = 11.96 (s, 1H), 9.54 (s, 1H), 9.16 (s, 1H), 8.84 (d, 1H, *J* = 2.0 Hz), 8.24 (s, 1H), 8.11 (s, 2H), 7.97 (d, 1H, *J* = 8.8 Hz), 7.80 (dd, 1H, *J* = 2.0 Hz & 8.8 Hz), 6.77 (s, 1H), 6.38 (br s, 1H), 4.18 (br s, 2H), 3.66 (t, 2H, *J* = 5.7 Hz), 3.10 (m, 4H), 2.52 (m, 2H), 1.77 (m, 2H), 1.07 (s, 6H), 1.04 (m, 4H). LC/MS: *m/z* 552.09 [MH⁺] (10), *t_R* = 1.99 min (ZQ2000, polar_5min).

[391] **EXAMPLE 125: 1-{4-[4-(Benzothiazol-6-ylamino)-7*H*-pyrrolo[2,3-*d*]-pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridin-1-yl}-3-(3,5-dimethylpiperazin-1-yl)-2,2-dimethylpropan-1-one.**



[392] Following the general procedure, the title compound was isolated as yellow powder. ¹H NMR (400 MHz, DMSO-*d*₆): δ = 11.98 (s, 1H), 9.58 (s, 1H), 9.17 (s, 1H), 8.85 (d, 1H, *J* = 2.0 Hz), 8.27 (s, 1H), 8.21 (s, 2H), 7.97 (d, 1H, *J* = 8.9 Hz), 7.77 (dd, 1H, *J* = 2.0 Hz & 8.9 Hz), 6.78 (d, 1H, *J* = 4.1 Hz), 6.38 (br s, 1H), 4.19 (s, 2H), 3.69 (t, 2H, *J* = 5.2 Hz), 2.84 (m, 4H), 2.64 (br s, 2H), 2.61 (br s, 2H), 2.52 (br s, 2H), 1.86 (t, 2H, *J* = 11.0 Hz), 1.16 (s, 6H), 0.89 (d, 6H, *J* = 6.3 Hz). LC/MS: *m/z* 545.07 [MH⁺] (15), *t_R* = 1.96 min (ZQ2000, polar_5min).


[393] **EXAMPLE 126: 1-{4-[4-(Benzothiazol-6-ylamino)-7*H*-pyrrolo[2,3-*d*]-pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridin-1-yl}-2-(2-methoxyethoxy)-ethanone.**



[394] To a suspension of benzothiazol-6-yl-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl]-amine tris-hydrochloride (138.0mg, 0.2984mmol), 1-hydroxybenzotriazole (40.8mg, 0.302mmol), and PS-Carbodiimide (1.37mmol/g loading; 873mg, 1.20mmol) in anhydrous *N,N*-dimethylformamide (10mL), *N,N*-diisopropylethylamine (260μL, 1.5mmol) was added. A small amount of sonication was used to get majority of solid into solution. 2-(2-Methoxyethoxy)acetic acid (45.7mg, 0.334mmol) in anhydrous DMF (1mL) was added, and the reaction was vigorously shaken at rt for 5.5h. An additional 0.2eq of 2-(2-methoxyethoxy)acetic acid (8.1mg, 0.060mmol) in anhydrous *N,N*-dimethylformamide (0.5mL) was added (after 7h), and the reaction was shaken overnight at rt. The resin was filtered off (M-size frit) and rinsed several times with DMF. The filtrate


was concentrated in vacuo at medium temp (bath temp: max 43 °C), redissolved in MeOH and DCM, and concentrated again under reduced pressure. The crude material was adsorbed onto Hydromatrix, dry loaded, and purified by chromatography on silica gel [Jones Flashmaster, 10g / 70mL cartridge, eluting with MeOH:DCM 2% → 5% → 10%]. Fractions containing product were combined and concentrated in vacuo, affording the title compound, as an off-white solid. The material was further purified by trituration in MeOH / sonication, affording the title compound, as an off-white solid. ¹H NMR (400 MHz, DMSO-*d*₆): δ = 2.36–2.56 (s, br, rotamers, 2H), 3.19 (s, 3H), 2.38–2.45 (m, 2H), 3.49–3.55 (m, 2H), 3.58 & 3.64 (t, *J* = 5.2 Hz, rotamers, 2H), 4.08 & 4.10 (s, br, rotamers, 2H), 4.14 & 4.18 (s, rotamers, 2H), 6.37 (s, br, 1H), 6.77 & 6.78 (s, rotamers, 1H), 7.80 (dd, *J* = 8.8, 2.0 Hz, 1H), 7.97 (d, *J* = 8.8 Hz, 1H), 8.28 (s, 1H), 8.85 (s, 1H), 9.17 (s, 1H), 9.54 (s, –NH), 11.95 (d, *J* = 9.2 Hz, –NH). MS (ES⁺): *m/z* 465.01 (100) [MH⁺]. HPLC: *t*_R = 2.24 min (ZQ2000, polar_5min).

[395] **EXAMPLE 127: 4-[4-(Benzothiazol-6-ylamino)-7*H*-pyrrolo[2,3-*d*]-pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridin-1-ylmorpholin-4-ylmethanone.**




[396] To a suspension of benzothiazol-6-yl-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl]-amine tris-hydrochloride (200mg, 0.44mmol) in *N,N*-dimethylformamide (4mL) was added *N,N*-diisopropylethylamine (0.5mL, 3mmol). The reaction mixture was stirred at 0°C for 5min prior to the addition of 4-chloro-carbonylmorpholine (65mg, 0.44mmol) in DMF (0.5mL). The resulting mixture was stirred at 0°C for 1h, diluted with EtOAc (30mL), washed with water (2 × 15mL), brine (15mL), and dried over anhydrous sodium sulfate. The filtrate was concentrated to 5mL, and the resulting off-white solid was collected by filtration to give the title compound. LC-MS (ES, Pos.): 462 [MH⁺], and ¹H NMR (DMSO-*d*₆, 400 MHz): δ = 2.53 (m, 2H), 3.17 (m, 4H), 3.43 (m, 2H), 3.60 (m, 4H), 3.96 (m, 2H), 6.42 (s, 1H), 6.82 (d, *J* = 1.2 Hz, 1H), 7.88 (dd, *J* = 8.8 Hz, 2.0 Hz, 1H), 8.04 (d, *J* = 8.8 Hz, 1H), 8.34 (s, 1H), 8.91 (d, *J* = 2.0 Hz, 1H), 9.23 (s, 1H), 9.60 (s, 1H), 12.0 (s, 1H).

[397] **EXAMPLE 128: {4-[4-(Benzothiazol-6-ylamino)-7*H*-pyrrolo[2,3-*d*]-pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridin-1-yl}-(1-hydroxymethylcyclopropyl)-methanone.**




[398] To a suspension of benzothiazol-6-yl-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-*d*]pyrimidin-4-yl]-amine tris-hydrochloride (230mg, 0.50mmol) in *N,N*-dimethylformamide (4mL) were added *N,N*-diisopropylethylamine (0.7mL, 4.0mmol), 1-hydroxymethyl-cyclopropanecarboxylic acid (70mg, 0.6mmol) and 2-(1*H*-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (190mg, 0.6mmol). The resulting mixture was stirred at rt overnight. The mixture was diluted with water (30mL), and the precipitate was collected by filtration and dried in vacuum, giving the title compound as brown solid. LC-MS (ES, Pos.): 447 [MH⁺]. ¹H NMR (DMSO-*d*₆, 400 MHz): δ = 0.74 (s, 2H), 0.77 (s, 2H), 2.51 (m, 2H), 3.50 (d, *J* = 5.9 Hz, 2H), 3.85 (m, 2H), 4.20 (m, 2H), 4.90 (br s, 1H), 6.44 (s, 1H), 6.84 (s, 1H), 7.88 (dd, *J* = 8.9 Hz, 2.1 Hz, 1H), 8.04 (d, *J* = 8.9 Hz, 1H), 8.34 (s, 1H), 8.92 (d, *J* = 2.1 Hz, 1H), 9.24 (s, 1H), 9.62 (s, 1H), 12.02 (s, 1H).

[399] **1-Hydroxymethylcyclopropanecarboxylic acid**



[400] [Ref.: Estieu, K., *et al. Tetrahedron Letters*, **1996**, 37(5), 623–624]: Ethyl α -bromocyclobutanecarboxylate (2.07g, 10.0mmol) was added to a solution of potassium hydroxide (2.80g, 50.0mmol) in water (50mL), the resulting mixture was refluxed overnight. Evaporation under reduced pressure to remove most of water, the residue was acidified to pH = 1 with 6N HCl, the white solid was filtered off. The filtrate was saturated with solid NaCl, extracted with EtOAc (3×20mL), and the organic layers were combined and dried over anhydrous sodium sulfate. Evaporation afforded a light-yellow oil, which was purified by chromatography on silica gel, eluting with Hex: EtOAc = 50:50 → 30:70 → 100% EtOAc to give the title compound as a colorless oil. ¹H NMR (CDCl₃, 400 MHz): δ = 0.98 (dd, *J* = 7.1 Hz, 4.2Hz, 2H), 1.38 (dd, *J* = 7.1 Hz, 4.2Hz, 2H), 3.65 (s, 2H).

[401] **EXAMPLE 129: {4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-(1-piperidin-1-ylmethylcyclopropyl)-methanone.**




[402] To a solution of {4-[4-(benzothiazol-6-ylamino)-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-(1-hydroxymethylcyclopropyl)-methanone (23.0mg, 0.05mmol) in *N,N*-dimethylformamide (1mL) were added *N,N*-diisopropylethylamine (0.05mL, 0.3mmol) and methanesulfonic anhydride (11mg, 0.06mmol). The resulting mixture was stirred at rt overnight. LC-MS showed the reaction produced the desired

product, but there was still 70% SM, another 1.2eq. of methanesulfonic anhydride was added. 2h later, LC-MS showed the reaction was complete. To the reaction mixture was added piperidine (0.05mL, 0.5mmol), and the resulting mixture was stirred at rt overnight. LC-MS showed the reaction was complete. The mixture was diluted with MeOH (1mL) and purified by mass-directed purification to give the title compounds as an off-white solid. LC-MS (ES, Pos.): 514 [MH⁺]. ¹H NMR (CD₃OD, 400 MHz): δ = 0.76 (s, 2H), 0.99 (s, 2H), 1.41-1.54 (m, 6H), 2.42-2.69 (m, 8H), 3.99 (m, 2H), 4.23 (m, 1H), 4.50 (m, 1H), 6.35 (s, 1H), 6.73 (s, 1H), 7.78 (dd, J = 8.9 Hz, 2.1 Hz, 1H), 8.01 (d, J = 8.9 Hz, 1H), 8.29 (s, 1H), 8.74 (d, J = 2.1 Hz, 1H), 9.12 (s, 1H).

[403] *General procedure for preparation of an α -cyclopropylpropane-1-one library:*


[404] To the DMF solution of methanesulfonic acid 1-{4-[4-(benzothiazol-6-ylamino)-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carbonyl}-cyclopropylmethyl ester (578.9mg, divided into 13 aliquots for a 13-member library), prepared as described in the previous example, were added 10eq. of *N,N*-diisopropylethylamine and 10eq. of corresponding amine. If the amines were used as salts, additional DIPEA was used. The solutions were degassed with N₂ and left at rt for 96h. The products were purified by preparative HPLC with water / acetonitrile / formic acid mixture and are assumed to be formate salts.

[405] **EXAMPLE 130:** {4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-[1-(4-methylpiperazin-1-ylmethyl)-cyclopropyl]-methanone.




[406] Following the general procedure, the title compound was isolated as yellow powder. ¹H NMR (400 MHz, DMSO-*d*₆): δ = 11.94 (s, 1H), 9.54 (s, 1H), 9.17 (s, 1H), 8.84 (d, 1H, J = 2.0 Hz), 8.27 (s, 1H), 8.17 (s, 2H), 7.96 (d, 1H, J = 8.9 Hz), 7.80 (dd, 1H, J = 2.0 Hz & 8.9 Hz), 6.77 (s, 1H), 6.39 (s, 1H), 4.17 (br s, 2H), 3.74 (br s, 2H), 2.54 (br s, 2H), 2.43 (s, 2H), 2.13 (m, 4H), 2.02 (s, 3H), 0.79 (s, 2H), 0.59 (s, 2H). LC/MS: m/z 528.98 (10) [MH⁺], t_R = 1.90 min (ZQ2000, polar_5min).

[407] **EXAMPLE 131:** {4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-(1-pyrrolidin-1-ylmethylcyclopropyl)-methanone.




[408] Following the general procedure, the title compound was isolated as yellow powder. ^1H NMR (400 MHz, DMSO-d_6): δ = 11.96 (s, 1H), 9.54 (s, 1H), 9.16 (s, 1H), 8.85 (d, 1H, J = 2.0 Hz), 8.26 (s, 1H), 8.13 (s, 2H), 7.97 (d, 1H, J = 8.9 Hz), 7.81 (dd, 1H, J = 2.0 Hz & 8.9 Hz), 6.77 (s, 1H), 6.38 (s, 1H), 4.09 (br s, 2H), 3.74 (m, 2H), 2.53 (s, 2H), 2.52 (m, 2H), 2.47 (m, 2H), 1.55 (s, 4H), 1.05 (d, 2H, J = 6.6 Hz), 0.79 (br s, 2H), 0.60 (dd, 2H, J = 1.7 Hz & 6.6 Hz). LC/MS: m/z 499.57 [MH^+] (80), t_R = 1.88 min (ZQ2000, polar_5min).

[409] **EXAMPLE 132:** {4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-d]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-(1-diethylaminomethylcyclopropyl)-methanone.



[410] Following the general procedure, the title compound was isolated as yellow powder. ^1H NMR (400 MHz, DMSO-d_6): δ = 11.96 (s, 1H), 9.48 (s, 1H), 9.17 (s, 1H), 8.85 (d, 1H, J = 2.0 Hz), 8.28 (s, 1H), 8.12 (s, 2H), 7.97 (d, 1H, J = 8.9 Hz), 7.80 (dd, 1H, J = 2.0 Hz & 8.9 Hz), 6.77 (s, 1H), 6.38 (br s, 1H), 4.06 (br s, 2H), 3.71 (t, 2H, J = 5.3 Hz), 2.52 (br s, 2H), 2.51 (m, 4H), 1.08 (t, 2H, J = 7.2 Hz), 0.82 (t, 6H, J = 7.1 Hz), 0.78 (d, 2H, J = 8.5 Hz), 0.60 (t, 2H, J = 7.1 Hz). LC/MS: m/z 502.03 [MH^+] (100), t_R = 1.93 min (ZQ2000, polar_5min).


[411] **EXAMPLE 133:** {4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-d]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-(1-piperidin-1-ylmethylcyclopropyl)-methanone.



[412] Following the general procedure, the title compound was isolated as yellow powder. ^1H NMR (400 MHz, DMSO-d_6): δ = 11.96 (s, 1H), 9.54 (s, 1H), 9.16 (s, 1H), 8.85 (s, 1H, J = 2.0 Hz), 8.28 (s, 1H), 8.10 (s, 2H), 7.97 (d, 1H, J = 8.9 Hz), 7.80 (dd, 1H, J = 2.0 Hz & 8.9 Hz), 6.77 (s, 1H), 6.28 (s, 1H), 4.08 (m, 2H), 3.71 (m, 2H), 2.52 (m, 2H), 2.48 (m,


2H), 2.42 (br s, 4H), 1.34 (br s, 4H), 1.25 (br s, 2H), 0.80 (br s, 2H), 0.60 (dd, 2H, $J = 1.5$ Hz & 6.2 Hz). LC/MS: m/z 514.04 [MH^+] (100), $t_R = 1.94$ min (ZQ2000, polar_5min).

[413] **EXAMPLE 134:** {4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-d]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-[1-(*tert*-butylaminomethyl)-cyclopropyl]-methanone.




[414] Following the general procedure, the title compound was isolated as yellow powder. ^1H NMR (400 MHz, DMSO- d_6): $\delta = 11.97$ (s, 1H), 9.56 (s, 1H), 9.17 (s, 1H), 8.85 (d, 1H, $J = 2.0$ Hz), 8.24 (s, 1H), 8.13 (s, 2H), 7.97 (d, 1H, $J = 8.9$ Hz), 7.77 (dd, 1H, $J = 2.0$ Hz & 8.9 Hz), 6.78 (s, 1H), 6.39 (br s, 1H), 4.19 (br s, 2H), 3.72 (br s, 2H), 2.74 (s, 2H), 2.52 (br s, 2H), 0.96 (s, 9H), 0.81 (t, 2H, $J = 6.9$ Hz), 0.75 (t, 2H, $J = 6.9$ Hz). LC/MS: m/z 501.98 [MH^+] (70), $t_R = 1.93$ min (ZQ2000, polar_5min).

[415] **EXAMPLE 135:** {4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-d]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-(1-dimethylaminomethylcyclopropyl)-methanone.




[416] Following the general procedure, but using a sealed tube and saturating the reaction mixture with dimethylamine gas, the title compound was isolated as yellow powder. ^1H NMR (400 MHz, DMSO- d_6): $\delta = 11.94$ (s, 1H), 9.55 (s, 1H), 9.19 (s, 1H), 8.84 (d, 1H, $J = 2.0$ Hz), 8.27 (s, 1H), 8.15 (s, 2H), 7.96 (d, 1H, $J = 8.9$ Hz), 7.68 (dd, 1H, $J = 2.0$ Hz & 8.9 Hz), 6.78 (s, 1H), 6.31 (br s, 1H), 4.10 (br s, 2H), 3.78 (br s, 2H), 2.52 (br s, 2H), 2.42 (s, 2H), 2.10 (s, 6H), 0.81 (br s, 2H), 0.56 (t, 2H, $J = 4.5$ Hz). LC/MS: m/z 474.11 [MH^+] (70), $t_R = 1.84$ min (ZQ2000, polar_5min).

[417] **EXAMPLE 136:** {4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-d]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-[1-(3-hydroxypyrrolidin-1-ylmethyl)-cyclopropyl]-methanone.




[418] Following the general procedure, the title compound was isolated as yellow powder. ^1H NMR (400 MHz, DMSO- d_6): δ = 11.95 (s, 1H), 9.55 (s, 1H), 9.17 (s, 1H), 8.85 (d, 1H, J = 2.0 Hz), 8.24 (s, 1H), 8.12 (s, 2H), 7.97 (d, 1H, J = 8.9 Hz), 7.78 (dd, 1H, J = 2.0 Hz & 8.9 Hz), 6.77 (d, 1H), 6.36 (br s, 1H), 4.07 (m, 2H), 3.72 (m, 2H), 2.78 (m, 2H), 2.54 (m, 2H), 2.52 (br s, 2H), 2.22 (dd, 1H, J = 4.2 Hz & 9.7 Hz), 1.85 (m, 2H), 1.40 (m, 2H), 1.07 (d, 2H, J = 6.6 Hz), 0.79 (br s, 2H), 0.60 (t, 2H, J = 5.2 Hz). LC/MS: m/z 515.99 [MH^+] (75), t_R = 1.84 min (ZQ2000, polar_5min).

[419] **EXAMPLE 137: (1-Azepan-1-ylmethylcyclopropyl)-{4-[4-(benzothiazol-6-ylamino)-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-methanone.**




[420] Following the general procedure, the title compound was isolated as yellow powder. ^1H NMR (400 MHz, DMSO- d_6): δ = 11.96 (s, 1H), 9.53 (s, 1H), 9.16 (s, 1H), 8.85 (d, 1H, J = 2.1 Hz), 8.28 (s, 1H), 8.11 (s, 2H), 7.97 (d, 1H, J = 8.7 Hz), 7.81 (dd, 1H, J = 2.1 Hz & 8.7 Hz), 6.77 (s, 1H), 6.39 (s, 1H), 4.08 (br s, 2H), 3.73 (br s, 4H), 2.62 (m, 4H), 2.52 (br s, 2H), 1.43 (br s, 4H), 1.40 (br s, 4H), 0.80 (br s, 2H), 0.59 (t, 2H, J = 5.6 Hz). LC/MS: m/z 528.13 [MH^+] (15), t_R = 1.94 min (ZQ2000, polar_5min).

[421] **EXAMPLE 138: {4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-[1-(4-hydroxypiperidin-1-ylmethyl)-cyclopropyl]-methanone.**




[422] Following the general procedure, the title compound was isolated as yellow powder. ^1H NMR (400 MHz, DMSO- d_6): δ = 11.95 (s, 1H), 9.49 (s, 1H), 9.17 (s, 1H), 8.84 (d, 1H, J = 2.0 Hz), 8.28 (s, 1H), 8.12 (s, 2H), 7.98 (d, 1H, J = 8.9 Hz), 7.83 (dd, 1H, J = 2.0 Hz & 8.9 Hz), 6.77 (s, 1H), 6.39 (s, 1H), 4.09 (br s, 2H), 3.71 (br s, 2H), 3.50 (m, 1H), 3.31 (m, 2H), 2.74 (br s, 2H), 2.52 (br s, 2H), 2.40 (s, 1H), 1.98 (t, 2H, J = 9.9 Hz), 1.55 (m, 2H), 1.23 (m, 2H), 0.80 (br s, 2H), 0.58 (t, 2H, J = 1.4 Hz). LC/MS: m/z 529.97 [MH^+] (20), t_R = 1.86 min (ZQ2000, polar_5min).

[423] **EXAMPLE 139: {4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-[1-(4-isopropylpiperazin-1-ylmethyl)-cyclopropyl]-methanone.**




[424] Following the general procedure, the title compound was isolated as yellow powder. ^1H NMR (400 MHz, DMSO-d_6): δ = 12.02 (s, 1H), 9.61 (s, 1H), 9.26 (s, 1H), 8.92 (d, 1H, J = 2.0 Hz), 8.34 (s, 1H), 8.20 (s, 2H), 8.06 (d, 1H, J = 8.9 Hz), 7.83 (dd, 1H, J = 2.0 Hz & 8.9 Hz), 6.84 (s, 1H), 6.46 (br s, 1H), 4.14 (br s, 2H), 3.68 (m, 2H), 3.26 (m, 4H), 2.52 (br s, 2H), 2.49 (br s, 2H), 2.45 (br s, 4H), 2.17 (m, 1H), 0.91 (d, 6H, J = 6.0 Hz), 0.88 (br s, 2H), 0.65 (t, 2H, J = 4.8 Hz). LC/MS: m/z 557.02 [MH^+] (20), t_R = 1.93 min (ZQ2000, polar_5min).

[425] **EXAMPLE 140:** {4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-d]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-(1-morpholin-4-ylmethyl)cyclopropyl-methanone.



[426] Following the general procedure, the title compound was isolated as yellow powder. ^1H NMR (400 MHz, DMSO-d_6): δ = 11.96 (s, 1H), 9.54 (s, 1H), 9.17 (s, 1H), 8.85 (d, 1H, J = 2.0 Hz), 8.31 (s, 1H), 8.09 (s, 2H), 7.97 (d, 1H, J = 8.6 Hz), 7.81 (dd, 1H, J = 2.0 Hz & 8.6 Hz), 6.73 (s, 1H), 6.33 (br s, 1H), 4.17 (br s, 2H), 3.72 (m, 2H), 3.42 (br s, 2H), 2.53 (br s, 2H), 2.35 (br s, 2H), 2.26 (br s, 6H), 0.81 (br s, 2H), 0.58 (t, 2H, J = 5.9 Hz). LC/MS: m/z 515.99 [MH^+] (50), t_R = 1.87 min (ZQ2000, polar_5min).


[427] **EXAMPLE 141:** {4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-d]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-[1-(4,4-difluoropiperidin-1-ylmethyl)cyclopropyl]-methanone.



[428] Following the general procedure, but using 4,4-difluoropiperidine hydrochloride and additional 2eq. of *N,N*-diisopropylethylamine, the title compound was isolated as yellow powder. ^1H NMR (400 MHz, DMSO-d_6): δ = 11.96 (s, 1H), 9.54 (s, 1H), 9.16 (s, 1H), 8.84 (d, 1H, J = 2.0 Hz), 8.24 (s, 1H), 7.97 (d, 1H, J = 8.8 Hz), 7.80 (dd, 1H, J =

2.0 Hz & 8.8 Hz), 6.77 (s, 1H), 6.38 (br s, 1H), 4.18 (br s, 2H), 3.66 (t, 2H, $J = 5.7$ Hz), 2.54 (br s, 6H), 1.78 (br s, 6H), 0.81 (s, 2H), 0.60 (t, 2H, $J = 5.4$ Hz). LC/MS: m/z 550.01 [MH^+] (30), $t_R = 2.01$ min (ZQ2000, polar_5min).

[429] **EXAMPLE 142:** {4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-*d*]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-(1-[(2-isopropylaminopropyl)-methylamino]-methyl)-cyclopropyl-methanone.




[430] Following the general procedure, the title compound was isolated as yellow powder. ^1H NMR (400 MHz, DMSO- d_6): $\delta = 11.97$ (s, 1H), 9.57 (s, 1H), 9.17 (s, 1H), 8.85 (d, 1H, $J = 2.0$ Hz), 8.27 (s, 1H), 8.21 (s, 2H), 7.97 (d, 1H, $J = 8.9$ Hz), 7.77 (dd, 1H, $J = 2.0$ Hz & 8.9 Hz), 6.78 (s, 1H), 6.38 (br s, 1H), 4.19 (s, 2H), 3.69 (m, 2H), 2.85 (m, 2H), 2.54 (m, 2H), 2.48 (br s, 2H), 1.61 (t, 2H, $J = 10.4$ Hz), 0.89 (m, 6H), 0.81 (br s, 2H), 0.59 (br s, 2H). LC/MS: m/z 543.05 [MH^+] (15), $t_R = 1.92$ min (ZQ2000, polar_5min).

[431] *General procedure for the preparation of a urea library:*


[432] To a solution of benzothiazol-6-yl-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-*d*]pyrimidin-4-yl]-amine tris-hydrochloride (396mg, in DMF (12mL) and dichloromethane (1mL) at 4°C was added *N,N*-diisopropylethylamine followed by 4-nitrophenyl chloroformate (200mg, 1.0eq.). The resulting mixture was allowed to warm up to rt and left overnight. This solution of 4-[4-(benzothiazol-6-ylamino)-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid 4-nitrophenyl ester was divided into 10 aliquots, and 5eq. of *N,N*-diisopropylethylamine and 10eq. of the corresponding amine were added. The solutions were degassed with N_2 and heated at 50°C for 96h. The products were purified by preparative HPLC with water / acetonitrile / formic acid mixtures and are assumed to be formate salts.

[433] **EXAMPLE 143:** 4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid 4-nitrophenyl ester.




[434] LC/MS: m/z 513.94 [MH^+] (100), $t_R = 3.05$ min (ZQ2000, polar_5min).

[435] **EXAMPLE 144: 4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-d]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid (2-dimethylamino-ethyl)-amide.**




[436] Following the general procedure, the title compound was isolated as yellow powder. ^1H NMR (400 MHz, DMSO- d_6): δ = 11.99 (s, 1H), 9.60 (s, 1H), 9.24 (s, 1H), 8.91 (d, 1H, J = 2.0 Hz), 8.34 (s, 1H), 8.24 (s, 2H), 8.04 (d, 1H, J = 8.9 Hz), 7.87 (dd, 1H, J = 2.0 Hz & 8.9 Hz), 6.84 (s, 1H), 6.43 (s, 1H), 4.02 (s, 2H), 3.55 (m, 2H), 3.43 (m, 2H), 3.29 (m, 2H), 2.33 (m, 2H), 2.19 (s, 6H). LC/MS: m/z 463.05 [MH^+] (15), t_R = 1.81 min (ZQ2000, polar_5min).

[437] **EXAMPLE 145: 4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-d]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid (2-diethylaminoethyl)-amide.**



[438] Following the general procedure, the title compound was isolated as yellow powder. ^1H NMR (400 MHz, DMSO- d_6): δ = 11.92 (s, 1H), 9.53 (s, 1H), 9.17 (s, 1H), 8.85 (d, 1H, J = 2.0 Hz), 8.27 (s, 1H), 8.14 (s, 2H), 7.97 (d, 1H, J = 8.9 Hz), 7.81 (dd, 1H, J = 2.0 Hz & 8.9 Hz), 6.76 (s, 1H), 6.47 (t, 1H, J = 5.3 Hz), 6.37 (br s, 1H), 3.95 (s, 2H), 3.48 (m, 2H), 3.40 (m, 4H), 3.10 (m, 2H), 2.51 (q, 4H, J = 7.1 Hz), 0.93 (t, 6H, J = 7.1 Hz). LC/MS: m/z 491.11 [MH^+] (30), t_R = 1.88 min (ZQ2000, polar_5min).


[439] **EXAMPLE 146: 4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-d]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid (2-isopropylamino-ethyl)-amide.**



[440] Following the general procedure, the title compound was isolated as yellow powder. ^1H NMR (400 MHz, DMSO- d_6): δ = 11.92 (s, 1H), 9.53 (s, 1H), 9.17 (s, 1H), 8.85 (d, 1H, J = 2.0 Hz), 8.27 (s, 1H), 8.14 (s, 2H), 7.97 (d, 1H, J = 8.9 Hz), 7.81 (dd, 1H, J = 2.0 Hz & 8.9 Hz), 7.00 (t, 1H, J = 4.7 Hz), 6.78 (s, 1H), 6.38 (br s, 1H), 4.07 (s, 2H), 3.52 (t, 2H,


$J = 5.5$ Hz), 3.26 (q, 2H, $J = 5.5$ Hz), 3.16 (m, 1H), 2.86 (t, 2H, $J = 5.9$ Hz), 2.69 (m, 2H), 1.14 (d, 6H, $J = 6.4$ Hz). LC/MS: m/z 477.08 [MH^+] (30), $t_R = 1.83$ min (ZQ2000, polar_5min).

[441] **EXAMPLE 147: 4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-d]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid (2-piperazin-1-ylethyl)-amide.**




[442] Following the general procedure, the title compound was isolated as yellow powder. ^1H NMR (400 MHz, DMSO- d_6): $\delta = 11.91$ (s, 1H), 9.52 (s, 1H), 9.16 (s, 1H), 8.84 (d, 1H, $J = 2.0$ Hz), 8.26 (s, 1H), 8.14 (s, 2H), 7.97 (d, 1H, $J = 8.9$ Hz), 7.91 (s, 1H), 7.80 (dd, 1H, $J = 2.0$ Hz & 8.9 Hz), 6.76 (s, 1H), 6.42 (t, 1H, $J = 5.3$ Hz), 6.37 (br s, 1H), 3.94 (s, 2H), 3.48 (t, 2H, $J = 5.6$ Hz), 3.28 (m, 4H), 3.11 (m, 2H), 2.91 (m, 2H), 2.51 (m, 2H), 2.33 (m, 2H), 2.27 (t, 2H, $J = 5.3$ Hz). LC/MS: m/z 504.06 [MH^+] (10), $t_R = 1.70$ min (ZQ2000, polar_5min).

[443] **EXAMPLE 148: 4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-d]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid (2-diisopropylamino-ethyl)-amide.**




[444] Following the general procedure, the title compound was isolated as yellow powder. ^1H NMR (400 MHz, DMSO- d_6): $\delta = 11.91$ (s, 1H), 9.52 (s, 1H), 9.16 (s, 1H), 8.84 (d, 1H, $J = 2.0$ Hz), 8.26 (s, 1H), 8.14 (s, 2H), 7.97 (d, 1H, $J = 8.9$ Hz), 7.91 (s, 1H), 7.80 (dd, 1H, $J = 2.0$ Hz & 8.9 Hz), 6.77 (s, 1H), 6.71 (br s, 1H), 6.37 (br s, 1H), 3.96 (s, 2H), 3.50 (t, 2H, $J = 5.4$ Hz), 3.08 (m, 4H), 2.59 (t, 2H, $J = 7.2$ Hz), 2.45 (br s, 2H), 0.99 (d, 12H, $J = 6.6$ Hz). LC/MS: m/z 519.10 [MH^+] (30), $t_R = 1.94$ min (ZQ2000, polar_5min).

[445] **EXAMPLE 149: 4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-d]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid (2-methoxyethyl)-amide.**




[446] Following the general procedure, the title compound was isolated as yellow powder. ^1H NMR (400 MHz, DMSO- d_6): δ = 12.10 (s, 1H), 9.71 (s, 1H), 9.35 (s, 1H), 9.03 (d, 1H, J = 2.0 Hz), 8.46 (s, 1H), 8.42 (s, 1H), 8.15 (d, 1H, J = 8.9 Hz), 8.00 (dd, 1H, J = 2.0 Hz & 8.9 Hz), 6.95 (s, 1H), 6.70 (t, 1H, J = 5.6 Hz), 6.55 (br s, 1H), 4.14 (s, 2H), 3.68 (t, 2H, J = 5.6 Hz), 3.47 (m, 2H), 3.37 (s, 3H), 3.34 (q, 2H, J = 6.9 Hz), 2.61 (br s, 2H). LC/MS: m/z 450.04 [MH^+] (100), t_R = 2.20 min (ZQ2000, polar_5min).

[447] **EXAMPLE 150: 4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-*d*]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid bis-(2-methoxyethyl)-amide.**




[448] Following the general procedure, the title compound was isolated as yellow powder. ^1H NMR (400 MHz, DMSO- d_6): δ = 11.92 (s, 1H), 9.52 (s, 1H), 9.16 (s, 1H), 8.84 (d, 1H, J = 2.0 Hz), 8.26 (s, 1H), 8.14 (s, 2H), 7.97 (d, 1H, J = 8.9 Hz), 7.91 (s, 1H), 7.80 (dd, 1H, J = 2.0 Hz & 8.9 Hz), 6.75 (s, 1H), 6.36 (br s, 1H), 3.81 (br s, 2H), 3.38 (t, 4H, J = 6.1 Hz), 3.29 (m, 4H), 3.18 (s, 6H), 2.71 (s, 2H), 2.52 (br s, 2H). LC/MS: m/z 508.04 [MH^+] (100), t_R = 2.39 min (ZQ2000, polar_5min).

[449] **EXAMPLE 151: 4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-*d*]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid (2-piperidin-1-ylethyl)-amide.**




[450] Following the general procedure, the title compound was isolated as yellow powder. ^1H NMR (400 MHz, DMSO- d_6): δ = 12.02 (s, 1H), 9.53 (s, 1H), 9.15 (s, 1H), 8.84 (d, 1H, J = 2.0 Hz), 8.26 (s, 1H), 8.14 (s, 2H), 7.97 (d, 1H, J = 8.9 Hz), 7.91 (s, 1H), 7.80 (dd, 1H, J = 2.0 Hz & 8.9 Hz), 6.76 (s, 1H), 6.54 (t, 1H, J = 5.2 Hz), 6.38 (br s, 1H), 3.95 (s, 2H), 3.49 (t, 2H, J = 5.4 Hz), 3.17 (q, 2H, J = 6.4 Hz), 2.55 (m, 6H), 2.51 (br s, 2H), 1.48 (m, 4H), 1.34 (m, 2H). LC/MS: m/z 503.10 [MH^+] (25), t_R = 1.85 min (ZQ2000, polar_5min).

[451] **EXAMPLE 152: 4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-*d*]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid (2-morpholin-4-ylethyl)-amide.**



[452] Following the general procedure, the title compound was isolated as yellow powder. ^1H NMR (400 MHz, DMSO- d_6): δ = 11.91 (s, 1H), 9.52 (s, 1H), 9.16 (s, 1H), 8.84 (d, 1H, J = 2.0 Hz), 8.26 (s, 1H), 8.14 (s, 2H), 7.97 (d, 1H, J = 8.9 Hz), 7.91 (s, 1H), 7.80 (dd, 1H, J = 2.0 Hz & 8.9 Hz), 6.76 (s, 1H), 6.42 (t, 1H, J = 5.5 Hz), 6.37 (br s, 1H), 3.95 (s, 2H), 3.48 (t, 2H, J = 5.6 Hz), 3.49 (t, 6H, J = 4.4 Hz), 3.11 (q, 2H, J = 6.3 Hz), 2.49 (br s, 2H), 2.31 (m, 4H). LC/MS: m/z 505.07 [MH^+] (30), t_R = 1.80 min (ZQ2000, polar_5min).


[453] **EXAMPLE 153: 4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-*d*]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid (2-pyrrolidin-1-ylethyl)-amide.**



[454] Following the general procedure, the title compound was isolated as yellow powder. ^1H NMR (400 MHz, DMSO- d_6): δ = 11.91 (s, 1H), 9.52 (s, 1H), 9.16 (s, 1H), 8.84 (d, 1H, J = 2.0 Hz), 8.26 (s, 1H), 8.14 (s, 2H), 7.97 (d, 1H, J = 8.9 Hz), 7.91 (s, 1H), 7.80 (dd, 1H, J = 2.0 Hz & 8.9 Hz), 6.76 (s, 1H), 6.41 (t, 1H, J = 5.4 Hz), 6.37 (br s, 1H), 3.94 (s, 2H), 3.50 (t, 2H, J = 5.5 Hz), 3.18 (q, 2H, J = 6.3 Hz), 2.67 (m, 6H), 2.48 (br s, 2H), 1.68 (t, 4H, J = 3.2 Hz). LC/MS: m/z 489.03 [MH^+] (55), t_R = 1.83 min (ZQ2000, polar_5min).


[455] *The following examples were prepared following the same procedure:*

[456] **EXAMPLE 154: {4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-*d*]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-piperazin-1-ylmethanone.**




[457] Following the general procedure, the title compound was isolated as yellow powder. ^1H NMR (400 MHz, DMSO- d_6): δ = 11.95 (s, 1H), 9.55 (s, 1H), 9.17 (s, 1H), 8.84 (d, 1H, J = 2.0 Hz), 8.27 (s, 1H), 8.20 (s, 2H), 7.97 (d, 1H, J = 8.9 Hz), 7.80 (dd, 1H, J = 2.0 Hz & 8.9 Hz), 6.76 (s, 1H), 6.35 (s, 1H), 4.40 (br s, 4H), 3.89 (s, 2H), 3.36 (t, 2H, J = 5.6 Hz), 3.17 (s, 3H), 2.85 (br s, 2H), 2.52 (br s, 2H). LC/MS: m/z 461.05 [MH^+] (40), t_R = 1.77 min (ZQ2000, polar_5min).

[458] **EXAMPLE 155:** {4-[4-(Benzothiazol-6-ylamino)-7*H*-pyrrolo[2,3-*d*]-pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridin-1-yl}-(4-ethylpiperazin-1-yl)-methanone.




[459] Following the general procedure, the title compound was isolated as yellow powder. ¹H NMR (400 MHz, DMSO-*d*₆): δ = 11.92 (s, 1H), 9.53 (s, 1H), 9.16 (s, 1H), 8.84 (d, 1H, *J* = 2.0 Hz), 8.27 (s, 1H), 8.10 (s, 2H), 7.97 (d, 1H, *J* = 8.9 Hz), 7.80 (dd, 1H, *J* = 2.0 Hz & 8.9 Hz), 6.76 (s, 1H), 6.34 (s, 1H), 3.86 (br s, 2H), 3.34 (t, 2H, *J* = 5.6 Hz), 3.11 (br s, 4H), 2.54 (br s, 2H), 2.30 (d, 4H, *J* = 6.6 Hz), 2.29 (q, 2H, *J* = 7.1 Hz), 0.94 (t, 3H, *J* = 7.1 Hz). LC/MS: *m/z* 489.08 [MH⁺] (30), *t*_R = 1.81 min (ZQ2000, polar_5min).

[460] **EXAMPLE 156:** {4-[4-(Benzothiazol-6-ylamino)-7*H*-pyrrolo[2,3-*d*]-pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridin-1-yl}-(4-isopropylpiperazin-1-yl)-methanone.




[461] Following the general procedure, the title compound was isolated as yellow powder. ¹H NMR (400 MHz, DMSO-*d*₆): δ = 11.92 (s, 1H), 9.54 (s, 1H), 9.17 (s, 1H), 8.84 (d, 1H, *J* = 2.0 Hz), 8.27 (s, 1H), 8.10 (s, 2H), 7.96 (d, 1H, *J* = 8.9 Hz), 7.80 (dd, 1H, *J* = 2.0 Hz & 8.9 Hz), 6.71 (s, 1H), 6.39 (s, 1H), 3.87 (br s, 4H), 3.34 (t, 4H, *J* = 5.3 Hz), 3.11 (br s, 4H), 2.63 (m, 1H), 2.54 (br s, 2H), 0.92 (d, 6H, *J* = 6.5 Hz). LC/MS: *m/z* 503.05 [MH⁺] (50), *t*_R = 1.85 min (ZQ2000, polar_5min).

[462] **EXAMPLE 157:** {4-[4-(Benzothiazol-6-ylamino)-7*H*-pyrrolo[2,3-*d*]-pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridin-1-yl}-(3,5-dimethylpiperazin-1-yl)-methanone.




[463] Following the general procedure, the title compound was isolated as yellow powder. ¹H NMR (400 MHz, DMSO-*d*₆): δ = 11.93 (s, 1H), 9.53 (s, 1H), 9.17 (s, 1H), 8.84 (d, 1H, *J* = 2.0 Hz), 8.27 (s, 1H), 8.15 (s, 2H), 7.99 (d, 1H, *J* = 8.9 Hz), 7.80 (dd, 1H, *J* = 2.0 Hz & 8.9 Hz), 6.76 (s, 1H), 6.34 (s, 1H), 3.87 (br s, 2H), 3.65 (br s, 1H), 3.45 (s, 2H), 3.42 (s, 1H), 3.34 (t, 1H, *J* = 5.6 Hz), 2.80 (m, 2H), 2.54 (br s, 2H), 2.38 (m, 2H), 0.96 (d, 6H, *J* = 6.1 Hz). LC/MS: *m/z* 489.08 [MH⁺] (30), *t*_R = 1.82 min (ZQ2000, polar_5min).

[464] **EXAMPLE 158:** {4-[4-(Benzothiazol-6-ylamino)-7*H*-pyrrolo[2,3-*d*]-pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridin-1-yl}-(4-cyclopentylpiperazin-1-yl)-methanone.




[465] Following the general procedure, the title compound was isolated as yellow powder. ¹H NMR (400 MHz, DMSO-*d*₆): δ = 11.92 (s, 1H), 9.53 (s, 1H), 9.16 (s, 1H), 8.84 (d, 1H, *J* = 2.0 Hz), 8.27 (s, 1H), 8.10 (s, 2H), 7.96 (d, 1H, *J* = 8.9 Hz), 7.80 (dd, 1H, *J* = 2.0 Hz & 8.9 Hz), 6.75 (s, 1H), 6.35 (s, 1H), 3.86 (br s, 2H), 3.33 (t, 2H, *J* = 5.6 Hz), 3.10 (br s, 4H), 2.53 (br s, 2H), 2.43 (m, 1H), 2.36 (br s, 4H), 1.69 (m, 2H), 1.53 (m, 2H), 1.43 (m, 2H), 1.26 (m, 2H). LC/MS: *m/z* 529.08 [*MH*⁺] (40), *t_R* = 1.90 min (ZQ2000, polar_5min).

[466] **EXAMPLE 159:** {4-[4-(Benzothiazol-6-ylamino)-7*H*-pyrrolo[2,3-*d*]-pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridin-1-yl}-(1-methylazepan-4-yl)-methanone.



[467] Following the general procedure, the title compound was isolated as yellow powder. ¹H NMR (400 MHz, DMSO-*d*₆): δ = 11.94 (s, 1H), 9.54 (s, 1H), 9.17 (s, 1H), 8.84 (d, 1H, *J* = 2.0 Hz), 8.27 (s, 1H), 8.17 (s, 2H), 7.96 (d, 1H, *J* = 8.9 Hz), 7.80 (dd, 1H, *J* = 2.0 Hz & 8.9 Hz), 6.77 (s, 1H), 6.39 (s, 1H), 3.64 (br s, 2H), 3.36 (t, 6H, *J* = 6.5 Hz), 2.66 (br s, 2H), 2.56 (m, 2H), 2.52 (br s, 2H), 2.28 (s, 3H), 1.79 (m, 2H). LC/MS: *m/z* 489.08 [*MH*⁺] (20), *t_R* = 1.81 min (ZQ2000, polar_5min).

[468] **EXAMPLE 160:** {4-[4-(Benzothiazol-6-ylamino)-7*H*-pyrrolo[2,3-*d*]-pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridin-1-yl}-[4-(2-methoxyethyl)-piperazin-1-yl]-methanone.




[469] Following the general procedure, the title compound was isolated as yellow powder. ¹H NMR (400 MHz, DMSO-*d*₆): δ = 11.92 (s, 1H), 9.53 (s, 1H), 9.17 (s, 1H), 8.84 (s, 1H, *J* = 2.0 Hz), 8.27 (s, 1H), 8.10 (s, 2H), 7.97 (d, 1H, *J* = 8.9 Hz), 7.80 (dd, 1H, *J* = 2.0 Hz & 8.9 Hz), 6.76 (s, 1H), 6.35 (s, 1H), 3.86 (br s, 2H), 3.37 (t, 2H, *J* = 5.8 Hz), 3.34 (t, 2H,

$J = 5.6$ Hz), 3.17 (s, 3H), 3.10 (br s, 4H), 2.53 (br s, 2H), 2.41 (m, 2H), 2.37 (br s, 4H).

LC/MS: m/z 519.10 $[MH^+]$ (25), $t_R = 1.82$ min (ZQ2000, polar_5min).


[470] **EXAMPLE 161:** {4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-*d*]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-[4-(2-dimethylaminoethyl)-piperazin-1-yl]-methanone.



[471] Following the general procedure, the title compound was isolated as yellow powder. ^1H NMR (400 MHz, DMSO- d_6): $\delta = 11.93$ (s, 1H), 9.55 (s, 1H), 9.17 (s, 1H), 8.84 (d, 1H, $J = 2.0$ Hz), 8.27 (s, 1H), 8.16 (s, 2H), 7.96 (d, 1H, $J = 8.9$ Hz), 7.80 (dd, 1H, $J = 2.0$ Hz & 8.9 Hz), 6.77 (s, 1H), 6.39 (s, 1H), 3.87 (br s, 2H), 3.34 (t, 2H, $J = 5.1$ Hz), 3.11 (br s, 4H), 2.65 (t, 2H, $J = 6.3$ Hz), 2.53 (br s, 2H), 2.43 (m, 2H), 2.37 (m, 4H), 2.35 (s, 6H).


LC/MS: m/z 532.06 $[MH^+]$ (35), $t_R = 1.82$ min (ZQ2000, polar_5min).

[472] **EXAMPLE 162:** 4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-*d*]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid methyl-(1-methyl-piperidin-4-yl)-amide.




[473] Following the general procedure, the title compound was isolated as yellow powder. ^1H NMR (400 MHz, DMSO- d_6): $\delta = 11.92$ (s, 1H), 9.54 (s, 1H), 9.17 (s, 1H), 8.84 (d, 1H, $J = 2.0$ Hz), 8.27 (s, 1H), 8.14 (s, 2H), 7.96 (d, 1H, $J = 8.9$ Hz), 7.80 (dd, 1H, $J = 2.0$ Hz & 8.9 Hz), 6.77 (s, 1H), 6.39 (s, 1H), 3.80 (br s, 2H), 3.42 (m, 3H), 3.30 (t, 2H, $J = 5.3$ Hz), 2.80 (d, 2H, $J = 10.8$ Hz), 2.63 (s, 3H), 2.52 (br s, 2H), 2.13 (s, 3H), 1.94 (t, 2H, $J = 11.8$ Hz), 1.67 (m, 2H), 1.50 (d, 2H, $J = 10.8$ Hz). LC/MS: m/z 503.11 $[MH^+]$ (10), $t_R = 1.83$ min (ZQ2000, polar_5min).

[474] **EXAMPLE 163:** {4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-*d*]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-thiomorpholin-4-ylmethanone.




[475] Following the general procedure, the title compound was isolated as yellow powder. ^1H NMR (400 MHz, DMSO- d_6): δ = 11.93 (s, 1H), 9.53 (s, 1H), 9.17 (s, 1H), 8.84 (d, 1H, J = 2.0 Hz), 8.27 (s, 1H), 8.14 (s, 2H), 7.96 (d, 1H, J = 8.9 Hz), 7.80 (dd, 1H, J = 2.0 Hz & 8.9 Hz), 6.75 (s, 1H), 6.35 (s, 1H), 3.86 (br s, 2H), 3.35 (m, 4H), 2.56 (m, 4H), 2.52 (br s, 2H), 2.43 (m, 2H). LC/MS: m/z 478.02 [MH^+] (100), t_R = 2.58 min (ZQ2000, polar_5min).

[476] **EXAMPLE 164:** {4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-*d*]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-(*cis*-2,6-dimethylmorpholin-4-yl)-methanone.




[477] Following the general procedure, the title compound was isolated as yellow powder. ^1H NMR (400 MHz, DMSO- d_6): δ = 10.00 (s, 1H), 9.61 (s, 1H), 9.23 (s, 1H), 8.90 (d, 1H, J = 2.0 Hz), 8.34 (s, 1H), 8.19 (s, 2H), 8.11 (d, 1H, J = 8.9 Hz), 7.82 (dd, 1H, J = 2.0 Hz & 8.9 Hz), 6.79 (s, 1H), 6.41 (s, 1H), 3.95 (br s, 2H), 3.45 (m, 4H), 2.54 (s, 2H), 2.49 (m, 2H), 2.08 (s, 2H), 1.08 (d, 6H, J = 6.1 Hz). LC/MS: m/z 490.07 [MH^+] (100), t_R = 2.52 min (ZQ2000, polar_5min).

[478] **EXAMPLE 165:** {4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-*d*]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-(4-hydroxypiperidin-1-yl)-methanone.




[479] Following the general procedure, the title compound was isolated as yellow powder. ^1H NMR (400 MHz, DMSO- d_6): δ = 11.91 (s, 1H), 9.53 (s, 1H), 9.16 (s, 1H), 8.84 (d, 1H, J = 2.0 Hz), 8.27 (s, 1H), 8.13 (s, 1H), 7.97 (d, 1H, J = 8.9 Hz), 7.81 (dd, 1H, J = 2.0 Hz & 8.9 Hz), 6.75 (d, 1H, J = 1.8 Hz), 6.35 (s, 1H), 4.53 (br s, 1H), 3.85 (br s, 2H), 3.56 (m, 2H), 3.31 (m, 2H), 2.81 (m, 2H), 2.53 (br s, 2H), 1.67 (m, 2H), 1.28 (m, 2H). LC/MS: m/z 476.07 [MH^+] (100), t_R = 2.16 min (ZQ2000, polar_5min).

[480] **EXAMPLE 166:** {4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-*d*]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-(3-hydroxypyrrolidin-1-yl)-methanone.




[481] Following the general procedure, the title compound was isolated as yellow powder. ^1H NMR (400 MHz, DMSO- d_6): δ = 11.93 (s, 1H), 9.53 (s, 1H), 9.16 (s, 1H), 8.85 (d, 1H, J = 2.0 Hz), 8.27 (s, 1H), 8.10 (s, 2H), 7.96 (d, 1H, J = 8.9 Hz), 7.80 (dd, 1H, J = 2.0 Hz & 8.9 Hz), 6.76 (s, 1H), 6.36 (s, 1H), 4.17 (br s, 1H), 3.86 (br s, 2H), 3.46 (m, 1H), 3.42 (m, 2H), 3.22 (m, 2H), 3.04 (d, 2H, J = 10.9 Hz), 1.75 (m, 2H), 1.68 (m, 2H). LC/MS: m/z 462.04 [MH^+] (100), t_R = 2.15 min (ZQ2000, polar_5min).

[482] **EXAMPLE 167: 4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-*d*]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid diethylamide.**




[483] Following the general procedure, the title compound was isolated as yellow powder. ^1H NMR (400 MHz, DMSO- d_6): δ = 11.92 (s, 1H), 9.53 (s, 1H), 9.16 (s, 1H), 8.84 (d, 1H, J = 2.0 Hz), 8.34 (s, 1H), 8.27 (s, 2H), 7.97 (d, 1H, J = 8.9 Hz), 7.80 (dd, 1H, J = 2.0 Hz & 8.9 Hz), 6.76 (s, 1H), 6.36 (s, 1H), 3.80 (br s, 2H), 3.31 (m, 2H), 3.08 (q, 4H, J = 7.0 Hz), 2.47 (br s, 2H), 1.00 (t, 6H, J = 7.0 Hz). LC/MS: m/z 448.08 [MH^+] (100), t_R = 2.65 min (ZQ2000, polar_5min).

[484] **EXAMPLE 168: Azetidin-1-yl-{4-[4-(benzothiazol-6-ylamino)-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-methanone.**




[485] Following the general procedure, the title compound was isolated as yellow powder. ^1H NMR (400 MHz, DMSO- d_6): δ = 11.93 (s, 1H), 9.53 (s, 1H), 9.16 (s, 1H), 8.84 (d, 1H, J = 2.0 Hz), 8.26 (s, 1H), 8.22 (s, 2H), 7.98 (d, 1H, J = 8.9 Hz), 7.80 (dd, 1H, J = 2.0 Hz & 8.9 Hz), 6.76 (s, 1H), 6.34 (s, 1H), 3.87 (m, 4H), 3.40 (t, 2H, J = 5.6 Hz), 3.27 (br s, 2H), 2.54 (br s, 2H), 2.10 (m, 2H). LC/MS: m/z 432.03 [MH^+] (100), t_R = 2.36 min (ZQ2000, polar_5min).

[486] **EXAMPLE 169: {4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-*d*]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-pyrrolidin-1-ylmethanone.**




[487] Following the general procedure, the title compound was isolated as yellow powder. ¹H NMR (400 MHz, DMSO-d₆): δ = 11.92 (s, 1H), 9.52 (s, 1H), 9.16 (s, 1H), 8.84 (d, 1H, *J* = 2.0 Hz), 8.27 (s, 1H), 8.05 (s, 2H), 7.97 (d, 1H, *J* = 8.9 Hz), 7.81 (dd, 1H, *J* = 2.0 Hz & 8.9 Hz), 6.75 (s, 1H), 6.36 (s, 1H), 3.86 (br s, 2H), 3.36 (t, 2H, *J* = 5.6 Hz), 3.24 (t, 4H, *J* = 6.3 Hz), 2.52 (br s, 2H), 1.70 (m, 4H). LC/MS: *m/z* 446.06 [MH⁺] (100), *t_R* = 2.52 min (ZQ2000, polar_5min).

[488] **EXAMPLE 170:** {4-[4-(Benzothiazol-6-ylamino)-7*H*-pyrrolo[2,3-*d*]-pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridin-1-yl}-(4,4-difluoropiperidin-1-yl)-methanone.




[489] Following the general procedure, the title compound was isolated as yellow powder. ¹H NMR (400 MHz, DMSO-d₆): δ = 11.94 (s, 1H), 9.53 (s, 1H), 9.17 (s, 1H), 8.83 (d, 1H, *J* = 2.0 Hz), 8.26 (s, 1H), 8.13 (s, 1H), 7.99 (d, 1H, *J* = 8.9 Hz), 7.81 (dd, 1H, *J* = 2.0 Hz & 8.9 Hz), 6.76 (d, 1H, *J* = 1.8 Hz), 6.35 (s, 1H), 3.91 (br s, 2H), 3.37 (q, 2H, *J* = 5.8 Hz), 3.22 (t, 4H, *J* = 4.8 Hz), 2.52 (br s, 2H), 1.93 (m, 4H). LC/MS: *m/z* 496.02 [MH⁺] (100), *t_R* = 2.72 min (ZQ2000, polar_5min).

[490] **EXAMPLE 171:** {4-[4-(Benzothiazol-6-ylamino)-7*H*-pyrrolo[2,3-*d*]-pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridin-1-yl}-(4-propylpiperazin-1-yl)-methanone.




[491] Following the general procedure, the title compound was isolated as yellow flakes. ¹H NMR (400 MHz, DMSO-d₆): δ = 11.92 (s, 1H), 9.53 (s, 1H), 9.16 (s, 1H), 8.84 (d, 1H, *J* = 2.0 Hz), 8.27 (s, 1H), 8.10 (s, 2H), 7.97 (d, 1H, *J* = 8.9 Hz), 7.80 (dd, 1H, *J* = 2.0 Hz & 8.9 Hz), 6.76 (s, 1H), 6.34 (s, 1H), 3.86 (br s, 2H), 3.34 (m, 2H), 3.29 (m, 2H), 3.10 (br s, 4H), 2.54 (br s, 2H), 2.30 (br s, 2H), 2.18 (t, 2H, *J* = 7.2 Hz), 1.35 (m, 2H), 0.79 (t, 3H, *J* = 7.4 Hz). LC/MS: *m/z* 503.11 (65) [MH⁺], *t_R* = 1.89 (ZQ2000, polar_5min).

[492] **EXAMPLE 172:** {4-[4-(Benzothiazol-6-ylamino)-7*H*-pyrrolo[2,3-*d*]-pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridin-1-yl}-(4-isobutylpiperazin-1-yl)-methanone.




[493] Following the general procedure, the title compound was isolated as yellow flakes. ¹H NMR (400 MHz, DMSO-d₆): δ = 12.02 (s, 1H), 9.76 (s, 1H), 9.35 (s, 1H), 9.07 (d, 1H, *J* = 2.0 Hz), 8.58 (s, 1H), 8.35 (s, 1H), 8.20 (d, 1H, *J* = 8.9 Hz), 8.04 (dd, 1H, *J* = 2.0 Hz & 8.9 Hz), 6.91 (s, 1H), 6.57 (s, 1H), 4.10 (br s, 2H), 3.34 (m, 2H), 3.29 (m, 2H), 3.10 (br s, 4H), 2.54 (br s, 2H), 2.30 (br s, 2H), 2.21 (d, 2H, *J* = 7.4 Hz), 1.90 (m, 1H), 1.02 (d, 6H, *J* = 6.5 Hz). LC/MS: *m/z* 517.14 (30) [MH⁺], *t_R* = 1.90 (ZQ2000, polar_5min).

[494] **EXAMPLE 173:** {4-[4-(Benzothiazol-6-ylamino)-7*H*-pyrrolo[2,3-*d*]-pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridin-1-yl}-[4-(1-ethylpropyl)-piperazin-1-yl]-methanone.



[495] Following the general procedure, the title compound was isolated as yellow flakes. ¹H NMR (400 MHz, DMSO-d₆): δ = 11.92 (s, 1H), 9.53 (s, 1H), 9.16 (s, 1H), 8.84 (d, 1H, *J* = 2.0 Hz), 8.27 (s, 1H), 8.10 (s, 1H), 7.97 (d, 1H, *J* = 8.9 Hz), 7.80 (dd, 1H, *J* = 2.0 Hz & 8.9 Hz), 6.76 (s, 1H), 6.34 (s, 1H), 3.86 (br s, 2H), 3.34 (m, 2H), 3.29 (m, 2H), 3.10 (br s, 4H), 2.54 (br s, 2H), 2.30 (br s, 2H), 2.36 (t, 1H, *J* = 6.7 Hz), 1.68 (m, 2H), 1.48 (m, 2H), 1.08 (t, 6H, *J* = 7.3 Hz). LC/MS: *m/z* 531.15 (35) [MH⁺], *t_R* = 1.95 (ZQ2000, polar_5min).

[496] **EXAMPLE 174:** {4-[4-(Benzothiazol-6-ylamino)-7*H*-pyrrolo[2,3-*d*]-pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridin-1-yl}-(4-cyclobutylmethylpiperazin-1-yl)-methanone.




[497] The reaction mixture derived from the preparation of {4-[4-(benzothiazol-6-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridin-1-yl}-piperazin-1-ylmethanone (**EXAMPLE 154**) was reacted with (bromomethyl)cyclobutane (90mg, 5eq.) in the presence of DIPEA at 60°C for 72h before the mixture was purified by HPLC, giving the title compound as yellow powder. ¹H NMR (400 MHz, DMSO-d₆): δ = 11.78 (s, 1H), 9.52 (s, 1H), 9.16 (s, 1H), 8.84 (d, 1H, *J* = 2.0 Hz), 8.26 (s, 1H), 8.14 (s, 1H), 7.97 (d, 1H, *J* = 8.9 Hz), 7.91 (s, 1H), 7.80 (dd, 1H, *J* = 2.0 Hz & 8.9 Hz), 6.82 (d, 1H, *J* = 1.7 Hz), 6.57 (br s, 1H), 3.94 (s, 2H), 3.46 (m, 4H), 3.36 (m, 4H), 3.18 (m, 4H), 2.54 (br s, 2H), 2.46 (m, 1H), 2.34 (m, 3H), 2.03 (m, 1H), 1.84 (m, 1H), 1.65 (m, 1H). LC/MS: *m/z* 529.17 (15) [MH⁺], *t_R* = 1.94 (ZQ2000, polar_5min).

[498] *General procedure for the preparation of an aminoethylurea library via bromide displacement:*


[499] To a solution of benzothiazol-6-yl-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-*d*]pyrimidin-4-yl]-amine tris-hydrochloride (303mg) in DMF (8mL) at 4°C was added *N,N*-diisopropylethylamine followed by 2-bromoethyl isocyanate (100mg). The resulting mixture was allowed to warming up to rt and left overnight. To this solution, divided into 8 aliquots, were added 10eq. of *N,N*-diisopropylethylamine and 10eq. of corresponding amine. If an amine was used as hydrochloride, additional 2eq. of *N,N*-diisopropylethylamine were added. The above solutions were degassed with N₂ and heated at 40°C for 72h. The products were purified by preparative HPLC with water / acetonitrile / formic acid mixtures and are assumed to be formate salts.

[500] **EXAMPLE 175: 4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid (2-bromoethyl)-amide.**




[501] LC/MS: *m/z* 418.01 (40) [MH⁺-Br], *t_R* = 1.83 min (ZQ2000, polar_5min).

[502] **EXAMPLE 176: 4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid [2-(4-methylpiperazin-1-yl)-ethyl]-amide.**




[503] Following the general procedure, the title compound was isolated as yellow powder. ¹H NMR (400 MHz, DMSO-*d*₆): δ = 11.92 (s, 1H), 9.53 (s, 1H), 9.17 (s, 1H), 8.85 (d, 1H, *J* = 2.0 Hz), 8.28 (s, 1H), 8.11 (s, 2H), 7.97 (d, 1H, *J* = 8.9 Hz), 7.81 (dd, 1H, *J* = 2.0 Hz & 8.9 Hz), 6.77 (s, 1H), 6.44 (t, 1H, *J* = 5.3 Hz), 6.38 (s, 1H), 3.95 (br s, 4H), 3.45 (t, 4H, *J* = 5.6 Hz), 3.11 (q, 4H, *J* = 6.3 Hz), 2.43 (br s, 2H), 2.35 (t, 4H, *J* = 7.1 Hz), 2.21 (s, 3H). LC/MS: *m/z* 518.09 [MH⁺] (40), *t_R* = 1.80 min (ZQ2000, polar_5min).

[504] **EXAMPLE 177: 4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid (2-*tert*-butylaminoethyl)-amide.**




[505] Following the general procedure, the title compound was isolated as yellow powder. ^1H NMR (400 MHz, DMSO- d_6): δ = 12.00 (s, 1H), 9.63 (s, 1H), 9.23 (s, 1H), 8.91 (d, 1H, J = 2.0 Hz), 8.34 (s, 1H), 8.33 (s, 2H), 8.04 (d, 1H, J = 8.9 Hz), 7.88 (dd, 1H, J = 2.0 Hz & 8.9 Hz), 7.21 (br s, 1H), 6.85 (s, 1H), 6.45 (s, 1H), 4.06 (br s, 2H), 3.60 (m, 2H), 3.35 (q, 4H, J = 5.3 Hz), 2.90 (t, 2H, J = 6.1 Hz), 1.23 (s, 9H). LC/MS: m/z 491.11 [MH^+] (40), t_R = 1.91 min (ZQ2000, polar_5min).

[506] **EXAMPLE 178: 4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-d]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid [2-(3-hydroxypyrrolidin-1-yl)-ethyl]-amide.**




[507] Following the general procedure, the title compound was isolated as yellow powder. ^1H NMR (400 MHz, DMSO- d_6): δ = 11.98 (s, 1H), 9.60 (s, 1H), 9.23 (s, 1H), 8.91 (d, 1H, J = 2.0 Hz), 8.34 (s, 1H), 8.22 (s, 2H), 8.04 (d, 1H, J = 8.9 Hz), 7.88 (dd, 1H, J = 2.0 Hz & 8.9 Hz), 6.83 (s, 1H), 6.57 (t, 1H, J = 5.3 Hz), 6.44 (s, 1H), 4.19 (m, 1H), 4.02 (br s, 2H), 3.56 (m, 1H), 3.19 (m, 2H), 2.80 (m, 1H), 2.70 (m, 1H), 2.56 (br s, 2H), 1.98 (m, 1H), 1.56 (m, 1H). LC/MS: m/z 505.07 [MH^+] (15), t_R = 1.79 min (ZQ2000, polar_5min).

[508] **EXAMPLE 179: 4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-d]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid (2-azepan-1-ylethyl)-amide.**




[509] Following the general procedure, the title compound was isolated as yellow powder. ^1H NMR (400 MHz, DMSO- d_6): δ = 11.92 (s, 1H), 9.53 (s, 1H), 9.17 (s, 1H), 8.85 (d, 1H, J = 2.0 Hz), 8.27 (s, 1H), 8.12 (s, 2H), 7.97 (d, 1H, J = 8.9 Hz), 7.81 (dd, 1H, J = 2.0 Hz & 8.9 Hz), 6.77 (s, 1H), 6.55 (t, 1H, J = 5.0 Hz), 6.37 (s, 1H), 3.96 (br s, 2H), 3.50 (t, 2H, J = 5.6 Hz), 3.15 (q, 4H, J = 6.1 Hz), 2.77 (t, 4H, J = 5.6 Hz), 2.67 (t, 2H, J = 7.0 Hz), 1.57 (br s, 4H), 1.47 (br s, 4H). LC/MS: m/z 517.14 [MH^+] (40), t_R = 1.94 min (ZQ2000, polar_5min).

[510] **EXAMPLE 180:** 4-[4-(Benzothiazol-6-ylamino)-7*H*-pyrrolo[2,3-*d*]-pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid [2-(4-hydroxypiperidin-1-yl)-ethyl]-amide.




[511] Following the general procedure, the title compound was isolated as yellow powder. ¹H NMR (400 MHz, DMSO-*d*₆): δ = 11.92 (s, 1H), 9.53 (s, 1H), 9.17 (s, 1H), 8.85 (d, 1H, *J* = 2.0 Hz), 8.28 (s, 1H), 8.13 (s, 2H), 7.97 (d, 1H, *J* = 8.9 Hz), 7.81 (dd, 1H, *J* = 2.0 Hz & 8.9 Hz), 6.77 (s, 1H), 6.58 (t, 1H, *J* = 5.0 Hz), 6.38 (s, 1H), 3.96 (br s, 2H), 3.50 (t, 4H, *J* = 5.3 Hz), 3.17 (q, 2H, *J* = 5.8 Hz), 2.86 (q, 2H, *J* = 6.0 Hz), 2.55 (t, 2H, *J* = 6.6 Hz), 2.42 (br s, 2H), 2.36 (m, 1H), 1.70 (m, 2H), 1.40 (m, 2H). LC/MS: *m/z* 519.14 [*MH*⁺] (30), *t_R* = 1.80 min (ZQ2000, polar_5min).

[512] **EXAMPLE 181:** 4-[4-(Benzothiazol-6-ylamino)-7*H*-pyrrolo[2,3-*d*]-pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid [2-(4-isopropylpiperazin-1-yl)-ethyl]-amide.



[513] Following the general procedure, the title compound was isolated as yellow powder. ¹H NMR (400 MHz, DMSO-*d*₆): δ = 11.92 (s, 1H), 9.53 (s, 1H), 9.17 (s, 1H), 8.85 (d, 1H, *J* = 2.0 Hz), 8.27 (s, 1H), 8.12 (s, 2H), 7.97 (d, 1H, *J* = 8.9 Hz), 7.81 (dd, 1H, *J* = 2.0 Hz & 8.9 Hz), 6.77 (s, 1H), 6.43 (t, 1H, *J* = 5.3 Hz), 6.37 (s, 1H), 3.95 (br s, 4H), 3.48 (t, 4H, *J* = 5.6 Hz), 3.12 (q, 4H, *J* = 6.3 Hz), 2.64 (m, 1H), 2.52 (br s, 2H), 2.41 (m, 2H), 2.33 (t, 2H, *J* = 7.3 Hz), 0.91 (d, 6H, *J* = 6.6 Hz). LC/MS: *m/z* 546.20 [*MH*⁺] (20), *t_R* = 1.80 min (ZQ2000, polar_5min).


[514] **EXAMPLE 182:** 4-[4-(Benzothiazol-6-ylamino)-7*H*-pyrrolo[2,3-*d*]-pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid [2-(4,4-difluoropiperidin-1-yl)-ethyl]-amide.



[515] Following the general procedure, but using 4,4-difluoropiperidine hydrochloride and an additional 2eq. of *N,N*-diisopropylethylamine, the title compound was

isolated as yellow powder. ^1H NMR (400 MHz, DMSO- d_6): δ = 11.92 (s, 1H), 9.52 (s, 1H), 9.17 (s, 1H), 8.85 (d, 1H, J = 2.0 Hz), 8.28 (s, 1H), 8.02 (s, 2H), 7.97 (d, 1H, J = 8.9 Hz), 7.81 (dd, 1H, J = 2.0 Hz & 8.9 Hz), 6.77 (s, 1H), 6.43 (t, 1H, J = 5.3 Hz), 6.37 (s, 1H), 3.95 (br s, 2H), 3.49 (t, 2H, J = 5.3 Hz), 3.11 (q, 4H, J = 6.3 Hz), 2.52 (br s, 2H), 2.38 (t, 4H, J = 7.1 Hz), 1.86 (m, 4H). LC/MS: m/z 539.08 [MH^+] (40), t_R = 1.94 min (ZQ2000, polar_5min).

[516] **EXAMPLE 183: 4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-*d*]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid [2-(3,5-dimethylpiperazin-1-yl)-ethyl]-amide.**




[517] Following the general procedure, the title compound was isolated as yellow powder. ^1H NMR (400 MHz, DMSO- d_6): δ = 11.93 (s, 1H), 9.55 (s, 1H), 9.17 (s, 1H), 8.85 (d, 1H, J = 2.0 Hz), 8.28 (s, 1H), 8.11 (s, 2H), 7.97 (d, 1H, J = 8.9 Hz), 7.81 (dd, 1H, J = 2.0 Hz & 8.9 Hz), 6.77 (s, 1H), 6.42 (t, 1H, J = 5.2 Hz), 6.37 (s, 1H), 3.94 (br s, 2H), 3.49 (t, 2H, J = 5.6 Hz), 3.11 (q, 2H, J = 6.3 Hz), 3.00 (m, 2H), 2.85 (m, 2H), 2.41 (br s, 2H), 2.33 (t, 2H, J = 6.8 Hz), 1.76 (t, 2H, J = 11.4 Hz), 1.03 (d, 6H, J = 6.3 Hz). LC/MS: m/z 532.15 [MH^+] (60), t_R = 1.77 min (ZQ2000, polar_5min).

[518] *General procedure for 3-aminopropyl derivatives:*


[519] To a solution of benzothiazol-6-yl-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-*d*]pyrimidin-4-yl]-amine tris-hydrochloride (65.3mg) in DMF (4mL) at rt were added *N,N*-diisopropylethylamine (5eq.) followed by 1-chloro-3-iodopropane (30.0mg). The resulting mixture was left at rt for 5d. To this solution, containing benzothiazol-6-yl-{6-[1-(3-chloropropyl)-1,2,3,6-tetrahydropyridin-4-yl]-7H-pyrrolo[2,3-*d*]pyrimidin-4-yl}-amine, divided into 2 aliquots, were added 1mg of KI, 5eq. *N,N*-diisopropylethylamine, and 5eq. of the corresponding amine. The above solutions were degassed with N_2 and heated at 60°C for 2d. The products were purified by preparative HPLC with water / acetonitrile / formic acid mixtures and are assumed to be formate salts.

[520] **EXAMPLE 184: Benzothiazol-6-yl-{6-[1-(3-chloropropyl)-1,2,3,6-tetrahydropyridin-4-yl]-7H-pyrrolo[2,3-*d*]pyrimidin-4-yl}-amine.**




[521] LC/MS: m/z 424.95 [MH^+] (20), t_R = 1.86 min (ZQ2000, polar_5min).

[522] **EXAMPLE 185: Benzothiazol-6-yl-(6-{1-[3-(4-methylpiperazin-1-yl)-propyl]-1,2,3,6-tetrahydropyridin-4-yl}-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine.**




[523] Following the general procedure, the title compound was isolated as yellow powder. ^1H NMR (400 MHz, DMSO- d_6): δ = 11.94 (s, 1H), 9.56 (s, 1H), 9.19 (s, 1H), 8.85 (d, 1H, J = 2.0 Hz), 8.29 (s, 1H), 8.08 (s, 2H), 7.97 (d, 1H, J = 8.9 Hz), 7.80 (dd, 1H, J = 2.0 Hz & 8.9 Hz), 6.72 (d, 1H), 6.29 (s, 1H), 3.21 (br s, 4H), 2.81 (t, 2H, J = 6.9 Hz), 2.66 (m, 4H), 2.56 (t, 2H, J = 7.4 Hz), 2.52 (m, 4H), 2.36 (s, 3H), 1.69 (m, 2H). LC/MS: m/z 489.03 [MH^+] (20), t_R = 1.53 min (ZQ2000, polar_5min).

[524] **EXAMPLE 186: Benzothiazol-6-yl-{6-[1-(3-piperidin-1-ylpropyl)-1,2,3,6-tetrahydropyridin-4-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}-amine.**



[525] Following the general procedure, the title compound was isolated as yellow powder. ^1H NMR (400 MHz, DMSO- d_6): δ = 11.91 (s, 1H), 9.55 (s, 1H), 9.16 (s, 1H), 8.84 (d, 1H, J = 2.0 Hz), 8.27 (s, 1H), 8.08 (s, 2H), 7.97 (d, 1H, J = 8.9 Hz), 7.65 (dd, 1H, J = 2.0 Hz & 8.9 Hz), 6.74 (d, 1H), 6.32 (s, 1H), 3.20 (br s, 2H), 3.03 (br s, 4H), 2.90 (t, 2H, J = 7.6 Hz), 2.67 (t, 2H, J = 5.6 Hz), 2.52 (m, 4H), 1.79 (m, 2H), 1.59 (m, 4H), 1.44 (m, 2H). LC/MS: m/z 474.04 [MH^+] (30), t_R = 1.55 min (ZQ2000, polar_5min).


[526] **EXAMPLE 187: 4-[4-(1-Ethyl-1H-pyrazol-4-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl ester.**



[527] A mixture of 4-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl ester (110mg, 0.33mmol) and 1-ethyl-4-amino-1H-pyrazole (44mg, 0.39mmol) in 1-butanol (3mL) was heated at 120°C overnight, LC-MS showed the desired product and some de-Boc product. After the mixture was cooled to rt, it was diluted with methylene chloride (3mL), then *N,N*-diisopropylethylamine (0.11mL, 0.66mmol) and di-*tert*-butyldicarbonate (72mg, 0.33mmol) were added, the resulting mixture was stirred at rt for 30min. The mixture was diluted with EtOAc (30mL), then washed with


brine (20mL), and dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure, and the residue was crystallized with EtOAc to give the title compound as an off-white solid. LC-MS (ES, Pos.): 410 $[MH^+]$. ^1H NMR ($CDCl_3$, 400 MHz): δ = 1.51 (s, 9H), 1.56 (t, J = 7.3 Hz, 3H), 2.50 (m, 2H), 3.66 (m, 2H), 4.16 (m, 2H), 4.22 (q, J = 7.3 Hz, 2H), 6.04 (s, 1H), 6.17 (s, 1H), 6.57 (s, 1H), 7.56 (s, 1H), 7.95 (s, 1H), 8.38 (s, 1H), 10.96 (br s, 1H).

[528] 4-Amino-1-ethyl-1H-pyrazole




[529] To a solution of 1-ethyl-4-nitro-1H-pyrazole (59mg, 0.42mmol) in ethyl acetate (2mL) and ethanol (2mL) was added 10% Pd-C (20mg), and the resulting mixture was stirred under hydrogen atmosphere overnight. TLC showed the reaction was complete. The catalyst was removed by filtration through a pad of celite, and the filtrate was concentrated under reduced pressure to give the title compound as red oil. ^1H NMR ($CDCl_3$, 400 MHz): δ = 1.43 (t, J = 7.3 Hz, 3H), 2.90 (br s, 2H), 4.05 (q, J = 7.3 Hz, 2H), 7.02 (d, J = 0.8 Hz, 1H), 7.15 (d, J = 0.8 Hz, 1H).

[530] 1-Ethyl-4-nitro-1H-pyrazole



[531] To a solution of 4-nitro-1H-pyrazole (226mg, 2.0mmol) in *N,N*-dimethylformamide (3mL) were added potassium carbonate (0.33g, 2.4mmol) and iodoethane (0.37g, 2.4mmol). The resulting mixture was stirred at rt overnight. TLC showed the reaction was complete. The mixture was diluted with EtOAc (40mL), then washed with water (2 $\times$ 20mL), brine (20mL), and dried over anhydrous sodium sulfate. The crude material was purified by chromatography on silica gel, eluting with Hex:EtOAc = 70:30 to give the title compound as a white solid. ^1H NMR ($CDCl_3$, 400 MHz): δ = 1.55 (t, J = 7.3 Hz, 3H), 4.22 (q, J = 7.3 Hz, 2H), 8.07 (s, 1H), 8.14 (s, 1H).


[532] EXAMPLE 188: 4-[4-(1-Phenethyl-1H-pyrazol-3-ylamino)-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl ester.



[533] A mixture of 4-(4-chloro-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl ester (110mg, 0.33mmol) and 3-amino-1-phenethyl-1H-pyrazole (74mg, 0.39mmol) in 1-butanol (3mL) was heated at 120°C overnight, LC-MS


showed the reaction was complete. The mixture was concentrated, then dissolved in MeOH-DMSO, and purified by MSDP (using water / acetonitrile / HCOOH mixtures) to give the title compound as a brown solid. LC-MS (ES, Pos.): 486 [MH⁺]. ¹H NMR (CD₃OD, 400 MHz): δ = 1.49 (s, 9H), 2.54 (m, 2H), 3.16 (t, J = 7.1 Hz, 2H), 3.65 (m, 2H), 4.12 (m, 2H), 4.32 (t, J = 7.1 Hz, 2H), 6.27 (s, 1H), 6.48 (d, J = 2.3 Hz, 1H), 6.53 (s, 1H), 7.14-7.28 (m, 5H), 7.36 (d, J = 2.3 Hz, 1H), 8.21 (s, 1H).

[534] 3-Amino-1-phenethyl-1H-pyrazole




[535] To a solution of 3-nitro-1-phenethyl-1H-pyrazole (90mg, 0.41mmol) in ethyl acetate (2mL) and ethanol (2mL) was added 10% Pd-C (20mg), the resulting mixture was stirred under hydrogen atmosphere overnight. TLC showed the reaction was complete. The catalyst was removed by filtration through a pad of celite, and the filtrate was concentrated under reduced pressure to give the title compound as colorless oil. LC-MS (ES, Pos.): 188 [MH⁺]. ¹H NMR (CDCl₃, 400 MHz): δ = 3.10 (t, J = 7.2 Hz, 2H), 3.64 (br s, 2H), 4.12 (t, J = 7.2 Hz, 2H), 5.51 (d, J = 2.3 Hz, 1H), 6.91 (d, J = 2.3 Hz, 1H), 7.08-7.11 (m, 2H), 7.20-7.30 (m, 3H).

[536] 3-Nitro-1-phenethyl-1H-pyrazole



[537] To a solution of 3-nitro-1H-pyrazole (226mg, 2.0mmol) in *N,N*-dimethylformamide (3mL) were added potassium carbonate (0.33g, 2.4mmol) and 1-bromo-2-phenylethane (0.44g, 2.4mmol). The resulting mixture was stirred at rt overnight. TLC showed the reaction was complete. The mixture was diluted with EtOAc (40mL), then washed with water (2 × 20mL), brine (20mL), and dried over anhydrous sodium sulfate. The crude material was purified by chromatography on silica gel, eluting with Hex:EtOAc = 80:20 → 70:30 to give the title compound as a white solid. NOE experiment confirmed the structure. ¹H NMR (CDCl₃, 400 MHz): δ = 3.22 (t, J = 7.1 Hz, 2H), 4.43 (t, J = 7.1 Hz, 2H), 6.79 (d, J = 2.5 Hz, 1H), 7.06-7.09 (m, 2H), 7.12 (d, J = 2.5 Hz, 1H), 7.23-7.32 (m, 3H).


[538] 3-Nitro-1H-pyrazole



[539] [Ref.: Janssen, J.W.A.M. and Habraken, C.L., *J. Org. Chem.*, **1971**, 36, 3081.] A solution of 1-nitro-1H-pyrazole (3.0g, 0.026 mol) in anisole (200mL) was heated at 145°C overnight. The mixture was cooled to rt, the white solid was collected by filtration and washed with hexanes. The mother liquid was diluted with hexanes (500mL) and cooled to –


20°C, and the resulting off-white solid was collected and combined with the previous solid. LC-MS (ES, Pos.): 114 [MH⁺]. ¹H NMR (DMSO-d₆, 400 MHz): δ = 7.04 (d, *J* = 2.5 Hz, 1H), 8.04 (d, *J* = 2.5 Hz, 1H), 13.96 (br s, 1H).

[540] **EXAMPLE 189: 4-[4-(1-Phenethyl-1*H*-pyrazol-4-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester.**




[541] A mixture of 4-(4-chloro-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl)-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester (110mg, 0.33mmol) and 4-amino-1-phenethyl-1*H*-pyrazole (74mg, 0.39mmol) in 1-butanol (3mL) was heated at 120°C overnight, LC-MS showed the desired product and some de-Boc product (ca. 1:1 ratio). After the mixture was cooled to rt, it was diluted with methylene chloride (3mL), then *N,N*-diisopropylethylamine (0.11mL, 0.66mmol) and di-*tert*-butyldicarbonate (72mg, 0.33mmol) were added, the resulting mixture was stirred at rt for 30min. The mixture was diluted with EtOAc (30mL), then washed with brine (20mL), and dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure, and the residue was crystallized with EtOAc to give the title compound as an off-white solid. LC-MS (ES, Pos.): 486 [MH⁺]. ¹H NMR (CDCl₃, 400 MHz): δ = 1.50 (s, 9H), 2.50 (m, 2H), 3.23 (t, *J* = 7.3 Hz, 2H), 3.66 (m, 2H), 4.17 (m, 2H), 4.38 (t, *J* = 7.3 Hz, 2H), 6.08 (s, 1H), 6.17 (s, 1H), 6.55 (s, 1H), 7.17-7.32 (m, 5H), 7.60 (s, 1H), 7.80 (s, 1H), 8.37 (s, 1H), 10.99 (br s, 1H).

[542] **4-Amino-1-phenethyl-1*H*-pyrazole**




[543] To a solution of 4-nitro-1-phenethyl-1*H*-pyrazole (90mg, 0.41mmol) in ethyl acetate (2mL) and ethanol (2mL) was added 10% Pd-C (20mg), and the resulting mixture was stirred under hydrogen atmosphere overnight. TLC showed the reaction was complete. The catalyst was removed by filtration through a pad of celite, and the filtrate was concentrated under reduced pressure to give the title compound as red oil. ¹H NMR (CDCl₃, 400 MHz): δ = 2.36 (br s, 2H), 3.11 (t, *J* = 7.5 Hz, 2H), 4.21 (t, *J* = 7.5 Hz, 2H), 6.83 (d, *J* = 0.8 Hz, 1H), 7.10-7.12 (m, 2H), 7.18 (d, *J* = 0.8 Hz, 1H), 7.20-7.28 (m, 3H).

[544] **4-Nitro-1-phenethyl-1*H*-pyrazole**




[545] To a solution of 4-nitro-1*H*-pyrazole (226mg, 2.0mmol) in *N,N*-dimethylformamide (3mL) were added potassium carbonate (0.33g, 2.4mmol) and 1-bromo-2-phenylethane (0.44g, 2.4mmol). The resulting mixture was stirred at rt overnight. TLC showed the reaction was complete. The mixture was diluted with EtOAc (40mL), then washed with water (2 × 20mL), brine (20mL), and dried over anhydrous sodium sulfate. The crude material was purified by chromatography on silica gel, eluting with Hex:EtOAc = 80:20 → 70:30 to give the title compound as a white solid. ¹H NMR (CDCl₃, 400 MHz): δ = 3.20 (t, *J* = 7.0 Hz, 2H), 4.37 (t, *J* = 7.0 Hz, 2H), 7.04-7.07 (m, 2H), 7.25-7.32 (m, 3H), 7.81 (s, 1H), 8.09 (s, 1H).

[546] **4-Nitro-1*H*-pyrazole**



[547] [Ref: Huettel, R. and Buechele, F., *Chem. Ber.* **1955**, 88, 1586-1590] 1-Nitro-1*H*-pyrazole (2.2g, 0.019 mol) was dissolved in sulfuric acid (10mL) at -10°C, and the resulting mixture was slowly warmed to rt overnight. The solution was added to ice (100g) dropwise, and the resulting white solid was collected by filtration and washed with water. The aqueous phase was extracted with EtOAc (3×30mL), the combined organic phases were washed with brine (2×30mL), and dried over anhydrous sodium sulfate. Evaporation under reduced pressure provided an off-white solid, which was combined with the first solid and dried *in vacuo* to provide the title compound. LC-MS (ES, Pos.): 114 [MH⁺]. ¹H NMR (DMSO-*d*₆, 400 MHz): δ = 8.27 (s, 1H), 8.90 (s, 1H), 13.96 (br s, 1H).


[548] **EXAMPLE 190: 4-[4-(Biphenyl-3-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester.**



[549] A mixture of 4-(4-chloro-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl)-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester (60.0mg, 0.179mmol) and biphenyl-3-ylamine (30.5mmol, 0.180mmol) in *n*BuOH (3mL) was heated to 80°C (bath temp.) for 17h. The solvent was evaporated, water/NaHCO₃ solution was added, the mixture was extracted with CH₂Cl₂ (3×20mL), and the combined extracts were washed with brine and dried over MgSO₄. MgSO₄ was filtered off, the filtrate was concentrated, and the residue was chromatographed on silica gel [Jones Flashmaster, 5g / 25mL cartridge, eluting with CH₂Cl₂ (1-9) → 1% MeOH in CH₂Cl₂ (10-19) → 2% MeOH in CH₂Cl₂ (20-30)]. Fr.17-26 were combined and dried *in vacuo* overnight. One obtained the title compound as off-white solid. MS (ES⁺): *m/z*

468.1 (100) $[\text{MH}^+]$. HPLC: $t_R = 3.2$ min (ZQ2000, nonpolar_5min). ^1H NMR (CDCl_3 , 400 MHz): $\delta = 1.50$ (s, 9H), 2.44–2.55 (brs, 2H), 3.61–3.71 (m, 2H), 4.13–4.22 (m, 2H), 6.15 (s, 1H), 6.24 (s, 1H), 7.11 (brs, 1H), 7.37 (t, $J = 7.4$ Hz, 1H), 7.40–7.52 (m, 4H), 7.60–7.67 (m, 3H), 7.80 (t, $J = 1.6$ Hz, 1H), 8.43 (s, 1H), 11.83 (brs, 1H).

[550] **EXAMPLE 191: 4-[4-(3-Chloro-1*H*-indazol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester.**




[551] A mixture of 4-(4-chloro-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl)-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester (49.6mg, 0.148mmol) and 5-amino-3-chloroindazole (26.5mg, 0.155mmol) in isopropyl alcohol (2.5mL, 0.033 mol) in a sealed tube was heated to 90°C (bath temp.) for 3.5h. The bath temperature was increased to 105°C, and heating was continued overnight. The bath temperature was increased to 120°C, and heating was continued for 5d. LC/MS at that time indicated loss of Boc group, i.e., (3-chloro-1*H*-indazol-5-yl)-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl]-amine, $\text{C}_{18}\text{H}_{16}\text{ClN}_7$, MW = 365.83. Solvents were evaporated. The reddish residue was suspended in *N,N*-dimethylformamide (3mL). *N,N*-diisopropylethylamine (52 μL , 0.30mmol) and di-*tert*-butyldicarbonate (33mg, 0.15mmol) were added, and the mixture was stirred at rt for 2h. DMF was evaporated, water and CH_2Cl_2 were added, and the insoluble brown material was filtered off and washed with CH_2Cl_2 and water. The layers of the filtrate were separated; the organic layer was washed with water (2 $\times$) and brine and dried over MgSO_4 . The drying agent was filtered off, and the filtrate was concentrated, redissolved in MeOH, passed a through 0.45 μm filter, and purified by MDP. One obtained the title compound as light tan solid. MS (ES+): m/z 465.9/467.9 (100/38) $[\text{MH}^+]$. HPLC: $t_R = 2.7$ min (ZQ2000, polar_5min). ^1H NMR ($\text{DMSO}-d_6$, 400 MHz): $\delta = 1.43$ (s, 9H), 2.37–2.44 (brs, 2H), 3.51–3.58 (m, 2H), 3.99–4.07 (m, 2H), 6.36 (s, 1H), 6.54 (s, 1H), 7.49 (d, $J = 8.8$ Hz, 1H), 7.55 (d, $J = 8.8$ Hz, 1H), 8.05 (s, 1H), 8.12 (s, 1H), 9.21 (s, 1H), 11.88 (brs, 1H), 13.43 (brs, 1H).

[552] *Alternative synthesis:* To a suspension of (3-chloro-1*H*-indazol-5-yl)-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl]-amine trifluoroacetate (179.8mg, 0.2457mmol, 1eq) and di-*tert*-butyldicarbonate (63.1mg, 0.286mmol, 1.16eq) in anhydrous DCM (3mL), Hünig's base (300 μL , 2mmol, 7eq) was added. Addition of anhydrous DMF (1mL) aided solubility. The reaction was stirred at rt for 2h and concentrated *in vacuo*. The crude material was adsorbed onto Hydromatrix, dry loaded, and purified by chromatography on silica gel [Jones Flashmaster, 10g / 70mL cartridge, eluting with


MeOH:DCM 1% → 2% → 5% → 7%]. Fractions 35-53 were combined and concentrated *in vacuo*. The material was purified on the Mass Directed Purification System (MDPS), yielding the title compound as a white solid. ¹H NMR (400 MHz, MeOH-*d*₄): δ = 1.50 (s, 9H), 2.49 (s, br, 2H), 3.64 (s, br, 2H), 4.12 (s, br, 2H), 6.27 (s, br, 1H), 6.39 (s, br, 1H), 7.56 (s, 2H), 8.06 (s, 1H), 8.14 (s, 1H). MS (ES⁺): *m/z* 465.95/467.97 [MH⁺]. HPLC: *t*_R = 2.67 min (ZQ2000, polar_5min).

[553] (3-Chloro-1*H*-indazol-5-yl)-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl]-amine trifluoroacetate




[554] Into a 10mL sealed tube, to a suspension / solution of 4-(4-chloro-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl)-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester (85.3mg, 0.229mmol, 1eq) and 5-amino-3-chloroindazole (3) (43.3mg, 0.258mmol, 1.13eq) in 2,2,2-trifluoroethanol (TFE) (6mL), trifluoroacetic acid (TFA) (88μL, 1.1mmol, 5eq) was added and the reaction was allowed to stir for 5d at 100°C. The reaction was cooled to rt and concentrated under reduced pressure. Purification of the crude material most likely to have been problematic—*N*-BOC protection carried out for easier purification by chromatography on silica gel. MS (ES⁺): *m/z* 365.98/367.98 (30/10) [MH⁺]. HPLC: *t*_R = 0.48 & 1.57 min (ZQ2000, polar_5min).

[555] 5-amino-3-chloroindazole




[556] A mixture of 5-aminoindazole (1.373g, 10.00mmol) and *N*-chlorosuccinimide (1.381g, 10.14mmol) in methylene chloride (50mL) was sonicated at rt for 30min. The brown mixture was then stirred overnight at rt. The suspension was diluted with CH₂Cl₂ to ≈100mL, water and aq. K₂CO₃ solution were added, and the insoluble brown material was filtered off and washed with CH₂Cl₂ and water. The layers of the filtrate were separated; the organic layer was washed with water (3×) and brine and dried over MgSO₄. The dried solution was filtered through a pad of silica gel, washing with 5% MeOH in CH₂Cl₂ until no more product eluted as indicated by TLC. Concentrating and drying *in vacuo* gave the title compound as yellow solid. MS (ES⁺): *m/z* 168.2/170.2 (100/37) [MH⁺]. HPLC: *t*_R = 2.1 min (ZQ2000, polar_5min). ¹H NMR (CDCl₃, 400 MHz): δ = 5.06 (s, 2H), 6.96 (d, *J* = 8.5 Hz, 1H), 7.27 (d, *J* = 8.5 Hz, 1H), 7.78 (s, 1H), 12.95 (brs, 1H).

[557] **EXAMPLE 192: 1-{4-[4-(3-Chloro-1*H*-indazol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridin-1-yl]-3-piperidin-1-yl-propan-1-one.**



[558] To a suspension of (3-chloro-1*H*-indazol-5-yl)-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl]-amine *tris*-hydrochloride (46.9mg, 0.0967mmol, 1eq), 1-piperidinepropanoic acid (40.5mg, 0.255mmol, 2.6eq), *N*-(3-dimethylaminopropyl)-*N*'-ethylcarbodiimide hydrochloride (EDC) (56.2mg, 0.293mmol, 3eq), and 1-hydroxybenzotriazole (HOBt) (13.9mg, 0.103mmol, 1eq) in anhydrous DMF (5mL), DiPEA (85μL, 0.48mmol, 5eq) was added under an atmosphere of N₂. The reaction was stirred at rt for 18h, after which all solvent was evaporated under reduced pressure. The crude material was adsorbed onto Hydromatrix, dry loaded, and purified by chromatography on silica gel [Jones Flashmaster, 5g / 25mL cartridge, eluting with MeOH:DCM 5% → 7N NH₃/MeOH:DCM 2% → 5% → 8% → 15%]. Fractions 25-39 were combined and concentrated *in vacuo*, yielding the desired amide, but which contained a considerable amount of 1-(3-dimethylaminopropyl)-3-ethylurea. The yellow solid was triturated in hot MeOH / sonication, giving the title compound as an off-white solid. ¹H NMR (400 MHz, CDCl₃): δ = 1.26 (s, br, 2H), 1.63 (m, 4H), 2.37–2.56 (m, 6H), 2.56–2.68 (m, 2H), 2.68–2.80 (m, 2H), 3.68 & 3.76 (t, *J* = 5.6 Hz, rotamers, 2H), 4.22 & 4.25 (s, br, rotamers, 2H), 5.92 & 5.98 (s, rotamers, 1H), 6.18 & 6.22 (s, br, rotamers, 1H), 7.49 (d, *J* = 8.8 Hz, 1H), 7.79 (dd, *J* = 8.8, 1.6 Hz, 1H), 8.13 (s, 1H), 8.26 (s, 1H). MS (ES⁺): *m/z* 505.00/506.99 (27/10) [MH⁺]; *m/z* 407.96/409.98 (100/36) [MH⁺-C₆H₁₄N]. HPLC: *t_R* = 1.75 min (ZQ2000, polar_5min).

[559] **(3-Chloro-1*H*-indazol-5-yl)-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl]-amine *tris*-hydrochloride.**




[560] A suspension of 4-[4-(3-chloro-1*H*-indazol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester (45.4mg, 0.0945mmol, 1eq) in 4.0M of HCl in 1,4-dioxane (3.25mL, 140eq) was allowed to stir at rt for 2h. The reaction was concentrated *in vacuo* to dryness, affording the title compound, as a yellow solid. ¹H NMR (400 MHz, MeOH-*d*₄): δ = 2.83 (s, br, 2H), 3.52 (t, *J* = 6.0 Hz, 2H),

3.95 (s, br, 2H), 6.44 (s, 1H), 6.83 (s, br, 1H), 7.56 (d, $J = 8.8$ Hz, 1H), 7.75 (dd, $J = 8.8, 0.8$ Hz, 1H), 8.19 (s, 1H), 8.28 (d, $J = 0.8$ Hz, 1H). MS (ES⁺): m/z 365.98/368.00 (20/8) [MH^+]. HPLC: $t_R = 0.48$ & 1.56 min (ZQ2000, polar_5min).

[561] *General procedure for preparation of a 3,6-dihydro-2H-pyridin-1-yl-ethanone library:*


[562] To a solution of benzothiazol-6-yl-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-*d*]pyrimidin-4-yl]-amine tris-hydrochloride (525mg, 1.15mmol) in DMF (12mL) and dichloromethane (1mL) at 4°C was added *N,N*-diisopropylethylamine (0.7g, 6.0mmol) followed by chloroacetyl chloride (130mg, 1.15mmol). The resulting solution was allowed to warm up to rt and stirred overnight. This solution containing 1-{4-[4-(benzothiazol-6-ylamino)-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-2-chloroethanone was divided into 13 aliquots to synthesize a 13-membered library, and 1mg of KI, 5eq. DIPEA, and 5eq. of the amines were added. If the amines were used as salts, additional DIPEA was used. The above solutions were degassed with N₂ and heated at 50°C for 12h. The products were purified by preparative HPLC with water / acetonitrile / formic acid mixtures and are assumed to be formate salts.

[563] **EXAMPLE 193: 1-{4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-2-chloroethanone.**




[564] MS: m/z 424.9/426.9 (100/45) [MH^+]; HPLC: $t_R = 2.45$ min (ZQ2000, polar_5min).

[565] **EXAMPLE 194: 1-{4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-2-(4-methylpiperazin-1-yl)-ethanone.**




[566] Following the general procedure, the title compound was isolated as yellow powder. ¹H NMR (400 MHz, DMSO-*d*₆): $\delta = 11.96$ (d, 1H, $J = 10.3$ Hz), 9.55 (br s, 1H), 9.17 (s, 1H), 8.85 (d, 1H, $J = 2.0$ Hz), 8.27 (s, 1H), 8.12 (s, 2H), 7.97 (d, 1H, $J = 8.9$ Hz), 7.80 (dd, 1H, $J = 2.1$ Hz & 8.9 Hz), 6.78 (1H, d), 6.37 (s, 1H), 4.25 (s, 1H), 4.08 (s, 2H), 3.68 (t, 1H, $J = 5.4$ Hz), 3.64 (t, 1H, $J = 5.4$ Hz), 3.18 (d, 2H, $J = 6.4$ Hz), 2.53 (br s, 2H), 2.41 (m, 7H), 2.16 (s, 3H). MS: m/z 489.04 (35) [MH^+]. HPLC: $t_R = 1.81$ min (ZQ2000, polar_5min).

[567] **EXAMPLE 195:** 1-{4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-d]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-2-pyrrolidin-1-ylethanone.




[568] Following the general procedure, the title compound was isolated as yellow powder. ^1H NMR (400 MHz, DMSO- d_6): δ = 11.96 (d, 1H, J = 17.2 Hz), 9.55 (d, 1H, J = 5.3 Hz), 9.17 (s, 1H), 8.90 (s, 1H), 8.26 (s, 1H), 8.13 (s, 2H), 7.97 (d, 1H, J = 8.9 Hz), 7.80 (d, 1H, J = 8.9 Hz), 6.78 (d, 1H, J = 8.9 Hz), 6.37 (d, 1H, J = 3.1 Hz), 4.21 (s, 1H), 4.09 (s, 1H), 3.66 (t, 2H, J = 5.4 Hz), 3.48 (d, 2H, J = 6.2 Hz), 2.60 (m, 5H), 2.51 (br s, 1H), 1.68 (d, 4H, J = 2.5 Hz). MS: m/z 460.02 (70) [MH^+]. HPLC: t_R = 1.82 min (ZQ2000, polar_5min).

[569] **EXAMPLE 196:** 1-{4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-d]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-2-diethylaminoethanone.



[570] Following the general procedure, the title compound was isolated as yellow powder. ^1H NMR (400 MHz, DMSO- d_6): δ = 11.98 (d, 1H, J = 15.8 Hz), 9.54 (d, 1H, J = 12.7 Hz), 9.18 (s, 1H), 8.85 (d, 1H, J = 2.0 Hz), 8.24 (s, 1H), 8.12 (s, 2H), 7.97 (d, 1H, J = 8.9 Hz), 7.82 (d, 1H, J = 8.9 Hz), 6.79 (d, 1H), 6.34 (s, 1H), 4.27 (s, 1H), 4.15 (s, 1H), 3.68 (m, 2H), 3.46 (d, 2H, J = 11.1 Hz), 2.53 (m, 6H), 0.96 (t, 6H, J = 7.1 Hz). MS: m/z 462.04 (80) [MH^+]. HPLC: t_R = 1.84 min (ZQ2000, polar_5min).

[571] **EXAMPLE 197:** 1-{4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-d]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-2-piperidin-1-ylethanone.




[572] Following the general procedure, the title compound was isolated as yellow powder. ^1H NMR (400 MHz, DMSO- d_6): δ = 11.95 (d, 1H, J = 19.3 Hz), 9.50 (br s, 1H), 9.13 (s, 1H), 8.81 (s, 1H, J = 2.0 Hz), 8.21 (s, 1H), 8.08 (d, 2H), 8.00 (d, 1H, J = 8.9 Hz), 7.78 (dd, 1H, J = 2.0 Hz & 8.9 Hz), 6.75 (s, 1H), 6.34 (s, 1H), 4.22 (s, 1H), 4.04 (s, 1H), 3.65 (t, 1H, J = 5.3 Hz), 3.60 (t, 1H, J = 5.3 Hz), 3.17 (d, 2H, J = 7.9 Hz), 2.51 (br s, 1H), 2.36 (m,

4H), 1.42 (m, 3H), 1.29 (m, 2H), 1.07 (d, 2H, $J = 6.6$ Hz). MS: m/z 474.04 (100) [MH^+].


HPLC: $t_R = 1.86$ min (ZQ2000, polar_5min).

[573] **EXAMPLE 198:** 1-{4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-*d*]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-2-*tert*-butylaminoethanone.




[574] Following the general procedure, the title compound was isolated as yellow powder. ^1H NMR (400 MHz, DMSO- d_6): $\delta = 11.99$ (d, 1H, $J = 19.2$ Hz), 9.63 (s, 1H), 9.17 (s, 1H), 8.84 (t, 1H), 8.27 (d, 1H, $J = 2.7$ Hz), 8.17 (s, 2H), 8.00 (d, 1H, $J = 8.8$ Hz), 7.81 (dd, 1H, $J = 2.1$ Hz & 8.8 Hz), 6.80 (d, 1H, $J = 7.9$ Hz), 6.40 (br s, 1H), 4.18 (s, 1H), 4.13 (s, 1H), 3.72 (m, 2H), 3.63 (t, 1H, $J = 5.4$ Hz), 2.55 (br s, 1H), 1.13 (s, 9H), 2.75 (br s, 1H), 2.60 (m, 2H), 1.41 (s, 9H). MS: m/z 462.04 (80) [MH^+]. HPLC: $t_R = 1.87$ min (ZQ2000, polar_5min).

[575] **EXAMPLE 199:** 1-{4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-*d*]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-2-dimethylaminoethanone.



[576] Following the general procedure, but saturating the reaction solution with dimethylamine gas in a sealed tube and reacting it at rt for two days, the title compound was isolated as yellow powder. ^1H NMR (400 MHz, DMSO- d_6): $\delta = 11.94$ (d, 1H, $J = 7.8$ Hz), 9.53 (d, 1H, $J = 7.2$ Hz), 9.21 (s, 1H), 8.84 (s, 1H), 8.27 (s, 1H), 8.15 (s, 2H), 7.96 (d, 1H, $J = 8.9$ Hz), 7.68 (dd, 1H, $J = 2.0$ Hz & 8.9 Hz), 6.77 (d, 1H, $J = 6.4$ Hz), 6.36 (d, 1H, $J = 3.5$ Hz), 4.25 (br s, 1H), 4.07 (br s, 1H), 3.55 (m, 3H), 2.51 (br s, 1H), 2.15 (d, 6H, $J = 6.4$ Hz). MS: m/z 434.00 (30) [MH^+]. HPLC: $t_R = 1.79$ min (ZQ2000, polar_5min).


[577] **EXAMPLE 200:** 1-{4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-*d*]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-2-(3-hydroxypyrrolidin-1-yl)-ethanone.



[578] Following the general procedure, the title compound was isolated as yellow powder. ^1H NMR (400 MHz, DMSO- d_6): $\delta = 11.98$ (d, 1H, $J = 18.3$ Hz), 9.55 (s, 1H), 9.16 (s, 1H), 8.85 (d, 1H, $J = 1.7$ Hz), 8.40 (s, 1H), 8.14 (s, 2H), 7.94 (d, 1H, $J = 8.6$ Hz), 7.81 (dd,


1H, $J = 1.9$ Hz & 8.6 Hz), 6.78 (d, 1H, $J = 7.2$ Hz), 6.21 (br s, 1H), 4.21 (br s, 1H), 4.14 (br s, 1H), 4.08 (s, 1H), 3.70 (m, 2H), 3.35 (m, 2H), 2.82 (m, 2H), 2.63 (m, 2H), 2.45 (m, 1H), 2.42 (m, 2H), 1.88 (m, 1H), 1.50 (m, 1H). MS: m/z 476.00 (60) $[MH^+]$. HPLC: $t_R = 1.78$ min (ZQ2000, polar_5min).

[579] **EXAMPLE 201: 2-Azepan-1-yl-1-{4-[4-(benzothiazol-6-ylamino)-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-ethanone.**




[580] Following the general procedure, the title compound was isolated as yellow powder. ^1H NMR (400 MHz, DMSO- d_6): $\delta = 12.06$ (s, 1H), 9.54 (d, 1H, $J = 3.7$ Hz), 9.17 (s, 1H), 8.84 (d, 1H, $J = 2.0$ Hz), 8.31 (s, 1H), 8.12 (s, 2H), 7.97 (d, 1H, $J = 8.7$ Hz), 7.80 (dd, 1H, $J = 2.0$ Hz & 9.2 Hz), 6.78 (s, 1H), 6.38 (s, 1H), 4.27 (s, 1H), 4.07 (s, 1H), 3.69 (t, 2H, $J = 5.6$ Hz), 3.65 (t, 1H, $J = 5.6$ Hz), 3.38 (s, 2H), 2.62 (m, 4H), 2.55 (m, 1H), 1.50 (m, 8H). LC/MS: m/z 488.07 (25) $[MH^+]$, $t_R = 1.91$ min (ZQ2000, polar_5min).

[581] **EXAMPLE 202: 1-{4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-2-(4-hydroxypiperidin-1-yl)-ethanone.**




[582] Following the general procedure, the title compound was isolated as yellow powder. ^1H NMR (400 MHz, DMSO- d_6): $\delta = 11.97$ (d, 1H, $J = 15.3$ Hz), 9.53 (s, 1H), 9.16 (s, 1H), 8.85 (s, 1H), 8.27 (d, 1H, $J = 1.5$ Hz), 8.09 (s, 2H), 7.97 (d, 1H, $J = 8.9$ Hz), 7.81 (dd, 1H, $J = 1.5$ Hz & 8.9 Hz), 6.79 (s, 1H), 6.38 (s, 1H), 4.22 (br s, 1H), 4.09 (br s, 1H), 3.66 (m, 2H), 3.44 (m, 2H), 3.36 (s, 1H), 2.74 (m, 3H), 2.54 (m, 1H), 2.35 (m, 1H), 2.22 (m, 2H), 1.70 (m, 2H), 1.39 (m, 2H). LC/MS: m/z 490.03 (45) $[MH^+]$, $t_R = 1.77$ min (ZQ2000, polar_5min).

[583] **EXAMPLE 203: 1-{4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-2-(4-isopropylpiperazin-1-yl)-ethanone.**




[584] Following the general procedure, the title compound was isolated as yellow powder. ^1H NMR (400 MHz, DMSO- d_6): δ = 11.96 (d, 1H, J = 19.8 Hz), 9.54 (d, 1H, J = 4.6 Hz), 9.17 (s, 1H), 8.85 (s, 1H), 8.36 (s, 1H), 8.10 (s, 2H), 7.97 (d, 1H, J = 9.7 Hz), 7.80 (dd, 1H, J = 2.0 Hz & 9.7 Hz), 6.75 (s, 1H), 6.37 (br s, 1H), 4.25 (br s, 2H), 4.15 (br s, 2H), 3.70 (t, 2H, J = 5.2 Hz), 3.62 (t, 1H, J = 5.2 Hz), 3.18 (d, 4H, J = 6.4 Hz), 2.67 (m, 2H), 2.52 (m, 4H), 0.91 (d, 6H, J = 6.5 Hz). LC/MS: m/z 517.07 (95) [MH^+], t_R = 1.84 min (ZQ2000, polar_5min).

[585] **EXAMPLE 204: 1-{4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-d]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-2-morpholin-4-ylethanone.**




[586] Following the general procedure, the title compound was isolated as yellow powder. ^1H NMR (400 MHz, DMSO- d_6): δ = 11.98 (d, 1H, J = 14.6 Hz), 9.61 (s, 1H), 9.17 (s, 1H), 8.85 (d, 1H, J = 2.0 Hz), 8.31 (s, 1H), 8.11 (s, 2H), 7.97 (d, 1H, J = 8.6 Hz), 7.81 (dd, 1H, J = 2.0 Hz & 8.6 Hz), 6.78 (s, 1H), 6.38 (br s, 1H), 4.26 (br s, 1H), 4.08 (br s, 1H), 3.70 (t, 2H, J = 5.2 Hz), 3.62 (t, 2H, J = 5.2 Hz), 3.51 (m, 4H), 3.17 (d, 2H, J = 11.6 Hz), 2.52 (m, 1H), 2.29 (br s, 3H). LC/MS: m/z 476.00 (95) [MH^+], t_R = 1.81 min (ZQ2000, polar_5min).

[587] **EXAMPLE 205: 1-{4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-d]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-2-(4,4-difluoropiperidin-1-yl)-ethanone.**



[588] Following the general procedure, but using 4,4-difluoropiperidine hydrochloride and additional 2 equiv. of DIPEA, the title compound was isolated as yellow powder. ^1H NMR (400 MHz, DMSO- d_6): δ = 11.98 (d, 1H, J = 14.3 Hz), 9.54 (d, 1H, J = 3.6 Hz), 9.16 (s, 1H), 8.85 (d, 1H, J = 2.0 Hz), 8.27 (s, 1H), 8.11 (s, 2H), 7.97 (d, 1H, J = 8.8 Hz), 7.80 (dd, 1H, J = 2.0 Hz & 8.8 Hz), 6.78 (s, 1H), 6.32 (br s, 1H), 4.22 (br s, 1H), 4.08 (br s, 1H), 3.66 (t, 2H, J = 5.7 Hz), 3.54 (t, 1H, J = 5.7 Hz), 3.45 (m, 1H), 3.27 (d, 2H, J = 9.5 Hz), 2.53 (br s, 4H), 1.87 (m, 4H). LC/MS: m/z 509.99 (40) [MH^+], t_R = 1.98 min (ZQ2000, polar_5min).

[589] **EXAMPLE 206: 1-{4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-d]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-2-(3,5-dimethylpiperazin-1-yl)-ethanone.**




[590] Following the general procedure, the title compound was isolated as yellow powder. Its structure has been confirmed by 2D ROESY NMR experiments. It's derived from *cis/trans* 2,6-dimethylpiperazine, with predominantly *cis* isomer. ¹H NMR (400 MHz, DMSO-d₆): δ = 11.98 (d, 1H, *J* = 17.2 Hz), 9.56 (s, 1H), 9.16 (s, 1H), 8.85 (d, 1H, *J* = 2.1 Hz), 8.27 (s, 1H), 8.20 (s, 2H), 7.96 (d, 1H, *J* = 8.9 Hz), 7.75 (dd, 1H, *J* = 2.1 Hz & 8.9 Hz), 6.78 (d, 1H, *J* = 4.1 Hz), 6.36 (br s, 1H), 4.20 (s, 1H), 4.15 (s, 1H), 3.64 (q, 2H, *J* = 5.5 Hz), 3.51 (s, 2H), 3.22 (br s, 2H), 2.97 (m, 2H), 2.73 (m, 2H), 2.51 (br s, 1H), 1.91 (m, 1H), 1.01 (m, 6H). LC/MS: *m/z* 503.05 (30) [MH⁺], *t_R* = 1.83 min (ZQ2000, polar_5min).

[591] *General procedure for preparation of a 3,6-dihydro-2H-pyridin-1-yl-propanone library:*

[592] To a solution of benzothiazol-6-yl-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-*d*]pyrimidin-4-yl]-amine tris-hydrochloride (187mg, 0.408mmol) in DMF (12mL) and dichloromethane (1mL) at 4°C was added *N,N*-diisopropylethylamine (0.3g, 2.0mmol), followed by 3-chloropropanoyl chloride (52mg, 0.41mmol). The resulting mixture was allowed to warm up to rt and stirred overnight. This solution containing 1-{4-[4-(benzothiazol-6-ylamino)-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-3-chloropropan-1-one and 1-{4-[4-(benzothiazol-6-ylamino)-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-propanone was divided into 13 aliquots to synthesize a 13-membered library, and 1mg of KI, 5eq. DIPEA, and 5eq. of the amines were added. If the amines were used as salts, additional DIPEA was used. The solutions were degassed with N₂ and heated at 70°C for 48h. The products were purified by preparative HPLC with water / acetonitrile / formic acid mixture and are assumed to be formate salts.


[593] **EXAMPLE 207: 1-{4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-3-chloropropan-1-one.**



[594] HPLC purification of the reaction mixture gave the title compound as yellow powder. ¹H NMR (400 MHz, DMSO-d₆): δ = 11.99 (d, 1H, *J* = 17.2 Hz), 9.55 (s, 1H), 9.17 (s, 1H), 8.84 (s, 1H), 8.28 (s, 1H), 7.97 (d, 1H, *J* = 8.9 Hz), 7.79 (d, 1H, *J* = 11.8 Hz), 6.78 (1H, d, *J* = 6.3 Hz), 6.38 (s, 1H), 4.18 (d, 2H, *J* = 17.2 Hz), 3.81 (q, 2H, *J* = 6.6 Hz), 3.64 (m,


2H, $J = 5.5$ Hz), 2.90 (t, 1H, $J = 6.6$ Hz), 2.84 (t, 1H, $J = 6.6$ Hz), 2.51 (s, 1H). LC/MS: m/z 438.98/440.94 (100/40) [MH^+], $t_R = 2.52$ min (ZQ2000, polar_5min).

[595] **EXAMPLE 208:** 1-{4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-d]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-propenone.




[596] HPLC purification of the reaction mixture gave the title compound as yellow powder. ^1H NMR (400 MHz, DMSO- d_6): $\delta = 11.96$ (d, 1H, $J = 17.2$ Hz), 9.55 (s, 1H), 9.20 (s, 1H), 9.16 (s, 1H), 8.28 (d, 2H, $J = 6.5$ Hz), 7.97 (d, 1H, $J = 8.9$ Hz), 7.81 (d, 1H, $J = 11.8$ Hz), 6.88 (m, 1H), 6.78 (m, 1H), 6.38 (s, 1H), 6.09 (d, 1H, $J = 16.2$ Hz), 4.27 (s, 1H), 4.16 (s, 1H), 3.72 (m, 3H), 2.95 (t, 1H, $J = 6.6$ Hz). LC/MS: m/z 402.98 (100) [MH^+], $t_R = 2.30$ min (ZQ2000, polar_5min).

[597] **EXAMPLE 209:** 1-{4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-d]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-3-(4-methylpiperazin-1-yl)-propan-1-one.



[598] Following the general procedure, the title compound was isolated as yellow powder. ^1H NMR (400 MHz, DMSO- d_6): $\delta = 12.30$ (1H, d, $J = 17.2$ Hz), 9.61 (s, 1H), 9.27 (s, 1H), 8.92 (s, 1H), 8.34 (s, 1H), 8.04 (d, 1H, $J = 8.9$ Hz), 7.88 (d, 1H, $J = 8.9$ Hz), 6.84 (1H, d, $J = 6.4$ Hz), 6.44 (s, 1H), 4.24 (1H, s), 4.14 (1H, s), 3.77 (t, 2H, $J = 6.6$ Hz), 3.30 (m, 10H), 2.93 (s, 1H, $J = 6.6$ Hz), 2.89 (s, 1H), 2.74 (s, 1H), 2.73 (d, 1H, $J = 0.5$ Hz), 2.14 (t, 3H, $J = 8.1$ Hz). LC/MS: m/z 503.01 (30) [MH^+], $t_R = 1.79$ min (ZQ2000, polar_5min).


[599] **EXAMPLE 210:** 1-{4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-d]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-3-pyrrolidin-1-ylpropan-1-one.



[600] Following the general procedure, the title compound was isolated as yellow powder. ^1H NMR (400 MHz, DMSO- d_6): $\delta = 12.34$ (d, 1H, $J = 17.2$ Hz), 9.61 (s, 1H), 9.23 (s, 1H), 8.91 (s, 1H), 8.34 (s, 1H), 8.03 (d, 1H, $J = 8.8$ Hz), 7.87 (d, 1H, $J = 8.9$ Hz), 6.84 (1H, d, $J = 7.0$ Hz), 6.44 (s, 1H), 4.23 (1H, s), 4.13 (1H, s), 3.71 (t, 2H, $J = 5.5$ Hz), 3.32 (s, 6H),


2.60 (m, 3H), 2.14 (d, 1H, $J = 5.2$ Hz), 1.66 (m, 4H). LC/MS: m/z 473.94 (70) $[MH^+]$, $t_R = 1.82$ min (ZQ2000, polar_5min).

[601] **EXAMPLE 211:** 1-{4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-*d*]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-3-diethylaminopropan-1-one.




[602] Following the general procedure, the title compound was isolated as yellow powder. ^1H NMR (400 MHz, DMSO- d_6): $\delta = 12.30$ (d, 1H, $J = 17.2$ Hz), 9.60 (s, 1H), 9.24 (s, 1H), 8.91 (s, 1H), 8.34 (s, 1H), 8.03 (d, 1H, $J = 8.9$ Hz), 7.87 (d, 1H, $J = 8.9$ Hz), 6.83 (d, 1H, $J = 6.4$ Hz), 6.44 (s, 1H), 4.24 (s, 1H), 4.14 (s, 1H), 3.71 (t, 2H, $J = 5.5$ Hz), 3.32 (s, 2H), 2.65 (m, 2H), 2.54 (br s, 1H), 2.51 (m, 1H), 2.47 (m, 4H), 0.93 (q, 6H, $J = 7.90$ Hz). LC/MS: m/z 475.96 (70) $[MH^+]$, $t_R = 1.85$ min (ZQ2000, polar_5min).

[603] **EXAMPLE 212:** 1-{4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-*d*]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-3-diisopropylaminopropan-1-one.




[604] The general procedure was followed, except that 10eq. of diisopropylamine were used and that the reaction was heated for 5d. LC/MS: m/z 504.04 (15) $[MH^+]$, $t_R = 1.91$ (ZQ2000, polar_5min).

[605] **EXAMPLE 213:** 1-{4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-*d*]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-3-*tert*-butylaminopropan-1-one.




[606] Following the general procedure, but using 10eq. of *tert*-butylamine, the title compound was isolated as yellow powder. ^1H NMR (400 MHz, DMSO- d_6): $\delta = 12.21$ (d, 1H, $J = 17.2$ Hz), 9.79 (s, 1H), 9.41 (s, 1H), 9.07 (d, 1H, $J = 2.0$ Hz), 8.50 (d, 1H, $J = 1.5$ Hz), 8.43 (s, 4H), 8.21 (d, 1H, $J = 5.7$ Hz), 8.04 (dd, 1H, $J = 2.1$ Hz & 8.8 Hz), 7.99 (d, 1H, 1.5 Hz), 7.68 (br s, 1H), 7.02 (d, 1H, $J = 4.8$ Hz), 6.60 (br s, 1H), 4.36 (1H, s), 3.94 (t, 1H, $J = 5.7$ Hz), 3.83 (t, 1H, $J = 5.7$ Hz), 3.21 (t, 2H, $J = 6.3$ Hz), 2.99 (t, 1H, $J = 10.8$), 2.90 (s, 1H, $J = 10.8$ Hz), 2.75 (br s, 1H), 2.60 (m, 2H), 1.41 (s, 9H). LC/MS: m/z 476.00 (100) $[MH^+]$, $t_R = 1.89$ min (ZQ2000, polar_5min).

[607] **EXAMPLE 214: 3-Azetidin-1-yl-1-{4-[4-(benzothiazol-6-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-propan-1-one.**




[608] Following the general procedure, the title compound was isolated as yellow powder. ¹H NMR (400 MHz, DMSO-d₆): δ = 12.01 (d, 1H, *J* = 17.2 Hz), 9.85 (s, 1H), 9.21 (s, 1H), 8.90 (s, 1H), 8.29 (d, 1H, *J* = 1.0 Hz), 8.23 (s, 2H), 7.97 (d, 1H, *J* = 5.7 Hz), 7.81 (dd, 1H, *J* = 2.1 Hz & 8.8 Hz), 6.80 (d, 1H, *J* = 5.4 Hz), 6.40 (br s, 1H), 4.16 (d, 1H, *J* = 10.1 Hz), 3.68 (t, 1H, *J* = 5.1 Hz), 3.63 (t, 1H, *J* = 4.9 Hz), 3.01 (t, 1H, *J* = 8.3 Hz), 2.85 (m, 2H), 2.34 (t, 4H, *J* = 6.6 Hz), 2.13 (m, 2H), 2.09 (t, 2H, *J* = 4.2 Hz), 1.67 (t, 2H, *J* = 7.2 Hz). LC/MS: *m/z* 126.01 (100%), 320.02 (50%), 332.01 (90%) [*MH*⁺ – H₂NCOCH₂CH₂N(CH₂)₃], 390.98 (35) [*MH*⁺ – CH₂N(CH₂)₃]⁺, *t*_R = 1.62 min (ZQ2000, polar_5min).

[609] **EXAMPLE 215: 1-{4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-3-(3-hydroxypyrrolidin-1-yl)-propan-1-one.**



[610] Following the general procedure, the title compound was isolated as yellow powder. ¹H NMR (400 MHz, DMSO-d₆): δ = 11.84 (d, 1H, *J* = 14.3 Hz), 9.42 (s, 1H), 9.03 (s, 1H), 8.76 (s, 1H), 8.15 (s, 1H), 8.01 (s, 4H), 7.87 (d, 1H, *J* = 8.6 Hz), 7.67 (dd, 1H, *J* = 1.9 Hz & 10.9 Hz), 6.65 (d, 1H, *J* = 8.1 Hz), 6.21 (br s, 1H), 4.09 (br s, 2H), 3.96 (br s, 1H), 3.51 (m, 4H), 2.81 (m, 1H), 2.75 (m, 2H), 2.54 (m, 3H), 2.44 (m, 3H), 2.11 (s, 1H), 1.82 (m, 1H). LC/MS: *m/z* 490.00 (50) [*MH*⁺], *t*_R = 1.79 min (ZQ2000, polar_5min).


[611] **EXAMPLE 216: 3-Azepan-1-yl-1-{4-[4-(benzothiazol-6-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-propan-1-one.**



[612] Following the general procedure, the title compound was isolated as yellow powder. ¹H NMR (400 MHz, DMSO-d₆): δ = 12.06 (d, 1H, *J* = 16.8 Hz), 9.62 (s, 1H), 9.24 (s, 1H), 8.92 (s, 1H), 8.35 (s, 1H), 8.25 (s, 3H), 8.04 (d, 1H, *J* = 8.7 Hz), 7.88 (d, 1H, *J* = 9.2 Hz), 6.85 (d, 1H, *J* = 5.1 Hz), 6.45 (s, 1H), 4.91 (s, 1H), 4.55 (s, 1H), 3.74 (t, 2H, *J* = 9.6 Hz),


2.90 (m, 2H), 2.70 (m, 3H), 2.68 (m, 1H), 1.57 (m, 12H). LC/MS: m/z 502.03 (10) $[MH^+]$, t_R = 1.91 min (ZQ2000, polar_5min).

[613] **EXAMPLE 217: 1-{4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-*d*]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-3-(4-hydroxypiperidin-1-yl)-propan-1-one.**




[614] Following the general procedure, the title compound was isolated as yellow powder. ^1H NMR (400 MHz, DMSO- d_6): δ = 12.00 (d, 1H, J = 18.3 Hz), 9.61 (s, 1H), 9.17 (s, 1H), 8.85 (s, 1H), 8.28 (d, 1H, J = 1.5 Hz), 8.12 (s, 3H), 7.97 (d, 1H, J = 8.9 Hz), 7.81 (dd, 1H, J = 2.1 Hz & 8.9 Hz), 6.77 (d, 1H, J = 5.8 Hz), 6.37 (d, 1H, J = 2.1 Hz), 4.30 (br s, 1H), 4.17 (br s, 1H), 3.63 (d, 2H, J = 3.9 Hz), 3.36 (m, 1H), 2.78 (m, 4H), 2.59 (m, 4H), 2.54 (m, 2H), 2.20 (m, 2H), 1.66 (m, 2H). LC/MS: m/z 503.99 (20) $[MH^+]$, t_R = 1.79 min (ZQ2000, polar_5min).

[615] **EXAMPLE 218: 1-{4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-*d*]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-3-(4-isopropylpiperazin-1-yl)-propan-1-one.**




[616] Following the general procedure, the title compound was isolated as yellow powder. ^1H NMR (400 MHz, DMSO- d_6): δ = 12.07 (d, 1H, J = 18.3 Hz), 9.63 (s, 1H), 9.23 (s, 1H), 8.92 (s, 1H), 8.34 (s, 1H), 8.19 (s, 2H), 8.04 (d, 1H, J = 8.9 Hz), 7.78 (d, 1H, J = 15.2 Hz), 6.84 (d, 1H, J = 5.3 Hz), 6.45 (br s, 1H), 4.27 (br s, 2H), 4.24 (br s, 2H), 3.78 (t, 6H, J = 5.9 Hz), 2.67 (m, 1H), 2.58 (m, 8H), 0.97 (t, 6H, J = 6.2 Hz). LC/MS: m/z 531.04 (20) $[MH^+]$, t_R = 1.81 min (ZQ2000, polar_5min).

[617] **EXAMPLE 219: 1-{4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-*d*]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-3-morpholin-4-ylpropan-1-one.**




[618] Following the general procedure, the title compound was isolated as yellow powder. ^1H NMR (400 MHz, DMSO- d_6): δ = 12.01 (d, 1H, J = 14.6 Hz), 9.60 (s, 1H), 9.17 (s, 1H), 8.83 (s, 1H), 8.28 (d, 1H, J = 1.2 Hz), 8.11 (s, 2H), 7.99 (d, 1H, J = 8.6 Hz), 7.81 (dd, 1H, J = 1.7 Hz & 9.3 Hz), 6.77 (d, 1H, J = 6.3 Hz), 6.38 (br s, 1H), 4.20 (br s, 1H), 3.99 (br s, 1H), 3.63 (t, 4H, J = 5.2 Hz), 3.50 (t, 4H, J = 4.3 Hz), 2.52 (m, 4H), 2.27 (m, 4H). LC/MS: m/z 489.96 (70) [MH^+], t_R = 1.81 min (ZQ2000, polar_5min).

[619] **EXAMPLE 220:** 1-{4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-*d*]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-3-(4,4-difluoropiperidin-1-yl)-propan-1-one.




[620] Following the general procedure, but using 4,4-difluoropiperidine hydrochloride and additional 2 equiv. of DIPEA, the title compound was isolated as yellow powder. ^1H NMR (400 MHz, DMSO- d_6): δ = 11.97 (d, 1H, J = 14.3 Hz), 9.56 (s, 1H), 9.18 (s, 1H), 8.86 (d, 1H, J = 2.1 Hz), 8.27 (d, 1H, J = 1.4 Hz), 8.11 (s, 2H), 7.97 (s, 1H), 7.85 (dd, 1H, J = 2.1 Hz & 8.9 Hz), 6.79 (d, 1H, J = 6.3 Hz), 6.39 (br s, 1H), 4.19 (br s, 1H), 4.09 (br s, 1H), 3.79 (t, 2H, J = 5.7 Hz), 3.41 (m, 6H), 2.48 (m, 2H), 1.92 (m, 6H). LC/MS: m/z 523.96 (30) [MH^+], t_R = 1.93 min (ZQ2000, polar_5min).

[621] **EXAMPLE 221:** 1-{4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-*d*]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-3-(3,5-dimethylpiperazin-1-yl)-propan-1-one.




[622] Following the general procedure, the title compound was isolated as yellow powder. Its structure has been confirmed by 2D ROESY NMR experiments. It's derived from *cis/trans* 2,6-dimethylpiperazine, with predominantly *cis* isomer. ^1H NMR (400 MHz, DMSO- d_6): δ = 11.92 (d, 1H, J = 17.2 Hz), 9.62 (s, 1H), 9.08 (s, 1H), 8.72 (s, 1H), 8.08 (s, 1H), 7.98 (d, 2H), 7.89 (d, 1H, J = 8.9 Hz), 7.68 (d, 1H, J = 8.9 Hz), 6.65 (1H, d, J = 5.4 Hz), 6.26 (s, 1H), 4.05 (2H, s), 3.95 (2H, s), 3.51 (s, 4H), 2.76 (m, 1H), 2.47 (s, 1H), 2.43 (m, 1H), 1.91 (br s, 1H), 1.64 (br s, 1H), 1.48 (m, 3H), 0.74 (t, 6H, J = 6.0 Hz). LC/MS: m/z 516.00 (30) [MH^+], t_R = 1.99 min (ZQ2000, polar_5min).

[623] **EXAMPLE 222: 1-4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-d]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl-3-piperidin-1-ylpropan-1-one.**



[624] To a suspension/solution of benzothiazol-6-yl-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-amine *tris*-hydrochloride (100.9mg, 0.220mmol, 1eq), 1-piperidinepropanoic acid (87.9mg, 0.554mmol, 2.5eq), EDC (130.8mg, 0.682mmol, 3eq), and HOBT (30.3mg, 0.224mmol, 1eq) in anhydrous DMF (6mL), DiPEA (192 μ L, 1.1mmol, 5eq) was added at rt, under an atmosphere of N₂. The reaction mixture was stirred at rt for 15h and was concentrated under reduced pressure. The residue was dissolved in a 5% MeOH : DCM mixture and washed with NaHCO₃ (1 $\times$) and brine (1 $\times$), dried over anhydrous Na₂SO₄, filtered, and concentrated *in vacuo*. The crude material was adsorbed onto Hydromatrix, dry loaded, and purified by chromatography on silica gel [Jones Flashmaster, 5g / 25mL cartridge, eluting with MeOH:DCM 5% $\rightarrow$ 10% $\rightarrow$ 7N NH₃/MeOH:DCM 5%]. Fractions containing product were combined and concentrated *in vacuo*. Further purification of the yellow solid thus obtained by trituration in hot DCM / sonication gave the title compound as light tan solid. ¹H NMR (400 MHz, MeOH-*d*₄): δ = 1.45–1.58 (s, br, 2H), 1.60–1.72 (m, 4H), 2.49–2.85 (m, 10H), 3.81 & 3.85 (t, *J* = 5.6 Hz, rotamers, 2H), 4.27 & 4.32 (s, br, rotamers, 2H), 6.34 (d, *J* = 1.2 Hz, 1H), 6.74 & 6.76 (s, rotamers, 1H), 7.78 & 7.80 (dd, *J* = 8.8, 2.8 Hz, rotamers, 1H), 8.02 (d, *J* = 8.8 Hz, 1H), 8.29 & 8.30 (s, rotamers, 1H), 8.75 & 8.76 (d, *J* = 2.0 Hz, rotamers, 1H), 9.13 (s, 1H). MS (ES⁺): *m/z* 487.97 (75) [MH⁺]. HPLC: *t*_R = 1.89 min (ZQ2000, polar_5min).


[625] **EXAMPLE 223: 1-4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-d]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl-3-dimethylaminopropan-1-one.**



[626] The title compound was obtained following the procedure for 1-4-[4-(benzothiazol-6-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl-3-piperidin-1-ylpropan-1-one, using 3-dimethylaminopropionic acid, as brown solid. ¹H NMR (400 MHz, MeOH-*d*₄): δ = 2.33 & 2.35 (s, rotamers, 6H), 2.62 (s, br, 2H), 2.67–2.73 (m, 4H), 3.83 & 3.86 (t, *J* = 5.6 Hz, rotamers, 2H), 4.29 & 4.33 (s, br, rotamers, 2H), 6.36 (d, *J* = 1.6 Hz, 1H), 6.75 & 6.77 (s, rotamers, 1H), 7.79 & 7.81 (dd, *J* = 8.8, 2.8 Hz, rotamers, 1H), 8.04 (d, *J* = 8.8 Hz, 1H), 8.31 & 8.32 (s, rotamers, 1H), 8.77 & 8.78 (d, *J* = 2.0 Hz, rotamers,

1H), 9.15 (s, 1H). MS (ES+): m/z 448.00 (12) $[MH^+]$. HPLC: t_R = 2.00 min (ZQ2000, polar_5min).

[627] **EXAMPLE 224: Benzothiazol-6-yl-[6-(1-methanesulfonyl-1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-*d*]pyrimidin-4-yl]amine.**




[628] To a solution of benzothiazol-6-yl-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-*d*]pyrimidin-4-yl]amine trihydrochloride (100mg, 0.2mmol) in DMF (5mL) was added *N,N*-diisopropylethylamine (0.4mL, 2.0mmol) and methanesulfonic anhydride (42mg, 0.24mmol). The reaction mixture was left to stir at rt for 1h. The mixture was concentrated *in vacuo* and purified via MDP, which afforded the title compound as a tan solid. MS (ES+): m/z : 426.98 (100) $[MH^+]$. HPLC: t_R = 2.44 min (ZQ2000: polar_5 min). ^1H NMR (400 MHz, $CDCl_3$): δ = 2.64 (m, 2H), 3.13–3.20 (m, 3H), 3.91 (s, 2H), 6.47 (s, 1H), 6.87 (s, 1H), 7.87 (dd, J = 1.6, 8.8 Hz, 1H), 8.02 (d, J = 8.8 Hz, 1H), 8.35 (s, 1H), 8.92 (d, J = 2.0 Hz, 1H), 9.23 (s, 1H), 9.64 (s, 1H), 12.04 (s, 1H).

[629] *General procedure for preparation of a sulfonamide library:*


[630] To a solution of benzothiazol-6-yl-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-*d*]pyrimidin-4-yl]-amine tris-hydrochloride (25.3mg, 0.069mmol) in DMF (0.5mL) at 4°C was added *N,N*-diisopropylethylamine (40mg, 5eq.) followed by the corresponding sulfonyl chloride (1eq.). The resulting mixture was allowed to warming up to rt and stirred for 3h. The products were purified by preparative HPLC with water / acetonitrile / formic acid mixtures and are assumed to be formate salts.

[631] **EXAMPLE 225: Benzothiazol-6-yl-[6-(1-ethanesulfonyl-1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-*d*]pyrimidin-4-yl]-amine.**




[632] Following the general procedure, the title compound was isolated as tan powder. ^1H NMR (400 MHz, $DMSO-d_6$): δ = 11.97 (s, 1H), 9.56 (s, 1H), 9.17 (s, 1H), 8.85 (d, 1H, J = 2.1 Hz), 8.28 (s, 1H), 7.99 (d, 1H, J = 8.9 Hz), 7.80 (dd, 1H, J = 2.1 Hz & 8.9 Hz), 6.87 (s, 1H), 6.40 (s, 1H), 3.91 (br s, 2H), 3.43 (t, 2H, J = 5.7 Hz), 3.07 (q, 2H, J = 4.3 Hz), 2.54 (br s, 2H), 1.19 (t, 3H, J = 5.7 Hz). LC/MS: m/z 440.92 $[MH^+]$ (100), t_R = 2.57 min (ZQ2000, polar_5min).

[633] **EXAMPLE 226: Benzothiazol-6-yl-{6-[1-(propane-1-sulfonyl)-1,2,3,6-tetrahydropyridin-4-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}-amine.**




[634] Following the general procedure, the title compound was isolated as tan powder. ^1H NMR (400 MHz, DMSO- d_6): δ = 12.02 (s, 1H), 9.56 (s, 1H), 9.19 (s, 1H), 8.86 (d, 1H, J = 2.1 Hz), 8.28 (s, 1H), 7.99 (d, 1H, J = 8.9 Hz), 7.80 (dd, 1H, J = 2.1 Hz & 8.9 Hz), 6.79 (s, 1H), 6.40 (s, 1H), 3.90 (br s, 2H), 3.42 (t, 2H, J = 5.7 Hz), 3.04 (t, 2H, J = 5.7 Hz), 2.53 (br s, 2H), 1.64 (m, 2H), 0.93 (t, 3H, J = 7.4 Hz). LC/MS: m/z 454.96 [MH^+] (100), t_R = 2.72 min (ZQ2000, polar_5min).

[635] **EXAMPLE 227: Benzothiazol-6-yl-{6-[1-(propane-2-sulfonyl)-1,2,3,6-tetrahydropyridin-4-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}-amine.**




[636] Following the general procedure, the title compound was isolated as tan powder. ^1H NMR (400 MHz, DMSO- d_6): δ = 11.97 (s, 1H), 9.56 (s, 1H), 9.18 (s, 1H), 8.85 (d, 1H, J = 2.1 Hz), 8.29 (s, 1H), 7.97 (d, 1H, J = 8.9 Hz), 7.81 (dd, 1H, J = 2.1 Hz & 8.9 Hz), 6.79 (s, 1H), 6.39 (s, 1H), 3.95 (br s, 2H), 3.51 (t, 2H, J = 5.5 Hz), 3.38 (m, 1H), 2.51 (br s, 2H), 1.18 (d, 6H, J = 6.8 Hz). LC/MS: m/z 454.95 [MH^+] (100), t_R = 2.68 min (ZQ2000, polar_5min).

[637] **EXAMPLE 228: Benzothiazol-6-yl-[6-(1-cyclopropanesulfonyl)-1,2,3,6-tetrahydropyridin-4-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}-amine.**




[638] Following the general procedure, the title compound was isolated as tan powder. ^1H NMR (400 MHz, DMSO- d_6): δ = 11.93 (s, 1H), 9.56 (s, 1H), 9.17 (s, 1H), 8.85 (d, 1H, J = 2.0 Hz), 8.28 (s, 1H), 7.97 (d, 1H, J = 8.9 Hz), 7.78 (dd, 1H, J = 2.0 Hz & 8.9 Hz), 6.80 (s, 1H), 6.41 (s, 1H), 3.93 (br s, 2H), 3.41 (t, 2H, J = 5.6 Hz), 2.62 (m, 1H), 2.57 (br s, 2H), 0.92 (m, 4H). LC/MS: m/z 452.94 [MH^+] (100), t_R = 2.64 min (ZQ2000, polar_5min).

[639] **EXAMPLE 229: 4-[4-(Benzothiazol-6-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-sulfonic acid dimethylamide.**




[640] Following the general procedure, the title compound was isolated as tan powder. ^1H NMR (400 MHz, DMSO-d_6): δ = 11.97 (s, 1H), 9.56 (s, 1H), 9.17 (s, 1H), 8.86 (d, 1H, J = 2.1 Hz), 8.27 (s, 1H), 7.97 (d, 1H, J = 8.9 Hz), 7.78 (dd, 1H, J = 2.1 Hz & 8.9 Hz), 6.79 (s, 1H), 6.38 (s, 1H), 3.87 (br s, 2H), 3.39 (t, 2H, J = 5.7 Hz), 2.78 (s, 6H), 2.52 (br s, 2H). LC/MS: m/z 455.97 [MH^+] (100), t_R = 2.66 min (ZQ2000, polar_5min).

[641] **EXAMPLE 230: Benzothiazol-6-yl-{6-[1-(butane-2-sulfonyl)-1,2,3,6-tetrahydropyridin-4-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}-amine.**




[642] Following the general procedure, the title compound was isolated as tan powder. ^1H NMR (400 MHz, DMSO-d_6): δ = 11.97 (s, 1H), 9.60 (s, 1H), 9.18 (s, 1H), 8.85 (d, 1H, J = 2.1 Hz), 8.27 (s, 1H), 7.97 (d, 1H, J = 8.9 Hz), 7.81 (dd, 1H, J = 2.1 Hz & 8.9 Hz), 6.79 (s, 1H), 6.39 (s, 1H), 3.95 (br s, 2H), 3.51 (m, 2H), 3.19 (m, 1H), 2.53 (br s, 2H), 1.83 (m, 1H), 1.39 (m, 1H), 1.17 (d, 3H, J = 6.8 Hz), 0.89 (t, 3H, J = 7.5 Hz). LC/MS: m/z 468.98 [MH^+] (100), t_R = 2.84 min (ZQ2000, polar_5min).

[643] **EXAMPLE 231: [6-(1-Benzenesulfonyl)-1,2,3,6-tetrahydropyridin-4-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl-benzothiazol-6-ylamine.**




[644] Following the general procedure, the title compound was isolated as tan powder. ^1H NMR (400 MHz, DMSO-d_6): δ = 11.98 (s, 1H), 9.54 (s, 1H), 9.16 (s, 1H), 8.84 (d, 1H, J = 2.1 Hz), 8.29 (s, 1H), 7.96 (d, 1H, J = 8.9 Hz), 7.81 (dd, 1H, J = 2.1 Hz & 8.9 Hz), 7.76 (dd, 2H, J = 1.5 Hz & 7.8 Hz), 7.67 (m, 1H), 7.59 (dd, J = 7.8 Hz & 7.8 Hz), 6.74 (s, 1H), 6.31 (s, 1H), 3.68 (br s, 2H), 3.17 (t, 2H, J = 5.7 Hz), 2.54 (br s, 2H). LC/MS: m/z 488.88 [MH^+] (100), t_R = 2.97 min (ZQ2000, polar_5min).

[645] **EXAMPLE 232: 1-4-[4-(1H-Indol-5-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl-3-piperidin-1-ylpropan-1-one.**



[646] A mixture of 1-[4-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-3,6-dihydro-2H-pyridin-1-yl]-3-piperidin-1-ylpropan-1-one (67.7mg, 0.114mmol, 1eq), 5-aminoindole (18.0mg, 0.136mmol, 1.2eq), and TFA (45 μ L, 0.58mmol, 5eq) in TFE (1.2mL), in a sealed tube, was heated at 100°C for 5d and concentrated under reduced pressure. The crude material was adsorbed onto Hydromatrix, dry loaded, and purified by chromatography on silica gel [Jones Flashmaster, 5g / 25mL cartridge, eluting with MeOH:DCM 5% $\rightarrow$ 7N NH₃/MeOH:DCM 2% $\rightarrow$ 6%]. Fractions containing product were combined, concentrated *in vacuo*, and purified by HPLC to give the title compound as a yellow solid. ¹H NMR (400 MHz, CDCl₃): δ = 1.46 (s, br, 2H), 1.60 (sextet, J = 5.6 Hz, 4H), 2.22 & 2.29 (s, br, rotamers, 2H), 2.44 (s, br, 4H), 2.51–2.61 (m, 2H), 2.63–2.70 (m, 2H), 3.58 & 3.68 (t, J = 5.6 Hz, rotamers, 2H), 4.16 & 4.21 (s, br, rotamers, 2H), 5.50 & 5.51 (s, br, rotamers, 1H), 6.05 & 6.10 (s, br, rotamers, 1H), 6.54 (t, J = 3.2 Hz, 1H), 7.19 & 7.21 (dt, J = 8.4, 2.0 Hz, 1H), 7.29 (d, J = 3.2 Hz, 1H), 7.43 (d, J = 8.4 Hz, 1H), 7.67 (d, J = 2.0 Hz, 1H), 8.21 (s, 1H). MS (ES⁺): m/z 373.05 (100) [MH⁺]. HPLC: t_R = 1.72 min (ZQ2000, polar_5min).


[647] **1-[4-(4-Chloro-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-3,6-dihydro-2H-pyridin-1-yl]-3-piperidin-1-ylpropan-1-one**



[648] To a suspension/solution of 4-chloro-6-(1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidine *bis*-hydrochloride (19.1mg, 0.0621mmol, 1eq), 1-piperidinepropanoic acid (24.5mg, 0.156mmol, 2.5eq), 1-hydroxybenzotriazole (HOBt) (8.5mg, 0.063mmol, 1eq), and *N*-(3-dimethylaminopropyl)-*N*'-ethylcarbodiimide hydrochloride (EDC) (36.3mg, 0.189mmol, 3eq) in anhydrous DMF (1.3mL), DiPEA (64 μ L, 0.37mmol, 6eq) was added and the reaction was stirred at rt, under N₂, for 16h. Solvent was concentrated *in vacuo* and the residue was dissolved in DCM, washed with NaHCO₃ (2 $\times$) and brine (1 $\times$), dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude material was purified on MDPS giving the title compound as a yellow solid. ¹H NMR (400 MHz, MeOH-*d*₄): δ = 1.45–1.56 (s, br, 2H), 1.64 (sextet, J = 5.6 Hz, 4H), 2.46–2.78 (m, 10H), 3.81 & 3.84 (t, J = 5.6 Hz, rotamers, 2H), 4.29 & 4.33 (d, J = 2.0 Hz, rotamers, 2H), 6.48 (s, br, 1H), 6.62 & 6.63 (s, rotamers, 1H), 8.50 (d, 1H). MS (ES⁺): m/z 373.99/376.00 (100/36) [MH⁺]. HPLC: t_R = 1.86 min (ZQ2000, polar_5min).


[649] Alternative preparation: To a suspension/solution of 4-chloro-6-(1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-*d*]pyrimidine *bis*-hydrochloride (495.4mg, 1.610mmol, 1eq), 1-piperidinepropanoic acid (335.4mg, 2.133mmol, 1.3eq), and TBTU (624.4mg, 1.945mmol, 1.2eq) in anhydrous DMF (15mL), DiPEA (1.4mL, 8mmol, 5eq) was added at rt, under N₂, and stirred for 2h. The solvent was evaporated under reduced pressure. The crude material was adsorbed onto Hydromatrix, dry loaded, and purified by chromatography on silica gel [Jones Flashmaster, 50g / 150mL cartridge, eluting with MeOH:DCM 2% → 5% → 10% → 7N NH₃/MeOH:DCM 2% → 5%]. Fractions containing product were combined and concentrated *in vacuo*, affording the title compound as a yellow solid.

[650] **4-Chloro-6-(1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-*d*]pyrimidine *bis*-hydrochloride**



[651] To 4-(4-chloro-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl ester (601.6mg, 1.797mmol, 1eq), a 4.0 M solution of HCl in 1,4-dioxane (15mL, 33eq) was added and the reaction was stirred at rt for 18h. The solid was then filtered off, washed several times with ether, and dried under vacuum pressure, yielding the title compound as a yellow solid. ¹H NMR (400 MHz, DMSO-*d*₆): δ = 2.77 (s, 2H), 3.33 (d, *J* = 4.8 Hz, 2H), 3.83 (s, br, 2H), 5.27–5.65 (s, br, –NH + H₂O), 6.60 (s, 1H), 6.71 (d, *J* = 1.6 Hz, 1H), 8.59 (s, 1H), 9.30 (s, br, –NH), 12.85 (s, H⁺). MS (ES⁺): *m/z* 235.09/237.11 (3) [MH⁺]; 206.12/208.14 (100) [MH⁺–CH₃N]. HPLC: *t*_R = 1.52 min (ZQ2000, polar_5min).


[652] **EXAMPLE 233: 1-4-[4-(Benzotriazol-1-yloxy)-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl-3-piperidin-1-ylpropan-1-one.**



[653] The title compound was also isolated from the TBTU-coupling reaction mixture from the preparation of 1-[4-(4-chloro-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl)-3,6-dihydro-2H-pyridin-1-yl]-3-piperidin-1-ylpropan-1-one, after concentration *in vacuo* at ≈50°C bath temp., and purified by HPLC, yielding a yellow solid. ¹H NMR (400 MHz, CDCl₃): δ = 1.45 (s, br, 2H), 1.61 (pentet, *J* = 5.6 Hz, 4H), 2.50 (s, br, 4H), 2.55–2.73 (m, 4H), 2.74–2.84 (m, 2H), 3.73 & 3.84 (t, *J* = 5.6 Hz, rotamers, 2H), 4.20 & 4.30 (s, br, rotamers, 2H), 6.34 & 6.41 (s, br, rotamers, 1H), 6.49 & 6.54 (s, rotamers, 1H), 7.44–7.51 (m,


2H), 7.52–7.58 (m, 1H), 8.15 (d, $J = 8.4$ Hz, 1H), 8.27 (s, 1H). MS (ES+): m/z 473.03 (100) [MH⁺]. HPLC: $t_R = 2.08$ min (ZQ2000, polar_5min).

[654] **EXAMPLE 234: 4-[4-([1,2,3]Triazolo[4,5-*b*]pyridin-3-yloxy)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester.**



[655] A solution of 4-(4-chloro-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl)-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester (11.5mg, 0.0343mmol, 1eq) and 1-hydroxy-7-azabenzotriazole (HOAt) (5.6mg, 0.041mmol, 1.2eq) in *n*-butanol (1mL) was stirred at 80 °C for 15h. Solid that had formed during the course of the reaction was filtered over a Hirsh funnel and washed with minimal *n*-butanol. The filtrate was concentrated *in vacuo*. To a solution of the solid (3-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yloxy]-3*H*-[1,2,3]triazolo[4,5-*b*]pyridine) (6.4mg, 0.015mmol, 1eq) in DMSO (1mL), di-*tert*-butyldicarbonate (5.0mg, 0.023mmol, 1.5eq) and DiPEA (20 μ L, 0.1mmol, 7eq) were added and the reaction was stirred at rt for 2h. This solution was combined with the concentrated filtrate and purified on the MDPS yielding the title compound. ¹H NMR (400 MHz, MeOH-*d*₄): $\delta = 1.51$ (s, 9H), 2.64 (s, br, 2H), 3.70 (s, br, 2H), 4.17 (s, br, 2H), 6.46 (s, br, 1H), 6.74 (s, 1H), 7.61 (dd, $J = 8.4, 4.4$ Hz, 1H), 8.13 (s, 1H), 8.61 (d, $J = 8.0$ Hz, 1H), 8.74 (d, $J = 4.4$ Hz, 1H). MS (ES+): m/z 435.00 (62) [MH⁺]. HPLC: $t_R = 3.36$ min (ZQ2000, polar_5min).

[656] **3-[6-(1,2,3,6-Tetrahydropyridin-4-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yloxy]-3*H*-[1,2,3]triazolo[4,5-*b*]pyridine**




[657] ¹H NMR (400 MHz, DMSO-*d*₆): $\delta = 2.81$ (s, br, 2H), 3.35–3.45 (m, 2H + H₂O), 3.85 (s, br, 2H), 6.63 (s, 1H), 6.96 (d, $J = 1.6$ Hz, 1H), 7.67 (dd, $J = 8.0, 8.4$ Hz, 1H), 8.26 (s, 1H), 8.75–8.82 (m, 2H), 9.41 (s, br, –NH), 13.01 (s, –NH). MS (ES+): m/z 335.04 (2) [MH⁺]. HPLC: $t_R = 1.73$ min (ZQ2000, polar5min).

[658] *General procedure for coupling of aminopyridines with 4-(4-chloro-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl)-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester (EXAMPLES 235–237):*


[659] To a mixture of 4-(4-chloro-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl)-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester (134mg, 0.4mmol), substituted-4-aminopyridine (0.6mmol), (*R*)-(+)-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (75mg, 0.04mmol) and sodium *t*-butoxide (77mg, 0.8mmol) was added degassed DMF (3mL), and the reaction was heated overnight at 70°C under N₂. The reaction was cooled to RT, filtered and purified through mass directed HPLC purification system. The product obtained was further purified by preparative TLC using DCM:methanol mixture as eluent to afford pure product.

[660] **EXAMPLE 235: 4-{4-[2-(4-Methylpiperazin-1-yl)-pyridin-4-ylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester.**




[661] Following the general procedure described above, and employing 2-(4-methylpiperazin-1-yl)-pyridin-4-ylamine, the reaction afforded 4-{4-[2-(4-methylpiperazin-1-yl)-pyridin-4-ylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester. ¹H NMR (400 MHz, CD₃OD): δ = 8.21–8.26 (m, 1H), 7.82–7.86 (m, 1H), 7.46 (d, *J* = 7.1 Hz, 1H), 7.09–7.11 (m, 1H), 6.64 (s, 1H), 6.38–6.43 (m, 1H), 6.19 (bs, 1H), 4.01 (bs, 1H), 3.52–3.57 (m, 2H), 3.40–3.44 (m, 4H), 3.17–3.20 (m, 1H), 2.46–2.51 (m, 6H), 2.26 (s, 3H), 1.39 (s, 9H); MS (ES⁺): *m/z* 491.11 (100) [MH⁺]; HPLC: *t*_R = 1.90 min (ZQ2000, polar_5min).

[662] **2-(4-Methylpiperazin-1-yl)-pyridin-4-ylamine**




[663] To a mixture of 1-methyl-4-(4-nitropyridin-2-yl)-piperidine (450mg, 2.024mmol), iron powder (1.130g, 20.2mmol), ethanol (8mL) and water (2mL) was added concentrated HCl (0.055mL, 0.6mmol) and the mixture was heated to reflux for 3h. The reaction mixture was cooled to RT, filtered, filter cake washed with ethanol and the filtrate was evaporated. To the residue, aqueous saturated sodium bicarbonate solution (5mL) and water (20mL) were added and extracted with DCM (3×40mL). The DCM extract was washed with brine, dried over anhydrous sodium sulphate and evaporated to afford the title compound as a reddish pink solid. MS (ES⁺): *m/z* 193.27 (100) [MH⁺]; HPLC: *t*_R = 0.32 min (ZQ2000, polar_5min).

[664] **1-Methyl-4-(4-nitropyridin-2-yl)-piperazine**




[665] To a solution of 2-chloro-4-nitropyridine (793mg, 5mmol) in pyridine (10mL) was added 1-methylpiperazine (0.555mL, 5mmol) and the mixture was heated to 90°C overnight. The reaction mixture was evaporated under reduced pressure, water was added to the residue followed by saturated aqueous sodium bicarbonate (3mL) and extracted with DCM (4×50mL). The combined DCM layer was washed with brine, dried over anhydrous sodium sulfate and evaporated under reduced pressure. The crude product was purified by chromatography on silica gel [Jones Flashmaster, 70g / 150mL cartridge, eluting with DCM:Methanol 100:0 → 98:2], yielding the title compound as orange-yellow solid (311mg, 28 %). ¹H NMR (400 MHz, CDCl₃): δ = 8.36 (dd, *J* = 5.3, 0.36 Hz, 1H), 7.32 (d, *J* = 1.6 Hz, 1H), 7.24 (dd, *J* = 5.4, 1.8 Hz, 1H), 3.67 (t, *J* = 5.3 Hz, 4H), 2.53 (t, *J* = 5.2 Hz, 4H), 2.36 (s, 3H); MS (ES⁺): *m/z* 223.21 (100) [MH⁺]; HPLC: *t_R* = 0.49 & 1.37 min (ZQ2000, polar_5min).

[666] **EXAMPLE 236: 4-{4-[2-Chloro-6-(4-methylpiperazin-1-yl)-pyridin-4-ylamino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl}-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl ester.**



[667] Following the general procedure described above, and employing 2-chloro-6-(4-methylpiperazin-1-yl)-pyridin-4-ylamine, the reaction afforded the title compound. ¹H NMR (400 MHz, CD₃OD): δ = 8.23–8.27 (m, 1H), 7.21–7.24 (m, 2H), 6.87 (s, 1H), 6.42 (s, 1H), 6.20 (bs, 1H), 4.02 (bs, 1H), 3.50–3.60 (m, 2H), 3.41–3.47 (m, 4H), 3.19–3.21 (m, 1H), 2.42–2.47 (m, 6H), 2.25 (s, 3H), 1.40 (s, 9H); MS (ES⁺): *m/z* 525.04 (100) [MH⁺]; HPLC: *t_R* = 2.31 min (ZQ2000, polar_5min).


[668] **2-Chloro-6-(4-methylpiperazin-1-yl)-pyridin-4-ylamine & 2,6-Bis-(4-methylpiperazin-1-yl)-pyridin-4-ylamine**



[669] A mixture of 4-amino-2,6-dichloropyridine (1.00g, 6.14mmol) and 1-methylpiperazine (0.68mL, 6.1mmol) in pyridine (10 mL) was heated at 150°C for 3d under N₂. The


reaction mixture was evaporated under reduced pressure, and to the residue water was added followed by saturated aqueous sodium bicarbonate (5mL) and extracted with DCM (4×50mL). The combined DCM layer was washed with brine, dried over anhydrous sodium sulfate and evaporated under reduced pressure. The crude product was purified by chromatography on silica gel [Jones Flashmaster, 70g / 150mL cartridge, eluting with DCM:2N NH₃ in methanol [100:0 → 75:25], yielding the title compounds. 2-Chloro-6-(4-methylpiperazin-1-yl)-pyridin-4-ylamine: MS (ES⁺): *m/z* 227.18 (100) [MH⁺]; HPLC: *t_R* = 0.48 & 1.07 min (ZQ2000, polar_5min). 2,6-Bis-(4-methylpiperazin-1-yl)-pyridin-4-ylamine: MS (ES⁺): *m/z* 291.21 (100) [MH⁺]; HPLC: *t_R* = 0.31 min (ZQ2000, polar_5min).

[670] **EXAMPLE 237: 4-{4-[2,6-Bis-(4-methylpiperazin-1-yl)-pyridin-4-ylamino]-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl ester.**



[671] Following the general procedure described above, and employing 2,6-bis-(4-methylpiperazin-1-yl)-pyridin-4-ylamine, the reaction afforded the title compound. ¹H NMR (400 MHz, CD₃OD+CDCl₃): δ = 8.27–8.31 (m, 1H), 6.48–6.55 (m, 3H), 6.19 (bs, 1H), 4.09 (bs, 2H), 3.60 (t, *J* = 5.6 Hz, 2H), 3.47–3.51 (m, 8H), 2.50–2.54 (m, 10H), 2.30 (s, 6H), 1.45 (s, 9H); MS (ES⁺): *m/z* 589.13 (100) [MH⁺]; HPLC: *t_R* = 1.84 min (ZQ2000, polar_5min).


[672] **EXAMPLE 238: 4-[4-(6-Carbamoylpyridin-3-ylamino)-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl ester.**



[673] Into the DMF (1mL) solution of 4-(4-chloro-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl ester (122mg, 0.363mmol) was added *t*-BuOK (1M in *t*-BuOH, 0.726mL, 0.726mmol) dropwise at RT under N₂ over 5min. The mixture was then put in an ice/water bath and stirred for 10min. After that time, the DMF (1mL) solution of 5-aminopyridine-2-carboxylic acid amide (99.5mg, 0.726mmol) was added into the above mixture dropwise. The reaction mixture was warmed to RT. Pd₂(dba)₃·CHCl₃ (9.4mg, 2.5%eq.) and *R*(+)-BINAP (22.6mg, 0.1eq.) were added, and the


mixture was heated at 100°C for 24h. The mixture was filtered and the filtrate was concentrated *in vacuo*. The crude was submitted to MS directed purification. A brown oil was obtained that was purified further by HPLC to obtain the title compound as an off-white solid. ¹H NMR (DMSO-*d*₆, 400 MHz): δ = 1.50 (s, 9 H), 2.50 (m, 2 H), 3.64 (t, 2 H, *J* = 5.6 Hz), 4.12 (brs, 2 H), 6.50 (brs, 1 H), 6.88 (s, 1 H), 7.53 (d, 1 H, *J* = 4.2 Hz), 8.04 – 8.05 (m, 1 H), 8.08 (d, 1 H, *J* = 8.8 Hz), 8.44 (s, 1 H), 8.68 (dd, 1 H, *J* = 2.4 & 8.4 Hz), 9.12 (d, 1 H, *J* = 2.4 Hz), 9.91 (s, 1 H), 12.18 (s, 1 H). MS (ES⁺): *m/z* 436.10 (100) [MH⁺]. HPLC: *t*_R = 2.75 min (ZQ2000, polar_5 min).

[674] **5-Aminopyridine-2-carboxylic acid amide**




[675] MeOH (30mL) was added into the mixture of 5-aminopyridine-2-carbonitrile (1191mg, 10.00mmol), NaBO₃·H₂O (2995mg, 30.00mmol), and H₂O (30mL), and the mixture was then heated at 50°C for 16h. The mixture was then concentrated *in vacuo*, then treated with water (30mL), and extracted with EtOAc (4 × 50mL). The combined extracts were dried over MgSO₄, filtered, and concentrated *in vacuo* to obtain a yellow solid. The solid was triturated with 40mL of 40% EtOAc/hexane to yield the title compound as yellow solid. ¹H NMR (DMSO-*d*₆, 400 MHz): δ = 5.86 (s, 2 H), 6.89 (dd, 1 H, *J* = 2.4 & 8.4 Hz), 7.07 (brs, 1 H), 7.59 (brs, 1 H), 7.64 (d, 1 H, *J* = 8.4 Hz), 7.83 (d, 1 H, *J* = 2.4 Hz). MS (ES⁺): *m/z* 138.18 (100) [MH⁺]. HPLC: *t*_R = 0.75 min (ZQ2000, polar_5 min).

[676] **EXAMPLE 239: 4-[4-(6-Methoxypyridin-3-ylamino)-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl ester.**




[677] The title compound was obtained following the procedure for the synthesis of 4-[4-(6-carbamoylpyridin-3-ylamino)-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl ester, but using 6-methoxypyridin-3-ylamine in place of 5-aminopyridine-2-carboxylic acid amide. ¹H NMR (CD₃OD, 400 MHz): δ = 1.40 (s, 9 H), 2.47 (m, 2 H), 3.57 (m, 2 H), 4.00 (m, 2 H), 6.19 (brs, 1 H), 6.50 (s, 1 H), 6.74 (s, 1 H, d, 1 H, *J* = 9.2 Hz), 7.48 (dd, 1 H, *J* = 2.8 Hz & 8.8 Hz), 8.04 – 8.05 (m, 1 H), 8.07 (s, 1 H), 8.31 (d, 1 H, *J* = 3.2 Hz). MS (ES⁺): *m/z* 423.08 (100) [MH⁺]. HPLC: *t*_R = 2.86 min (ZQ2000, polar_5 min).

[678] **EXAMPLE 240:** 4-[4-(6-Oxo-1,6-dihydropyridin-3-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester.




[679] Into the suspension of 4-[4-(6-methoxypyridin-3-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester (68.4mg, 79% purity, 0.127mmol) and NaI (19.1mg, 0.127mmol) in CH₃CN (10mL) was added trimethylsilyl chloride (1 M in THF, 0.765mL, 0.765mmol) at rt. The mixture was then heated at 80°C in a flask under N₂ for 48h. After that time, the mixture was cooled at 0°C and the aqueous solution (H₂O, 8mL) of NaHCO₃ (159mg) and NaS₂O₄·5H₂O (318mg) was added while stirring. The solid was filtered off and washed with water to obtain a brown-red solid. Boc₂O (30.8mg, 0.140mmol), DMAP (17.1mg, 0.140mmol) and the above solid were dissolved in pyridine and the mixture was stirred at rt for 18h. After that time, the mixture was concentrated *in vacuo* to obtain a green-yellow oil that was submitted for MS directed purification. One obtained the title compound as off-white solid. ¹H NMR (DMSO-*d*₆, 400 MHz): δ = 1.44 (s, 9 H), 2.46 (brs, 2 H), 3.56 (t, 2 H, *J* = 5.4 Hz), 4.00 (brs, 2 H), 6.38 (s, 1 H), 6.40 (s, 1 H), 6.67 – 7.70 (m, 1 H), 8.02 (d, 1 H, *J* = 2.4 Hz), 8.20 (s, 1 H), 9.06 (s, 1 H), 11.40 (brs, 1 H), 11.92 (s 1 H). MS (ES⁺): *m/z* 409.05 (100) [MH⁺]. HPLC: *t*_R = 2.33 min (ZQ2000, polar_5 min).


[680] **EXAMPLE 241:** 4-[4-(1-Methyl-6-oxo-1,6-dihydropyridin-3-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester.



[681] The title compound was obtained following the General method for the reaction of amines with *tert*-butyl 4-(4-chloro-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl)-3,6-dihydropyridine-1(2*H*)-carboxylate, using 5-amino-1-methyl-1*H*-pyridin-2-one. ¹H NMR (DMSO-*d*₆, 400 MHz): δ = 1.44 (s, 9 H), 2.43 (brs, 2 H), 3.46 (s, 3 H), 3.56 (t, 2 H, *J* = 6.4 Hz), 4.04 (brs, 2 H), 6.38 (brs, 1 H), 6.43 (d, 1 H, *J* = 9.6 Hz), 6.61 (s, 1 H), 7.63 (dd, 1 H, *J* = 2.8 & 9.6 Hz), 8.18 – 8.20 (m, 2 H), 9.07 (s, 1 H), 11.91 (s, 1 H). MS (ES⁺): *m/z* 423.07 (100) [MH⁺]. HPLC: *t*_R = 2.38 min (ZQ2000, polar_5 min).


[682] 5-Amino-1-methyl-1H-pyridin-2-one

[683] To a suspension of 5-nitro-1-methyl-2(1H)-pyridone (154mg, 0.999mmol) in ethyl acetate (3mL) and ethanol (3mL) was added 5% Pd-C (36mg), and the resulting mixture was stirred under hydrogen atmosphere overnight. The reaction mixture was filtered and the filtrate was concentrated *in vacuo* to obtain the title compound as light-green oil. ¹H NMR (CD₃OD 400 MHz): δ = 3.53 (s, 3 H), 6.49 (d, 1 H, J = 9.6 Hz), 7.07 (d, 1 H, J = 3.2 Hz), 7.28 (dd, 1 H, J = 2.8 & 9.6 Hz). MS (ES⁺): m/z 125.04 (100) [MH⁺]. HPLC: t_R = 0.43 min (ZQ2000, polar_5 min).

[684] 1-Methyl-5-nitro-1H-pyridin-2-one

[685] Tetra-*N*-butylammonium bromide (3220mg, 10.00mmol), sodium hydroxide (400.0mg, 10.00mmol) and methyl iodide (3113 μ L, 50.00mmol) were sequentially added into the two-phase mixture of 2-hydroxy-5-nitropyridine (700.0mg, 5.000mmol) in water (25mL) and methylene chloride (50mL). The above mixture was stirred at rt for 1h and then partitioned between CH₂Cl₂ (50mL) and water (75mL). The aqueous layer was extracted with CH₂Cl₂ (50mL). The combined organic phases were dried over MgSO₄, filtered, and concentrated *in vacuo* to obtain a beige solid. Silica gel (134 g) was used to purify the above solid eluting with 2500mL EtOAc to obtain the title compound as beige powder. ¹H NMR (CDCl₃, 400 MHz): δ = 3.66 (s, 3 H), 6.57 (d, 1 H, J = 10.0 Hz), 8.10 (dd, 1 H, J = 2.8 & 10.0 Hz), 8.63 (d, 1 H, J = 2.8 Hz). MS (ES⁺): m/z 155.15 (100) [MH⁺]. HPLC: t_R = 1.69 min (ZQ2000, polar_5 min).


[686] EXAMPLE 242: 4-[4-(1-Methyl-6-oxo-1,6-dihydropyridin-3-ylamino)-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butylamide.



[687] 4-[4-(1-Methyl-6-oxo-1,6-dihydropyridin-3-ylamino)-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl ester (38.0mg, 0.0845mmol), 9M of Hydrogen chloride in Methanol (2mL) and Methanol (2mL) were combined, and the above mixture was stirred at rt for 3h. The reaction mixture was concentrated *in vacuo* to obtain a black solid. DMF (3mL), NEt₃ (58.9 μ L, 0.423mmol) and


tert-butyl isocyanate (14.5 μ L, 0.127 mol) were added, and the mixture was stirred at rt under N₂ for 1.5h. Another portion of *tert*-butyl isocyanate was added and the reaction was stirred overnight. The mixture was concentrated *in vacuo*, and the residue was purified by HPLC to obtain the title compound as pink solid. ¹H NMR (CD₃OD, 400 MHz): δ = 1.36 (s, 9 H), 2.56 (brs, 2 H), 3.61 (m, 2 H), 3.62 (s, 3 H), 4.07 (brs, 2 H), 6.29 (brs, 1 H), 6.58 (s, 1 H), 6.60 (d, 1 H, J = 9.6 Hz), 7.71 (dd, 1 H, J = 2.8 & 9.6 Hz), 8.16 (brs, 2 H), 8.19 (s, 1 H), 8.25 (d, 1 H, J = 2.4 Hz). MS (ES⁺): m/z 422.12 (100) [MH⁺]. HPLC: t_R = 2.11 min (ZQ2000, polar_5 min).

[688] **EXAMPLE 243: 4-[4-(4-Carbamoylphenylamino)-7*H*-pyrrolo[2,3-*d*]-pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester.**




[689] The title compound was obtained following the General method for the reaction of amines with *tert*-butyl 4-(4-chloro-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl)-3,6-dihydropyridine-1(2*H*)-carboxylate, using 4-aminobenzamide. ¹H NMR (DMSO-*d*₆, 400 MHz): δ = 1.44 (s, 9 H), 2.50 (m, 2 H), 3.58 (t, 2 H, J = 5.2 Hz), 4.05 (brs, 2 H), 6.43 (brs, 1 H), 6.84 (s, 1 H), 7.21 (brs, 1 H), 7.86 (m, 3 H), 8.00 (d, 1 H, J = 8.4 Hz), 8.34 (s, 1 H), 9.57 (s, 1 H), 12.04 (s, 1 H). MS (ES⁺): m/z 435.09 (100) [MH⁺]. HPLC: t_R = 2.61 min (ZQ2000, polar_5 min).

[690] **EXAMPLE 244: 4-[4-(1-Oxo-2,3-dihydro-1*H*-isoindol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester.**




[691] The title compound was obtained following the General method for the reaction of amines with *tert*-butyl 4-(4-chloro-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl)-3,6-dihydropyridine-1(2*H*)-carboxylate, using 5-amino-2,3-dihydroisoindol-1-one. ¹H NMR (DMSO-*d*₆, 400 MHz): δ 1.47 (s, 9 H), 2.50 (m, 2 H), 3.61 (t, 2 H, J = 5.6 Hz), 4.08 (brs, 2 H), 4.42 (s, 2 H), 6.46 (brs, 1 H), 6.89 (s, 1 H), 7.65 (d, 1 H, J = 8.4 Hz), 7.90 (dd, 1 H, J = 0.8 & 8.4 Hz), 8.37 – 8.40 (m, 3 H), 9.67 (s, 1 H), 12.08 (s, 1 H). MS (ES⁺): m/z 447.10 (100) [MH⁺]. HPLC: t_R = 2.61 min (ZQ2000, polar_5 min).

[692] **5-Amino-2,3-dihydroisoindol-1-one**




[693] Iron powder (158mg, 2.83mmol), water (61μL), and HCl (37%, 5μL, 0.566mmol) were added into the suspension of 5-nitro-2,3-dihydroisoindol-1-one (50.4mg, 0.283mmol) in EtOH (754μL). The above mixture was heated at 95°C for 2h. After that time, several drops of 7N NH₃ in MeOH were added to basify the solution, and the solid was filtered off. The filtrate was concentrated *in vacuo* to obtain a light-yellow solid that was purified by preparative TLC eluting with 10% MeOH/CH₂Cl₂ to give a light-yellow solid of 5-amino-2,3-dihydroisoindol-1-one. ¹H NMR (CD₃OD, 400 MHz): δ = 7.48 (s, 1 H), 8.08 (s, 2 H), 9.91 (s, 1 H), 10.66 (d, 1 H, *J* = 8.8 Hz). MS (ES⁺): *m/z* 149.21 (100) [MH⁺]. HPLC: *t_R* = 1.20 min (ZQ2000, polar_5 min).

[694] **5-Nitro-2,3-dihydroisoindol-1-one**



[695] AIBN (58.6mg, 0.357mmol), NBS (785mg, 4.46mmol), and 2-methyl-4-nitrobenzoic acid methyl ester (696mg, 3.57mmol) were suspended in CCl₄ (35mL) in a sealed tube. The above mixture was flushed with N₂ for 5min and heated at 80°C for 22h. After cooling, the solid was filtered off and the filtrate was concentrated to dryness to obtain a crude light-brown solid. To above solid was added NH₃ (7 N in MeOH, 5mL), and the mixture was stirred at rt for 2h and concentrated *in vacuo* to obtain a yellow solid. This crude solid was triturated with EtOAc (15mL) and was then cooled at -20 °C. The mixture was filtered to obtain the title compound as yellow solid. ¹H NMR (DMSO-*d*₆, 400 MHz): δ = 4.51 (s, 2 H), 7.13 (brs, 2 H), 7.91 (d, 1 H, *J* = 8.4 Hz), 8.25 (dd, 1 H, *J* = 2.0 & 8.4 Hz), 8.48 (d, 1 H, *J* = 2.0 Hz), 9.04 (brs, 1 H). MS (ES⁺): *m/z* 179.22 (100) [MH⁺]. HPLC: *t_R* = 2.14 min (ZQ2000, polar_5 min).


[696] **2-Methyl-4-nitrobenzoic acid methyl ester**



[697] H₂SO₄ (98%, 0.030mL) was added dropwise into the MeOH (30mL) solution of 2-methyl-4-nitrobenzoic acid at rt. The mixture was then heated at 55°C. After 50h, the solvent was removed *in vacuo* and the residue was partitioned between EtOAc and H₂O (25mL each). The aqueous layer was extracted with another portion of EtOAc (25mL). The combined extracts were washed with saturated NaHCO₃ (25mL), H₂O (2 × 25mL), and brine (25mL), dried over MgSO₄, filtered and concentrated *in vacuo* to give the title compound as


light-yellow solid. ^1H NMR (CDCl_3 , 400 MHz): δ = 2.69 (s, 3 H), 3.95 (s, 3 H), 8.03 – 8.12 (m, 3 H). MS (ES+): m/z 196.25 (100) $[\text{MH}^+]$. HPLC: t_R = 3.29 min (ZQ2000, polar_5 min).

[698] **EXAMPLE 245: 4-[4-(4-Benzyloxy-3-chlorophenylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl ester.**




[699] The title compound was obtained following the General method for the reaction of amines with *tert*-butyl 4-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-3,6-dihydropyridine-1(2H)-carboxylate, using 4-benzyloxy-3-chlorophenylamine. ^1H NMR ($\text{DMSO}-d_6$, 400 MHz): δ = 1.44 (s, 9 H), 2.52 (brs, 2 H), 3.57 (t, 2 H, J = 5.6 Hz), 4.05 (brs, 2 H), 5.19 (s, 2 H), 6.40 (brs, 1 H), 6.74 (s, 1 H), 7.23 (d, 1 H, J = 9.2 Hz), 7.33 – 7.37 (m, 1 H), 7.40 – 7.44 (m, 2 H), 7.48 – 7.50 (m, 2 H), 7.68 – 7.72 (m, 1 H), 8.13 – 8.15 (m, 1 H), 8.27 (d, 1 H, J = 1.2 Hz), 9.34 (s, 1 H), 11.96 (s, 1 H). MS (ES+): m/z 532.02/533.98 (100/38) $[\text{MH}^+]$. HPLC: t_R = 3.81 min (ZQ2000, polar_5 min).

[700] **EXAMPLE 246: 4-[4-(2-Aminobenzothiazol-6-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl ester.**




[701] The title compound was obtained following the General method for the reaction of amines with *tert*-butyl 4-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-3,6-dihydropyridine-1(2H)-carboxylate, using benzothiazole-2,6-diamine. ^1H NMR ($\text{DMSO}-d_6$, 400 MHz): δ = 1.40 (s, 9 H), 2.50 (brs, 2 H), 3.52 (brs, 2 H), 4.00 (brs, 2 H), 6.29 (brs, 1 H), 6.65 (brs, 1 H), 7.21 – 7.46 (m, 4 H), 8.21 – 8.28 (m, 2 H), 9.27 (brs, 1 H), 11.88 (brs, 1 H). MS (ES+): m/z 464.03 (50) $[\text{MH}^+]$. HPLC: t_R = 2.34 min (ZQ2000, polar_5 min).

[702] **EXAMPLE 247: 4-[4-(2-Amino-1H-benzimidazol-5-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl ester.**




[703] The title compound was obtained following the General method for the reaction of amines with *tert*-butyl 4-(4-chloro-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl)-3,6-dihydropyridine-1(2*H*)-carboxylate, using benzimidazole-2,5-diamine, except that the heating was conducted at 140 °C for 24h. ¹H NMR (CD₃OD, 400 MHz): δ = 1.50 (s, 9 H), 2.48 (brs, 2 H), 3.61 (brs, 2 H), 4.11 (brs, 2 H), 6.24 (brs, 1 H), 6.36 (brs, 1 H), 7.12 (dd, 1 H, *J* = 2.0 & 8.8 Hz), 7.19 (d, 1 H, *J* = 8.0 Hz), 7.48 (s, 1 H), 8.12 (s, 1 H). MS (ES⁺): *m/z* 447.03 (60) [MH⁺]. HPLC: *t_R* = 1.97 min (ZQ2000, polar_5 min).

[704] **EXAMPLE 248: 4-{4-[3-(2*H*-[1,2,3]Triazol-4-yl)-phenylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester.**




[705] The title compound was obtained following the General method for the reaction of amines with *tert*-butyl 4-(4-chloro-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl)-3,6-dihydropyridine-1(2*H*)-carboxylate, using 3-(2*H*-[1,2,3]triazol-4-yl)phenylamine. ¹H NMR (DMSO-*d*₆, 400 MHz): δ = 1.40 (s, 9 H), 2.47 (brs, 2 H), 3.54 (t, 2 H, *J* = 5.2 Hz), 4.01 (brs, 2 H), 6.37 (brs, 1 H), 6.80 (s, 1 H), 7.37 (t, 1 H, *J* = 8.0 Hz), 7.43 (d, 1 H, *J* = 8.0 Hz), 7.98 (d, 1 H, *J* = 8.4 Hz), 8.19 (s, 1 H), 8.26 – 8.31 (m, 2 H), 9.44 (s, 1 H), 11.94 (s, 1 H). MS (ES⁺): *m/z* 458.96 (100) [MH⁺]. HPLC: *t_R* = 2.74 min (ZQ2000, polar_5 min).

[706] **3-(2*H*-[1,2,3]Triazol-4-yl)phenylamine**




[707] The mixture of azidotrimethylsilane (137 μL, 1.03 mmol) and 3-amino-phenylacetylene (117 mg, 1.00 mmol) was heated in a sealed tube at 150 °C for 16 h. After that time, the mixture was cooled down and triturated by EtOAc/hexane (50%, 10 mL). The mother liquor was purified by TLC eluting with 7% MeOH/CH₂Cl₂ to give the title compound as brown oil. ¹H NMR (CD₃OD, 400 MHz): δ = 6.61 – 6.64 (m, 1 H), 7.01 – 7.09 (m, 3 H), 7.94 (s, 1 H). MS (ES⁺): *m/z* 161.20 (38) [MH⁺]. HPLC: *t_R* = 1.54 min (ZQ2000, polar_5 min).

[708] **EXAMPLE 249: 4-[4-(3-Thiophen-2-yl-phenylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester.**




[709] The title compound was obtained following the General method for the reaction of amines with *tert*-butyl 4-(4-chloro-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl)-3,6-dihydropyridine-1(2*H*)-carboxylate, using 3-thiophen-2-ylphenylamine. ¹H NMR (CD₃OD, 400 MHz): δ = 1.52 (s, 9 H), 2.58 (brs, 2 H), 3.68 (brs, 2 H), 4.14 (brs, 2 H), 6.31 (brs, 1 H), 6.69 (s, 1 H), 7.11 – 7.13 (m, 1 H), 7.38 – 7.43 (m, 4 H), 7.68 – 7.71 (m, 1 H), 8.07 (s, 1 H), 8.26 (s, 1 H). MS (ES⁺): *m/z* 473.95 (100) [MH⁺]. HPLC: *t_R* = 3.71 min (ZQ2000, polar_5 min).

[710] **EXAMPLE 250: 4-{4-[3-(4-Methylpiperazin-1-yl)-phenylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester.**




[711] The title compound was obtained following the General method for the reaction of amines with *tert*-butyl 4-(4-chloro-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl)-3,6-dihydropyridine-1(2*H*)-carboxylate, using 3-(4-methylpiperazin-1-yl)-phenylamine. ¹H NMR (CD₃OD, 400 MHz): δ = 1.51 (s, 9 H), 2.56 (brs, 2 H), 2.86 (s, 3 H), 3.31 (brs, 4 H), 3.54 (brs, 4 H), 3.67 (brs, 2 H), 4.14 (brs, 2 H), 6.29 (brs, 1 H), 6.63 (s, 1 H), 6.78 – 6.80 (m, 1 H), 7.20 (d, 1 H, *J* = 8.0 Hz), 7.26 – 7.30 (m, 1 H), 7.53 (s, 1 H), 8.22 (s, 1 H), 8.41 (brs, 2 H). MS (ES⁺): *m/z* 490.08 (100) [MH⁺]. HPLC: *t_R* = 2.15 min (ZQ2000, polar_5 min).

[712] **3-(4-Methylpiperazin-1-yl)-phenylamine**




[713] Into the solution of 1-methyl-4-(3-nitrophenyl)-piperazine (123mg, 0.556mmol) in ethanol (5mL) was added Pd (10% on carbon, 12.0mg). The mixture was degassed for 5 min and was then stirred under H₂ atmosphere (balloon pressure) at rt for 24h. After that time, the reaction mixture was filtered and the filtrate was concentrated *in vacuo* to obtain the title compound as light yellow oil. ¹H NMR (CDCl₃, 400 MHz): δ = 2.35 (s, 3 H), 2.56 (t, 4 H, *J* = 5.2 Hz), 3.18 (t, 4 H, *J* = 5.0 Hz), 3.60 (brs, 2 H), 6.21 – 6.23 (m, 1 H), 6.27 (t, 1 H, *J* = 2.2 Hz), 6.36 – 6.39 (m, 1 H), 7.05 (m, 1 H). MS (ES⁺): *m/z* 192.31 (100) [MH⁺]. HPLC: *t_R* = 0.39 min (ZQ2000, polar_5 min).

[714] **1-Methyl-4-(3-nitrophenyl)-piperazine**


[715] A mixture of 1-fluoro-3-nitrobenzene (282mg, 2.00mmol), 1-methyl-piperazine (401mg, 4.00mmol), potassium carbonate (276mg, 2.00mmol), and DMF (3mL) was stirred and heated at 110°C for 24h. After cooling to rt, the mixture was poured into brine (10mL) and extracted with EtOAc (3 × 10mL). The combined organic extracts were extracted with aqueous HCl (1 N, 2 × 20mL). The acidic extracts were basified by aqueous NaOH until pH>10. The basified aqueous solution was extracted with EtOAc (2 × 30mL). The extracts were then washed with H₂O (3 × 20mL) and brine (20mL), dried over MgSO₄, filtered and concentrated *in vacuo* to give the title compound as yellow oil. ¹H NMR (CD₃OD, 400 MHz): δ = 2.22 (s, 3 H), 2.48 (t, 4 H, *J* = 5.0 Hz), 3.16 (t, 4 H, *J* = 5.2 Hz), 7.16 – 7.18 (m, 1 H), 7.27 (t, 1 H, *J* = 8.2 Hz), 7.46 – 7.49 (m, 1 H), 7.57 (t, 1 H, *J* = 2.2 Hz). MS (ES⁺): *m/z* 222.26 (100) [MH⁺]. HPLC: *t_R* = 1.55 min (ZQ2000, polar_5 min).

[716] **EXAMPLE 251: 4-{4-[3-Chloro-5-(4-methylpiperazin-1-yl)-phenyl]-amino]-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl ester.**




[717] A mixture of 4-(4-chloro-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl ester (88.0mg, 0.263mmol), 3-chloro-5-(4-methylpiperazin-1-yl)-phenylamine (71.2mg, 0.316mmol), trifluoroacetic acid (203μL, 2.63mmol), and DMF (2mL) was stirred in a sealed tube at 70°C for 18h. The mixture was concentrated *in vacuo*, sodium bicarbonate (221mg, 2.63mmol), di-*tert*-butyldicarbonate (86.1mg, 0.394mmol), and DMF (2mL) were added to the residue, and the resulting mixture was stirred at rt under N₂ for 16h. After that time, the mixture was filtered, and the filtrate was concentrated *in vacuo* and submitted for MS-directed purification. One obtained the title compound as light-brown solid. ¹H NMR (CD₃OD, 400 MHz): δ = 1.50 (s, 9 H), 2.57 (brs, 2 H), 2.86 (s, 3 H), 3.29 (brs, 4 H), 3.46 (brs, 4 H), 3.67 (brs, 2 H), 4.13 (brs, 2 H), 6.29 (brs, 1 H), 6.68 (s, 1 H), 6.74 (s, 1 H), 7.44 (s, 1 H), 7.47 (s, 1 H), 8.28 (s, 1 H). MS (ES⁺): *m/z* 523.99/525.95(100/40) [MH⁺]. HPLC: *t_R* (polar-5 mins) = 2.28 min (ZQ2000, polar_5 min).

[718] **3-Chloro-5-(4-methylpiperazin-1-yl)-phenylamine**




[719] The title compound was obtained by following the procedure for the reduction of 5-nitro-2,3-dihydroisindol-1-one with iron powder, but using 1-(3-chloro-5-nitrophenyl)-4-methylpiperazine. ^1H NMR ($\text{DMSO}-d_6$, 400 MHz): δ = 2.33 (s, 3 H), 2.58 (brs, 4 H), 3.11 (brs, 4 H), 5.21 (brs, 2 H), 6.05 – 6.06 (m, 2 H), 6.12 – 6.13 (m, 1 H). MS (ES $^+$): m/z 226.17/228.19 (100/33) [MH^+]. HPLC: t_R = 1.42 min (ZQ2000, polar_5 min).

[720] **1-(3-Chloro-5-nitrophenyl)-4-methylpiperazine**



[721] The title compound was obtained by following the procedure for the halide displacement of 3-fluoronitrobenzene with methylpiperazine, but using 1,3-dichloro-5-nitrobenzene and conducting the reaction at 130 °C. ^1H NMR (CDCl_3 , 400 MHz): δ = 2.34 – 2.40 (m, 3 H), 2.56 – 2.59 (m, 4 H), 3.30 – 3.33 (m, 4 H), 7.11 – 7.15 (m, 1 H), 7.61 – 7.64 (m, 2 H). MS (ES $^+$): m/z 256.12/258.07 (100/33) [MH^+]. HPLC: t_R = 1.94 min (ZQ2000, polar_5 min).


[722] **EXAMPLE 252: 4-{4-[3-Chloro-5-(4-methylpiperazin-1-yl)-phenyl]-amino]-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butylamide.**



[723] A mixture of 4-(4-chloro-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl ester (88.0mg, 0.263mmol), 3-chloro-5-(4-methylpiperazin-1-yl)-phenylamine (71.2mg, 0.316mmol), trifluoroacetic acid (243 μL , 3.16mmol), and DMF (2mL) was stirred in a sealed tube at 80°C for 16h. After cooling, *N,N*-diisopropylethylamine (550 μL , 3.16mmol) was added, and the mixture turned into a dark clear solution. Into above solution was added *tert*-butyl isocyanate (36.0 μL , 0.316mmol) and the solution was stirring at rt for 1h. After that time, the mixture was concentrated *in vacuo* to obtain dark-brown oil that was submitted for MS-directed purification to obtain a light-brown oil. Further purification by HPLC gave the title compound as an off-white powder. ^1H NMR ($\text{DMSO}-d_6$, 400 MHz): δ = 1.29 (s, 9 H), 2.23 (s, 3 H), 2.46 (t, 4 H, J = 4.6 Hz), 3.18 (t, 4 H, J = 4.8 Hz), 3.53 (t, 2 H, J = 5.4 Hz), 4.00 (brs, 2 H), 5.79 (s, 1 H), 6.43 (s, 1 H), 6.63 (d, 1 H,


$J = 1.6$ Hz), 6.78 (s, 1 H), 7.30 (s, 1 H), 7.75 (d, 1 H, $J = 1.6$ Hz), 8.32 (s, 1 H), 9.27 (s, 1 H), 11.98 (s, 1 H). MS (ES⁺): m/z 522.98/525.01(100/33) [MH^+]. HPLC: $t_R = 2.13$ min (ZQ2000, polar_5 min).

[724] **EXAMPLE 253: 4-{4-[3-(2-Aminothiazol-4-yl)-phenylamino]-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl ester.**




[725] The title compound was obtained following the General method for the reaction of amines with *tert*-butyl 4-(4-chloro-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl)-3,6-dihydropyridine-1(2H)-carboxylate, using 4-(3-aminophenyl)-thiazol-2-ylamine. ¹H NMR (CD₃OD, 400 MHz): $\delta = 1.52$ (s, 9 H), 2.58 (brs, 2 H), 3.68 (brs, 2 H), 4.13 (brs, 2 H), 6.30 (brs, 1 H), 6.65 (s, 1 H), 6.86 (s, 1 H), 7.36 – 7.40 (m, 1 H), 7.52 – 7.54 (m, 1 H), 7.65 – 7.67 (m, 1 H), 8.07 – 8.08 (m, 1 H), 8.24 (s, 1 H). MS (ES⁺): m/z 489.94 (38) [MH^+]. HPLC: $t_R = 2.71$ min (ZQ2000, polar_5 min).

[726] **4-(3-Aminophenyl)-thiazol-2-ylamine**



[727] The title compound was obtained by following the procedure for the reduction of 5-nitro-2,3-dihydroisindol-1-one with iron powder, but using 4-(3-nitrophenyl)-thiazol-2-ylamine. ¹H NMR (DMSO-*d*₆, 400 MHz): $\delta = 5.03$ (brs, 2 H), 6.43 (d, 1 H, $J = 7.2$ Hz), 6.75 (s, 1 H), 6.89–7.00 (m, 5 H). MS (ES⁺): m/z 192.24 (100) [MH^+]. HPLC: $t_R = 1.45$ min (ZQ2000, polar_5 min).


[728] **4-(3-Nitrophenyl)-thiazol-2-ylamine**



[729] A solution of 3-nitrophenacyl bromide (244mg, 1.00mmol) and thiourea (76.1mg, 1.00mmol) in DMF (2mL) was stirred at 60°C for 16h. The mixture was concentrated *in vacuo* to obtain a yellow solid that was then washed with H₂O and dried to yield a yellow solid (206mg). The solid was dissolved in DMSO and purified by SCX column (4 × 6mL capacity), eluted with CH₂Cl₂ (4 × 6mL), MeOH (4 × 12mL) and then released by NH₃ (7 N in MeOH, 4 × 6mL) to give a light-yellow solid of 4-(3-aminophenyl)-thiazol-2-ylamine. ¹H NMR (DMSO-*d*₆, 400 MHz): $\delta = 7.24$ (brs, 2 H), 7.35 (s, 1 H), 7.65 – 7.69 (m, 1 H), 8.10 – 8.13 (m, 1 H), 8.23 – 8.26 (m, 1 H), 8.62 (t, 1 H, $J = 1.8$ Hz). MS


(ES+): m/z 223.12 (45) $[MH^+]$. HPLC: t_R = 2.82 min (ZQ2000, polar_5 min). The combined CH_2Cl_2 and MeOH solution was concentrated *in vacuo* to give a yellow solid of 4-(3-aminophenyl)-1*H*-imidazole-2-thiol. ^1H NMR (DMSO- d_6 , 400 MHz): δ = 7.75 (t, 1 H, J = 8.0 Hz), 8.01 (d, 1 H, J = 0.8 Hz), 8.17 – 8.20 (m, 1 H), 8.35 – 8.37 (m, 1 H), 8.56 (d, 1 H, J = 1.6 Hz), 8.72 (t, 1 H, J = 1.8 Hz), 12.56 (s, 1 H). MS (ES+): m/z 222.12 (15) $[MH^+]$. HPLC: t_R = 2.97 min (ZQ2000, polar_5 min).

[730] **EXAMPLE 254: *tert*-Butyl 4-[4-(3-iodo-4-methoxyphenylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylate.**




[731] 3-Iodo-4-methoxyaniline (0.670g, 2.0mmol) was added to a solution of *tert*-butyl 4-(chloro-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl)-3,6-dihydro-2*H*-pyridine-1-carboxylate (0.598g, 2.4mmol) in *n*-butanol (10mL). The mixture was heated to 95°C for 15h. The solvent was removed and the residue was purified by silica gel chromatography (5% MeOH in dichloromethane) to afford the title compound. ^1H -NMR (DMSO- d_6 , 400 MHz): δ = 1.43 (s, 9 H), 2.46 (m, 2 H), 3.56 (m, 2 H), 3.80 (s, 3 H), 4.03 (m, 2 H), 6.38 (s, 1 H), 6.72 (s, 1 H), 7.00 (d, J = 9.2 Hz, 1 H), 7.85 (dd, J = 2.8, 8.8 Hz, 1 H), 8.34 (s, 1 H), 9.27 (s, 1 H), 11.93 (s, 1 H). MS (ES+): m/z 547.91 $[MH^+]$. HPLC: t_R = 3.39 min (ZQ2000, polar_5min).

[732] **EXAMPLE 255: *tert*-Butyl 4-[4-(3-iodophenylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylate.**



[733] The title compound was prepared following the above procedure, but using 3-iodoaniline. MS (ES+): m/z 517.91. HPLC: t_R = 3.75 min (ZQ2000, polar_5min).


[734] **EXAMPLE 256: *tert*-Butyl 4-[4-[3-(1*H*-pyrrol-2-yl)phenylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylate.**



[735] To a stirred solution of *tert*-butyl 4-[4-(3-iodophenylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylate (77.6mg, 0.15mmol), *N*-Boc-2-


pyrrolylboronic acid (47.5mg, 0.225mmol) and potassium carbonate (41.5mg, 0.3mmol) in dioxane/water (4:1) (1.0mL) was added PdCl₂(dppf)·CH₂Cl₂ (12.2mg, 0.015mmol). The mixture was heated at reflux for 18h. Solvents were removed *in vacuo* and the residue was dissolved in DMF (≈2mL). The DMF solution was filtered and purified by HPLC to afford the title compound. ¹H-NMR(CD₃OD, 400 MHz): δ = 1.50 (s, 9 H), 2.53 (m, 2 H), 3.64 (m, 2 H), 4.11 (m, 2 H), 6.16 (t, *J* = 2.8 Hz, 2 H), 6.26 (s, 1 H), 6.48 (dd, *J* = 1.2, 3.6 Hz, 1 H), 6.60 (s, 1 H), 6.81 (dd, *J* = 1.2, 2.8 Hz, 1 H), 7.31 (s, 1 H), 7.33 (s, 1 H), 7.42-7.45 (m, 1 H), 7.87 (s, 1 H), 8.21 (s, 1 H). MS (ES⁺): *m/z* 457.08 [MH⁺]. HPLC: *t_R* = 3.15 min (ZQ2000, polar_5min).

[736] **EXAMPLE 257: *tert*-Butyl 4-[4-(3-thiophen-3-ylphenylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylate.**




[737] The title compound was prepared following the procedure for *tert*-butyl 4-[4-[3-(1*H*-pyrrol-2-yl)phenylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylate, but using 3-thienylboronic acid. ¹H-NMR (CD₃OD, 400 MHz): δ = 1.50 (s, 9 H), 2.56 (m, 2 H), 3.67 (m, 2 H), 4.13 (m, 2 H), 6.30 (s, br, 1 H), 6.66 (s, 1 H), 7.37-7.42 (m, 2 H), 7.47-7.50 (m, 2 H), 7.63-7.66 (m, 2 H), 8.01-8.02 (m, 1 H), 8.23 (s, 1 H). MS (ES⁺): *m/z* 474.04 [MH⁺]. HPLC: *t_R* = 3.58 min (ZQ2000, polar_5min).

[738] **EXAMPLE 258: *tert*-Butyl 4-[4-[3-(1*H*-pyrazol-4-yl)phenylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylate.**




[739] The title compound was prepared following the procedure for *tert*-butyl 4-[4-[3-(1*H*-pyrrol-2-yl)phenylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylate, but using 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1*H*-pyrazole. ¹H-NMR (CD₃OD, 400 MHz): δ = 1.50 (s, 9 H), 2.57 (m, 2 H), 3.67 (m, 2 H), 4.14 (m, 2 H), 6.29 (s, br, 1 H), 6.66 (s, 1 H), 7.33-7.39 (m, 2 H), 7.58 (dt, *J* = 2.0, 7.2 Hz, 1 H), 7.92 (d, *J* = 1.2 Hz, 1 H), 7.93-8.00 (m, 2 H), 8.23 (s, 1 H). MS (ES⁺): *m/z* 458.03 [MH⁺]. HPLC: *t_R* = 2.70 min (ZQ2000, polar_5min).

[740] **EXAMPLE 259: *tert*-Butyl 4-[4-[4-methoxy-3-(1*H*-pyrrol-2-yl)-phenylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylate.**



[741] To a stirred solution of *tert*-butyl 4-[4-(3-iodo-4-methoxyphenylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylate (82.1mg, 0.15mmol), *N*-Boc-2-pyrrolylboronic acid (47.5mg, 0.225mmol) and potassium carbonate (41.5mg, 0.3mmol) in dioxane/water (4:1) (1.0mL) was added PdCl₂(dppf)·CH₂Cl₂ (12.2mg, 0.015mmol). The mixture was heated at reflux for 18h. Solvents were removed and the residue was dissolved in DMF (≈2mL). The DMF solution was filtered and sent to mass-directed HPLC purification. The pyrrole-Boc-protected product obtained was stirred with NaOH (s, 369mg) in 9mL of methanol at rt for 17h. The solvent was removed and the residue was dissolved in DMF (≈1.5mL) and purified by HPLC purification to give the title compound. ¹H-NMR (DMSO-*d*₆, 400 MHz): δ = 1.43 (s, 9 H), 2.46 (m, 2 H), 3.56 (m, 2 H), 3.87 (s, 3 H), 4.03 (m, 2 H), 6.11 (q, *J* = 2.4 Hz, 1 H), 6.37 (s, br, 1 H), 6.49 (s, 1 H), 6.71 (s, 1 H), 6.81 (q, *J* = 2.4 Hz, 1 H), 7.04 (d, *J* = 9.2 Hz, 1 H), 7.63 (d, *J* = 6.0 Hz, 1 H), 7.92 (d, *J* = 2.4 Hz, 1 H), 8.20 (d, *J* = 4.4 Hz, 1 H), 9.22 (s, 1 H), 10.91 (s, 1 H), 11.89 (s, 1 H). MS (ES⁺): *m/z* 487.04 [MH⁺]. HPLC: *t*_R = 2.96 min (ZQ2000, polar_5min).


[742] **EXAMPLE 260:** *tert*-Butyl 4-[4-(4-methoxy-3-thiophen-3-ylphenyl-amino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylate.



[743] To a stirred solution of *tert*-butyl 4-[4-(3-iodo-4-methoxyphenylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylate (82.1mg, 0.15mmol), 3-thienylboronic acid (28.8mg, 0.225mmol) and potassium carbonate (41.5mg, 0.3mmol) in dioxane/water (4:1) (1.0mL) was added [1,1'-*bis*(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (1:1) (12mg, 0.015mmol). The resulting mixture was bubbled N₂ for 5min and then heated at reflux for 16h. After cooled to rt, the solvents were removed under reduced pressure. The residue was dissolved in DMF (2mL). The DMF solution was filtered and purified by HPLC to give the title compound. ¹H-NMR (DMSO-*d*₆, 400 MHz): δ = 1.43 (s, 9 H), 3.56 (m, 2 H), 3.82 (s, 3 H), 4.03 (m, 2 H), 6.38 (s, br, 1 H), 6.73 (s, 1 H), 7.09 (d, *J* = 9.2 Hz, 1 H), 7.45 (dd, *J* = 0.8, 5.2 Hz, 1 H), 7.60 (dd, *J* = 2.8, 4.8 Hz, 1 H), 7.76 (m, 1 H), 7.80 (dd, *J* = 2.8, 8.8 Hz, 1 H), 7.94 (d, *J* = 2.8 Hz, 1 H), 8.22


(s, 1 H), 9.26 (s, 1 H), 11.90 (s, 1 H). MS (ES⁺): m/z 504.05 [MH⁺]. HPLC: t_R = 3.22 min (ZQ2000, polar_5min).

[744] **EXAMPLE 261: *tert*-Butyl 4-[4-(4-hydroxy-3-thiazol-5-ylphenylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylate.**




[745] 4-Amino-2-thiazol-5-ylphenol (70.0mg, 0.364mmol) was added to a solution of *tert*-butyl 4-(chloro-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl)-3,6-dihydro-2*H*-pyridine-1-carboxylate (192mg, 0.546mol) in *n*-butanol (2.0mL). The reaction was stirred at 120°C for 14h. The solvent was removed and the residue was dissolved in DMF. The DMF solution was filtered and purified by HPLC to give the title compound. ¹H-NMR (DMSO-*d*₆, 400 MHz): δ = 1.43 (s, 9 H), 2.46 (m, 2 H), 3.56 (t, J = 5.6 Hz, 2 H), 4.04 (s, 2 H), 6.38 (s, br, 1 H), 6.70 (s, 1 H), 6.97 (d, J = 8.8 Hz, 1 H), 7.70 (dd, J = 2.4, 8.8 Hz, 1 H), 8.07 (d, J = 2.4 Hz, 1 H), 8.22 (s, 1 H), 8.32 (s, 1 H), 9.05 (s, 1 H), 9.23 (s, 1 H), 10.25 (s, br, 1 H), 11.88 (s, 1 H). MS (ES⁺): m/z 490.94 (MH⁺). HPLC: t_R = 2.51 min (ZQ2000, polar_5min).

[746] **4-Amino-2-thiazol-5-ylphenol**



[747] 4-Nitro-2-thiazol-5-ylphenol (100mg, 0.4mmol) in methanol (5mL) was hydrogenated in the presence of 10% Pd/C (80mg) for 16h. The reaction mixture was filtered through a Celite pad. The filtrate was concentrated *in vacuo* to afford the title compound, which was used directly in the next step without purification. ¹H-NMR (CD₃OD, 400 MHz): δ = 7.18 (d, J = 8.8 Hz, 1 H), 7.39 (dd, J = 2.4, 8.8 Hz, 1 H), 7.91 (d, J = 2.8 Hz, 1 H), 8.91 (s, 1 H), 9.97 (s, 1 H). MS (ES⁺): m/z 193.14 [MH⁺]. HPLC: t_R = 0.48 min (ZQ2000, polar_5min).


[748] **4-Nitro-2-thiazol-5-ylphenol**



[749] A mixture of 5-(2-methoxy-5-nitrophenyl)thiazole (156mg, 0.660mmol) and anhydrous sodium sulfide (309mg, 3.96mmol) in *N*-methylpyrrolidinone (2mL) was heated at 160°C for 2h. After cooling to rt, the solvent was removed *in vacuo*, and the residue was partitioned between water (5mL) and dichloromethane (20mL). The organic phase was separated, dried over MgSO₄, and purified by silica gel chromatography (3% MeOH in


dichloromethane) to afford the title compound. $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ = 7.18 (d, J = 9.2 Hz, 1 H), 8.08 (dd, J = 1.6, 9.2 Hz, 1 H), 8.45 (s, 1 H), 8.52 (d, J = 2.4 Hz, 1 H), 8.86 (s, 1 H), 11.95 (s, br, 1 H). MS (ES⁺): m/z 223.14 [MH^+]. HPLC: t_R = 2.68 min (ZQ2000, polar_5min).

[750] **5-(2-Methoxy-5-nitrophenyl)thiazole**




[751] N_2 was bubbled through a solution of 2-iodo-4-nitroanisole (2.8g, 10.0mmol), thiazole (2.55g, 30.0mmol), potassium acetate (1.47g, 15.0mmol), and tetrakis(triphenyl phosphine)palladium(0) (0.81g, 0.70mmol) in DMF (15mL) for 10min. The mixture was then heated to 100°C and stirred overnight. Solvent was removed under reduced pressure, and the residue was purified by silica gel chromatography (dichloromethane:MeOH = 96:4) to afford the title compound. $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ = 4.08 (s, 3 H), 7.09 (d, J = 9.2 Hz, 1 H), 8.25 (dd, J = 2.8, 9.2 Hz, 1 H), 8.37 (s, 1 H), 8.54 (d, J = 3.2 Hz, 1 H), 8.88 (s, 1 H). MS (ES⁺): m/z 237.13 [MH^+]. HPLC: t_R = 3.07 min (ZQ2000, polar_5min).

[752] **EXAMPLE 262: *tert*-Butyl 4-[4-(3-chloro-5-thiazol-5-ylphenylamino)-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylate.**



[753] The title compound was obtained following the General method for the reaction of amines with *tert*-butyl 4-(4-chloro-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl)-3,6-dihydropyridine-1(2H)-carboxylate, using 3-chloro-5-thiazol-5-ylphenylamine. $^1\text{H-NMR}$ (CD_3OD , 400 MHz): δ = 1.50 (s, 9 H), 2.58 (m, 2 H), 3.67 (m, 2 H), 4.13 (s, 2 H), 6.30 (s, br, 1 H), 6.72 (s, 1 H), 7.35 (t, J = 1.6 Hz, 1 H), 8.05-8.07 (m, 2 H), 8.21 (d, J = 0.4 Hz, 1 H), 8.33 (s, 1 H), 9.00 (d, J = 0.8 Hz, 1 H). MS (ES⁺): m/z 508.81 (MH^+ , ^{35}Cl), 510.91 (MH^+ , ^{37}Cl). HPLC: t_R = 3.75 min (ZQ2000, polar_5min).


[754] **3-Chloro-5-thiazol-5-ylphenylamine**



[755] To a solution of 5-(3-chloro-5-nitrophenyl)thiazole (0.120g, 0.499mmol) in ethanol (5mL) was added tin dichloride (0.9555g, 4.986mmol). The mixture was stirred at 90°C for 1.5h. After cooling to rt, sat. NaHCO_3 (aq) was added dropwise to adjust the pH to


9–10. The resulting suspension was filtered through a Celite pad. The filtrate was concentrated to dryness *in vacuo* to afford the title compound, which was used directly in the next step without purification. ¹H-NMR (CD₃OD, 400 MHz): δ = 6.67 (t, J = 2.0 Hz, 1 H), 6.85 (t, J = 1.6 Hz, 1 H), 6.88 (t, J = 1.6 Hz, 1 H), 8.10 (s, 1 H), 8.94 (s, 1 H). MS (ES⁺): m/z 211.10 (MH⁺, ³⁵Cl), 213.12 (MH⁺, ³⁷Cl). HPLC: t_R = 2.92 min (ZQ2000, polar_5min).

[756] **5-(3-Chloro-5-nitrophenyl)thiazole**




[757] N₂ was bubbled through a solution of 3,5-dichloronitrobenzene (0.384g, 2.00mmol), thiazole (0.204g, 2.40mmol), potassium acetate (0.294g, 3.00mmol), and tetrakis(triphenylphosphine)palladium(0) (0.16g, 0.14 mol) in DMF (5mL) for 10min. The mixture was then heated to 120°C and stirred for 17h. The solvents were removed *in vacuo*. The residue was purified by chromatography on silica gel (MeOH in methylene chloride: 1% to 5%) to afford the title compound. ¹H-NMR (CDCl₃, 400 MHz): δ = 7.88 (t, J = 2.0 Hz, 1 H), 8.20 (t, J = 2.4 Hz, 1 H), 8.22 (s, 1 H), 8.32 (t, J = 2.0 Hz, 1 H), 8.90 (s, 1 H). MS (ES⁺): m/z 241.04 (³⁵Cl, MH⁺), 243.00 (³⁷Cl, MH⁺). HPLC: t_R = 3.35 min (ZQ2000, polar_5min).

[758] **EXAMPLE 263: *tert*-Butyl 4-{4-[3-(4-methyl-4*H*-[1,2,4]triazol-3-yl)-phenylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2*H*-pyridine-1-carboxylate.**




[759] The title compound was obtained following the General method for the reaction of amines with *tert*-butyl 4-(4-chloro-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl)-3,6-dihydropyridine-1(2*H*)-carboxylate, using 3-(4-methyl-4*H*-[1,2,4]triazol-3-yl)-phenylamine. ¹H-NMR (CD₃OD, 400 MHz): δ = 1.50 (s, 9 H), 2.58 (m, 2 H), 3.67 (m, 2 H), 3.89 (s, 3 H), 4.13 (m, 2 H), 6.30 (s, br, 1 H), 6.73 (s, 1 H), 7.41 (dt, J = 1.2, 7.6 Hz, 1 H), 7.54 (t, J = 7.6 Hz, 1 H), 7.93 (dq, J = 0.8, 8.4 Hz, 1 H), 8.26 (s, 1 H), 8.30 (t, J = 1.6 Hz, 1 H), 8.57 (s, 1 H). MS (ES⁺): m/z 473.01 [MH⁺]. HPLC: t_R = 2.60 min (ZQ2000, polar_5min).

[760] **EXAMPLE 264: *tert*-Butyl 4-[4-(1*H*-indol-4-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylate.**




[761] The title compound was obtained following the General method for the reaction of amines with *tert*-butyl 4-(4-chloro-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl)-3,6-dihydropyridine-1(2*H*)-carboxylate, using 4-aminoindole. ¹H-NMR (CD₃OD, 400 MHz): δ = 1.49 (s, 9 H), 2.42 (m, 2 H), 3.61 (m, 2 H), 4.09 (m, 2 H), 6.22 (br, 2 H), 6.39 (dd, J = 1.2, 2.8 Hz, 1 H), 7.13-7.18 (m, 2 H), 7.21 (d, J = 3.2 Hz, 1 H), 7.32-7.34 (m, 1 H), 8.07 (s, 1 H). MS (ES⁺): m/z 431.09 [MH⁺]. HPLC: t_R = 2.47 min (ZQ2000, polar_5min).

[762] **EXAMPLE 265: 4-[4-(Naphthalen-1-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester.**



[763] A suspension containing naphthalen-1-yl-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl]-amine (120mg, 0.35mmol), di-*tert*-butyldicarbonate (77mg, 0.35mmol) and *N,N*-diisopropylethylamine (122 μ L, 0.70mmol) in anhydrous *N,N*-dimethylformamide (2mL) was stirred overnight at rt. The reaction mixture was poured into saturated NaHCO₃ solution (50mL) and extracted with EtOAc (3 $\times$ 40mL). The combined organics were washed with brine (3 $\times$ 100mL), dried (MgSO₄), filtered and concentrated. Flash chromatography (2 to 4% MeOH in DCM) gave the title compound as a white solid. ¹H NMR (DMSO-*d*₆, 400 MHz): δ = 8.28 (1H, s), 8.14-8.12 (2H, m), 7.94 (1H, d, J = 7.5Hz), 7.87 (1H, d, J = 7.4 Hz), 7.67 (1H, d, J = 7.1 Hz), 7.56-7.48 (3H, m), 6.13 (1H, s), 5.35 (1H, s), 4.02 (2H, s), 3.52 (2H, s), 2.21 (2H, s), 1.47 (9H, s); MS (ES⁺): m/z 442.08 [MH⁺], HPLC: t_R = 2.96 min (MicromassZQ, polar_5min).


[764] **Naphthalen-1-yl-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl]amine**



[765] A sealed tube containing a solution of 4-(4-chloro-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl)-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester (250mg, 0.75mmol), 1-naphthylamine (160mg, 1.12mmol) and trifluoroacetic acid (287 μ L, 3.73mmol) in 2,2,2-trifluoroethanol (5mL) was heated at 80°C and maintained at this temperature


overnight. The product was poured into saturated NaHCO₃ solution (50mL) and the precipitate was filtered off, giving the title compound as an off-white solid. ¹H NMR (DMSO-d₆, 400MHz): δ = 9.48 (1H, s), 8.14-7.92 (3H, m), 7.82 (1H, d, J = 8.0Hz), 7.64 (1H, d, J = 7.2 Hz), 7.61-7.44 (3H, m), 6.40 (1H, s), 4.02 (2H, brs), 3.51 (2H, brs), 2.89 (2H, brs); MS (ES⁺): m/z 342.11 [MH⁺], HPLC: t_R = 1.71 min (MicromassZQ, polar_5min).

[766] **EXAMPLE 266: 4-[4-(Naphthalen-1-ylamino)-7H-pyrrolo[2,3-*d*]-pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butylamide.**



[767] A suspension containing naphthalen-1-yl-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-*d*]pyrimidin-4-yl]-amine (120mg, 0.35mmol), *tert*-butyl isocyanate (35mg, 0.35mmol) and *N,N*-diisopropylethylamine (122 μ L, 0.70mmol) in anhydrous *N,N*-dimethylformamide (2mL) was stirred overnight at rt. The reaction mixture was poured into saturated NaHCO₃ solution (50mL) and extracted with EtOAc (3 $\times$ 50ml). The combined organics were washed with brine (3 $\times$ 50mL), dried (MgSO₄), filtered and concentrated. Flash chromatography (2 to 4% MeOH in DCM) gave the title compound as a white solid. ¹H NMR (DMSO-d₆, 400MHz): δ = 8.13 (1H, s), 8.08-8.02 (2H, m), 7.89 (1H, d, J = 8.1Hz), 7.74-7.71 (1H, m), 7.63-7.54 (3H, m), 6.55 (1H, d, J = 8.3 Hz), 6.43 (1H, s), 5.83 (1H, s), 4.04 (2H, s), 3.55 (2H, t, J = 5.6 Hz), 2.42 (2H, s), 1.34 (9H, s); MS (ES⁺): m/z 441.08 [MH⁺], HPLC: t_R = 2.59 min (MicromassZQ, polar_5min).


[768] **EXAMPLE 267: 4-[4-(6-Oxo-1-phenyl-1,6-dihydropyridin-3-ylamino)-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl ester.**



[769] A mixture of 4-(4-chloro-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl ester (75mg, 0.22mmol) and 5-amino-1-phenyl-1H-pyridin-2-one (50mg, 0.27mmol) in 1-butanol (3mL) was heated at 120°C overnight, LC-MS showed the desired product together with some de-Boc product. After the mixture was cooled to rt, it was diluted with methylene chloride (3mL), then *N,N*-diisopropylethylamine (0.1mL,


0.6mmol) and di-*tert*-butyldicarbonate (49mg, 0.22mmol) were added. The resulting mixture was stirred at rt for 30min. The mixture was diluted with EtOAc (30mL), then washed with brine (20mL), and dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure, and the residue was crystallized with EtOAc/Hexane to give the title compound as a green solid. LC-MS (ES, Pos.): 485 [MH⁺], and ¹H NMR (DMSO-d₆, 400 MHz): δ 1.43 (s, 9H), 2.50 (m, 2H), 3.56 (m, 2H), 4.04 (m, 2H), 6.39 (s, 1H), 6.56 (d, J = 9.7 Hz, 1H), 6.66 (s, 1H), 7.39-7.57 (m, 5H), 7.81 (dd, J = 9.7, 2.7 Hz, 1H), 8.17 (s, 1H), 8.34 (d, J = 2.7 Hz, 1H), 9.17 (s, 1H), 11.94 (br s, 1H).

[770] **5-Amino-1-phenyl-1H-pyridin-2-one**




[771] To a suspension of 5-nitro-1-phenyl-1H-pyridin-2-one (60mg, 0.28mmol) in ethyl acetate (2mL) and ethanol (2mL) was added 5% Pd-C (10mg), the resulting mixture was stirred under hydrogen atmosphere for 3h. The catalyst was removed by filtration, and the filtrate was concentrated to give the title compound as a green oil. The product was used to next step without further purification. LC-MS (ES, Pos.): 187 [MH⁺], and ¹H NMR (CDCl₃, 400 MHz): δ = 3.09 (br s, 2H), 6.60 (d, J = 9.6 Hz, 1H), 6.82 (d, J = 3.0 Hz, 1H), 7.12 (dd, J = 9.6, 3.0 Hz, 1H), 7.37-7.41 (m, 3H), 7.45-7.49 (m, 2H).

[772] **5-Nitro-1-phenyl-1H-pyridin-2-one**




[773] [Ref. Mederski, W.W.K.R., *et al. Tetrahedron*, **1999**, *55*, 12757-12770.] To a solution of 2-hydroxy-5-nitropyridine (1.07g, 7.64mmol) in dry methylene chloride (50mL) were added phenylboronic acid (1.86g, 15.3mmol), cupric acetate (1.71g, 9.41mmol), pyridine (1.2mL, 15.3mmol), triethylamine (2.1mL, 15.3mmol) and activated 4Å molecular sieves (2g). The resulting mixture was stirred in air at rt for 2d. The mixture was then filtered through celite and washed with methylene chloride. The crude material was purified by silica gel chromatography, eluting with CH₂Cl₂ : EtOAc (85:15) to give the title compound as a white solid. LC-MS (ES, Pos.): 217 [MH⁺], and ¹H NMR (CDCl₃, 400 MHz): δ = 6.67 (d, J = 10.1 Hz, 1H), 7.39-7.42 (m, 2H), 7.53-7.58 (m, 3H), 8.17 (dd, J = 10.1, 3.1 Hz, 1H), 8.67 (d, J = 3.1 Hz, 1H).

[774] **EXAMPLE 268: 4-[4-(6-Oxo-1-phenyl-1,6-dihydropyridin-3-ylamino)-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butylamide.**




[775] A mixture of 4-(4-chloro-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl)-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester (54.5mg, 0.163mmol), 5-amino-1-phenyl-1*H*-pyridin-2-one hydrochloride (43.5mg, 0.195mmol), dimethyl sulfoxide (3mL) and trifluoroacetic acid (125 μ L, 1.63mmol) in a sealed tube was heated at 100°C overnight. The mixture was concentrated *in vacuo* and was charged with *N,N*-dimethylformamide (2mL), triethylamine (272 μ L, 1.95mmol) and *tert*-butyl isocyanate (20.4 μ L, 0.179mmol). The above mixture was stirred at rt for 1.5h, concentrated *in vacuo*, and partitioned between water/EtOAc (10mL/15mL). The aqueous phase was extracted with EtOAc (2 $\times$ 15mL), and the combined organic phase was washed with brine (10mL), concentrated *in vacuo*, and dissolved in DMSO/MeOH for submission for MS-directed purification, which gave the title compound as beige solid. ¹H NMR (CD₃OD, 400 MHz): δ = 1.46 (s, 9 H), 2.67 (brs, 2 H), 3.69 – 3.72 (m, 2 H), 4.16(brs, 2 H), 6.41 (brs, 1 H), 6.72 (s, 1 H), 6.79 (d, 1 H, *J* = 9.6 Hz), 7.56 – 7.68 (m, 5 H), 7.95 (dd, 1 H, *J* = 2.8 & 9.6 Hz), 8.27 (s, 1 H), 8.39 (d, 1 H, *J* = 2.4 Hz), 8.64 (s, 1 H). MS (ES⁺): *m/z* 484.09 (100) [MH⁺]. HPLC: *t_R* = 2.44 min (ZQ2000, polar_5 min).

[776] **5-Amino-1-phenyl-1*H*-pyridin-2-one, hydrochloride**




[777] 5-(Benzhydrylideneamino)-1-phenyl-1*H*-pyridin-2-one (72.0 mg) was dissolved in tetrahydrofuran (3 ml), and aqueous HCl (2 M, 1.0 ml) was added while stirring at rt. The yellow color was faded. After 30 min, the reaction mixture was partitioned between aqueous HCl (1 M, 8 ml) and 40% EtOAc / hexane (15 ml). The aqueous layer was extracted with 40% EtOAc/hexane (15 ml), and the aqueous phase was then concentrated *in vacuo* to the title compound as beige foam. ¹H NMR (DMSO-*d*₆, 400 MHz): δ = 6.62 (d, 1 H, *J* = 10.0 Hz), 7.42 – 7.59 (m, 6 H), 7.90 (d, 1 H, *J* = 2.8 Hz), 10.34 (brs, 2 H). MS(ES⁺): *m/z* 187.22 (100) [MH⁺]. HPLC: *t_R* = 0.52 min (ZQ2000, polar_5min).

[778] **5-(Benzhydrylideneamino)-1-phenyl-1*H*-pyridin-2-one**




[779] Into a dried flask were added 5-bromo-1-phenyl-1*H*-pyridin-2-one (125 mg, 0.500 mmol), benzophenone imine (100 μ l, 0.600 mmol), tris(dibenzylideneacetone)-dipalladium(0) (1.14 mg, 1.25 μ mol), (*R*)-(+)-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (2.33 mg, 3.75 μ mol), sodium *tert*-butoxide (67.2 mg, 0.700 mmol), and toluene (3 ml). The above mixture was flushed with N₂ for 5 min and was then heated at 80 °C under an atmosphere of nitrogen for 5 h. After that time, the heating was stopped and the reaction mixture was diluted with ethyl ether (30 ml), filtered and concentrated to obtain light-brown oil, which was then purified by chromatography on silica gel (10 g) eluting with 100 ml of 10%, 20%, 30% and 40%, and 300 ml 50% EtOAc/hexane to obtain the title compound as a yellow solid. ¹H NMR (CDCl₃, 400 MHz): δ = 6.45 (d, 1 H, *J* = 9.6 Hz), 6.89 (d, 1 H, *J* = 2.8 Hz), 7.00 (dd, 1 H, *J* = 2.8 & 10.4 Hz), 7.13 – 7.16 (m, 2 H), 7.19 – 7.22 (m, 2 H), 7.33 – 7.48 (m, 9 H), 7.69 – 7.72 (m, 2 H). MS(ES⁺): *m/z* 351.05 (100) [MH⁺]. HPLC: *t_R* = 3.46 min (ZQ2000, polar_5min).

[780] **5-Bromo-1-phenyl-1*H*-pyridin-2-one**




[781] Into a one-neck round-bottom flask were added 5-bromo-1*H*-pyridin-2-one (696 mg, 4.00 mmol), phenylboronic acid (975 mg, 8.00 mmol), cupric acetate (1450 mg, 8.00 mmol), triethylamine (1120 μ l, 8.00 mmol), pyridine (647 μ l, 8.00 mmol), 4 Å molecular sieves (1056 mg) and methylene chloride (24 ml). The flask was loosely capped and the above mixture was stirred at rt in the atmosphere of air for 20 h. The mixture was filtered through a celite pad, washed with CH₂Cl₂. After concentration *in vacuo*, a green oil (2100 mg) was obtained, which was then purified by chromatography on silica gel (64 g) eluting with 1000 ml 20%, 2000 ml 40% and 1000 ml 50% EtOAc/hexane to obtain the title compound as a light-yellow wax-like material. ¹H NMR (CDCl₃, 400 MHz): δ = 5.59 (d, 1 H, *J* = 9.6 Hz), 7.35 – 7.38 (m, 2 H), 7.41 – 7.46 (m, 2 H), 7.49 – 7.52 (m, 3 H). MS(ES⁺): *m/z* 250.06/252.02 (100/97) [MH⁺]. HPLC: *t_R* = 2.71 min (ZQ2000, polar_5 min).

[782] **EXAMPLE 269: *tert*-Butyl 4-[4-(6-hydroxy-5-thiazol-5-ylpyridin-3-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylate.**




[783] The title compound was obtained following the General method for the reaction of amines with *tert*-butyl 4-(4-chloro-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl)-3,6-dihydropyridine-1(2*H*)-carboxylate, using 5-amino-3-thiazol-5-ylpyridin-2-ol. ¹H-NMR (DMSO-*d*₆, 400 MHz): δ = 1.43 (s, 9 H), 2.47 (m, 2 H), 3.57 (t, *J* = 5.6 Hz, 2 H), 4.04 (m, 2 H), 6.38 (br, 1 H), 6.66 (s, 1 H), 8.15 (s, 1 H), 8.23 (s, 1 H), 8.37 (d, *J* = 3.2 Hz, 1 H), 8.49 (s, 1 H), 9.04 (s, 1 H), 9.22 (s, 1 H), 11.96 (s, 1 H), 12.10 (s, br, 1 H). MS (ES⁺): *m/z* 491.98 [MH⁺]. HPLC: *t*_R = 2.49 min (ZQ2000, polar_5min).

[784] **5-Amino-3-thiazol-5-ylpyridin-2-ol**




[785] A solution of 5-nitro-3-thiazol-5-ylpyridin-2-ol (218mg, 0.977mmol) and 10% Pd/C (100mg) in methanol (5mL) was hydrogenated under 1atm at rt for 5h. The resulting mixture was filtered through a Celite pad. The filtrate was concentrated under reduced pressure to give 170mg of the title compound, which was used directly in the next step without purification. ¹H-NMR (DMSO-*d*₆, 400 MHz): δ = 4.38 (s, br, 2 H), 6.78 (d, *J* = 2.8 Hz, 1 H), 7.80 (d, *J* = 2.8 Hz, 1 H), 8.41 (s, 1 H), 8.97 (s, 1 H), 11.52 (s, br, 1 H). MS (ES⁺): *m/z* 194.15 [MH⁺]. HPLC: *t*_R = 0.49 and 0.90 min (ZQ2000, polar_5min).

[786] **5-Nitro-3-thiazol-5-ylpyridin-2-ol**




[787] N₂ was bubbled through a solution of 3-iodo-5-nitropyridin-2-ol (1.33g, 5.00mmol), thiazole (2.13g, 25.0mmol), potassium acetate (1.47g, 15.0mmol), and tetrakis(triphenylphosphine)palladium(0) (0.4g, 0.4mmol) in DMF (10mL) for 10 min. The mixture was then heated to 120°C and stirred for 17h. The solvents were removed *in vacuo*. The residue was stirred with methanol (5mL) and dichloromethane (10mL) for 30min. The solids were collected by filtration, washed with dichloromethane (2mL) and water (3×8mL), and dried *in vacuo* to afford the title compound as an off-white solid. ¹H-NMR (DMSO-*d*₆, 400 MHz): δ = 8.74 (d, *J* = 2.8 Hz, 1 H), 8.77 (s, 1 H), 8.79 (d, *J* = 2.8 Hz, 1 H), 9.12 (s, 1 H), 13.26 (s, br, 1 H). MS (ES⁺): *m/z* 224.09 [MH⁺]. HPLC: *t*_R = 2.16 min (ZQ2000, polar_5min).

[788] **EXAMPLE 270: *tert*-Butyl 4-[4-(1-methyl-6-oxo-5-thiazol-5-yl)-1,6-dihydropyridin-3-ylamino]-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylate.**




[789] 5-Amino-1-methyl-3-thiazol-5-yl-1H-pyridin-2-one (99.0mg, 0.478mmol) was added to a solution of *tert*-butyl 4-(chloro-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl)-3,6-dihydro-2H-pyridine-1-carboxylate (133mg, 0.398mmol) in 1-butanol (2.0mL). The reaction was stirred at 120°C for 15h. DMF (≈1.5mL) was added and the mixture was filtered. The filtrate was purified by HPLC to yield the title compound. ¹H-NMR (CD₃OD, 400 MHz): δ = 1.50 (s, 9 H), 2.57 (m, 2 H), 3.67 (m, 2 H), 3.73 (s, 3 H), 4.13 (m, 2 H), 6.30 (s, br, 1 H), 6.62 (s, 1 H), 8.21 (s, 1 H), 8.33 (d, *J* = 2.4 Hz, 1 H), 8.34 (d, *J* = 2.4 Hz, 1 H), 8.47 (s, 1 H), 8.99 (s, 1 H). MS (ES⁺): *m/z* 506.08 [MH⁺]. HPLC: *t_R* = 2.62 min (ZQ2000, polar_5min).

[790] **5-Amino-1-methyl-3-thiazol-5-yl-1H-pyridin-2-one**



[791] To a solution of 1-methyl-5-nitro-3-thiazol-5-yl-1H-pyridin-2-one (290mg, 1.22mmol) in ethanol (10mL) was added SnCl₂ (2.342g, 12.22mmol). The mixture was stirred at 90°C for 15h. After cooled to rt, sat. NaHCO₃ (aq) was added dropwise to the reaction to adjust the pH to 9–10. The resulting solution was filtered through a Celite pad. The filtrate was concentrated to dryness *in vacuo* to afford the crude product, which was used directly in the next step without purification. MS (ES⁺): *m/z* 208.21 [MH⁺]. HPLC: *t_R* = 1.47 min (ZQ2000, polar_5min).


[792] **1-Methyl-5-nitro-3-thiazol-5-yl-1H-pyridin-2-one**



[793] N₂ was bubbled through a solution of 3-iodo-1-methyl-5-nitro-1H-pyridin-2-one (840mg, 3.0mmol), thiazole (1280mg, 15.0mmol), potassium acetate (0.883g, 9.0mmol), and tetrakis(triphenylphosphine)palladium(0) (0.243g, 0.21mmol) in DMF (8mL) for 10min. The mixture was then heated to 120°C and stirred for 28h. The solvents were removed *in vacuo*. The black-colored residue was dissolved in a mixture of methanol (8mL) and methylene chloride (250mL). Water (30mL) and sat. NaHCO₃ (aq) (15mL) were added.


Layers were separated and the aqueous phase was extracted with methylene chloride (3 × 80mL). The combined organic phases were dried over MgSO₄, filtered, and concentrated under reduced pressure to ≈15mL. The product precipitated and was collected by filtration to afford the desired product as a black solid. ¹H-NMR (DMSO-d₆, 400 MHz): δ = 3.70 (s, 3 H), 8.79 (s, 1 H), 8.82 (d, *J* = 2.8 Hz, 1 H), 9.13 (s, 1 H), 9.29 (d, *J* = 3.2 Hz, 1 H). MS (ES⁺): *m/z* 238.15 [MH⁺]. HPLC: *t*_R = 2.33 min (ZQ2000, polar_5min).

[794] **3-Iodo-1-methyl-5-nitro-1*H*-pyridin-2-one**



[795] A solution of 3-iodo-5-nitropyridin-2-ol (2.66g, 10.0mmol) in THF (30mL) was cooled to -20°C. NaH (60% dispersion in mineral oil, 0.600g, 15.0mmol) was added cautiously in three portions. After being stirred for 30min at this temperature, methyl iodide (6.23mL, 100.0mmol) was added dropwise through a syringe. The resulting mixture was allowed to warm to rt during a 30min period. Stirring was continued for 18h at rt. Water (15mL) was added with caution to quench the reaction. THF was removed under reduced pressure and methylene chloride (80mL) was added to the aqueous phase. Layers were separated and the aqueous phase was extracted with methylene chloride (2×50mL). The combined organic phases were dried over MgSO₄, filtered, and concentrated to afford the desired product as a yellow crystalline solid. ¹H-NMR (CDCl₃, 400 MHz): δ = 3.73 (s, 3 H), 8.65 (d, *J* = 2.8 Hz, 1 H), 8.74 (d, *J* = 2.8 Hz, 1 H). MS (ES⁺): *m/z* 280.96 [MH⁺]. HPLC: *t*_R = 2.55 min (ZQ2000, polar_5min).


[796] **EXAMPLE 271: *tert*-Butyl 4-(4-{3-[1-(2-dimethylaminoethyl)-1*H*-imidazol-2-yl]phenylamino}-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl)-3,6-dihydro-2*H*-pyridine-1-carboxylate.**



[797] The title compound was obtained following the General method for the reaction of amines with *tert*-butyl 4-(4-chloro-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl)-3,6-dihydropyridine-1(2*H*)-carboxylate, using 3-[1-(2-dimethylaminoethyl)-1*H*-imidazol-2-yl]phenylamine. ¹H-NMR (CD₃OD, 400 MHz): δ = 1.50 (s, 9 H), 2.17 (s, 6 H), 2.58 (m, 2 H), 2.68 (t, *J* = 7.2 Hz, 2 H), 3.67 (m, 2 H), 4.13 (s, 2 H), 4.28 (t, *J* = 6.4 Hz, 2 H), 6.30 (s, br, 1 H), 6.71 (s, 1 H), 7.06 (d, *J* = 2.4 Hz, 1 H), 7.29 (dt, *J* = 2.4, 7.6 Hz, 1 H), 7.31 (d, *J* = 1.2 Hz, 1 H), 7.49 (t, *J* = 8.0 Hz, 1 H), 8.24 (dq, *J* = 0.8, 8.0 Hz, 1 H), 8.16 (t, *J* = 1.6 Hz, 1 H),


8.26 (d, $J = 1.2$ Hz, 1 H). MS (ES⁺): m/z 529.06 [MH⁺]. HPLC: $t_R = 1.90$ min (ZQ2000, polar_5min).

[798] 3-[1-(2-Dimethylaminoethyl)-1H-imidazol-2-yl]phenylamine




[799] Dimethyl-{2-[2-(3-nitrophenyl)imidazol-1-yl]ethyl}amine (88mg, 0.34mmol) in methanol (5mL) was hydrogenated in the presence of 10% Pd/C (80mg) for 16h. The reaction mixture was filtered through a Celite pad. The filtrate was concentrated *in vacuo* to afford the title compound, which was used directly in the next step without purification. ¹H-NMR (CDCl₃, 400 MHz): $\delta = 2.23$ (s, 6 H), 2.63 (t, $J = 7.2$ Hz, 2 H), 4.13 (d, $J = 7.2$ Hz, 2 H), 6.72-6.75 (m, 1 H), 6.90-6.92 (m, 1 H), 6.96 (t, $J = 2.0$ Hz, 1 H), 7.08 (d, $J = 1.2$ Hz, 1 H), 7.11 (d, $J = 1.2$ Hz, 1 H), 7.22 (t, $J = 7.6$ Hz, 1 H). MS (ES⁺): m/z 231.22 [MH⁺]. HPLC: $t_R = 0.33$ min (ZQ2000, polar_5min).

[800] Dimethyl-{2-[2-(3-nitrophenyl)imidazol-1-yl]ethyl}amine



[801] At rt and under N₂, to a solution of 2-(3-nitrophenyl)-1H-imidazole (0.189g, 1.00mmol) and (2-bromoethyl)dimethylamine hydrobromide (0.280g, 1.20mmol) in anhydrous DMF (5mL) was added NaH (60% in mineral oil, 160mg, 4.0mmol) in two portions with caution. The mixture was stirred at rt for 15h. Water (0.3mL) was added cautiously to quench the reaction. Solvent was removed *in vacuo*, and the residue was purified by silica gel chromatography (5% MeOH in dichloromethane) to afford the title compound. ¹H-NMR (CDCl₃, 400 MHz): $\delta = 2.24$ (s, 6 H), 2.69 (t, $J = 7.2$ Hz, 2 H), 4.13 (d, $J = 6.8$ Hz, 2 H), 7.17 (d, $J = 1.2$ Hz, 1 H), 7.19 (d, $J = 1.2$ Hz, 1 H), 7.65 (t, $J = 8.0$ Hz, 1 H), 8.04 (dt, $J = 0.8, 8.0$ Hz, 1 H), 8.28 (dq, $J = 1.2, 8.4$ Hz, 1 H), 8.56 (t, $J = 1.6$ Hz, 1 H). MS (ES⁺): m/z 261.17 [MH⁺]. HPLC: $t_R = 0.46$ min (ZQ2000, polar_5min).


[802] 2-(3-Nitrophenyl)-1H-imidazole



[803] 3-Nitrobenzaldehyde (4.53g, 30.0mmol), 40% aqueous glyoxal solution (23.9g, 165mmol), and sodium acetate (11.6g, 141mmol) were dissolved at rt in 90mL of aqueous ammonium hydroxide solution (28-30 wt%) and 180mL of methanol. The solution was stirred at rt for 16h. Solvents were removed *in vacuo*, and 80mL of sat. NaHCO₃ (aq) was added to the residue. The aqueous solution was extracted with EtOAc (3×300mL). The


combined organic phases were dried over MgSO_4 , filtered, and concentrated to give a black oily residue, which was purified by silica gel chromatography (5% MeOH in CH_2Cl_2) to afford the title compound as light brown solid. $^1\text{H-NMR}$ (DMSO-d_6 , 400 MHz): δ = 7.11 (s, br, 1 H), 7.36 (s, br, 1 H), 7.75 (t, J = 8.0 Hz, 1 H), 8.18 (dt, J = 0.8, 8.0 Hz, 1 H), 8.37 (dd, J = 0.8, 7.6 Hz, 1 H), 8.79 (s, 1 H). MS (ES⁺): m/z 190.18 [MH^+]. HPLC: t_R = 1.43 min (ZQ2000, polar_5min).

[804] **EXAMPLE 272: 4-{4-[3-(1*H*-Imidazol-2-yl)-phenylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester.**




[805] Into a sealed tube were added 4-(4-chloro-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl)-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester (368mg, 1.10mmol), 3-(1*H*-imidazol-2-yl)-phenylamine (210mg, 1.32mmol), trifluoroacetic acid (847 μL , 11.0mmol) and 1-butanol (10mL). The above mixture was heated at 80°C for 24h. After that time, the mixture was concentrated *in vacuo*, and the residue was dissolved in DMSO for submission for MS-directed purification to obtain brown oil, which was purified again to give the title compound. $^1\text{H NMR}$ (CD_3OD , 400 MHz): δ = 1.52 (s, 9 H), 2.58 (brs, 2 H), 3.68 (brs, 2 H), 4.14 (brs, 2 H), 6.30 (brs, 1 H), 6.68 (s, 1 H), 7.16 (s, 2 H), 7.45 (t, 1 H, J = 8.0 Hz), 7.57–7.60 (m, 1 H), 7.76–7.79 (m, 1 H), 8.21 (t, 1 H, J = 1.6 Hz), 9.26 (s, 1 H). MS (ES⁺): m/z 458.06 (100) [MH^+]. HPLC: t_R = 2.17 min (ZQ2000, polar_5min).

[806] **3-(1*H*-Imidazol-2-yl)-phenylamine**




[807] The compound was obtained from 2-(3-nitrophenyl)-1*H*-imidazole following the procedure for dimethyl- $\{2\text{-}[2\text{-}(3\text{-nitrophenyl})\text{imidazol-1-yl}]\text{ethyl}\}$ amine], except that ethanol was used as solvent. $^1\text{H NMR}$ (DMSO-d_6 , 400 MHz): δ = 5.14 (s, 2 H), 6.52–6.55 (m, 1 H), 6.96 (s, 1 H), 7.02–7.08 (m, 3 H), 7.16–7.21 (m, 2 H). MS (ES⁺): m/z 106.19 (100) [MH^+]. HPLC: t_R = 0.48 min (ZQ2000, polar_5min).

[808] **EXAMPLE 273: 4-{4-[3-(1*H*-Imidazol-2-yl)-phenylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butylamide.**



[809] Into the solution of 4-{4-[3-(1*H*-imidazol-2-yl)-phenylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester (59.4mg, 0.118mmol) in methanol (1.0mL) was added HCl in methanol (9 M, 1.0mL). The above mixture was stirred at rt for 4h. After that time, the mixture was concentrated *in vacuo* and was then suspended in DMF (2mL). Into the above suspension were added triethylamine (159μL, 1.18mmol) and *tert*-butyl isocyanate (14.8μL, 0.130mmol). The above mixture was stirred at rt under an atmosphere of N₂ for 1h. After that time, the mixture was concentrated *in vacuo* to obtain brown oil that was purified by HPLC to yield the title compound. ¹H NMR (CD₃OD, 400 MHz): δ = 1.35 (s, 9 H), 2.55 (brs, 2 H), 3.59 (t, 2 H, *J* = 4.2 Hz), 4.05 (brs, 2 H), 6.28 (brs, 1 H), 6.65 (s, 1 H), 7.13 (d, 2 H, *J* = 1.2 Hz), 7.42 (t, 1 H, *J* = 8.4 Hz), 7.55 (dd, 1 H, *J* = 0.8 & 7.6 Hz), 7.74 (dd, 1 H, *J* = 0.8 & 8.0 Hz), 7.75–8.19 (m, 1 H), 8.23 (d, 1 H, *J* = 1.2 Hz). MS (ES⁺): *m/z* 457.12 (100) [MH⁺]. HPLC: *t_R* = 2.00 min (ZQ2000, polar_5 min).


[810] **EXAMPLE 274:** *tert*-Butyl 4-(4-{3-[3-(2-dimethylaminoethyl)-3*H*-imidazol-4-yl]phenylamino}-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl)-3,6-dihydro-2*H*-pyridine-1-carboxylate.



[811] 3-[3-(2-Dimethylaminoethyl)-3*H*-imidazol-4-yl]phenylamine (110mg, 0.478mmol) was added to a solution of *tert*-butyl 4-(chloro-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl)-3,6-dihydro-2*H*-pyridine-1-carboxylate (133mg, 0.398mmol) in 1-butanol (2.0mL). The reaction was stirred at 120°C for 48h. 0.8mL of 1N HCl in ether was then added and the mixture was stirred further at 120°C for 15h. LC-MS showed the displacement reaction was complete and the BOC group in the desired product was completely removed. Di-*tert*-butyldicarbonate (347mg, 1.59mmol) and *N,N*-diisopropylethylamine (0.347mL, 1.99mmol) were added, and the resulting mixture was stirred at rt for 30min. DMF (≈1.5mL) was added and the mixture was filtered. The filtrate was purified by HPLC purification to give the title compound. ¹H-NMR (CD₃OD, 400 MHz): δ = 1.50 (s, 9 H), 2.52 (s, 6 H), 2.58 (m, 2 H), 3.04 (t, *J* = 6.8 Hz, 2 H), 3.67 (m, 2 H), 4.13 (m, 2 H), 4.53 (t, *J* = 6.8 Hz, 2 H), 6.30 (s, br, 1 H), 6.72 (s, 1 H), 7.18 (s, 1 H), 7.19 (d, *J* = 7.6 Hz, 1 H), 7.48-7.52 (m, 1 H), 7.72 (dd, *J* = 2.4,


8.0 Hz, 1 H), 8.06 (s, 1 H), 8.12 (m, 1 H), 8.26 (s, 1 H). MS (ES⁺): m/z 529 [MH⁺]. HPLC: t_R = 2.00 min (ZQ2000, polar_5min).

[812] 3-[3-(2-Dimethylaminoethyl)-3H-imidazol-4-yl]phenylamine




[813] A solution of dimethyl-{2-[5-(3-nitrophenyl)imidazol-1-yl]ethyl}amine (140mg, 0.54mmol) and 10% Pd/C (80mg) in methanol (8mL) was hydrogenated under 1 atm hydrogen pressure for 5h. The reaction mixture was filtered through a Celite pad. The filtrate was concentrated to dryness to afford the desired amine, which was used directly in the next step without purification. ¹H-NMR (CD₃OD, 400 MHz): δ = 2.15 (s, 6 H), 2.49 (t, J = 6.8 Hz, 2 H), 4.18 (t, J = 7.2 Hz, 2 H), 6.69-6.77 (m, 3 H), 6.91 (d, J = 1.2 Hz, 1 H), 7.18 (dt, J = 1.2, 7.6 Hz, 1 H), 7.44 (d, J = 0.8 Hz, 1 H). MS (ES⁺): m/z 231.29 [MH⁺]. HPLC: t_R = 0.39 min (ZQ2000, polar_5min).

[814] Dimethyl-{2-[5-(3-nitrophenyl)imidazol-1-yl]ethyl}amine



[815] A stirred mixture of 3-[2-(3-nitrophenyl)-2-oxoethyl]-3H-quinazolin-4-one (2.00g, 6.47mmol), *N,N*-dimethyl-1,2-ethanediamine (2.28g, 25.9mmol), and *p*-toluenesulfonic acid (2.23g, 12.9mmol) in xylenes (150mL) was refluxed for 48h. After cooling to rt, water (20mL) and sat. NaHCO₃ (aq) (15mL) were added. Layers were separated, and the aqueous phase was extracted with EtOAc (3 × 50mL). The combined organic phases were dried over MgSO₄, filtered, concentrated, and purified by silica gel chromatography (8% MeOH in CH₂Cl₂) to afford the desired product. ¹H-NMR (CD₃OD, 400 MHz): δ = 2.15 (s, 6 H), 2.54 (t, J = 7.2 Hz, 2 H), 4.22 (t, J = 6.8 Hz, 2 H), 7.15 (d, J = 1.2 Hz, 1 H), 7.74 (t, J = 8.0 Hz, 1 H), 7.89 (dt, J = 2.4, 7.6 Hz, 1 H), 7.90 (s, 1 H), 8.24-8.26 (m, 1 H), 8.30 (s, 1 H). MS (ES⁺): m/z 261.24 [MH⁺]. HPLC: t_R = 0.49 and 0.71 min (ZQ2000, polar_5min).


[816] 3-[2-(3-Nitrophenyl)-2-oxoethyl]-3H-quinazolin-4-one



[817] To a solution of 4(3H)-quinazolinone (2.19g, 15.0 mol) in anhydrous DMF (10mL) was added NaH (60% dispersion in mineral oil, 0.719g, 18.0mmol) in two portions with caution. The mixture was stirred at rt for 30min. 3-Nitrophenacyl bromide (4.39g,


18.0mmol) was added and the resulting suspension was stirred at rt for 16h. Solvent was removed under reduced pressure. To the residue were added water (10mL) and 4 N HCl (aq) to adjust the pH to ≈ 6 . The solid material was collected by filtration, washed with water (20mL) and dichloromethane (3 $\times$ 20mL) to afford the title compound as a white powder. $^1\text{H-NMR}$ (CD_3OD , 400 MHz): δ = 5.70 (d, J = 10.0 Hz, 2 H), 7.60 (d, J = 7.2 Hz, 1 H), 7.76 (d, J = 8.4 Hz, 1 H), 7.86-7.91 (m, 2 H), 8.25 (d, J = 8.0 Hz, 1 H), 8.30 (s, 1 H), 8.51-8.58 (m, 2 H), 8.90 (t, J = 1.2 Hz, 1 H). MS (ES $^+$): m/z 310.06 [MH^+]. HPLC: t_R = 2.90 min (ZQ2000, polar_5min).

[818] **EXAMPLE 275:** *tert*-Butyl 4-{4-[3-(1*H*-benzimidazol-2-yl)phenyl-amino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2*H*-pyridine-1-carboxylate.




[819] The title compound was obtained following the General method for the reaction of amines with *tert*-butyl 4-(4-chloro-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl)-3,6-dihydropyridine-1(2*H*)-carboxylate, using 3-(1*H*-Benzimidazol-2-yl)-phenylamine. $^1\text{H-NMR}$ (CD_3OD , 400 MHz): δ = 1.50 (s, 9 H), 2.58 (m, 2 H), 3.67 (m, 2 H), 4.13 (m, 2 H), 6.31 (s, br, 1 H), 6.72 (s, 1 H), 6.26-6.30 (m, 2 H), 7.54 (t, J = 8.0 Hz, 1 H), 7.63 (m, 2 H), 7.79 (dt, J = 0.8, 8.4 Hz, 1 H), 7.88 (dt, J = 0.8, 8.0 Hz, 1 H), 8.29 (s, 1 H), 8.50 (m, 1 H). MS (ES $^+$): m/z 508.03 [MH^+]. HPLC: t_R = 2.72 min (ZQ2000, polar_5min).

[820] **EXAMPLE 276:** *tert*-Butyl 4-{4-[3-(1-methylpiperidin-4-yl)phenyl-amino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2*H*-pyridine-1-carboxylate.




[821] The title compound was obtained following the General method for the reaction of amines with *tert*-butyl 4-(4-chloro-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl)-3,6-dihydropyridine-1(2*H*)-carboxylate, using 3-(1-methylpiperidin-4-yl)phenylamine. $^1\text{H-NMR}$ (CD_3OD , 400 MHz): δ = 1.49 (s, 9 H), 1.72-1.85 (m, 2 H), 1.93-1.97 (m, 2 H), 2.56 (m, 2 H), 2.74 (s, 3 H), 2.81 (m, 1 H), 3.21 (t, J = 12.8 Hz, 2 H), 3.64 (m, 2 H), 4.11 (m, 2 H), 4.86 (d, J = 13.2 Hz, 2 H), 6.25 (s, br, 1 H), 6.48 (dt, J = 2.4, 8.0 Hz, 1 H), 6.53-6.59 (m, 3 H), 7.05 (t, J = 7.6 Hz, 1 H), 8.12 (s, 1 H). MS (ES $^+$): m/z 489.14 [MH^+]. HPLC: t_R = 2.50 min (ZQ2000, polar_5min).

[822] **3-(1-Methylpiperidin-4-yl)phenylamine**




[823] A dried flask was charged with *tert*-butyl 4-(3-aminophenyl)piperidine-1-carboxylate (0.553g, 2.00mmol). Lithium aluminium hydride (1M in THF, 10mL, 10.0mmol) was added slowly through a syringe under N₂. The resulting mixture was stirred overnight at rt. Water (0.5mL) was cautiously added to quench the reaction. The resulting mixture was filtered. The filtrate was concentrated to dryness to give the title compound as a white solid, which was used without further purification in the next step. ¹H-NMR (CDCl₃, 400 MHz): δ = 1.80-1.85 (m, 2 H), 2.04 (dt, J = 4.0, 11.6 Hz, 2 H), 2.33 (s, 3 H), 2.40 (m, 1 H), 2.98 (m, 2 H), 3.64 (s, br, 2 H), 6.54-6.59 (m, 2 H), 6.66 (d, J = 7.6 Hz, 1 H), 7.10 (t, J = 7.6 Hz, 1 H). MS (ES⁺): m/z 191.26 [MH⁺]. HPLC: t_R = 0.49 min (ZQ2000, polar_5min).

[824] **EXAMPLE 277: *tert*-Butyl 4-[4-(3-piperidin-4-ylphenylamino)-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylate.**



[825] The title compound was also isolated from the above reaction mixture. ¹H-NMR (CD₃OD, 400 MHz): δ = 1.50 (s, 9 H), 1.71-1.80 (m, 2 H), 1.93-1.96 (m, 2 H), 2.56 (m, 2 H), 2.75-2.81 (m, 1 H), 3.21 (dt, J = 2.8, 13.2 Hz, 2 H), 3.64 (m, 2 H), 4.11 (m, 2 H), 4.86 (d, J = 13.2 Hz, 2 H), 6.26 (s, br, 1 H), 6.56-6.64 (m, 4 H), 7.02 (t, J = 7.6 Hz, 1 H), 8.12 (s, 1 H). MS (ES⁺): m/z 475.12 [MH⁺]. HPLC: t_R = 2.43 min (ZQ2000, polar_5min).


[826] **EXAMPLE 278: 4-[4-[4-Fluoro-3-(1-methylpiperidin-4-yl)-phenyl-amino]-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl ester.**



[827] A mixture of 4-(4-chloro-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl ester (167mg, 0.500mmol), 4-fluoro-3-(1-methylpiperidin-4-yl)-phenylamine (149mg, 0.600mmol), *N,N*-dimethylformamide (3mL), and trifluoroacetic acid (385 μ L, 5.18mmol) in a sealed tube was heated at 100°C for 15h. The mixture was concentrated *in vacuo*, charged with sodium bicarbonate (504mg, 6.00mmol), di-*tert*-butyldicarbonate (120mg, 0.550mmol), and *N,N*-dimethylformamide (2mL), and stirred at rt under N₂ for 24h. After that time, the mixture was filtered, and the filtrate was concentrated *in vacuo* to obtain a brown oil, which was dissolved in EtOAc


(30mL) and washed with water (3 × 20mL). The organic phase was concentrated *in vacuo* to obtain a light-brown oil that was purified by HPLC to give the title compound. ¹H NMR (CD₃OD, 400 MHz): δ = 1.51 (s, 9 H), 1.87 (brs, 4 H), 2.13–2.20 (m, 2 H), 2.32 (s, 3 H), 2.54 (brs, 2 H), 2.83–2.91 (m, 1 H), 2.99–3.01 (m, 2 H), 3.65 (brs, 2 H), 4.12 (brs, 2 H), 6.27 (brs, 1 H), 6.56 (s, 1 H), 7.03 (t, 1 H, *J* = 8.8 Hz), 7.57–7.60 (m, 2 H), 8.19 (s, 1 H). MS (ES⁺): *m/z* 507.17 (75) [MH⁺]. HPLC: *t_R* = 2.16 min (ZQ2000, polar_5min).

[828] **4-Fluoro-3-(1-methylpiperidin-4-yl)-phenylamine**




[829] Pd/C (10% w/w, 50% water, 77mg) was added to the solution of 3-fluoro-4-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-phenylamine (386mg, 1.57mmol) in methanol (10mL). The above mixture was degassed and then the H₂ balloon was applied. The mixture was stirred at rt under an atmosphere of H₂ overnight. Additional Pd/C (10%w/w, 50% water, 77mg) was added, and stirring was continued overnight. The mixture was filtered and concentrated *in vacuo* to give the title compound as brown oil that was used for the next reaction without further purification. ¹H NMR (DMSO-*d*₆, 400 MHz): δ = 1.55–1.64 (m, 4 H), 2.05–2.11 (m, 2 H), 2.22 (s, 3 H), 2.54–2.62 (m, 1 H), 2.88–2.97 (m, 2 H), 6.29–6.33 (m, 1 H), 6.38–6.41 (m, 1 H), 6.69–6.73 (m, 1 H). MS (ES⁺): *m/z* 209.29 (100) [MH⁺]. HPLC: *t_R* = 0.46 min (ZQ2000, polar_5 min).

[830] **4-Fluoro-3-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-phenylamine**




[831] A dried flask was charged with 4-(2-fluoro-5-nitrophenyl)-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester (645mg, 2.00mmol) and THF (10mL). Lithium aluminium hydride (1M in THF, 20mL, 20.0mmol) was added slowly through a syringe under N₂ (the reaction was very exothermic). The resulting mixture was stirred for 16h at rt. Water was cautiously added to quench the reaction. The resulting mixture was filtered, and the filtrate was concentrated to dryness to give the title compound as a brown oil. ¹H NMR (DMSO-*d*₆, 400 MHz): δ = 2.14 (s, 3 H), 2.38–2.44 (m, 2 H), 2.89–2.90 (m, 2 H), 3.22 (brs, 2 H), 5.95 (brs, 1 H), 7.24–7.29 (m, 1 H), 7.67–7.73 (m, 2 H), 8.16 (s, 1 H). MS (ES⁺): *m/z* 206.26 (100) [MH⁺]. HPLC: *t_R* = 1.68 min (ZQ2000, polar_5 min).

[832] **4-(2-fluoro-5-nitrophenyl)-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester**




[833] Into a 1-neck round-bottom flask were added 2-bromo-1-fluoro-4-nitrobenzene (1760mg, 8.000mmol), potassium carbonate (2210mg, 16.00mmol), 4-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl ester (2720mg, 8.800mmol), water (8mL) and 1,4-dioxane (32mL). The flask was degassed and filled with N₂ for 3 times, and then [1,1'-bis(diphenylphosphino)ferrocene]-dichloropalladium(II) complex with CH₂Cl₂ (1:1) (330.0mg, 0.4000mmol) was added. The mixture was degassed and filled with N₂ for 3 times again and was then heated at 100°C for 16h. After that time, the mixture was concentrated *in vacuo* and was then purified by silica gel (240 g) eluting with 1800mL of 5%, 1000mL of 10%, 1000mL of 15% and 1000mL of 20% EtOAc/hexane to obtain the title compound as a colorless oil. ¹H NMR (DMSO-*d*₆, 400 MHz): δ = 1.49 (s, 9 H), 2.52 – 2.55 (m, 2 H), 3.60 (t, 2 H, *J* = 5.6 Hz), 4.09 (brs, 2 H), 6.21 (brs, 1 H), 7.55 – 7.60 (m, 1 H), 8.21 – 8.29 (m, 2 H). MS (ES⁺): *m/z* 223.22 (100) [MH⁺ – Boc]. HPLC: *t*_R = 3.83 min (ZQ2000, polar_5min).

[834] **EXAMPLE 279: 4-[4-(3-Methyl-3H-benzimidazol-5-ylamino)-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl ester.**




[835] A mixture of 4-(4-chloro-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl ester (134mg, 0.400mmol) and 3-methyl-3H-benzimidazol-5-ylamine (70.6mg, 0.480mmol) in *n*-BuOH (3mL) in a sealed tube was heated at 120°C for 17h and concentrated *in vacuo* to obtain a brown solid that was purified using the mass-directed purification system to yield the title compound as beige solid. ¹H NMR (CD₃OD, 400 MHz): δ = 1.52 (s, 9 H), 2.57 (brs, 2 H), 3.68 (brs, 2 H), 3.93 (s, 3 H), 4.12 (brs, 2 H), 6.31 (brs, 1 H), 6.65 (brs, 1 H), 7.46 (dd, 1 H, *J* = 2.0 & 8.4 Hz), 7.66 (d, 1 H, *J* = 8.8 Hz), 8.14 – 8.15 (m, 2 H), 8.23 (s, 1 H), 8.24 (brs, 1 H). MS (ES⁺): *m/z* 464.12 (100) [MH⁺]. HPLC: *t*_R = 2.18 min (ZQ2000, polar_5 min).

[836] **3-Methyl-3H-benzimidazol-5-ylamine**




[837] Pd/C (17mg, 10%, with 50% water) was added into the suspension of 1-methyl-6-nitro-1*H*-1,3-benzimidazole (85.0mg, 0.480mmol) in ethanol (3mL). The mixture was degassed and filled with H₂. The mixture was stirred at rt under balloon pressure for 16h. After that time, the mixture was filtered and concentrated *in vacuo* to obtain the title compound as pink crystals. ¹H NMR (CD₃OD, 400 MHz): δ = 3.67 (s, 3 H), 6.69 – 6.73 (m, 2 H), 7.33 (dd, 1 H, *J* = 0.4 & 8.8 Hz), 7.77 (s, 1 H). MS (ES⁺): *m/z* 148.16 (100) [MH⁺]. HPLC: *t_R* = 0.43 min (ZQ2000, polar_5 min).

[838] **EXAMPLE 280: 4-[4-(3-Methyl-3*H*-benzimidazol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butylamide.**



[839] Into the solution of 4-{4-[3-(1*H*-imidazol-2-yl)-phenylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester (**EXAMPLE 279**) (59.4mg, 0.118mmol) in methanol (1.0mL) was added HCl in methanol (9M, 1.0mL). The above mixture was stirred at rt for 4h. After that time, the mixture was concentrated *in vacuo* and suspended in DMF (2mL). Into the above suspension were added triethylamine (159 μ L, 1.18mmol) and *tert*-butyl isocyanate (14.8 μ L, 0.130mmol). The above mixture was stirred at rt under of N₂ for 1h and concentrated *in vacuo* to obtain a brown oil that was purified using the mass-directed purification system to yield the title compound. ¹H NMR (CD₃OD, 400 MHz): δ = 1.37 (s, 9 H), 2.56 (brs, 2 H), 3.61 (t, 2 H, *J* = 4.8 Hz), 3.90 (s, 3 H), 4.07 (brs, 2 H), 5.69 (s, 1 H), 6.29 (brs, 1 H), 6.62 (s, 1 H), 7.43 (dd, 1 H, *J* = 2.0 & 8.8 Hz), 7.63 (d, 1 H, *J* = 8.8 Hz), 8.08 (s, 1 H), 8.11 (d, 1 H, *J* = 2.0 Hz), 8.22 (s, 1 H). MS (ES⁺): *m/z* 445.11 (100) [MH⁺]. HPLC: *t_R* = 2.00 min (ZQ2000, polar_5 min).


[840] **EXAMPLE 281: *tert*-Butyl 4-[4-(benzothiazol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxamide.**



[841] A solution of benzothiazol-5-yl-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl]amine trihydrochloride (23mg, 0.050mmol) and *N,N*-diisopropylethylamine (0.07mL, 0.402mmol) in DMF (2mL) was stirred at rt for 30min. *tert*-Butyl isocyanate (0.012mL, 0.10mmol) was added dropwise through a syringe. The resulting mixture was stirred for 1.5h at rt. MeOH (0.5mL) was added to quench the reaction. The


whole mixture was filtered and purified by HPLC to afford the desired product. ¹H-NMR (DMSO-d₆, 400 MHz): δ = 1.28 (s, 9 H), 2.48 (m, 2 H), 3.53 (m, 2 H), 4.01 (m, 2 H), 5.79 (s, 1 H), 6.43 (s, br, 1 H), 6.84 (s, 1 H), 7.92 (d, J = 8.4 Hz, 1 H), 8.08 (d, J = 8.8 Hz, 1 H), 8.35 (d, J = 1.2 Hz, 1 H), 8.88 (s, 1 H), 9.37 (d, J = 1.2 Hz, 1 H), 9.56 (s, 1 H), 11.99 (s, 1 H). MS (ES⁺): m/z 448.08 [MH⁺]. HPLC: t_R = 2.60 min (ZQ2000, polar_5min).

[842] **Benzothiazol-5-yl-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-*d*]pyrimidin-4-yl]amine trihydrochloride**




[843] To a suspension of *tert*-butyl 4-[4-(benzothiazol-5-ylamino)-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylate (28.3mg, 0.063mmol) in MeOH (3mL) was added 4 N HCl (aq) (3mL). The mixture was stirred at 60°C for 8h. Solvents were removed under reduced pressure to afford the title compound as yellow solid, which was used directly in the next step without purification. ¹H-NMR (DMSO-d₆, 400 MHz): δ = 2.70 (m, 2 H), 3.83 (m, 2 H), 6.45 (s, 1 H), 6.99 (s, 1 H), 7.82 (d, J = 8.4 Hz, 1 H), 8.19 (d, J = 8.8 Hz, 1 H), 8.36 (s, 1 H), 8.68 (s, 1 H), 9.07 (s, 1 H), 9.44 (s, 1 H), 10.32 (s, br, 1 H), 12.51 (s, 1 H). MS (ES⁺): m/z 349.06 [MH⁺]. HPLC: t_R = 1.73 min (ZQ2000, polar_5min).

[844] **EXAMPLE 282: *tert*-Butyl 4-[4-(benzothiazol-5-ylamino)-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylate.**




[845] The title compound was obtained following the General method for the reaction of amines with *tert*-butyl 4-(4-chloro-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl)-3,6-dihydropyridine-1(2H)-carboxylate, using benzothiazol-5-ylamine. ¹H-NMR (CD₃OD, 400 MHz): δ = 1.50 (s, 9 H), 2.58 (m, 2 H), 3.67 (m, 2 H), 4.14 (m, 2 H), 6.31 (s, br, 1 H), 6.73 (s, 1 H), 7.85 (dd, J = 2.4, 8.8 Hz, 1 H), 8.01 (d, J = 8.8 Hz, 1 H), 8.27 (s, 1 H), 8.67 (d, J = 1.6 Hz, 1 H), 9.24 (s, 1 H). MS (ES⁺): m/z 449.02 [MH⁺]. HPLC: t_R = 3.01 min (ZQ2000, polar_5min).

[846] **EXAMPLE 283: 4-[4-(3-Methyl-1H-indazol-5-ylamino)-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl ester.**



[847] A mixture of 4-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl ester (50.1mg, 0.150mmol) and 3-methyl-1H-indazol-5-ylamine (25.0mg, 0.170mmol) in *i*PrOH (2.5mL) in a sealed tube was heated to 90°C (bath temp.) for 16h. The solvent was evaporated, water/NaHCO₃ solution was added, the mixture was extracted with CH₂Cl₂ (3×30mL), and the combined extracts were washed with brine and dried over MgSO₄. The extracts were filtered through a pad of silica gel, washing with 5% MeOH in CH₂Cl₂ until no more product eluted as indicated by TLC. Concentration *in vacuo* gave a light brown solid. The solid was triturated with MeOH, filtered, washed with more MeOH, and dried *in vacuo* overnight. One obtained the title compound as white solid, mp. 245–250°C (decomp.). ¹H NMR (DMSO-*d*₆, 400 MHz): δ = 1.43 (s, 9H), 2.42–2.50 (brs, 2H), 2.47 (s, 3H), 3.53–3.59 (m, 2H), 3.99–4.08 (m, 2H), 6.38 (brs, 1H), 6.73 (brs, 1H), 7.43 (d, *J* = 8.8 Hz, 1H), 7.69 (dd, *J* = 1.6, 8.8 Hz, 1H), 8.15 (s, 1H), 8.23 (s, 1H), 9.32 (s, 1H), 11.88 (brs, 1H), 12.54 (s, 1H). MS (ES⁺): *m/z* 446.0 (100) [MH⁺]. HPLC: *t*_R = 2.4 min (ZQ2000, polar_5min).


[848] **EXAMPLE 284:** 1-{4-[4-(3-Methyl-1H-indazol-5-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-3-piperidin-1-yl-propan-1-one.



[849] Into the suspension of (3-methyl-1H-indazol-5-yl)-[6-(1,2,3,6-tetrahydro pyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-amine tris-hydrochloride (122mg, 0.190mmol), 1-piperidinepropanoic acid (48.4mg, 0.305mmol), *N*-(3-dimethylaminopropyl)-*N'*-ethylcarbodiimide hydrochloride (EDC·HCl) (76.7mg, 0.400mmol) and 1-hydroxy benzotriazole (HOBt·H₂O) (30.6mg, 0.200mmol) in DMF (4.5mL) was added *N,N*-diisopropylethylamine (167μL, 0.952mmol) under N₂ at rt. The reaction mixture, which became a clear wine-red solution, was stirred at rt for 18h. After that time, the reaction mixture was treated with water / saturated NaHCO₃ (5mL/5mL) and extracted with EtOAc (4 × 20mL). The combined extracts were washed with water (2 × 20mL) and brine (20mL), dried over MgSO₄, filtered and concentrated *in vacuo* to obtain a light-brown oil that was purified using the mass-directed purification system to yield the title compound as yellow oil. ¹H NMR (CD₃OD, 400 MHz): δ = 1.69 (brs, 2 H), 1.88 (brs, 4 H), 2.57 (s, 3 H), 2.66 (brs, 2


H), 2.95 – 3.03 (m, 2 H), 3.32 (brs, 4 H), 3.41 (t, 2 H, $J = 6.0$ Hz), 3.76 (t, 1 H, $J = 5.4$ Hz), 3.85 (t, 1 H, $J = 5.6$ Hz), 4.28 (brs, 2 H), 6.30 (d, 1 H, $J = 2.8$ Hz), 6.51 – 6.55 (m, 1 H), 7.49 (d, 1 H, $J = 8.4$ Hz), 7.55 – 7.59 (m, 1 H), 7.98 – 8.00 (m, 1 H), 8.19 (s, 1 H), 8.42 (s, 1 H). MS (ES+): m/z 485.00 (70) [MH^+]. HPLC: $t_R = 1.70$ min (ZQ2000, polar_5 min).

[850] **EXAMPLE 285: (3-Methyl-1H-indazol-5-yl)-[6-(1,2,3,6-tetrahydro-pyridin-4-yl)-7H-pyrrolo[2,3-*d*]pyrimidin-4-yl]-amine tris-hydrochloride.**




[851] To a suspension of 4-[4-(3-methyl-1H-indazol-5-ylamino)-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl ester (488mg, 1.10mmol) in MeOH (10mL) was added hydrogen chloride (9M in MeOH, 2.15mL, 19.4mmol), the mixture was stirred at rt for 3h and concentrated *in vacuo*. The residue was triturated with Et₂O and dried *in vacuo* to give the title compound. MS (ES+): m/z 347.12 (10) [MH^+]. HPLC: t_R (polar-5 mins) = 1.52 min (ZQ2000, polar_5 min). A purified sample was made by Gilson HPLC to record the ¹H NMR spectrum. ¹H NMR (DMSO-*d*₆, 400 MHz): δ = 2.34 (s, 3 H), 2.47 (brs, 2 H), 3.12 (brs, 2 H), 3.60 (brs, 2 H), 6.29 (s, 1 H), 6.92 (s, 1 H), 7.07 (s, 1 H), 7.19 (s, 1 H), 7.25 (d, 1 H, $J = 8.4$ Hz), 7.40 (d, 1 H, $J = 8.4$ Hz), 7.75 (s, 1 H), 8.06 (s, 1 H), 9.27 (brs, 1 H), 12.73 (brs 1 H).

[852] **EXAMPLE 286: 3-Dimethylamino-1-4-[4-(3-methyl-1H-indazol-5-yl-amino)-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-ylpropan-1-one.**




[853] The title compound (yellow solid) was prepared following the procedure for 1-{4-[4-(3-methyl-1H-indazol-5-ylamino)-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-3-piperidin-1-yl-propan-1-one, using 3-dimethylaminopropionic acid. ¹H NMR (400 MHz, MeOH-*d*₄): δ = 2.21 & 2.22 (s, rotamers, 6H), 2.47 (s, 4H), 2.49–2.57 (m, 2H), 2.60 (s, 3H), 3.68 & 3.72 (t, $J = 5.6$ Hz, rotamers, 2H), 4.16 & 4.20 (s, rotamers, 2H), 6.20 (s, 1H), 6.40 & 6.45 (s, rotamers, 1H), 7.38 (d, $J = 8.8$ Hz, 1H), 7.47 (d, $J = 8.8$ Hz, 1H), 7.88 (d, $J = 4.0$ Hz, 1H), 8.08 (s, 1H). MS (ES+): m/z 445.03 (50) [MH^+]. HPLC: $t_R = 1.63$ min (ZQ2000, polar_5min).

[854] **EXAMPLE 287: 3-Imidazol-1-yl-1-{4-[4-(3-methyl-1H-indazol-5-ylamino)-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl}-propan-1-one.**



[855] β -Bromopropionic acid (29.1mg, 0.190mmol), 1*H*-imidazole (19.4mg, 0.286mmol), potassium carbonate (160mg, 1.16mmol) and DMF (3mL) was combined together and stirred at rt for 20h. After that time, (3-methyl-1*H*-indazol-5-yl)-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl]-amine hydrogen chloride tri-salt (122mg, 0.190mmol), *N*-(3-dimethylaminopropyl)-*N'*-ethylcarbodiimide hydrochloride (76.7mg, 0.400mmol), and 1-hydroxybenzotriazole (27.0mg, 0.200mmol) was added into the above reaction mixture and was stirred at rt under an atmosphere of N₂ for 24h. After that time, the mixture was filtered and the filtrate was concentrated *in vacuo*. The residue was dissolved in DMSO for submission to MS-directed purification to obtain the title compound as beige oil. ¹H NMR (DMSO-*d*₆, 400 MHz): δ = 2.54–2.56 (m, 2 H), 2.59 (s, 3 H), 2.97–3.07 (m, 2 H), 3.73 (t, 1 H, *J* = 5.2 Hz), 3.80 (t, 1 H, *J* = 5.6 Hz), 4.25 (brs, 2 H), 4.30–4.33 (m, 2 H), 6.48 (d, 1 H, *J* = 4.0 Hz), 6.80 (d, 1 H, *J* = 18.8 Hz), 6.94 (d, 1 H, *J* = 0.8 Hz), 7.28–7.30 (m, 1 H), 7.52 (d, 1 H, *J* = 8.8 Hz), 7.73 (t, 1 H, *J* = 0.8 Hz), 7.76–7.80 (m, 1 H), 8.23 (dd, 1 H, *J* = 1.2 & 6.8 Hz), 8.32 (d, 1 H, *J* = 2.0 Hz), 9.40 (s, 1 H), 12.01 (brs, 1 H), 12.56 (brs, 1 H). MS (ES⁺): *m/z* 468.11 (10) [MH⁺]. HPLC: *t*_R = 1.62 min (ZQ2000, polar_5 min).


[856] **EXAMPLE 288: 4-[4-(3-Methoxy-1*H*-indazol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester.**



[857] A mixture of 4-(4-chloro-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl)-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester (48.2mg, 0.144mmol) and 5-amino-3-methoxyindazole-1-carboxylic acid *tert*-butyl ester (40.4mg, 0.153mmol) in isopropyl alcohol (3.0mL) in a sealed tube was heated to 85°C (bath temp.) for 16h. LC/MS at that time showed the product (minor), indazole-Boc-product (major), de-Boc product (minor), and both starting materials. The bath temperature was increased to 90°C, and heating was continued for 2d. After reaching rt, di-*tert*-butyldicarbonate (15mg, 0.069mmol) and *N,N*-diisopropylethylamine (0.1mL, 0.6mmol) were added to the reaction mixture, and the now clear solution was stirred at rt for 2h. LC/MS at that time indicated complete conversion of the de-Boc product to the product. 14.8 M of ammonia in Water (2.0mL) was added, and the mixture was stirred at rt overnight and heated to 90 °C for 5h. Sodium hydroxide (6.5mg,


0.16mmol) was added, and heating was continued overnight. Water and sat. NH_4Cl solution were added, the mixture was extracted with CH_2Cl_2 (100mL) and CH_2Cl_2 :MeOH 10:1 (50mL), and the combined organic layers were dried over MgSO_4 . The organic solution was filtered through a plug of silica gel ($\approx 1''$ in a 60mL glass frit), which was further washed with 5% MeOH in CH_2Cl_2 until the entire product was eluted. The solution containing the product was concentrated and dried overnight *in vacuo*. The solid from the aqueous phase was filtered off, washed with water, and dried *in vacuo* overnight. From the precipitate of the aqueous phase, one obtained the title compound as light brown solid. From the silica gel plug filtration, one obtained a light brown solid that was further purified by MDP to give the title compound as off-white solid. ^1H NMR ($\text{DMSO}-d_6$, 400 MHz): $\delta = 1.44$ (s, 9H), 2.42–2.50 (brs, 2H), 3.52–3.60 (m, 2H), 4.00 (s, 3H), 3.98–4.07 (m, 2H), 6.38 (brs, 1H), 6.75 (brs, 1H), 7.34 (d, $J = 8.8$ Hz, 1H), 7.62 (dd, $J = 2.0, 8.8$ Hz, 1H), 8.25 (s, 1H), 8.26 (s, 1H), 9.29 (s, 1H), 11.78 (s, 1H), 11.90 (s, 1H). MS (ES $^+$): m/z 462.0 (100) [MH^+]. HPLC: $t_R = 2.5$ min (ZQ2000, polar_5min).

[858] 5-Amino-3-methoxyindazole-1-carboxylic acid *tert*-butyl ester



[859] 3-Methoxy-5-nitroindazole-1-carboxylic acid *tert*-butyl ester (0.33g, 1.11mmol) and palladium (10% wt) on carbon (0.24g, 20% wt) were dissolved in EtOAc (25mL). The flask was evacuated and filled with N_2 ($\times 5$), then evacuated and filled with hydrogen ($\times 10$) and left over a weekend. The mixture was filtered over celite and the solvents removed *in vacuo*. Purification by column chromatography on silica gel (Jones, 20 g) loading in DCM and eluting in 5:1 Hexanes:EtOAc stepwise to 7:3 Hexanes:EtOAc yielded the title compound as a white powder. ^1H NMR (400 MHz, CDCl_3): $\delta = 1.69$ (s, 9H), 3.73 (brs, 2H), 4.15 (s, 3H), 6.85 (d, $J = 2.0$ Hz, 1H), 6.91 (dd, $J = 8.8, 2.4$ Hz, 1H), 7.74 (brs, 1H). MS (ES $^+$): m/z 164.3 (65) [MH^+] (fragment ion, loss of Boc group).


[860] 3-Methoxy-5-nitroindazole-1-carboxylic acid *tert*-butyl ester



[861] To a pre-dried flask were added 5-nitro-3-oxo-2,3-dihydroindazole-1-carboxylic acid *tert*-butyl ester (0.65g, 2.33mmol), triphenylphosphine (0.92g, 3.50mmol), methanol (115 μL , 2.80mmol) and anhydrous THF (10mL). The flask was evacuated and purged with N_2 then cooled to 0°C and diisopropylazodicarboxylate (690 μL , 3.50mmol) added dropwise over 5min. The mixture was stirred at rt overnight then diluted with EtOAc


and partitioned over water. The organic layer was washed with brine, dried (MgSO_4), filtered and concentrated. Purification by column chromatography on silica gel (Jones, 50g) loading and eluting in DCM revealed the title compound as a white powder. ^1H NMR (400 MHz, CDCl_3): δ = 1.68 (s, 9H), 4.21 (s, 3H), 8.10 (d, J = 8.8 Hz, 1H), 8.39 (dd, J = 9.2 Hz, 2.4 Hz, 1H), 8.61 (d, J = 2.0 Hz, 1H). MS (ES+): m/z 294.3 (20) [MH^+]. The *N*-alkylation product methyl-5-nitro-3-oxo-2,3-dihydroindazole-1-carboxylic acid *tert*-butyl ester was also isolated. ^1H NMR (400 MHz, CDCl_3): δ = 1.68 (s, 9H), 3.69 (s, 3H), 8.02 (d, J = 9.2 Hz, 1H), 8.48 (dd, J = 9.2, 2.4 Hz, 1H), 8.77 (d, J = 2.0 Hz, 1H).

[862] **5-Nitro-3-oxo-2,3-dihydroindazole-1-carboxylic acid *tert*-butyl ester**



[863] A suspension of 5-nitro-1,2-dihydroindazol-3-one (2.00g, 11.2mmol) and di-*tert*-butyl-dicarbonate (3.17g, 14.5mmol) was stirred in anhydrous DCM at 0 °C and DMAP (0.34g, 2.79mmol) was added. The mixture turned deep red in color and after 10 minutes a precipitate had formed. This precipitate was filtered and washed with DCM, then dried *in vacuo* to give the desired product as an off-white powder. ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ = 1.63 (s, 9H), 8.16 (d, J = 9.2 Hz, 1H), 8.42 (dd, J = 9.2, 2.0 Hz, 1H), 8.61 (d, J = 2.4 Hz, 1H), 12.63 (brs, 1H). MS (ES+): m/z 559.3 (100) [MH^+] (dimer).


[864] **EXAMPLE 289: 4-[4-(1-Methyl-1*H*-indazol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester.**



[865] A suspension of 4-(4-chloro-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl)-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester (638.1mg, 1.906mmol, 1eq) and 1-methyl-1*H*-indazol-5-ylamine (567.4mg, 3.855mmol, 2eq) in *n*-BuOH (26mL) was stirred at 120°C for 15h. A white precipitate was filtered off, washed several times with MeOH, and dried under high vacuum, giving the title compound, as a white solid. The filtrate was adsorbed onto Hydromatrix, dry loaded, and purified by chromatography on silica gel [Jones Flashmaster, 20g / 70mL cartridge, eluting with MeOH:DCM 2% → 4% → 6%]. Fractions containing product were combined and concentrated *in vacuo*, affording a second batch of the title compound, as a brown solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ = 1.44 (s, 9H), 2.43–2.53 (m, 2H), 3.57 (t, J = 5.6 Hz, 2H), 4.03 (s, 5H), 6.38 (s, br, 1H), 6.76 (s, br, 1H), 8.60 (d, J = 8.8 Hz, 1H), 7.69 (dd, J = 8.8, 2.0 Hz, 1H), 8.01 (d, J = 0.8 Hz, 1H), 8.26 (s, 1H), 8.39 (d, J =


1.6 Hz, 1H), 9.34 (s, -NH), 11.91 (d, $J = 2.0$ Hz, -NH). MS (ES+): m/z 446.07 (100) [MH^+].
HPLC: $t_R = 2.59$ min (ZQ2000, polar_5min).

[866] **EXAMPLE 290: (1-Methyl-1H-indazol-5-yl)-[6-(1,2,3,6-tetrahydro-pyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-amine tris-hydrochloride.**



[867] A 4.0M solution of HCl in 1,4-dioxane (4.7mL; 20eq) was added to a suspension of 4-[4-(1-methyl-1H-indazol-5-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl ester (415.4mg, 0.9324mmol, 1eq) in 1,4-dioxane (8mL) and stirred at rt for 2h. The solid was filtered off, washed several times with dioxane, and dried under vacuum, yielding the title compound, as a yellow solid. ^1H NMR (400 MHz, DMSO- d_6): $\delta = 2.65$ (s, br, 2H), 3.32 (s, br, 2H), 3.80 (s, br, 2H), 4.11 (s, 3H), 6.50 (s, 1H), 7.04 (s, br, 1H), 7.51 (dd, $J = 8.8, 1.6$ Hz, 1H), 7.83 (d, $J = 9.2$ Hz, 1H), 7.98 (s, 1H), 8.15 (s, 1H), 8.26 (s, 1H), 9.43 (s, br, -NH + -NH), 11.56 (s, br, -NH), 13.09 (s, H^+). MS (ES+): m/z 346.16 (31) [MH^+]. HPLC: $t_R = 1.57$ min (ZQ2000, polar_5min).


[868] **EXAMPLE 291: 4-[4-(1-Methyl-1H-indazol-5-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butylamide.**



[869] To a suspension of (1-methyl-1H-indazol-5-yl)-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-amine tris-hydrochloride (166.8mg, 0.3631mmol, 1eq) in anhydrous DMF (17mL), *N,N*-diisopropylethylamine (DiPEA) (260 μ L, 4.1eq) was added at rt. The solution was then cooled to $-20^\circ C$, after which *tert*-butyl isocyanate (36.5mg, 0.368mmol, 1eq in anhydrous DMF (2mL) was added. The solution was stirred at rt for 1h. The reaction was cooled to $0^\circ C$, after which additional *tert*-butyl isocyanate (11.4mg, 0.115mmol, 0.3eq) in anhydrous DMF (1mL) was added. The reaction was stirred again at rt for 4h. The reaction was quenched with MeOH, concentrated *in vacuo*, and dried under vacuum pressure. The crude material was adsorbed onto Hydromatrix, dry loaded, and purified by chromatography on silica gel [Jones Flashmaster, 5g / 25mL cartridge, eluting with MeOH:DCM 1% $\rightarrow$ 5%]. Fractions containing product were combined and concentrated *in vacuo*. The material was further purified by trituration in MeOH, yielding the title compound as an off-white solid. ^1H NMR (400 MHz, DMSO- d_6): $\delta = 1.28$ (s, 9H), 2.44


(s, br, 2H), 3.52 (t, $J = 5.6$ Hz, 2H), 3.99 (d, $J = 2.0$ Hz, 2H), 4.03 (s, 3H), 5.77 (s, -NH), 6.40 (s, br, 1H), 6.75 (s, 1H), 7.60 (d, $J = 8.8$ Hz, 1H), 7.69 (dd, $J = 8.8, 2.0$ Hz, 1H), 8.01 (s, 1H), 8.26 (s, 1H), 8.39 (s, 1H), 9.32 (s, -NH), 11.89 (s, -NH). MS (ES⁺): m/z 445.07 (100) [MH⁺]. HPLC: $t_R = 2.29$ min (ZQ2000, polar_5min).

[870] **EXAMPLE 292: 1-{4-[4-(1-Methyl-1*H*-indazol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridin-1-yl]-3-piperidin-1-yl-propan-1-one.**




[871] To a suspension of (1-methyl-1*H*-indazol-5-yl)-[6-(1,2,3,6-tetrahydro-pyridin-4-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl]-amine *tris*-hydrochloride (155.3mg, 0.3381mmol, 1eq), 1-piperidinepropanoic acid (150.1mg, 0.9548mmol, 2.8eq), 1-hydroxybenzotriazole (HOBt) (46.7mg, 0.346mmol, 1eq), and PS-carbodiimide (1.37mmol/g loading; 1008.7mg, 1.38mmol, 4eq) in anhydrous DMF (10mL), DiPEA (290μL, 1.7mmol, 5eq) was added and was shaken at rt for 13h. The resin was filtered off and rinsed several times with DMF. The filtrate was concentrated *in vacuo* at medium temp (bath temp: max 42° C), redissolved in MeOH and DCM, and concentrated again under reduced pressure. The crude material was adsorbed onto Hydromatrix, dry loaded, and purified by chromatography on silica gel [Jones Flashmaster, 10g / 70mL cartridge, eluting with MeOH:DCM 5% → 10% → 7N NH₃(MeOH):DCM 3% → 5%]. Fractions containing product were combined and concentrated *in vacuo*, affording the title compound as an off-white solid. ¹H NMR (400 MHz, DMSO-*d*₆): $\delta = 1.30$ – 1.40 (m, 2H), 1.45 – 1.53 (m, 4H), 2.30 – 2.41 (s, br, 4H), 2.41 – 2.63 (m, 6H), 3.69 (t, $J = 5.6$ Hz, 2H), 4.03 (s, 3H), 4.23 & 4.13 (s, br, rotamers, 2H), 6.41 (s, br, 1H), 6.75 & 6.77 (s, br, rotamers, 1H), 7.60 (d, $J = 9.2$ Hz, 1H), 7.69 (dd, $J = 8.8, 2.0$ Hz, 1H), 8.01 (s, 1H), 8.26 (d, $J = 2.0$ Hz, 1H), 8.38 & 8.39 (s, br, rotamers, 1H), 9.34 (s, -NH), 11.90 & 11.93 (s, rotamers, 1H). MS (ES⁺): m/z 485.11 (45) [MH⁺]. HPLC: $t_R = 1.72$ min (ZQ2000, polar_5min).

[872] **EXAMPLE 293: 2-(2-Methoxyethoxy)-1-{4-[4-(1-methyl-1*H*-indazol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridin-1-yl}-ethanone.**




[873] The title compound was obtained following the procedure for 1-{4-[4-(1-methyl-1*H*-indazol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridin-1-yl]-3-piperidin-1-yl}propan-1-one, using (2-methoxyethoxy)-acetic acid, and triturating the crude material once in MeOH, as an off-white solid. ¹H NMR (400 MHz, DMSO-*d*₆): δ = 2.44–2.61 (s, br, rotamers, 2H), 3.25 (s, 3H), 3.45–3.50 (m, 2H), 3.55–3.60 (m, 2H), 3.64 & 3.70 (t, *J* = 5.2 Hz, rotamers, 2H), 4.03 (s, 3H), 4.13 & 4.16 (s, br, rotamers, 2H), 4.20 & 4.24 (s, rotamers, 2H), 6.40 (s, br, 1H), 6.75 & 6.78 (s, br, rotamers, 1H), 7.60 (d, *J* = 8.8 Hz, 1H), 7.67 (dd, *J* = 8.8, 2.0 Hz, 1H), 8.01 (s, 1H), 8.26 (s, 1H), 8.38 & 8.39 (s, br, rotamers, 1H), 9.34 (s, –NH), 11.91 & 11.94 (s, rotamers, –NH). MS (ES⁺): *m/z* 462.08 (100) [MH⁺]. HPLC: *t*_R = 1.99 min (ZQ2000, polar_5min).

[874] **EXAMPLE 294:** {4-[4-(1-Methyl-1*H*-indazol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridin-1-yl}-(4-methylpiperazin-1-yl)-methanone.




[875] To a suspension of (1-methyl-1*H*-indazol-5-yl)-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl]-amine *tris*-hydrochloride (78.1mg, 0.172mmol, 1eq) in DMF (5mL), DiPEA (180μL, 1.0mmol, 6eq) was added. After cooling the suspension to 0°C, 4-methyl-1-piperazinecarbonyl chloride hydrochloride (28.6mg, 0.170mmol, 1eq) in DMF (1.5mL) was added and the reaction was stirred at 0°C for 2h. An additional 0.2eq of 4-methyl-1-piperazinecarbonyl chloride hydrochloride (6.1mg, 0.036mmol) in DMF (1mL) was added and the suspension was stirred again at 0°C for 3h. Still additional acid chloride was needed and 4-methyl-1-piperazinecarbonyl chloride hydrochloride (6.1mg, 0.036mmol, 0.2eq) in DMF (1mL) was added. After 5 h, the reaction was quenched / worked up as follows: reaction solution was added dropwise into water, filtered (M frit), washed with water and then EtOAc, and dried, giving the title compound as an off-white solid. ¹H NMR (400 MHz, DMSO-*d*₆): δ = 2.19 (s, 3H), 2.31 (s, br, 4H), 2.44–2.55 (m, 2H), 3.17 (s, br, 4H), 3.40 (t, *J* = 5.2 Hz, 2H), 3.92 (s, br, 2H), 4.03 (s, 3H), 6.38 (s, br, 1H), 6.75 (s, 1H), 7.60 (d, *J* = 8.4 Hz, 1H), 7.69 (d, *J* = 8.8 Hz, 1H), 8.01 (s, 1H), 8.25 (s, 1H), 8.38 (s, br, 1H), 9.33 (s, –NH), 11.89 (s, –NH). MS (ES⁺): *m/z* 472.14 (9) [MH⁺]. HPLC: *t*_R = 1.68 min (ZQ2000, polar_5min).

[876] **EXAMPLE 295:** 4-4-[2-(2-Dimethylaminoethylamino)-benzothiazol-6-ylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester.




[877] To a suspension of *N'*2'-(2-dimethylaminoethyl)-*N'*6'-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl]-benzothiazole-2,6-diamine (221.1mg, 0.346mmol, 1eq) in anhydrous DCM (5mL) and anhydrous DMF (4mL), DiPEA (425μL, 2.43mmol, 7eq) was added under an atmosphere of N₂. A solution of di-*tert*-butyldicarbonate (78.2mg, 0.355mmol, 1eq) in anhydrous DCM (3mL) and anhydrous DMF (0.5mL) was added via syringe. The reaction was allowed to stir at rt for 2h, after which it was concentrated *in vacuo*. The crude material (352.4mg) was adsorbed onto Hydromatrix, dry loaded, and purified by chromatography on silica gel [Jones Flashmaster, 10g / 70mL cartridge, eluting with neat EtOAc → MeOH:EtOAc 5% → 7*N* NH₃/MeOH:EtOAc 2% → 5%]. Fractions containing product were combined, concentrated *in vacuo*, and further purified by HPLC, affording the title compound as a yellow solid. ¹H NMR (400 MHz, MeOH-*d*₄): δ = 1.50 (s, 9H), 2.33 (s, 6H), 2.54 (s, br, 2H), 2.66 (t, *J* = 6.4 Hz, 2H), 3.59 (t, *J* = 6.4 Hz, 2H), 3.65 (s, br, 2H), 4.12 (s, br, 2H), 6.27 (s, br, 1H), 6.55 (s, 1H), 7.42 (d, *J* = 1.2 Hz, 2H), 8.05 (d, *J* = 0.8 Hz, 1H), 8.17 (s, 1H). MS (ES⁺): *m/z* 534.92 (95) [MH⁺]. HPLC: *t*_R = 2.07 min (ZQ2000, polar_5min).

[878] *N'*2'-(2-Dimethylaminoethyl)-*N'*6'-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl]-benzothiazole-2,6-diamine.




[879] A solution of *N'*2'-(2-dimethylaminoethyl)-benzothiazole-2,6-diamine (64.4mg, 0.267mmol, 1eq), 4-(4-chloro-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl)-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester (95.8mg, 0.286mmol, 1eq), and trifluoroacetic acid (TFA) (104μL, 1.34mmol, 5eq) in 2,2,2-trifluoroethanol (TFE) (4mL), in a sealed tube, was stirred at 100°C for 3.5h and concentrated *in vacuo*, giving the crude title compound. No workup or purification was performed prior to *N*-BOC protection. MS (ES⁺): *m/z* 434.92 (15) [MH⁺]. HPLC: *t*_R = 0.49 & 1.40 min (ZQ2000, polar_5min).

[880] *N'*2'-(2-Dimethylaminoethyl)-benzothiazole-2,6-diamine




[881] To a suspension of *N,N*-dimethyl-*N'*-(6-nitrobenzothiazol-2-yl)-ethane-1,2-diamine (190.3mg, 0.707mmol, 1eq) in MeOH (9mL) and Pd/C (10%, 50% H₂O, 0.06eq), H₂ (g) was introduced into the system and the reaction was allowed to stir for 4h at rt. Pd/C was filtered over a pad of Celite and rinsed with MeOH. The filtrate was concentrated *in vacuo*, yielding the title compound as a hard, yellow, plastic-like solid. ¹H NMR (400 MHz, MeOH-*d*₄): δ = 2.34 (s, 6H), 2.65 (t, *J* = 6.4 Hz, 2H), 3.53 (t, *J* = 6.4 Hz, 2H), 6.72 (dd, *J* = 8.4, 2.4 Hz, 1H), 6.98 (d, *J* = 2.4 Hz, 1H), 7.21 (d, *J* = 8.4 Hz, 1H). MS (ES⁺): *m/z* 237.20 (89) [MH⁺]. HPLC: *t*_R = 0.33 min (ZQ2000, polar_5min).

[882] *N,N*-Dimethyl-*N'*-(6-nitrobenzothiazol-2-yl)-ethane-1,2-diamine



[883] To a solution of 2-bromo-6-nitrobenzothiazole (195.2mg, 0.7384mmol, 1eq) in THF (8mL) *N,N*-dimethyl-1,2-ethanediamine (405 μL, 3.69mmol, 5eq) was added. The reaction was stirred for 1h at rt, after which all solvent was evaporated *in vacuo*. The residue was dissolved in DCM and washed with NaHCO₃ (2×) and brine (1×). The filtrate was dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The yellow crude material was adsorbed onto Hydromatrix and purified by chromatography on silica gel [Jones Flashmaster, 5g / 25mL cartridge, eluting with 1:1 EtOAc:DCM → 3% MeOH:DCM]. Fractions 19-61 were combined and concentrated *in vacuo*, affording the title compound as a yellow solid. ¹H NMR (400 MHz, CDCl₃): δ = 2.29 (s, 6H), 2.60 (t, *J* = 6.0 Hz, 2H), 3.54 (q, br, *J* = 4.8 Hz, 2H), 6.39 (s, br, -NH), 7.52 (d, *J* = 8.8 Hz, 1H), 8.20 (dd, *J* = 8.8, 2.0 Hz, 1H), 8.50 (d, *J* = 2.0 Hz, 1H). MS (ES⁺): *m/z* 267.10 (100) [MH⁺]. HPLC: *t*_R = 1.78 min (ZQ2000, polar_5min).


[884] 2-Bromo-6-nitrobenzothiazole



[885] Into a 150mL beaker, 2-amino-6-nitrobenzothiazole (5.1089g, 25.39mmol, 1eq) was mixed vigorously with phosphoric acid, 85 wt. % (22.6mL, 13eq) at 50 °C. The solution was then cooled to -20°C, using an acetone / dry ice bath. To this, a solution of NaNO₂ (1.943g, 28.16mmol, 1.1eq) in water (5.0mL), also cooled to -20°C, was added slowly over the course of 15min. After 1 h, the resulting suspension was poured over a solution of CuBr (4.593g, 32.02mmol, 1.3eq) in 48% HBr (25.3mL) at rt and was stirred. Additional HBr (≈ 35mL) aided in transfer. After 1h, the mixture was heated at 40°C for 2h. After 2h, the heat was turned off and the reaction continued to stir at rt for 16h. The crude mixture was diluted with water to a final volume of 200mL and was extracted with DCM


(3×). The organics were dried over anhydrous MgSO_4 , filtered, and concentrated under reduced pressure. The crude material was adsorbed onto silica gel, dry loaded, and purified by chromatography on silica gel [Jones Flashmaster, 50g / 150mL cartridge, eluting with DCM/Hex 1:1 → 2:1 → neat DCM]. Fractions containing product were combined, concentrated *in vacuo*, and re-chromatographed to give the title compound as an orange solid. ^1H NMR (400 MHz, CDCl_3): δ = 8.11 (d, J = 9.2 Hz, 1H), 8.38 (dd, J = 9.2, 2.4 Hz, 1H), 8.78 (d, J = 2.0 Hz, 1H). MS (ES+): m/z 258.95/260.96 (100/96) [MH^+]. HPLC: t_R = 3.43 min (ZQ2000, polar_5min).

[886] **EXAMPLE 296: 4-[4-(2-Benzylaminobenzothiazol-6-ylamino)-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl ester.**



[887] The title compound was prepared following the procedure for 4-4-[2-(2-dimethylaminoethylamino)-benzothiazol-6-ylamino]-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl ester, using *N*'2'-benzyl-*N*'6'-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-*d*]pyrimidin-4-yl]-benzothiazole-2,6-diamine, except that additional equivalents (2eq total) of BOC-anhydride were used, no DiPEA was used, and the material was purified only by column chromatography. Yellow gum. ^1H NMR (400 MHz, CDCl_3): δ = 1.49 (s, 9H), 2.42 (br, s, 2H), 3.62 (br, t, J = 5.2 Hz, 2H), 4.14 (br, s, 2H), 4.66 (s, 2H), 5.91 (br, s, 1H), 6.04 (br, s, -NH), 6.18 (br, s, 1H), 7.30–7.44 (m, 6H + -NH), 7.54 (d, J = 8.4 Hz, 1H), 7.95 (br, s, 1H), 8.30 (br, s, 1H), 11.51 (br, s, -NH). MS (ES+): m/z 553.94 (100) [MH^+]. HPLC: t_R = 3.03 min (ZQ2000, polar_5min).


[888] ***N*'2'-Benzyl-*N*'6'-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-*d*]pyrimidin-4-yl]-benzothiazole-2,6-diamine.**



[889] The title compound was prepared following the procedure for *N*'2'-(2-dimethylaminoethyl)-*N*'6'-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-*d*]pyrimidin-4-yl]-benzothiazole-2,6-diamine, using *N*'2'-benzylbenzothiazole-2,6-diamine, except for the following modifications: The reaction was heated for 18h at 100°C. The residue was dissolved in a 5% MeOH:DCM mixture and washed with NaHCO_3 (1×) and brine (1×), dried


over anhydrous Na_2SO_4 , filtered, and concentrated *in vacuo*. Any emulsion was dissolved in additional 5% MeOH:DCM and washed in the same manner. The crude material was adsorbed onto Hydromatrix, dry loaded, and purified by chromatography on silica gel [Jones Flashmaster, 2g / 20mL cartridge, eluting with MeOH:DCM 5% (1–24) → 10% (25–41) → 7N NH_3 /MeOH:DCM 5% (42–57) → 10% (58+)]. Fractions containing product were combined and concentrated under reduced pressure, affording the title compound. ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ = 2.48 (d, J = 2.4 Hz, 2H), 3.06 (t, J = 6.0 Hz, 2H), 3.51 (d, J = 2.8 Hz, 2H), 4.54 (s, 2H), 6.23 (s, br, 1H), 6.45 (s, br, 1H), 7.13–7.20 (m, 1H), 7.22–7.28 (m, 2H), 7.28–7.33 (m, 4H), 7.92–7.97 (m, 1H), 8.07 (s, 1H). MS (ES+): m/z 453.98 (13) [MH^+ –BOC]. HPLC: t_R = 2.11 min (MDP [Waters / Micromass], polar_5min).

[890] ***N'*2'-Benzylbenzothiazole-2,6-diamine**




[891] The title compound was prepared following the procedure for *N'*2'-(2-dimethylaminoethyl)-benzothiazole-2,6-diamine, using benzyl-(6-nitrobenzothiazol-2-yl)-amine. Brown solid. ^1H NMR (400 MHz, CDCl_3): δ = 3.56 (s, br, $-\text{NH}_2$), 4.61 (s, 2H), 5.25 (s, br, $-\text{NH}$), 6.69 (dd, J = 8.4, 2.4 Hz, 1H), 6.93 (d, J = 2.4 Hz, 1H), 7.28–7.42 (m, 6H). MS (ES+): m/z 256.19 (100) [MH^+]. HPLC: t_R = 2.01 min (ZQ2000, polar_5min).

[892] **Benzyl-(6-nitrobenzothiazol-2-yl)-amine**




[893] The title compound was prepared following the procedure for *N,N*-dimethyl-*N'*-(6-nitrobenzothiazol-2-yl)-ethane-1,2-diamine, using benzylamine. Modified workup: Solid that had precipitated during course of reaction (amine salt) was filtered; no aqueous workup was conducted. ^1H NMR (400 MHz, CDCl_3): δ = 4.70 (s, 2H), 6.07 (s, br, $-\text{NH}$), 7.33–7.39 (m, 1H), 7.39–7.42 (m, 4H), 7.51 (d, J = 8.8 Hz, 1H), 8.21 (dd, J = 8.8, 2.4 Hz, 1H), 8.51 (d, J = 2.4 Hz, 1H). MS (ES+): m/z 286.03 (100) [MH^+]. HPLC: t_R = 3.47 min (ZQ2000, polar_5min).

[894] **EXAMPLE 297: 4-[4-(2-Phenethylaminobenzothiazol-6-ylamino)-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl ester.**




[895] The title compound was prepared following the procedure for 4-4-[2-(2-dimethylaminoethoxyamino)-benzothiazol-6-ylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester, using *N*'2'-phenethyl-*N*'6'-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl]-benzothiazole-2,6-diamine. Off-white solid. ¹H NMR (400 MHz, DMSO-*d*₆): δ = 1.43 (s, 9H), 2.43–2.48 (s, br, 2H), 2.92 (t, *J* = 6.8 Hz, 2H), 3.53–3.63 (m, 4H), 4.03 (s, br, 2H), 6.38 (s, br, 1H), 6.73 (s, 1H), 7.19–7.24 (m, 1H), 7.26–7.34 (m, 4H), 7.36 (d, *J* = 8.4 Hz, 1H), 7.52 (dd, *J* = 8.8, 2.4 Hz, 1H), 7.99 (t, *J* = 5.2 Hz, –NH), 8.24 (s, 1H), 8.31 (d, *J* = 2.4 Hz, 1H), 9.30 (s, –NH), 11.90 (s, –NH). MS (ES⁺): *m/z* 567.98 (77) [MH⁺]. HPLC: *t*_R = 3.02 min (ZQ2000, polar_5min).

[896] ***N*'2'-Phenethyl-*N*'6'-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl]-benzothiazole-2,6-diamine.**




[897] The title compound was prepared following the procedure for *N*'2'-(2-dimethylaminoethyl)-*N*'6'-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl]-benzothiazole-2,6-diamine, using *N*'2'-phenethylbenzothiazole-2,6-diamine. MS (ES⁺): *m/z* 467.96 (25) [MH⁺]. HPLC: *t*_R = 2.01 min (ZQ2000, polar_5min).

[898] ***N*'2'-Phenethylbenzothiazole-2,6-diamine**




[899] The title compound was prepared following the procedure for *N*'2'-(2-dimethylaminoethyl)-benzothiazole-2,6-diamine, using (6-nitrobenzothiazol-2-yl)-phenethylamine. Brown gum. ¹H NMR (400 MHz, CDCl₃): δ = 2.98 (t, *J* = 6.8 Hz, 2H), 3.58 (s, br, –NH₂), 3.67 (q, *J* = 6.8 Hz, 2H), 4.92 (s, br, –NH), 6.68 (dd, *J* = 8.4, 2.4 Hz, 1H), 6.94 (d, *J* = 2.4 Hz, 1H), 7.21–7.37 (m, 6H). MS (ES⁺): *m/z* 270.13 (100) [MH⁺]. HPLC: *t*_R = 2.10 min (ZQ2000, polar_5min).

[900] **(6-Nitrobenzothiazol-2-yl)-phenethylamine**




[901] The title compound was prepared following the procedure for *N,N*-dimethyl-*N'*-(6-nitrobenzothiazol-2-yl)-ethane-1,2-diamine, using 4 eq of phenethylamine. Modified workup: Solid that had precipitated during course of reaction (amine salt) was filtered; no aqueous workup was conducted. ¹H NMR (400 MHz, CDCl₃): δ = 3.03 (t, *J* = 6.4 Hz, 3H), 3.77 (q, *J* = 6.4 Hz, 2H), 7.23–7.30 (m, 3H), 7.33–7.38 (m, 2H), 7.52 (d, *J* = 8.8 Hz, 1H), 8.21 (dd, *J* = 8.8, 2.4 Hz, 1H), 8.51 (d, *J* = 2.4 Hz, 1H). MS (ES⁺): *m/z* 300.10 [MH⁺]. HPLC: *t_R* = 3.57 min (ZQ2000, polar_5min).

[902] **EXAMPLE 298: 4-4-[2-(2-Methoxyethylamino)-benzothiazol-6-ylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester.**




[903] The title compound was prepared following the procedure for 4-4-[2-(2-dimethylaminoethylamino)-benzothiazol-6-ylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester, using *N*2'-(2-methoxyethyl)-*N*6'-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl]-benzothiazole-2,6-diamine. Tan solid. ¹H NMR (400 MHz, DMSO-*d*₆): δ = 1.43 (s, 9H), 2.43–2.48 (m, 2H), 3.29 (s, 3H), 3.52 (d, *J* = 2.8 Hz, 4H), 3.56 (t, *J* = 5.6 Hz, 2H), 4.00–4.07 (m, 2H), 6.38 (br, s, 1H), 6.73 (s, 1H), 7.34 (d, *J* = 8.4 Hz, 1H), 7.52 (dd, *J* = 8.8, 2.4, 1H), 8.00 (br, s, –NH), 8.23 (s, 1H), 8.29 (d, *J* = 2.0 Hz, 1H), 9.30 (s, –NH), 11.91 (s, –NH). MS (ES⁺): *m/z* 521.90 (96) [MH⁺]. HPLC: *t_R* = 2.54 min (ZQ2000, polar_5min).

[904] ***N*2'-(2-Methoxyethyl)-*N*6'-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl]-benzothiazole-2,6-diamine.**




[905] The title compound was prepared following the procedure for *N*2'-(2-dimethylaminoethyl)-*N*6'-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl]-benzothiazole-2,6-diamine, using *N*2'-(2-methoxyethyl)-benzothiazole-2,6-diamine, except that the reaction mixture was heated for 45h to 100 °C. MS (ES⁺): *m/z* 421.94 (61) [MH⁺]. HPLC: *t_R* = 0.50 & 1.62 min (ZQ2000, polar_5min).

[906] ***N*2'-(2-Methoxyethyl)-benzothiazole-2,6-diamine**




[907] The title compound was prepared following the procedure for *N*'2'-(2-dimethylaminoethyl)-benzothiazole-2,6-diamine, using (2-methoxyethyl)-(6-nitrobenzothiazol-2-yl)-amine. Pink solid. ^1H NMR (400 MHz, CDCl_3): δ = 3.39 (s, 3H), 3.58 (s, br, $-\text{NH}_2$), 3.62 (s, 4H), 5.26 (s, br, $-\text{NH}$), 6.68 (dd, J = 8.4, 2.4 Hz, 1H), 6.92 (d, J = 2.0 Hz, 1H), 7.35 (d, J = 8.8 Hz, 1H). MS (ES $^+$): m/z 224.21 (100) [MH^+]. HPLC: t_R = 0.49 & 1.05 min (ZQ2000, polar_5min).

[908] **(2-Methoxyethyl)-(6-nitrobenzothiazol-2-yl)-amine**



[909] The title compound was prepared following the procedure for *N,N*-dimethyl-*N'*-(6-nitrobenzothiazol-2-yl)-ethane-1,2-diamine, using 6.78 eq of 2-methoxyethylamine. ^1H NMR (400 MHz, CDCl_3): δ = 3.42 (s, 3H), 3.65 (td, J = 4.4, 0.8 Hz, 2H), 3.70 (t, br, J = 4.4 Hz, 2H), 5.92 (s, br, $-\text{NH}$), 7.53 (d, J = 8.8 Hz, 1H), 8.21 (dd, J = 9.2, 2.4 Hz, 1H), 8.51 (d, J = 2.4 Hz, 1H). MS (ES $^+$): m/z 254.10 (100) [MH^+]. HPLC: t_R = 2.89 min (ZQ2000, polar_5min).


[910] **EXAMPLE 299: *tert*-Butyl 4-[4-(4-methoxy-3-thiazol-5-ylphenylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylate.**



[911] Nitrogen was bubbled through a solution of *tert*-butyl 4-[4-(3-iodo-4-methoxyphenylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylate (109.5 mg, 0.2 mmol), thiazole (85.1 mg, 1.0 mmol), potassium acetate (39.3 mg, 0.4 mmol), and tetrakis(triphenylphosphine)-palladium (23.1 mg, 0.02 mmol) in DMF (0.8 mL) for 3 min. The mixture was then heated to 100 °C and stirred for 17 h. The solvents were removed *in vacuo* and the residue was dissolved in DMF (~2 mL). The DMF solution was filtered and sent to mass-directed HPLC purification to give the title compound. ^1H -NMR (CD_3OD , 400 MHz): δ = 1.50 (s, 9 H), 2.55 (m, 2 H), 3.66 (m, 2 H), 3.98 (s, 3 H), 4.13 (m, 2 H), 6.28 (s, br, 1 H), 6.60 (s, 1 H), 7.17 (d, J = 9.2 Hz, 1 H), 7.68 (dd, J = 2.4, 8.8 Hz, 1 H), 8.06 (d, J = 2.8 Hz, 1 H), 8.20 (s, 1 H), 8.31 (s, 1 H), 8.98 (s, 1 H). MS (ES $^+$): m/z 504.99 (MH^+). HPLC: t_R = 2.95 min (ZQ2000, polar_5min).


The following **EXAMPLES 300–301** are compounds of Formula (I) wherein X = C-CN.

[912] **EXAMPLE 300: 4-[5-Cyano-4-(1*H*-indazol-5-ylamino)-1*H*-pyrrolo[2,3-*b*]pyridin-2-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester.**



[913] To a mixture of 4-[5-bromo-4-(1*H*-indazol-5-ylamino)-1*H*-pyrrolo[2,3-*b*]pyridin-2-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester (8mg, 0.015mmol), DPPF (4.1mg, 0.007mmol), water (0.03mL) and zinc cyanide (3.7mg, 0.031mmol) in acetonitrile (3mL) was added Pd₂dba₃ (3.6mg, 0.004mmol) and the mixture was heated to reflux under N₂ overnight. The reaction mixture was evaporated and the crude product was purified by preparative TLC using 10% methanol in DCM as eluent to afford 4-[5-cyano-4-(1*H*-indazol-5-ylamino)-1*H*-pyrrolo[2,3-*b*]pyridin-2-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester as light gray solid. ¹H NMR (400 MHz, CD₃OD): δ = 8.05 (s, 1H), 7.96 (s, 1H), 7.62 (dd, *J* = 1.8, 0.5 Hz, 1H), 7.50 (s, 1H), 7.27 (dd, *J* = 8.8, 1.9 Hz, 1H), 6.05 (bs, 1H), 5.35 (bs, 1H), 3.93–3.97 (m, 2H), 3.40 (t, *J* = 6.2 Hz, 2H), 2.02–2.07 (m, 2H), 1.37 (s, 9H); MS (ES⁺): *m/z* 455.99 (100) [MH⁺]; HPLC: *t*_R = 2.97 min (ZQ2000, polar_5min).


[914] **4-[5-Bromo-4-(1*H*-indazol-5-ylamino)-1*H*-pyrrolo[2,3-*b*]pyridin-2-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester**



[915] To a mixture of (5-bromo-2-iodo-1*H*-pyrrolo[2,3-*b*]pyridin-4-yl)-(1*H*-indazol-5-yl)-amine (25mg, 0.069mmol), potassium carbonate (19mg, 0.14mmol), tetrakis(triphenylphosphine) palladium (10mg, 0.014mmol) and 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester (21.6mg, 0.069mmol) was added degassed DMF (3mL) and water (0.75mL) and the mixture was heated to reflux for 5h. Water was added to the reaction and filtered. The precipitate was washed with water and the filtrate was extracted with DCM. The precipitate was dissolved in DCM/MeOH mixture (9:1) and combined with the DCM extract and evaporated. The crude product was purified by preparative TLC using 8 % methanol in DCM as eluent to afford the title compound as beige solid. ¹H NMR (400 MHz, CD₃OD): δ = 10.32 (s, 1H), 8.11 (s, 1H), 8.02 (s, 1H), 7.58 (d, *J* = 0.8 Hz, 1H), 7.47 (d, *J* = 8.9 Hz, 1H), 7.26 (dd, *J* = 8.8, 1.9 Hz, 1H),


6.69 (s, 1H), 5.95 (bs, 1H), 5.16 (bs, 1H), 3.99–4.03 (m, 2H), 3.42 (t, $J = 5.4$ Hz, 2H), 2.00–2.07 (m, 2H), 1.39 (s, 9H); MS (ES⁺): m/z 510.89 (100) [MH⁺]; HPLC: $t_R = 2.63$ min (ZQ2000, polar_5min).

[916] **(5-Bromo-2-iodo-1*H*-pyrrolo[2,3-*b*]pyridin-4-yl)-(1*H*-indazol-5-yl)-amine**



[917] To a slurry of a mixture of 1-benzenesulfonyl-5-bromo-4-chloro-2-iodo-1*H*-pyrrolo[2,3-*b*]pyridine and 5-bromo-4-chloro-2-iodo-1-(2-iodobenzenesulfonyl)-1*H*-pyrrolo[2,3-*b*]pyridine (560mg, 1.0mmol) in trifluoroethanol (6mL) was added trifluoroacetic acid (0.041mL, 0.52mmol) and indazole (266mg, 2.0mmol), and the reaction was heated in a sealed tube at 120°C for 4d. Additional indazole (67mg, 0.5mmol) was added twice to the reaction on the second and third days. The reaction was cooled to RT, diluted with methanol (20mL), saturated sodium bicarbonate solution was added (1mL) and evaporated to dryness under reduced pressure. The residue obtained was triturated with methanol:DCM (1:1) mixture and filtered. The filtrate was evaporated and the crude obtained was purified by chromatography on silica gel [Jones Flashmaster, 70g / 150mL cartridge, eluting with DCM:Methanol 100:0 → 96:4], yielding the product, which was triturated with 4:1 methanol:DCM mixture and filtered. The precipitate obtained was dried under vacuum to afford the title compound as an off-white solid. The low polar fractions from the column were combined, evaporated and the residue was stirred with 3N NaOH in methanol (2mL) for 30 min and quenched with saturated ammonium chloride solution (2mL). Water (10mL) was added and filtered to afford additional title compound. MS (ES⁺): m/z 453.63 (100) [MH⁺]; HPLC: $t_R = 2.58$ min (ZQ2000, polar_5min).


[918] **1-Benzenesulfonyl-5-bromo-4-chloro-2-iodo-1*H*-pyrrolo[2,3-*b*]pyridine & 5-Bromo-4-chloro-2-iodo-1-(2-iodobenzenesulfonyl)-1*H*-pyrrolo[2,3-*b*]pyridine**



[919] To a solution of 1-benzenesulfonyl-5-bromo-4-chloro-1*H*-pyrrolo[2,3-*b*]pyridine (2.585g, 6.95mmol) in anhydrous THF (330mL) at –78°C was added LDA (11.6mL, 1.5 M solution, 17.39mmol), and the mixture was stirred for 30min. A solution of iodine (4.854g, 19.12mmol) in THF (20mL) was added and stirring was continued for an additional 2h at –78°C. The reaction was quenched with aqueous sodium thiosulfate solution


and extracted with DCM (4×80mL). The combined DCM layer was washed with brine, dried over anhydrous sodium sulfate and evaporated under reduced pressure. The crude product was purified by chromatography on silica gel [Jones Flashmaster, 70g / 150mL cartridge, eluting with hexane:ethyl acetate 100:0 → 99:2], yielding a mixture of the title compounds. 1-Benzenesulfonyl-5-bromo-4-chloro-2-iodo-1*H*-pyrrolo[2,3-*b*]pyridine: MS (ES⁺): *m/z* 498.58 (100) [MH⁺], HPLC: *t_R* = 7.19 min (ZQ2000, nonpolar_15min). 5-Bromo-4-chloro-2-iodo-1-(2-iodobenzenesulfonyl)-1*H*-pyrrolo[2,3-*b*]pyridine: MS (ES⁺): *m/z* 624.41 (100) [MH⁺], HPLC: *t_R* = 7.58 min (ZQ2000, nonpolar_15min).

[920] 1-Benzenesulfonyl-5-bromo-4-chloro-1*H*-pyrrolo[2,3-*b*]pyridine




[921] To a solution of 5-bromo-4-chloropyrrolopyridine (248mg, 1.07mmol) in THF (5mL) at 0°C was added sodium hydride (39mg, 1.6mmol) and the mixture was stirred for 15min. Benzenesulfonyl chloride (227mg, 1.28mmol) was added and the mixture was allowed to warm to RT and stirred for 4h. Water was added to the reaction mixture and extracted with DCM (3×25mL). The combined DCM layer was washed with brine, dried over anhydrous sodium sulfate and evaporated under reduced pressure. The crude product obtained was purified by chromatography on silica gel [Jones Flashmaster, 50g / 150mL cartridge, eluting with hexane:ethylacetate 100:0 → 95:05], yielding the title compound as colorless solid. ¹H NMR (400 MHz, CDCl₃): δ = 8.50 (s, 1H), 8.16–8.19 (m, 2H), 7.77 (d, *J* = 4.0 Hz, 1H), 7.59–7.64 (m, 1H), 7.49–7.53 (m, 2H), 6.69 (d, *J* = 4.0 Hz, 1H); MS (ES⁺): *m/z* 372.85 (100) [MH⁺]; HPLC: *t_R* = 4.39 min (ZQ2000, nonpolar_7min).

[922] 5-Bromo-4-chloro-1*H*-pyrrolo[2,3-*b*]pyridine




[923] To a solution of 5-bromo-4-chloro-1-triisopropylsilyl-1*H*-pyrrolo[2,3-*b*]pyridine (10.1g, ≈14.0mmol; crude material prepared according to *Tetrahedron Lett.*, **2004**, 45, 2317–2319) in IPA (250mL) at 0°C was added 2N H₂SO₄ (25mL) and the mixture was allowed to warm to RT and stirred overnight. IPA was evaporated at 35 °C and water was added to the residue and neutralized with 2N NaOH. The precipitate formed was filtered, washed with water followed by hexane, and dried under vacuum to yield the title compound as off-white solid. MS (ES⁺): *m/z* 233.01 (100) [MH⁺]; HPLC: *t_R* = 4.51 min (ZQ2000, polar_15min).

[924] **EXAMPLE 301: 4-[4-(Benzothiazol-6-ylamino)-5-cyano-1*H*-pyrrolo[2,3-*b*]pyridin-2-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester.**




[925] To a mixture of 4-[4-(benzothiazol-6-ylamino)-5-bromo-1*H*-pyrrolo[2,3-*b*]pyridin-2-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester (20mg, 0.038mmol), DPPF (10.1mg, 0.018mmol), water (0.04mL) and zinc cyanide (8.9mg, 0.075mmol) in acetonitrile (4mL) was added Pd₂dba₃ (7.0mg, 0.007mmol) and the mixture was heated to reflux under N₂ overnight. The reaction mixture was evaporated, and the crude product was purified by preparative TLC using 7% methanol in DCM as eluent to afford the title compound as light gray solid. ¹H NMR (400 MHz, CDCl₃): δ = 8.98 (s, 1H), 8.22 (s, 1H), 8.10 (d, *J* = 8.6 Hz, 1H), 7.78 (d, *J* = 2.0 Hz, 1H), 7.36 (dd, *J* = 8.6, 2.1 Hz, 1H), 6.95 (s, 1H), 5.93 (bs, 1H), 5.36 (s, 1H), 3.99–4.02 (m, 2H), 3.44 (t, *J* = 5.7 Hz, 2H), 3.42 (d, *J* = 4.9 Hz, 2H), 2.07–2.12 (m, 2H), 1.39 (s, 9H); MS (ES⁺): *m/z* 472.96 (100) [MH⁺]; HPLC: *t_R* = 3.25 min (ZQ2000, polar_5min).

[926] **4-[4-(Benzothiazol-6-ylamino)-5-bromo-1*H*-pyrrolo[2,3-*b*]pyridin-2-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester**




[927] To a mixture (55:45) of benzothiazol-6-yl-[5-bromo-2-(1,2,3,6-tetrahydropyridin-4-yl)-1*H*-pyrrolo[2,3-*b*]pyridin-4-yl]-amine and 5-bromo-4-chloro-2-(1,2,3,6-tetrahydropyridin-4-yl)-1*H*-pyrrolo[2,3-*b*]pyridine (101mg, 0.272mmol) in THF (5mL) was added triethylamine (83mg, 0.816mmol), DMAP (5mg) and (Boc)₂O (47mg, 0.215mmol) and the reaction was stirred overnight at RT under N₂. The solvent was evaporated and the residue was purified by preparative TLC using 4% methanol in DCM as eluent to afford a mixture of 4-(5-bromo-4-chloro-1*H*-pyrrolo[2,3-*b*]pyridin-2-yl)-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester and the title compound. 4-[4-(Benzothiazol-6-ylamino)-5-bromo-1*H*-pyrrolo[2,3-*b*]pyridin-2-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester: ¹H NMR (400 MHz, CDCl₃): δ = 8.98 (s, 1H), 8.19 (s, 1H), 8.11 (d, *J* = 8.6 Hz, 1H), 7.75 (d, *J* = 2.0 Hz, 1H), 7.37 (dd, *J* = 8.7, 2.1 Hz, 1H), 6.81 (s, 1H), 6.15 (bs, 1H), 5.51 (s, 1H), 4.90–4.15 (m, 2H), 3.54 (t, *J* = 5.3 Hz, 2H), 2.95 (s, 1H), 2.88 (s, 1H), 2.17–2.25 (m, 2H), 1.47 (s, 9H); MS (ES⁺): *m/z* 527.84 (100) [MH⁺]; HPLC: *t_R* = 3.30 min (ZQ2000, polar_5min).

[928] Benzothiazol-6-yl-[5-bromo-2-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl]-amine




[929] To a slurry of 4-(5-bromo-4-chloro-1H-pyrrolo[2,3-b]pyridin-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl ester (120mg, 0.29mmol) in trifluoroethanol (9mL) were added trifluoroacetic acid (0.112mL, 1.46mmol) and 6-benzothiazolamine (58mg, 1.5mmol), and the reaction was heated in a sealed tube at 120°C for 6d. Additional 6-benzothiazolamine (39mg, 0.29mmol) was added twice to the reaction mixture on the third and fifth days. The reaction was cooled to RT, diluted with methanol (20mL), saturated sodium bicarbonate solution was added (1mL) and evaporated to dryness under reduced pressure. The residue was triturated with methanol:DCM (1:1) mixture and filtered. The filtrate was evaporated and the crude product was purified by preparative TLC using 25% methanol in DCM to afford a mixture of benzothiazol-6-yl-[5-bromo-2-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl]-amine and 5-bromo-4-chloro-2-(1,2,3,6-tetrahydro-pyridin-4-yl)-1H-pyrrolo[2,3-b]pyridine as beige solid. Benzothiazol-6-yl-[5-bromo-2-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl]-amine: MS (ES⁺): *m/z* 427.79 (100) [MH⁺], HPLC: *t_R* = 2.12 min (ZQ2000, polar_5min). 5-Bromo-4-chloro-2-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrrolo[2,3-b]pyridine MS (ES⁺): *m/z* 313.85 (100) [MH⁺], HPLC: *t_R* = 2.30 min (ZQ2000, polar_5min).

[930] 4-(5-Bromo-4-chloro-1H-pyrrolo[2,3-b]pyridin-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl ester



[931] To a mixture of 5-bromo-4-chloro-2-iodo-1H-pyrrolo[2,3-b]pyridine (46mg, 0.12mmol), potassium carbonate (36mg, 0.25mmol), dichlorobis-(triphenylphosphine)palladium (9mg, 0.01mmol) and 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl ester (42mg, 0.13mmol) were added degassed dioxane (4mL) and water (1mL), and the mixture was heated to reflux for 5h. The reaction was evaporated under reduced pressure and the residue was dissolved in DCM and filtered. The DCM filtrate was evaporated and the crude product obtained was purified by chromatography on silica gel [Jones Flashmaster, 20g / 70mL cartridge, eluting with DCM:methanol 100:0 → 99.5:0.5], yielding the title compound. MS (ES⁺): *m/z* 413.84 (100) [MH⁺]; HPLC: *t_R* = 6.95 min (ZQ2000, nonpolar_15min).

[932] 5-Bromo-4-chloro-2-iodo-1*H*-pyrrolo[2,3-*b*]pyridine

[933] To a solution of a 4:6 mixture of 1-benzenesulfonyl-5-bromo-4-chloro-2-iodo-1*H*-pyrrolo[2,3-*b*]pyridine and 5-bromo-4-chloro-2-iodo-1-(2-iodobenzenesulfonyl)-1*H*-pyrrolo[2,3-*b*]pyridine (100mg, 0.178mmol) in THF (4mL) was added 3N NaOH in methanol (1mL), and the mixture was stirred at RT for 30min. The reaction was quenched with saturated ammonium chloride solution (2mL), water (5mL) was added, and the mixture was filtered. The precipitate obtained was washed with water (3×10mL) followed by hexane (3×10mL) and dried under vacuum to yield the title compound as white solid. ¹H NMR (400 MHz, CD₃OD): δ = 8.21 (s, 1H), 6.74 (s, 1H); MS (ES⁺): *m/z* 358.75 (100) [MH⁺]; HPLC: *t_R* = 5.68 min (ZQ2000, nonpolar_15min).

In vitro activity

[934] All kinases described in the assays below were recombinant and generated at Upstate (Dundee, UK) except for the KDR assay. Assays were run within 15μM of the apparent *K_m* for ATP where determined, or at 100μM ATP. For each enzyme, 1U activity is defined as the incorporation of 1nmol phosphate into the appropriate substrate for a given kinase per minute at 30°C with a final ATP concentration of 100μM.

[935] Assay ATP concentrations for individual kinases are included in the text.

[936] Abl (human) – 45μM ATP: In a final reaction volume of 25μL, Abl (h) (5-10mU) is incubated with 8mM MOPS pH 7.0, 0.2mM EDTA, 50μM EAIYAAPFAKKK, 10mM MgAcetate and [γ-33P-ATP] (specific activity approx. 500cpm/pmol, concentration as required). The reaction is initiated by the addition of the mgATP mix. After incubation for 40min at rt, the reaction is stopped by the addition of 5μL of a 3% phosphoric acid solution. Then, 10μL of the reaction is spotted onto a P30 filtermat and washed three times for 5min in 75mM phosphoric acid and once in methanol prior to drying and scintillation counting.

[937] Aurora-A (human) - 15μM ATP: In a final reaction volume of 25μL, Aurora-A (h) (5-10mU) is incubated with 8mM MOPS pH 7.0, 0.2mM EDTA, 200μM LRRASLG (Kemptide), 10mM MgAcetate and [γ-33P-ATP] (specific activity approx. 500cpm/pmol, concentration as required). The reaction is initiated by the addition of the mgATP mix. After incubation for 40min at rt, the reaction is stopped by the addition of 5μL of a 3% phosphoric acid solution. 10μL of the reaction is then spotted onto a P30 filtermat and washed three times for 5min in 50mM phosphoric acid and once in methanol prior to drying and scintillation counting.

[938] Blk (mouse) - 120μM ATP: In a final reaction volume of 25μL, Blk (m) (5-10mU) is incubated with 50mM Tris pH 7.5, 0.1mM EGTA, 0.1mM Na₃VO₄, 0.1% β-

mercaptoethanol, 0.1mg/mL poly(Glu, Tyr) 4:1, 10mM MgAcetate and [γ -33P-ATP] (specific activity approx. 500cpm/pmol, concentration as required). The reaction is initiated by the addition of themgATP mix. After incubation for 40min at rt, the reaction is stopped by the addition of 5 μ L of a 3% phosphoric acid solution. 10 μ L of the reaction is then spotted onto a Filtermat A and washed three times for 5min in 75mM phosphoric acid and once in methanol prior to drying and scintillation counting.

[939] Bmx (human) - 45 μ M ATP: In a final reaction volume of 25 μ L, Bmx (h) (5-10mU) is incubated with 8mM MOPS pH 7.0, 0.2mM EDTA, 0.1mg/ml poly(Glu, Tyr) 4:1, 10mM MgAcetate and [γ -33P-ATP] (specific activity approx. 500cpm/pmol, concentration as required). The reaction is initiated by the addition of themgATP mix. After incubation for 40min at rt, the reaction is stopped by the addition of 5 μ L of a 3% phosphoric acid solution. 10 μ L of the reaction is then spotted onto a Filtermat A and washed three times for 5min in 75mM phosphoric acid and once in methanol prior to drying and scintillation counting.

[940] CaMKII (rat) - 15 μ M ATP: In a final reaction volume of 25 μ L, CaMKII (r) (5-10mU) is incubated with 40mM HEPES pH 7.4, 5mM CaCl₂, 30 μ g/ml calmodulin, 30 μ M KKLNRNLTSLVA, 10mM MgAcetate and [γ -33P-ATP] (specific activity approx. 500cpm/pmol, concentration as required). The reaction is initiated by the addition of themgATP mix. After incubation for 40min at rt, the reaction is stopped by the addition of 5 μ L of a 3% phosphoric acid solution. 10 μ L of the reaction is then spotted onto a P30 filtermat and washed three times for 5min in 75mM phosphoric acid and once in methanol prior to drying and scintillation counting.

[941] c-RAF (human) - 45 μ M ATP: In a final reaction volume of 25 μ L, c-RAF (h) (5-10mU) is incubated with 25mM Tris pH 7.5, 0.02mM EGTA, 0.66mg/mL myelin basic protein, 10mM MgAcetate and [γ -33P-ATP] (specific activity approx. 500cpm/pmol, concentration as required). The reaction is initiated by the addition of themgATP mix. After incubation for 40min at rt, the reaction is stopped by the addition of 5 μ L of a 3% phosphoric acid solution. 10 μ L of the reaction is then spotted onto a P30 filtermat and washed three times for 5min in 75mM phosphoric acid and once in methanol prior to drying and scintillation counting.

[942] cSRC (human) - 200 μ M ATP: In a final reaction volume of 25 μ L, cSRC (h) (5-10mU) is incubated with 8mM MOPS pH 7.0, 0.2mM EDTA, 250 μ M KVEKIGEGTYGVVYK (Cdc2 peptide), 10mM MgAcetate and [γ -33P-ATP] (specific activity approx. 500cpm/pmol, concentration as required). The reaction is initiated by the addition of themgATP mix. After incubation for 40min at rt, the reaction is stopped by the addition of 5 μ L of a 3% phosphoric acid solution. 10 μ L of the reaction is then spotted onto a P30 filtermat and washed three times for 5min in 75mM phosphoric acid and once in methanol prior to drying and scintillation counting.

[943] EGFR (human) - 10 μ M ATP: In a final reaction volume of 25 μ L, EGFR (h) (5-10mU) is incubated with 8mM MOPS pH 7.0, 0.2mM EDTA, 10mM MnCl₂, 0.1mg/mL poly(Glu, Tyr) 4:1, 10mM MgAcetate and [γ -33P-ATP] (specific activity approx. 500cpm/pmol, concentration as required). The reaction is initiated by the addition of themgATP mix. After incubation for 40min at rt, the reaction is stopped by the addition of 5 μ L of a 3% phosphoric acid solution. 10 μ L of the reaction is then spotted onto a Filtermat A and washed three times for 5min in 75mM phosphoric acid and once in methanol prior to drying and scintillation counting.

[944] FGFR3 (human) - 15 μ M ATP: In a final reaction volume of 25 μ L, FGFR3 (h) (5-10mU) is incubated with 8mM MOPS pH 7.0, 0.2mM EDTA, 0.1mg/mL poly(Glu, Tyr) 4:1, 10mM MnCl₂, 10mM MgAcetate and [γ -33P-ATP] (specific activity approx. 500cpm/pmol, concentration as required). The reaction is initiated by the addition of themgATP mix. After incubation for 40min at rt, the reaction is stopped by the addition of 5 μ L of a 3% phosphoric acid solution. 10 μ L of the reaction is then spotted onto a Filtermat A and washed three times for 5min in 75 mM phosphoric acid and once in methanol prior to drying and scintillation counting.

[945] Flt3 (human) - 200 μ M ATP: In a final reaction volume of 25 μ L Flt3 (h) (5-10mU) is incubated with 8mM MOPS pH 7.0, 0.2mM EDTA, 50 μ M EAIYAAPFAKKK, 10mM MgAcetate and [γ -33P-ATP] (specific activity approx. 500cpm/pmol, concentration as required). The reaction is initiated by the addition of themgATP mix. After incubation for 40min at rt, the reaction is stopped by the addition of 5 μ L of a 3% phosphoric acid solution. 10 μ L of the reaction is then spotted onto a P30 filtermat and washed three times for 5min in 75mM phosphoric acid and once in methanol prior to drying and scintillation counting.

[946] GSK3 β (human) - 15 μ M ATP: In a final reaction volume of 25 μ L, GSK3 β (h) (5-10mU) is incubated with 8mM MOPS pH 7.0, 0.2mM EDTA, 20 μ M YRRAAVPPSPSLSRHSSPHQS(p)EDEEE (phospho GS2 peptide), 10mM MgAcetate and [γ -33P-ATP] (specific activity approx. 500cpm/pmol, concentration as required). The reaction is initiated by the addition of themgATP mix. After incubation for 40min at rt, the reaction is stopped by the addition of 5 μ L of a 3% phosphoric acid solution. 10 μ L of the reaction is then spotted onto a P30 filtermat and washed three times for 5min in 50mM phosphoric acid and once in methanol prior to drying and scintillation counting.

[947] Lck (human) - 90 μ M ATP: In a final reaction volume of 25 μ L, Lck (h) (5-10mU) is incubated with 50mM Tris pH 7.5, 0.1mM EGTA, 0.1mM Na₃VO₄, 250 μ M KVEKIGEGTYGVVYK (Cdc2 peptide), 10mM MgAcetate and [γ -33P-ATP] (specific activity approx. 500cpm/pmol, concentration as required). The reaction is initiated by the addition of themgATP mix. After incubation for 40min at rt, the reaction is stopped by the addition of 5 μ L of a 3% phosphoric acid solution. 10 μ L of the reaction is then spotted onto a

P30 filtermat and washed three times for 5min in 75mM phosphoric acid and once in methanol prior to drying and scintillation counting.

[948] MEK1 (human) - 10 μ M ATP: In a final reaction volume of 25 μ L, MEK1 (h) (1-5mU) is incubated with 50mM Tris pH 7.5, 0.2mM EGTA, 0.1% β -mercaptoethanol, 0.01% Brij-35, 1 μ M inactive MAPK2 (m), 10mM MgAcetate and cold ATP (concentration as required). The reaction is initiated by the addition of themgATP. After incubation for 40min at rt, 5 μ L of this incubation mix is used to initiate a MAPK2 (m) assay. In a final reaction volume of 25 μ L, MAPK2 (h) (5-10mU) is incubated with 25mM Tris pH 7.5, 0.02mM EGTA, 0.33mg/mL myelin basic protein, 10mM MgAcetate and [γ -33P-ATP] (specific activity approx. 500cpm/pmol, concentration as required). The reaction is initiated by the addition of themgATP mix. After incubation for 40min at rt, the reaction is stopped by the addition of 5 μ L of a 3% phosphoric acid solution. 10 μ L of the reaction is then spotted onto a P30 filtermat and washed three times for 5min in 75mM phosphoric acid and once in methanol prior to drying and scintillation counting.

[949] PDK1 (human) - 10 μ M ATP: In a final reaction volume of 25 μ L, PDK1 (h) (5-10mU) is incubated with 50mM Tris pH 7.5, 100 μ M KTFCGTPEYLAPEVRREPRILSEEEQEMFRDFDYIADWC (PDKtide), 0.1% β -mercaptoethanol, 10mM MgAcetate and [γ -33P-ATP] (specific activity approx. 500cpm/pmol, concentration as required). The reaction is initiated by the addition of themgATP mix. After incubation for 40min at rt, the reaction is stopped by the addition of 5 μ L of a 3% phosphoric acid solution. 10 μ L of the reaction is then spotted onto a P30 filtermat and washed three times for 5min in 75mM phosphoric acid and once in methanol prior to drying and scintillation counting.

[950] PRK2 (human) - 15 μ M ATP: In a final reaction volume of 25 μ L, PRK2 (h) (5-10 mU) is incubated with 50mM Tris pH 7.5, 0.1mM EGTA, 0.1% β -mercaptoethanol, 30 μ M AKRRRLSSLRA, 10 mM MgAcetate and [γ -33P-ATP] (specific activity approx. 500cpm/pmol, concentration as required). The reaction is initiated by the addition of themgATP mix. After incubation for 40min at rt, the reaction is stopped by the addition of 5 μ L of a 3% phosphoric acid solution. 10 μ L of the reaction is then spotted onto a P30 filtermat and washed three times for 5min in 75mM phosphoric acid and once in methanol prior to drying and scintillation counting.

[951] Ret (human) - 70 μ M ATP: In a final reaction volume of 25 μ L, Ret (h) (5-10mU) is incubated with 8mM MOPS pH 7.0, 0.2mM EDTA, 0.25mM KKKSPGEYVNIEFG, 10mM MgAcetate and [γ -33P-ATP] (specific activity approx. 500cpm/pmol, concentration as required). The reaction is initiated by the addition of themgATP mix. After incubation for 40min at rt, the reaction is stopped by the addition of 5 μ L of a 3% phosphoric acid solution. 10 μ L of the reaction is then spotted onto a P30

filtermat and washed three times for 5min in 75mM phosphoric acid and once in methanol prior to drying and scintillation counting.

[952] p70S6K (human) - 15 μ M ATP: In a final reaction volume of 25 μ L, p70S6K (h) (5-10mU) is incubated with 8mM MOPS pH 7.0, 0.2mM EDTA, 100 μ M KKRNRRLTV, 10mM MgAcetate and [γ -33P-ATP] (specific activity approx. 500cpm/pmol, concentration as required). The reaction is initiated by the addition of themgATP mix. After incubation for 40min at rt, the reaction is stopped by the addition of 5 μ L of a 3% phosphoric acid solution. 10 μ L of the reaction is then spotted onto a P30 filtermat and washed three times for 5min in 75mM phosphoric acid and once in methanol prior to drying and scintillation counting.

[953] SGK (human) - 90 μ M ATP: In a final reaction volume of 25 μ L, SGK (h) (5-10mU) is incubated with 8mM MOPS pH 7.0, 0.2mM EDTA, 30 μ M GRPRTSSFAEGKK, 10mM MgAcetate and [γ -33P-ATP] (specific activity approx. 500cpm/pmol, concentration as required). The reaction is initiated by the addition of themgATP mix. After incubation for 40min at rt, the reaction is stopped by the addition of 5 μ L of a 3% phosphoric acid solution. 10 μ L of the reaction is then spotted onto a P30 filtermat and washed three times for 5min in 75mM phosphoric acid and once in methanol prior to drying and scintillation counting.

[954] Tie2 (human) - 200 μ M ATP: In a final reaction volume of 25 μ L, Tie2 (h) (5-10mU) is incubated with 8mM MOPS pH 7.0, 0.2mM EDTA, 0.5mM MnCl₂, 0.1mg/mL poly(Glu, Tyr) 4:1, 10mM MgAcetate and [γ -33P-ATP] (specific activity approx. 500cpm/pmol, concentration as required). The reaction is initiated by the addition of themgATP mix. After incubation for 40min at rt, the reaction is stopped by the addition of 5 μ L of a 3% phosphoric acid solution. 10 μ L of the reaction is then spotted onto a Filtermat A and washed three times for 5min in 75mM phosphoric acid and once in methanol prior to drying and scintillation counting.

[955] KDR (human) - 18 μ M ATP: 96-well plates are coated with 0.5 μ g/75 μ L/well poly(Glu, Tyr) over night at 37°C. 50 μ L per well of 50mM Hepes, pH7.4, 125mM NaCl, 24mM MgCl₂, and 18 μ M ATP $\pm$ compounds are added. The reaction is initiated by the addition of 30 μ L (5ng) KDR (Prokinase) diluted in assay buffer. After incubation for 30min at rt, the plates are washed and phosphor Tyr detected using pY-20 HRP conjugated antibody with subsequent development using ABTS reagent (KPL) and detection by absorbance at 405nm.

[956] The **EXAMPLES 1-81**, except for **EXAMPLES 2, 3, 4, 8, 11-14, 21, 22, 24, 32, 34, 78, and 79** - for which limited assay results are available - inhibit at least two of the Abl, Aurora-A, Blk, c-Raf, cSRC, Src, PRK2, FGFR3, Flt3, Lck, Mek1, PDK-1, GSK3 β , EGFR, p70S6K, BMX, SGK, CaMKII, Tie-2, Ret, and KDR kinases at an IC₅₀ of greater than 50% inhibition at 10 μ M to 14nM. It is advantageous that the measured IC₅₀ be lower than 10 μ M. It is still more advantageous for the IC₅₀ to be lower than 5 μ M. It is even more

advantageous for the IC_{50} to be lower than $0.5\mu M$. It is yet more advantageous for the IC_{50} to be lower than $0.05\mu M$.

[957] Someone skilled in the art will appreciate that other assay formats may be used in place of those described above. For example, AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology was used with the kinases described below. Assay ATP concentrations for individual kinases are included in the text.

[958] KDR (human) – $100\mu M$ ATP: $9\mu L$ of the reaction mix containing ATP at the desired concentration, biotinylated poly(Glu,Tyr) ($84ng/mL$) and $0.334mM$ vanadate in assay buffer ($50mM$ HEPES ($pH = 7.4$), $12.5mM$ $MgCl_2$ and 1% glycerol) are added to a well of a 384 well plate along with $1\mu L$ of compound (or vehicle control, usually DMSO). DMSO concentration is controlled at a concentration of 1% . KDR is diluted to the optimized concentration (optimized on a lot-by-lot basis) in an enzyme diluent buffer ($50mM$ HEPES $pH = 7.4$, $12.5mM$ $MgCl_2$ and 1% glycerol, 0.03% Brij35 and $0.3mM$ EGTA). $5\mu L$ of this solution are then added to the well, and the complete reaction mixture is incubated for 60min at RT. In subdued light, $5\mu L$ of PT66 donor and acceptor beads (diluted 1:200 from manufacturers provision in a $25mM$ Tris HCl ($pH = 7.5$), $200mM$ NaCl, $100mM$ EDTA, 0.3% BSA buffer) are added to the wells. The plates are then incubated for 4h and read on an AlphaQuest plate reader.

[959] IGF-1R (human) – $100\mu M$ ATP: To a well of a 384 well plate are added $9\mu L$ of the reaction mix containing ATP at the desired concentration, biotinylated poly(Glu,Tyr) ($84ng/mL$) and $0.334mM$ vanadate in assay buffer ($50mM$ HEPES ($pH = 7.4$), $12.5mM$ $MgCl_2$ and 1% glycerol) along with $1\mu L$ of compound (or vehicle control, usually DMSO). DMSO concentration is controlled at a concentration of 1% . IGF-1R is diluted to the optimized concentration (optimized on a lot-by-lot basis) in an enzyme diluent buffer ($50mM$ HEPES $pH = 7.4$, $12.5mM$ $MgCl_2$ and 1% glycerol, 0.03% Brij35, $0.3mM$ EGTA, $6mM$ DTT, and 0.003% BSA). $5\mu L$ of this solution are then added to the well, and the complete reaction mixture is incubated for 60min at RT. In subdued light, $5\mu L$ of PT66 donor and acceptor beads (diluted 1:200 from manufacturer's provision in a $25mM$ Tris HCl ($pH = 7.5$), $200mM$ NaCl, $100mM$ EDTA, 0.3% BSA buffer) are added to the wells. The plates are then incubated for 4h and read on an AlphaQuest plate reader.

[960] Ron (human) – $100\mu M$ ATP: To a well of a 384 well plate are added $9\mu L$ of the reaction mix containing ATP at the desired concentration, biotinylated poly(Glu,Tyr) ($200ng/mL$) and $0.334mM$ vanadate in assay buffer ($50mM$ HEPES ($pH = 7.4$), $12.5mM$ $MgCl_2$ and 1% glycerol) along with $1\mu L$ of compound (or vehicle control, usually DMSO). DMSO concentration is controlled at a concentration of 1% . Ron is diluted to the optimized concentration (optimized on a lot-by-lot basis) in an enzyme diluent buffer ($50mM$ HEPES $pH = 7.4$, $12.5mM$ $MgCl_2$ and 1% glycerol, 0.03% Brij35, $0.3mM$ EGTA, $1mM$ DTT, and

0.003% BSA). 5 μ L of this solution are then added to the well, and the complete reaction mixture is incubated for 60min at RT. In subdued light, 5 μ L of PT66 donor and acceptor beads (diluted 1:160 from manufacturer's provision in a 25mM Tris HCl (pH = 7.5), 200mM NaCl, 100 mM EDTA, 0.3% BSA buffer) are added to the wells. The plates are then incubated for 4h and read on an AlphaQuest plate reader.

[961] EGFR (human) – 4 μ M ATP: To a well of a 384 well plate are added 1 μ L of compound (or vehicle control, usually DMSO; DMSO concentration is controlled at a concentration of 1%), followed by 9 μ L of the reaction mix (ATP, at the desired concentration, is added diluted in assay buffer (50mM HEPES (pH = 7.4), 12.5mM MgCl₂ and 1% glycerol), containing 69.4mM NaCl, biotinylated poly(Glu,Tyr) (84.5ng/mL) and 0.334 mM vanadate). EGFR is diluted to the optimized concentration (optimized on a lot-by-lot basis) in an enzyme diluent buffer (50mM HEPES pH = 7.4, 12.5 mM MgCl₂ and 1% glycerol, 0.3% Brij35 and 0.3mM EGTA) and Stablecoat (SurModics), and DTT is also added for a concentration of 3mM. 5 μ L of this solution are then added to the well, and the complete reaction mixture is incubated for 20min at RT. In subdued light, 5 μ L of PT66 donor and acceptor beads (diluted 1:200 from manufacturers provision in a 25 mM Tris HCl (pH = 7.5), 200 mM NaCl, 100 mM EDTA, 0.3% BSA buffer) are added to the wells. The plates are then incubated for 4h and read on an AlphaQuest plate reader.

[962] EGFR (human) – 100 μ M ATP: To a well of a 384 well plate are added 1 μ L of compound (or vehicle control, usually DMSO; DMSO concentration is controlled at a concentration of 1%), followed by 9 μ L of the reaction mix (ATP, at the desired concentration, is added diluted in assay buffer (50mM HEPES (pH = 7.4), 12.5mM MgCl₂ and 1% glycerol), containing 69.4mM NaCl, biotinylated poly(Glu,Tyr) (84.5ng/mL) and 0.334mM vanadate). EGFR is diluted to the optimized concentration (optimized on a lot-by-lot basis) in an enzyme diluent buffer (50mM HEPES pH = 7.4, 12.5 mM MgCl₂ and 1% glycerol, 0.3% Brij35 and 0.3mM EGTA) and Stablecoat (SurModics), and DTT is also added for a concentration of 3mM. 5 μ L of this solution are then added to the well, and the complete reaction mixture is incubated for 60min at RT. In subdued light, 5 μ L of PT66 donor and acceptor beads (diluted 1:200 from manufacturer's provision in a 25mM Tris HCl (pH = 7.5), 200mM NaCl, 100mM EDTA, 0.3% BSA buffer) are added to the wells. The plates are then incubated for 4h and read on an AlphaQuest plate reader.

[963] PDK-1 (human) – 100 μ M ATP: To a well of a 384 well plate are added 1 μ L of compound (or vehicle control, usually DMSO; DMSO concentration is controlled at a concentration of 1%), followed by 9 μ L of the reaction mix (ATP, at the desired concentration, is added diluted in assay buffer (50mM Tris pH = 7.4, 15mM MgCl₂, 0.1mg/mL Bovine gamma globulin, 2mM DTT) containing biotinylated peptide substrate (83.5nM)). PDK-1 (obtained from Upstate, 200ng/ μ L) is diluted 1:25000 in an enzyme diluent buffer (50mM

Tris pH = 7.4, 15mM MgCl₂, 0.1mg/mL Bovine gamma globulin, 2mM DTT). 5μL of this solution are then added to the well, and the complete reaction mixture is incubated for 2h at RT protected from light. 2.5μL/well of stop buffer (200mM EDTA in 20mM Tris / 200 nM NaCl) are added, and the mixture is incubated for 1h at RT protected from light. 2.5 μl/well of antibody/bead complex (antibody diluted 1:1250, donor and acceptor beads diluted 1:200 from manufacturer's provision) are added. The plates are then incubated for 2h at RT protected from light and read on an AlphaQuest plate reader.


[964] PDK-1 (human) – 4.5μM ATP: Same procedure, except for the different ATP concentration.

[965] The **EXAMPLES 82–301**, except for **EXAMPLES 104, 189, 225, 228, 229, 231, 234, 238, 239, 241, 243, 244, 253, 263, 270, 271, 275, 282, 285, 288, 297, 298, and 299** – for which limited assay results are available – inhibit at least two of the IGF-1R, PDK-1, KDR, EGFR, and Ron kinases at greater than 50% inhibition at 10μM. It is advantageous that the measured IC₅₀ be lower than 10μM. It is still more advantageous for the IC₅₀ to be lower than 5μM. It is even more advantageous for the IC₅₀ to be lower than 0.5μM. It is yet more advantageous for the IC₅₀ to be lower than 0.1μM.

Y is $-C(C_{0-6}alkyl)(C_{0-6}alkyl)-$, $-N(C_{0-6}alkyl)-$, $-N(C_{0-6}alkyl)-C_{1-6}alkyl-$, O, S, $>N-C_{2-6}alkyl-N-(C_{0-6}alkyl)(C_{0-6}alkyl)$, $>N-C_{2-6}alkyl-O-C_{0-6}alkyl$, $>N-C_{1-6}alkyl-C(O)-NH-C_{0-6}alkyl$, or $>N-C_{2-6}alkyl-N-C(O)-C_{1-6}alkyl$; and

R1 is aryl, hetaryl, or heterocyclyl, optionally substituted with 1-6 independent halo, $-CN$, $-OH$, $-C_{0-6}alkyl$, $-C_{3-10}cycloalkyl$, $-haloC_{1-6}alkyl$, $-C_{2-6}alkynyl$, $-N(C_{0-6}alkyl)(C_{0-6}alkyl)$, $-C(O)-C_{0-6}alkyl-N(C_{0-6}alkyl)(C_{0-6}alkyl)$, $-C(O)-C_{0-6}alkyl-(heterocyclyl)$, $-C_{1-6}alkyl-C(O)-C_{0-6}alkyl-N(C_{0-6}alkyl)(C_{0-6}alkyl)$, $-O-C_{0-6}alkyl-(heterocyclyl)$, $-C_{0-6}alkyl-O-C_{0-6}alkyl$, $-C_{0-6}alkyl-N(C_{0-6}alkyl)(C_{0-6}alkyl)$, $-O-C_{0-6}alkyl-(hetaryl)$, $-S(O)_2-N(C_{0-6}alkyl)(C_{0-6}alkyl)$, aryl, hetaryl, or heterocyclyl substituents, or substituted with an oxo ($=O$) using a bond from the aryl, hetaryl, or heterocyclyl ring, wherein any of the substituents optionally is substituted with 1-6 independent halo, CN , OH , $-C_{0-6}alkyl-O-C_{0-6}alkyl$, $-C_{0-6}alkyl-N(C_{0-6}alkyl)(C_{0-6}alkyl)$, $-C(O)-C_{0-6}alkyl-N(C_{0-6}alkyl)(C_{0-6}alkyl)$, $-C(O)-C_{0-6}alkyl-(heterocyclyl)$, or $C_{0-6}alkyl$.

2. The compound according to claim 1, or a stereoisomer, or a pharmaceutically

acceptable salt thereof, wherein Cy is .

3. The compound according to claim 1, or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein R1 is aryl optionally substituted with halo, $-CN$, $-OH$, $-C_{0-6}alkyl$, $-haloC_{1-6}alkyl$, $-C_{2-6}alkynyl$, $-N(C_{0-6}alkyl)(C_{0-6}alkyl)$, $-C(O)-C_{0-6}alkyl-N(C_{0-6}alkyl)(C_{0-6}alkyl)$, $-O-C_{0-6}alkyl-(heterocyclyl)$, $-O-C_{0-6}alkyl-(hetaryl)$, $-S(O)_2-N(C_{0-6}alkyl)(C_{0-6}alkyl)$, aryl, hetaryl, or heterocyclyl substituents, or substituted with an oxo ($=O$) using a bond from the aryl ring, wherein any of the substituents optionally is substituted with 1-6 independent halo or $C_{0-6}alkyl$.

4. The compound according to claim 1, or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein R1 is aryl optionally substituted with 1-6 independent halo, $-CN$, $-OH$, $-C_{0-6}alkyl$, $-C_{3-10}cycloalkyl$, $-haloC_{1-6}alkyl$, $-C_{2-6}alkynyl$, $-N(C_{0-6}alkyl)(C_{0-6}alkyl)$, $-C(O)-C_{0-6}alkyl-N(C_{0-6}alkyl)(C_{0-6}alkyl)$, $-C(O)-C_{0-6}alkyl-(heterocyclyl)$, $-C_{1-6}alkyl-C(O)-C_{0-6}alkyl-N(C_{0-6}alkyl)(C_{0-6}alkyl)$, $-O-C_{0-6}alkyl-(heterocyclyl)$, $-C_{0-6}alkyl-O-C_{0-6}alkyl$, $-C_{0-6}alkyl-N(C_{0-6}alkyl)(C_{0-6}alkyl)$, $-O-C_{0-6}alkyl-(hetaryl)$, $-S(O)_2-N(C_{0-6}alkyl)(C_{0-6}alkyl)$, aryl, hetaryl, or heterocyclyl substituents, or substituted with an oxo ($=O$) using a bond from the aryl, hetaryl, or heterocyclyl ring, wherein any of the substituents optionally is substituted with 1-6 independent halo, CN , OH , $-C_{0-6}alkyl-O-C_{0-6}alkyl$, $-C_{0-6}alkyl-N(C_{0-6}alkyl)(C_{0-6}alkyl)$, $-C(O)-C_{0-6}alkyl-N(C_{0-6}alkyl)(C_{0-6}alkyl)$, $-C(O)-C_{0-6}alkyl-(heterocyclyl)$, or $C_{0-6}alkyl$.

5. The compound according to claim 1, or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein R1 is hetaryl optionally substituted with halo, -CN, -OH, -C₀₋₆alkyl, -haloC₁₋₆alkyl, -C₂₋₆alkynyl, -N(C₀₋₆alkyl)(C₀₋₆alkyl), -C(O)-C₀₋₆alkyl-N(C₀₋₆alkyl)(C₀₋₆alkyl), -O-C₀₋₆alkyl-(heterocyclyl), -O-C₀₋₆alkyl-(hetaryl), -S(O)₂-N(C₀₋₆alkyl)(C₀₋₆alkyl), aryl, hetaryl, or heterocyclyl substituents, or substituted with an oxo (=O) using a bond from the hetaryl ring, wherein any of the substituents optionally is substituted with 1-6 independent halo or C₀₋₆alkyl.

6. The compound according to claim 1, or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein R1 is hetaryl optionally substituted with 1-6 independent halo, -CN, -OH, -C₀₋₆alkyl, -C₃₋₁₀cycloalkyl, -haloC₁₋₆alkyl, -C₂₋₆alkynyl, -N(C₀₋₆alkyl)(C₀₋₆alkyl), -C(O)-C₀₋₆alkyl-N(C₀₋₆alkyl)(C₀₋₆alkyl), -C(O)-C₀₋₆alkyl-(heterocyclyl), -C₁₋₆alkyl-C(O)-C₀₋₆alkyl-N(C₀₋₆alkyl)(C₀₋₆alkyl), -O-C₀₋₆alkyl-(heterocyclyl), -C₀₋₆alkyl-O-C₀₋₆alkyl, -C₀₋₆alkyl-N(C₀₋₆alkyl)(C₀₋₆alkyl), -O-C₀₋₆alkyl-(hetaryl), -S(O)₂-N(C₀₋₆alkyl)(C₀₋₆alkyl), aryl, hetaryl, or heterocyclyl substituents, or substituted with an oxo (=O) using a bond from the aryl, hetaryl, or heterocyclyl ring, wherein any of the substituents optionally is substituted with 1-6 independent halo, CN, OH, -C₀₋₆alkyl-O-C₀₋₆alkyl, -C₀₋₆alkyl-N(C₀₋₆alkyl)(C₀₋₆alkyl), -C(O)-C₀₋₆alkyl-N(C₀₋₆alkyl)(C₀₋₆alkyl), -C(O)-C₀₋₆alkyl-(heterocyclyl), or C₀₋₆alkyl.


7. The compound according to claim 1, or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein R1 is heterocyclyl optionally substituted with halo, -CN, -OH, -C₀₋₆alkyl, -haloC₁₋₆alkyl, -C₂₋₆alkynyl, -N(C₀₋₆alkyl)(C₀₋₆alkyl), -C(O)-C₀₋₆alkyl-N(C₀₋₆alkyl)(C₀₋₆alkyl), -O-C₀₋₆alkyl-(heterocyclyl), -O-C₀₋₆alkyl-(hetaryl), -S(O)₂-N(C₀₋₆alkyl)(C₀₋₆alkyl), aryl, hetaryl, or heterocyclyl substituents, or substituted with an oxo (=O) using a bond from the heterocyclyl ring, wherein any of the substituents optionally is substituted with 1-6 independent halo or C₀₋₆alkyl.

8. The compound according to claim 1, or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein R1 is heterocyclyl optionally substituted with 1-6 independent halo, -CN, -OH, -C₀₋₆alkyl, -C₃₋₁₀cycloalkyl, -haloC₁₋₆alkyl, -C₂₋₆alkynyl, -N(C₀₋₆alkyl)(C₀₋₆alkyl), -C(O)-C₀₋₆alkyl-N(C₀₋₆alkyl)(C₀₋₆alkyl), -C(O)-C₀₋₆alkyl-(heterocyclyl), -C₁₋₆alkyl-C(O)-C₀₋₆alkyl-N(C₀₋₆alkyl)(C₀₋₆alkyl), -O-C₀₋₆alkyl-(heterocyclyl), -C₀₋₆alkyl-O-C₀₋₆alkyl, -C₀₋₆alkyl-N(C₀₋₆alkyl)(C₀₋₆alkyl), -O-C₀₋₆alkyl-(hetaryl), -S(O)₂-N(C₀₋₆alkyl)(C₀₋₆alkyl), aryl, hetaryl, or heterocyclyl substituents, or substituted with an oxo (=O) using a bond from the aryl, hetaryl, or heterocyclyl ring, wherein any of the substituents optionally is substituted with 1-6 independent halo, CN, OH, -C₀₋₆alkyl-O-C₀₋₆alkyl, -C₀₋₆alkyl-N(C₀₋₆alkyl)(C₀₋₆alkyl), -C(O)-C₀₋₆alkyl-N(C₀₋₆alkyl)(C₀₋₆alkyl), -C(O)-C₀₋₆alkyl-(heterocyclyl), or

C₀₋₆alkyl.


9. The compound according to claim 1, or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein X is N.

10. The compound according to claim 9, or a stereoisomer, or a pharmaceutically

acceptable salt thereof, wherein Cy is .


11. The compound according to claim 9, or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein Y is -N(C₀₋₆alkyl)-.


12. The compound according to claim 1 represented by:










or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein R2 is -C₀₋₆alkyl, -C₂₋₆alkyl-N-(C₀₋₆alkyl)(C₀₋₆alkyl), -C₂₋₆alkyl-O-C₀₋₆alkyl, -C₁₋₆alkyl-C(O)-NH-C₀₋₆alkyl, or -C₂₋₆alkyl-N-C(O)-C₁₋₆alkyl.


13. The compound according to claim 1, represented by:




wherein  is selected from the following table:










or a stereoisomer, or a pharmaceutically acceptable salt thereof.

14. The compound according to claim 1, represented by:




or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein R2 is $-C_{0-6}$ alkyl, $-C_{2-6}$ alkyl-N-(C_{0-6} alkyl)(C_{0-6} alkyl), $-C_{2-6}$ alkyl-O- C_{0-6} alkyl, $-C_{1-6}$ alkyl-C(O)-NH- C_{0-6} alkyl, or $-C_{2-6}$ alkyl-N-C(O)- C_{1-6} alkyl.


15. The compound according to claim 1, represented by:




wherein

is selected from the following table:









or a stereoisomer, or a pharmaceutically acceptable salt thereof.

16. The compound according to claim 1, or a stereoisomer, or a pharmaceutically



17. The compound according to claim 1, or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein X is C-CN.

18. The compound according to claim 17, or a stereoisomer, or a pharmaceutically

acceptable salt thereof, wherein X is C-CN; and Cy is .

19. The compound according to claim 17, or a stereoisomer, or a pharmaceutically































acceptable salt thereof, wherein X is C-CN; and Y is -N(C₀₋₆alkyl)-.


20. The compound according to claim 1, or a stereoisomer, or a pharmaceutically


acceptable salt thereof, wherein Y is -N(C₀₋₆alkyl)-.

21. The compound according to claim 1, or a stereoisomer, or a pharmaceutically


acceptable salt thereof, wherein R1 is selected from the following table:


			
			
			
			
			
			
			
			







22. The compound according to claim 1, or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein Z is selected from the following:

























23. The compound according to claim 1, or a stereoisomer, or a pharmaceutically acceptable salt thereof, represented by:




wherein is selected from the following table:


		
		
		
		
		
		

or a stereoisomer, or a pharmaceutically acceptable salt thereof.











24. The compound according to claim 1 or a pharmaceutically acceptable salt



25. The compound according to claim 1, represented by



or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein Z is selected from:


		
		
		
		

26. A composition comprising a compound according to claim 1, or a stereoisomer, or a pharmaceutically acceptable salt thereof; and
an anti-neoplastic, anti-tumor, anti-angiogenic, or chemotherapeutic agent.

27. A composition comprising a compound according to claim 1, or a or a stereoisomer, pharmaceutically acceptable salt thereof, and a cytotoxic cancer therapeutic agent.


28. A composition comprising a compound according to claim 1, or a stereoisomer, or a pharmaceutically acceptable salt thereof, and an angiogenesis inhibiting cancer therapeutic agent.


29. A compound selected from the following:





or a stereoisomer, or a pharmaceutically acceptable salt thereof.


30. A compound selected from the following:



































or a stereoisomer, or a pharmaceutically acceptable salt thereof.

31. A compound selected from

- 4-[4-(4-Fluoro-3-thiazol-5-ylphenylamino)-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl ester;
- 4-[4-(4-Fluoro-3-thiazol-5-ylphenylamino)-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butylamide;
- 4-{4-[4-Fluoro-3-(1*H*-imidazol-2-yl)-phenylamino]-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl ester;
- 4-{4-[4-Fluoro-3-(1*H*-imidazol-2-yl)-phenylamino]-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butylamide;
- 4-[4-(4-Fluoro-3-imidazol-1-ylphenylamino)-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl ester;
- 4-[4-(4-Fluoro-3-imidazol-1-ylphenylamino)-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butylamide;
- 4-{4-[4-Fluoro-3-(4-methylpiperazin-1-yl)-phenylamino]-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl ester;
- 4-{4-[4-Fluoro-3-(4-methylpiperazin-1-yl)-phenylamino]-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butylamide;
- 4-{4-[4-Fluoro-3-(1-methylazetidin-3-ylmethyl)-phenylamino]-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl ester;
- 4-{4-[4-Fluoro-3-(1-methylazetidin-3-ylmethyl)-phenylamino]-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butylamide;
- 4-{4-[4-Fluoro-3-(1-methylazetidin-3-yloxy)-phenylamino]-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl ester;
- 4-{4-[4-Fluoro-3-(1-methylazetidin-3-yloxy)-phenylamino]-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl ester;
- 4-{4-[4-Fluoro-3-(4-methylpiperazin-1-ylmethyl)-phenylamino]-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl ester;
- 4-{4-[4-Fluoro-3-(4-methylpiperazin-1-ylmethyl)-phenylamino]-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butylamide;
- 4-{4-[4-Fluoro-3-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-phenylamino]-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl ester;
- 4-{4-[4-Fluoro-3-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-phenylamino]-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl amide;
- 4-{4-[4-Fluoro-3-(1-methyl-2,5-dihydro-1*H*-pyrrol-3-yl)-phenylamino]-7H-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl ester;

4-{4-[4-Fluoro-3-(1-methyl-2,5-dihydro-1*H*-pyrrol-3-yl)-phenylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl amide;
(*S*)-4-{4-[4-Fluoro-3-(1-methylpyrrolidin-3-yl)-phenylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester;
(*S*)-4-{4-[4-Fluoro-3-(1-methylpyrrolidin-3-yl)-phenylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl amide;
(*R*)-4-{4-[4-Fluoro-3-(1-methylpyrrolidin-3-yl)-phenylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester;
(*R*)-4-{4-[4-Fluoro-3-(1-methylpyrrolidin-3-yl)-phenylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl amide;
{4-[4-(Benzothiazol-6-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridin-1-yl}-(2,2,4-trimethylpiperazin-1-yl)-methanone;
{4-[4-(Benzothiazol-6-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridin-1-yl}-(2,4,5-trimethylpiperazin-1-yl)-methanone;
{4-[4-(Benzothiazol-6-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridin-1-yl}-(3,4,5-trimethylpiperazin-1-yl)-methanone;
{4-[4-(Benzothiazol-6-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridin-1-yl}-[4-(2,2,2-trifluoroethyl)-piperazin-1-yl]-methanone;
{4-[4-(Benzothiazol-6-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridin-1-yl}-(4-*tert*-butylpiperazin-1-yl)-methanone;
Benzothiazol-6-yl-[6-(3,6-dihydro-2*H*-[1,2']bipyridinyl-4-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl]-amine;
Benzothiazol-6-yl-[6-(1-thiazol-2-yl-1,2,3,6-tetrahydropyridin-4-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl]-amine;
Benzothiazol-6-yl-[6-(1-oxazol-2-yl-1,2,3,6-tetrahydropyridin-4-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl]-amine;
4-[4-(3-Phenyl-3*H*-benzimidazol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester;
4-[4-(3-Phenyl-3*H*-benzimidazol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butylamide;
4-{4-[3-(2-Carbamoylphenyl)-3*H*-benzimidazol-5-ylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butylamide;
4-{4-[3-(2-Carbamoylphenyl)-3*H*-benzimidazol-5-ylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester;
4-{4-[3-(2-Aminoethyl)-3*H*-benzimidazol-5-ylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butylamide;

- 4-{4-[3-(2-Aminoethyl)-3*H*-benzimidazol-5-ylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester;
- 4-{4-[3-(2-Dimethylaminoethyl)-3*H*-benzimidazol-5-ylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butylamide;
- 4-{4-[3-(2-Dimethylaminoethyl)-3*H*-benzimidazol-5-ylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester;
- 4-{4-[3-(2-Acetylaminoethyl)-3*H*-benzimidazol-5-ylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butylamide;
- 4-{4-[3-(2-Acetylaminoethyl)-3*H*-benzimidazol-5-ylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester;
- 4-[4-(Imidazo[1,2-*a*]pyridin-6-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butylamide;
- 4-[4-(Imidazo[1,2-*a*]pyridin-6-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester;
- 4-[4-(3-Methylimidazo[1,2-*a*]pyridin-6-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butylamide;
- 4-[4-(3-Methylimidazo[1,2-*a*]pyridin-6-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester;
- 4-[4-(3-Phenylimidazo[1,2-*a*]pyridin-6-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butylamide;
- 4-[4-(3-Phenylimidazo[1,2-*a*]pyridin-6-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester;
- 4-{4-[3-(2-Carbamoylphenyl)-imidazo[1,2-*a*]pyridin-6-ylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butylamide;
- 4-{4-[3-(2-Carbamoylphenyl)-imidazo[1,2-*a*]pyridin-6-ylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester;
- 4-{4-[3-(2-Dimethylaminoethyl)-imidazo[1,2-*a*]pyridin-6-ylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butylamide;
- 4-{4-[3-(2-Dimethylaminoethyl)-imidazo[1,2-*a*]pyridin-6-ylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester;
- 4-{4-[3-(2-Acetylaminoethyl)-imidazo[1,2-*a*]pyridin-6-ylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butylamide;
- 4-{4-[3-(2-Acetylaminoethyl)-imidazo[1,2-*a*]pyridin-6-ylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester;
- 4-[4-(3-Dimethylaminomethylimidazo[1,2-*a*]pyridin-6-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butylamide;

4-[4-(3-Dimethylaminomethylimidazo[1,2-*a*]pyridin-6-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester;

4-[4-(7-Aminomethyl-1*H*-indazol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butylamide;

4-[4-(7-Aminomethyl-1*H*-indazol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester;

4-[4-(7-Aminomethyl-1-methyl-1*H*-indazol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butylamide;

4-[4-(7-Aminomethyl-1-methyl-1*H*-indazol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester;

4-[4-(7-Dimethylaminomethyl-1-methyl-1*H*-indazol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butylamide;

4-[4-(7-Dimethylaminomethyl-1-methyl-1*H*-indazol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester;

4-[4-(7-Dimethylaminomethyl-1*H*-indazol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butylamide;

4-[4-(7-Dimethylaminomethyl-1*H*-indazol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester;

4-{4-[7-(2-Dimethylaminoethyl)-1*H*-indazol-5-ylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butylamide;

4-{4-[7-(2-Dimethylaminoethyl)-1*H*-indazol-5-ylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester;

4-{4-[7-(2-Dimethylaminoethyl)-1-methyl-1*H*-indazol-5-ylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butylamide;

4-{4-[7-(2-Dimethylaminoethyl)-1-methyl-1*H*-indazol-5-ylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl}-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester;

4-[4-(Imidazo[1,5-*a*]pyridin-6-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butylamide;

4-[4-(Imidazo[1,5-*a*]pyridin-6-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester;

4-[4-(3-Methylimidazo[1,5-*a*]pyridin-6-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butylamide;

4-[4-(3-Methylimidazo[1,5-*a*]pyridin-6-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester;

4-[4-(1-Methylimidazo[1,5-*a*]pyridin-6-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butylamide;

4-[4-(1-Methylimidazo[1,5-*a*]pyridin-6-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester;

4-[4-(Imidazo[1,5-*a*]pyridin-7-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butylamide;

4-[4-(Imidazo[1,5-*a*]pyridin-7-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester;

4-[4-(3-Methylimidazo[1,5-*a*]pyridin-7-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butylamide;

4-[4-(3-Methylimidazo[1,5-*a*]pyridin-7-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester;

4-[4-(1-Methylimidazo[1,5-*a*]pyridin-7-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butylamide;

4-[4-(1-Methylimidazo[1,5-*a*]pyridin-7-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butyl ester;

4-[4-(Benzothiazol-6-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid (2-hydroxy-1,1-dimethylethyl)-amide;

4-[4-(1-Methyl-1*H*-indazol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid (2-hydroxy-1,1-dimethylethyl)-amide;

4-[4-(Benzothiazol-6-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid (2-methoxy-1,1-dimethylethyl)-amide;

4-[4-(1-Methyl-1*H*-indazol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid (2-methoxy-1,1-dimethylethyl)-amide;

4-[4-(Benzothiazol-6-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid (2-dimethylamino-1,1-dimethylethyl)-amide;

4-[4-(1-Methyl-1*H*-indazol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid (2-dimethylamino-1,1-dimethylethyl)-amide;

4-[4-(Benzothiazol-6-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid (1,1-dimethyl-2-pyrrolidin-1-ylethyl)-amide;

4-[4-(1-Methyl-1*H*-indazol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid (1,1-dimethyl-2-pyrrolidin-1-ylethyl)-amide;

4-[4-(Benzothiazol-6-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid (1,1-dimethyl-2-morpholin-4-ylethyl)-amide;

4-[4-(1-Methyl-1*H*-indazol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid (1,1-dimethyl-2-morpholin-4-ylethyl)-amide;

4-[4-(1*H*-Indol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butylamide;

4-[4-(Quinolin-6-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridine-1-carboxylic acid *tert*-butylamide;
(Hexahydropyrrolo[1,2-*a*]pyrazin-2-yl)-{4-[4-(imidazo[1,2-*a*]pyridin-6-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridin-1-yl}-methanone;
(Hexahydropyrrolo[1,2-*a*]pyrazin-2-yl)-{4-[4-(3-methyl-3*H*-benzoimidazol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridin-1-yl}-methanone;
(Hexahydropyrrolo[1,2-*a*]pyrazin-2-yl)-{4-[4-(1-methyl-1*H*-indazol-5-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridin-1-yl}-methanone;
{4-[4-(Benzothiazol-6-ylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidin-6-yl]-3,6-dihydro-2*H*-pyridin-1-yl}-(hexahydropyrrolo[1,2-*a*]pyrazin-2-yl)-methanone;
or a stereoisomer, or a pharmaceutically acceptable salt thereof.

32. A method of treatment of hyperproliferative disorder comprising a step of administering an effective amount of the compound according to claim 1.

33. The method of claim 32, further comprising the step of administering an anti-neoplastic, anti-tumor, anti-angiogenic, or chemotherapeutic agent.

34. The method of claim 32 wherein the hyperproliferative disorder is breast cancer, head cancer, or neck cancer.

35. The method of claim 32 wherein the hyperproliferative disorder is gastrointestinal cancer.

36. The method of claim 32 wherein the hyperproliferative disorder is leukemia.

37. The method of claim 32 wherein the hyperproliferative disorder is ovarian, bronchial, lung, or pancreatic cancer.

38. The method of claim 32 wherein the hyperproliferative disorder is small cell lung or colon cancer.

39. The method of claim 32 wherein the hyperproliferative disorder is sinonasal natural killer/T-cell lymphoma, testicular cancer (seminoma), thyroid carcinoma, malignant melanoma, ovarian carcinoma, adenoid cystic carcinoma, acute myelogenous leukemia (AML), breast carcinoma, pediatric T-cell acute lymphoblastic leukemia, angiosarcoma, anaplastic large cell lymphoma, endometrial carcinoma, or prostate carcinoma.